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Abstract 
 
In this thesis we explore the applicability of the X.laevis chemical genetic screening model 
towards drug discovery and drug development. The NCI diversity set II compound library 
was screened to identify abnormal pigmentation generating phenotypes that may have 
therapeutic application towards the treatment of melanoma cancer. 13 hit compounds 
identified were shown to have significantly lower IC50’s in the A375 melanoma cell line when 
compared to two control cell lines. Using the structural data of compounds screened 
(combined with the phenotypic data generated by the X.laevis screen), a report in which 
targets were predicted for each phenotypic category is described. Of the 10 targets predicted 
to generate an abnormal melanophore migration phenotype, six presented abnormal 
pigmentation phenotypes by compound antagonists. Two of these targets had no known 
previous link towards melanoma cancer. Many of the identified targets were also predicted to 
be targeted by nine out of 13 of the identified NCI compounds in the library screen. 
 
Thus, through a combination of forward chemical genetic screening, appropriate cell based 
assays and chemoinformatical analysis we have developed an efficient and effective 
screening strategy for the rapid identification of hit compounds that are likely to be acting 
through either well known or novel targets that may have possible implications towards the 
treatment of melanoma cancer.  
 
To assess the applicability of the X.laevis model towards drug development, in collaboration 
with AstraZeneca we designed a renal function toxicity assay. Renal toxicity is a serious 
concern in the pharmaceutical industry, being responsible for 7% of preclinical compound 
dropouts. I developed a biochemical assay in which renal function would be monitored by 
quantfying the concentration of ammonia excreted by embryos into media. A decrease in 
ammonia detected in the presence of nephrotoxic compounds was hypothesised to 
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represent a decrease in renal function, and therefore indicate toxicity. Despite promising 
preliminary experiments, the original salicylic acid ammonia assay detection method was 
inhibited by the presence of the compound solvant DMSO. A second assay (the glutamate 
dehydrogenase assay (GDH)) was trialled which could not detect a change in renal function 
in response to nephrotoxic compounds when compared to the vehicle control. In its current 
form, the X.laevis renal function assay is not capable of identifying nephrotoxic compounds 
and so further work is required. 
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Chapter I 
 
1.0 Introduction 
 
The primary goal of this thesis is to assess the applicability of the Xenopus 
laevis animal model towards both drug discovery and development. Figure 1 
summarises how we believe X. laevis can be incorporated into the 
pharmaceutical pipeline at various stages. It displays the points at which we 
believe X. laevis can contribute to both target based and activity based 
strategies, the difference being that the target based strategy requires an 
identified target that has been proven to be functionally involved in a disease 
pathway whereas an activity based strategy does not. Instead, the activity based 
strategy screens for lead compounds on the basis of biological activities 
implicated with a therapeutic benefit. The significance of this distinction and its 
impact on the utilisation of the X. laevis model towards drug discovery is 
discussed in the next section. Figure 1 indicates how we believe the X. laevis 
model can be implemented at later phases in the pipeline, specifically for the 
purposes of this thesis preclinical development is highlighted. Preclinical 
development is the point at which identified hit compounds have passed the 
point of drug discovery and are now entering a phase of drug development. 
Drug development is the phase where previously identified hit compounds are 
assessed for their toxicity and efficacy (and is discussed in detail later in the 
introduction).  
 
It has been shown previously by Tomlinson et al., (2005) that X. laevis are 
highly amenable towards phenotypic chemical genetic screening having 
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identified numerous phenotypes. One specific compound (NCI210627) aided in 
the discovery of a potential new drug for the treatment of melanoma, and is 
currently undergoing human clinical trialling (Tomlinson et al., 2005; White et al., 
2011). We aim to improve upon this process and further validate the use of X. 
laevis as a prominent model for phenotypic screening in drug discovery. A 
secondary aim of this thesis is to assess the value of X. laevis towards drug 
development in the form of a novel toxicity assay for the early preclinical 
assessment of renal toxicity, which is outlined in the next section. To emphasise 
the difference between assessing X. laevis as a tool for drug discovery and drug 
development, this introduction is split into two separate sections accordingly. 
 
1.1 Pharmaceutical drug discovery 
 
Despite increasing levels of investment from industry and governments the 
number of approved medicines has declined over the past three decades  
(Weigelt, 2009). The research and development of new drug entities however 
has increased over the past 10 years due to advances in technology. For 
example, the sequencing of the human genome has greatly expanded the list of 
potential “druggable” (defined as the expressed proteome believed to be 
applicable to modulation by compounds with drug-like properties (Cheng et al., 
2007; Hopkins and Groom, 2002) expressed targets, increasing the list of known 
potential drug targets from around 500 to tens of thousands (Collins, 1999; 
Hurko, 2010). In addition, the advent of combinational chemistry has enabled 
the rapid synthesis of a large number of different, but structurally related 
compounds that were previously unavailable. This has allowed pharmaceutical 
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companies to create large (100000-1000000) novel compound libraries from 
which to source for drug screening (Bleicher et al., 2003).  
 
 
Figure 1. The capacity for incorporation of the X. laevis animal model in the 
drug discovery pipeline. Target based and activity based strategies are 
displayed. Arrows depict which drug development stages of both screening 
strategies the X. laevis can be incorporated. The blue box indicates where our 
X. laevis HTS incorporates into the drug discovery process. The red and green 
boxes indicate the drug discovery phases into which we believe using continued 
screening or novel assay design (such as the X. laevis renal assay outlined 
below) X. laevis may also be incorporated. Adapted from Wheeler and Brandli 
(2009).    
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The union of combinational chemistry and high-throughput screening (HTS) has 
allowed pharmaceutical companies to screen thousands of newly synthesised 
compounds with previously unexplored pharmacodynamic properties at an 
unprecedented rate (Donato and Castell, 2003; Tomlinson et al., 2005; Zon and 
Peterson, 2010; Zon and Peterson, 2005). HTS is able to identify those 
compounds that cause a desired interaction or therapeutic effect, singling them 
out for further screening to eventually become lead or “hit” compounds (Fox et 
al., 2006). HTS can be applied to cell based assays and/or model organisms 
ranging from  Caenorhabditis elegans (the nematode worm) (Boyd et al., 2010b) 
to vertebrate models such as Danio rerio (zebrafish) (den Hertog, 2005; Zon and 
Peterson, 2005) and X. laevis (the African clawed frog) (Tomlinson et al., 2005; 
Tomlinson et al., 2009a; Tomlinson et al., 2009b).  
 
The ultimate goal of using a chemical genetic approach is to identify specific 
small molecule compound inhibitors for every conceivable biochemical event 
(Carroll et al., 2003). However given the sheer number of possible drug targets 
and our current capacity to predict specific complementary binding targets of 
small molecules this may be a distant goal. A primary aim of this project is to 
assess X. laevis and its potential utility in the pharmaceutical industry as a 
model organism for chemical genetic screening. We also aim to show how X. 
laevis can be used in the pharmaceutical industry as an early preclinical toxicity 
screen to aid in the identification of toxic drugs that would otherwise progress 
further down the pipeline only to be dropped at a later time. 
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1.1.1 The drug discovery pipeline 
 
Drug discovery over the past century has evolved from simple serendipitous 
observations of positive therapeutic effects elicited in humans towards a highly 
coordinated and robust production line (Hausheer et al., 2003; Swinney and 
Anthony, 2011). For pharmaceutical companies the efficacy and efficiency of 
their production line is all encompassing, ultimately determining how well they 
can compete with rival companies in a race to be the first to meet specific unmet 
market demands. While all companies will differ in their overall strategy and 
direction, the small molecule drug discovery pipeline is consistent when broken 
down into the individual stages of a compounds logical progression from initial 
identification to government approval (Hughes et al., 2011). 
 
1.1.2 Lead compound identification  
 
Over the past two decades drug development has largely focused upon using a 
target-based strategy (Bleicher et al., 2003; Kell, 2013; Kubinyi, 2003) . Here a 
target in a disease pathway will already have been identified and is believed to 
be critical in alleviating or curing the desired condition. Target identification is 
the first step in the drug discovery pipeline and is a prerequisite in the target-
based strategy approach before compounds can even begin to be investigated. 
Industry often relies on external sources (predominantly academic literature 
(Bleicher et al., 2003)) when it comes to identifying novel targets associated with 
a disease pathway. Once a target is identified, compounds are screened against 
this target using reporter assay HTS technology. Compounds shown to bind to 
their desired target are considered lead compounds and are subsequently 
optimised and validated (Hughes et al., 2011).  
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Compound selection is a critical phase of early drug development. With the 
advent of combinatorial chemistry, many pharmaceutical companies in the early 
1990’s rapidly generated large compound libraries consisting of up to a million 
compounds (Bleicher et al., 2003). In addition, recent advances in HTS and 
reporter assay technology enabled companies to perform screens in which 
thousands of compounds could be screened against a target of interest over a 
short time period. Over time however, it became apparent that this brute force 
approach was inefficient. Indeed, there was no noticeable increase in lead 
compound identification when compared to the protocols that preceded this new 
approach (despite the screening of thousands more potential candidates) (Feher 
and Schmidt, 2003). This was attributed to the high structural complexity, poor 
drug like features and low product purity of the synthesised compounds 
(Bleicher et al., 2003; Hann et al., 2001). Rapidly the criteria by which 
compounds were chosen for screening shifted, where both quality and quantity 
of potential candidates were considered equally important (Ganesan, 2008; 
Villar and Hansen, 2009). 
 
Great investment has been made into our capacity to predict which compounds 
may or may not be successful leads before they are even assessed (Villar and 
Hansen, 2009). A wide variety of algorithms are available that screen in silico 
compound structure libraries using defined descriptors to identify properties that 
might be considered of value or potentially risky, such as potential hERG 
inhibition which has been shown to lead to abnormal QT intervals which in turn 
induce arrhythmia and death in patients (Bender, 2010; Caldwell et al., 2009). 
Such “chemoinformatical analysis” are integral for efficient lead compound 
prediction and generation, and are discussed in detail below. A lead compound 
is selected based not only on positive reporter assay data (it binds to its desired 
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target efficiently and specifically), but also on its capacity for modification and 
optimisation (Song et al., 2014). Should the structure be difficult to modify this 
would limit the opportunities available for subsequent improvement and 
therefore it might be dropped despite good in vitro data (Avdeef, 2001).  
 
An additional point is the use of natural products in drug discovery. Natural 
products are compounds that are derived from natural sources such as micro-
organisms, plants and animals. Such compounds have had millions of years to 
evolve and therefore may represent the most biologically relevant compounds 
available (Harvey, 2008). Half of the new drugs approved between 1994 and 
2008 were based on natural products, and this is during a time period where 
synthetic compound screening was heavily focused upon (Harvey, 2008). This 
would suggest that naturally derived compounds are an important source of 
novel therapeutics and remain a valuable resource for future compound 
screening. This is emphasised by the sharp rise in natural products currently 
undergoing development, and a shift to screening natural product based 
compound libraries (Harvey, 2008). 
 
In summary, lead compound selection is a complex and constantly evolving 
process, but ultimately is aimed at providing compounds which have the best 
possible chance of making it through the subsequent phases of drug 
development. 
 
Whilst it is essential to refine the compounds chosen for experimentation, it is 
equally important to focus on improving the assays used to screen the 
compounds themselves. If assays can be developed that detect and therefore 
disregard toxic compounds early in drug development then this has significant 
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economic implications. This has led to the research and development of 
numerous in vitro and in vivo high-throughput assays designed to be as reliable 
and robust as possible in identifying toxic compounds. 
 
1.1.3 Preclinical assessment 
 
Following the lead compound identification phase of drug development, 
compounds are subjected to preclinical efficacy and toxicity testing. Preclinical 
testing typically begins by subjecting lead compounds to biochemical and in vitro 
screening, followed by in vivo testing to identify any potential toxicity that would 
be undesirable in a therapeutic compound (discussed in detail below) (Han, 
2010). An additional and equally important goal is to assess the efficacy of the 
compound by using appropriate disease models (Rick, 2009). The level of 
acceptable toxicity is dependent upon the severity of the toxicity manifested and 
the intended use of the compound. Naturally all lethally toxic compounds are 
unacceptable, regardless of their efficacy in binding to their desired targets 
(Han, 2010). However a certain level of toxicity is acceptable when treating 
diseases such as cancer, as the patient’s life is already threatened. 
Chemotherapeutics have well documented side effects that can cause extreme 
discomfort in the short term but are acceptable due to their potential to save a 
patient’s life. A similar approach is considered when regarding efficacy whereby 
a new drug must have a higher efficacy than that of a competing drug already 
available on the market. However some diseases may have no or limited 
treatment options lowering the required efficacy normally required for approval 
(Rick, 2009). Despite this allowance many safety regulatory bodies have 
become significantly more stringent in what is to be considered ‘acceptable’ 
levels of toxicity and efficacy across all compound classes. This has contributed 
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to the decline in approved novel therapeutic compounds as in many instances 
companies have failed to match these high standards (Kola and Landis, 2004). 
 
1.1.4 Clinical testing and regulatory approval 
 
Clinical trialling is the phase at which lead compounds are tested on human 
patients. Compounds which have reached this phase have strong preclinical 
data which infer low toxicity and high efficacy to minimise risk and maximise 
patient benefit as much as possible. Clinical trials are heavily regulated, with 
local governing bodies only permitting them to be carried out if preclinical data 
strongly supports the value of the study. Clinical trialling can be split into four 
separate phases, with sequential progression through each stage edging the 
prospective drug closer to approval. Phase zero clinical trialling is the first in 
human trial, in which single low doses of the compounds are administered to a 
small subject group (typically 10-15 participants) to assess the 
pharmacodynamic and pharmacokinetic properties of the compounds in the 
human system. Phase one clinical trailing uses a larger group (20-80 
participants), testing the compound over a range of concentrations to assess 
any potential toxicity and determine safe dosage. Phase two and phase three 
clinical trialling expands the participant group (100-300 and 1000-3000 
participants respectively) to further assess safety and also efficacy when 
compared to other compounds on the market targeted towards the same 
disease. If the compound is shown to have minimal (or acceptable) levels of 
toxicity and the efficacy is sufficiently high, it will then be approved by the 
appropriate local regulatory body (Hackshaw, 2009). 
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Figure 2. Summary of large pharma productivity between 2005-2010 (includes 
Eli Lilly, GlaxoSmithKline, Merck, Norvartis, AstraZeneca, Bristol-Myers Squibb, 
Sanofi-Aventis, Pfizer and Roche). $M represents millions of US Dollars. Taken 
from (Bunnage, 2011). 
 
1.1.5 Challenges of modern industrial drug discovery 
 
The reward for generating a “first in class” compound is substantial. The highest 
grossing drug in United States history is the cholesterol lowering statin 
Atorvastatin (marketed under the trade name Lipitor), which through its patent 
lifespan earned an estimated total of $123 billion in global sales for its parent 
company Pfizer (King, 2013). Whilst Lipitor has eclipsed most other block buster 
drugs in terms of revenue (over double that of its closest competitor Plavix 
(Bristol-Myers Squibb and Sanofi)), it is still significant that profits such as these 
that have enabled pharmaceutical companies to become recognised global 
industrial giants in their own right. It should be noted however that drug 
development is not without risk. A successful drug candidate takes an estimated 
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10 years to be approved through clinical trialling and regulatory approval (not 
including preclinical development time) and costs an estimated $1.32 billion per 
newly approved drug (including failures) before any financial return can be 
expected (Kaitin, 2010; Silber, 2010). An additional constant concern associated 
with pharmaceutical drug discovery is commonly referred to as the “patent cliff”. 
This is the point at which a drug is no longer protected by the parent company’s 
patent. With its exclusivity lost and open to competition from other companies, 
cheaply made competing generics significantly reduce the revenue of the 
original compound (2011; Cahn, 2012). Over  the past two decades this concern 
has been compounded by the relative drop in successfully approved novel 
therapeutic compounds accompanied by the concerning lack of prospective 
entities in many of the larger pharmaceutical companies pipelines (Kaitin, 2010; 
Kola and Landis, 2004; Swinney and Anthony, 2011). One notable cause for the 
drop in newly approved compounds is increasingly high attrition rates. This has 
been attributed to a number of factors such as a focus on more complex 
diseases (Pammolli et al., 2011), increasingly stringent regulatory approval 
towards efficacy and toxicity (Paul et al., 2010) and the insufficient capacity of 
preclinical assays to accurately predict toxicity prior to clinical trials (Bleicher et 
al., 2003; Kaitin, 2010; Munos, 2009; Scannell et al., 2012; Wienkers and Heath, 
2005).  
 
Currently large pharmaceutical companies are actively  investing into the 
research and development process, with the world’s leading companies 
investing an average $10-50 billion between 1998 and 2004 (Tollman et al., 
2011). This is emphasised in Figure 2 in which large pharmaceutical company 
productivity between 2005-2010 is displayed, comparing new molecular entities 
approved (NMEs) versus year on year research and development spending 
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(Bunnage, 2011). Given the stated rise in compound development attrition and 
research expenditure this model of pharmaceutical development is clearly 
unsustainable. A change is required in the way pharmaceutical companies 
function, both in their research and development strategies and in their overall 
structure and role in the drug development process.  
 
A clear shift in industry attitude toward drug development has been observed in 
the past 10 years, ranging from moving primary research facilities to cheaper 
locations (I.e. Asia (Li, 2008; Wood, 2012)) and intriguingly a number of large 
scale acquisitions of small specialised biotech companies (such as 
AstraZeneca’s reported $15 billion acquisition of MedImmune in 2007 (Zimm, 
2007) or Pfizer’s unprecedented $68 billion acquisition of Wyeth in 2009 (Sorkin, 
2009)) (Drews, 2003; LaMattina, 2011). Such major acquisitions represent an 
attempt to diversify their research and development by utilising small and 
specialised biotech companies that have greater expertise in particular scientific  
fields or disease areas and are more flexible in adopting new technology than 
traditional large pharmaceutical powerhouses (Comanor and Scherer, 2013; 
Drews, 2003; LaMattina, 2011). There has also been a move towards open 
source collaboration between pharmaceutical competitors (Mullard, 2011) as 
well as academics in an attempt to share information and facilities with the 
admirable attitude that it is possible to achieve more though collaboration 
(Portilla and Alving, 2010). 
 
 
Academic institutions (much like small biotech companies) have the advantage 
of being extremely flexible in their approach to drug development, which has not 
gone unnoticed by large pharmaceutical companies who now commonly 
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collaborate with academic laboratories and academia based small biotechs. In 
the US there are now 78 academic or non-profit situated dedicated small drug 
discovery facilities (Frye et al., 2011). Such academic facilities in both the US 
and UK tend to focus on targets that lie outside of the traditional pathways 
typically focused upon by pharmaceutical companies, with roughly 50% of these 
targets being based on new discoveries (Frye et al., 2011; Tralau-Stewart et al., 
2013). Indeed, there is strong support for the utility of academia in drug 
discovery, which between 1998 and 2007 contributed intellectual property 
towards 56% of the new therapeutic compounds and biologics judged by the 
FDA to warrant priority review (Frye, 2013; Kneller, 2010; Silber, 2010). 
Academic projects have a key advantage in novel target discovery due to their 
project aims being rooted in furthering our knowledge of biology (Frye, 2013; 
Slusher et al., 2013). These projects are free to pursue obscure or untested 
targets and pathways without the risk of said target being discovered to have 
poor druggability (and therefore possess no monetary value) despite being 
important biologically in their own right (Slusher et al., 2013). This also allows 
academics to pursue low profile diseases which may affect a significantly 
smaller population group (such as rare genetic diseases) rather than high profile 
diseases (such as cancer and cardiovascular disease) (Kneller, 2010; Stevens 
et al., 2011). 
 
The direction and strategy to which large pharma has undertaken drug 
discovery is being forced to change significantly for the first time in its history. 
Never before has the sector been faced with the genuine prospect of failure to 
regularly bring new drugs to market, and whilst for the larger elite companies it 
is not yet a time of crisis, clear steps are being made to address what could 
soon become a precarious situation. Aside from a large shift in business 
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strategy, it is clear that the drug discovery process itself also needs to be 
overhauled to improve its diminished productivity. One approach that is gaining 
support within the literature is a return to phenotypic screening (Abdulla et al., 
2009; Dar et al., 2012; Kell, 2013; Lee et al., 2012; Sykes and Avery, 2013) via 
the adoption of ‘network pharmacology’ (Ho and Lieu, 2008; Hopkins, 2008; 
Schrattenholz and Soskic, 2008). Both of these concepts can be addressed 
through chemical genetic screening. 
 
1.1.6 Phenotypic versus target based chemical genetic screening  
 
Chemical genetic assays study biology by using small molecular compounds to 
modulate protein function and can be split into two types; phenotypic (forward) 
chemical genetics and target based (reverse) chemical genetics (Cong et al., 
2012). The latter refers to an assay in which the genetic or protein target is 
known and small molecules are screened against it to assess binding efficacy. 
Once a compound that is shown to interact with the known target is identified, 
the resulting phenotype is studied to determine the role the target gene or 
protein has in the model system (Spring, 2005). Forward chemical genetic 
assays screen compounds without a specific (or known) genetic or protein 
target. Those compounds that give rise to interesting or predicted phenotypes 
are identified as “hits” and undergo further investigation to identify the relevant 
genes involved (Spring, 2005). The advantages of using either a forward or 
reverse chemical genetic screening approach are outlined in Table 1. 
 
Whilst both forward and reverse chemical genetics have significant advantages 
and disadvantages in their application, in the context of compound screening for 
drug development, the past 20 years have been dominated by a reverse genetic 
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approach (Abdulla et al., 2009; Butcher, 2005; Kell, 2013; Kubinyi, 2003). This 
was due to the original belief that following the sequencing of the human 
genome it would be possible to identify the function of each of the 30000-40000 
identified genes by knocking each down separately so as to subsequently 
determine its biological role and assess its potential as a therapeutic target 
(Lander et al., 2001). This has since been shown to be impractical, not least 
because it is very rare that a small molecular compound binds to only a single 
target (Lee et al., 2012). Many commonly prescribed drugs on the market today 
have either numerous targets or their primary targets are unknown. For example 
lithium and valproic acid are widely used for the treatment of bipolar affective 
disorder and as a local anaesthetic respectively and have no universally 
accepted mechanism(s) of action (Williams, 2003). A consideration for the 
application of a forward chemical genetic approach to compound screening is 
the reintroduction of serendipity into the scientific process (Hausheer et al., 
2003; Proschak, 2013). For example, early antihistamines were noticed purely 
by chance to have significant antipsychotic and antidepressant effects, an 
observation that ultimately gave rise to the field of psychopharmaceuticals 
(Benson, 1996; Butcher, 2005). 
 
It has been observed in a variety of model organisms that single gene knockouts 
often present no overt observable phenotype and in fact only around 19% of 
genes are considered essential for survival (Austin et al., 2004; Giaever et al., 
2002; Hopkins, 2008; Winzeler et al., 1999). This is almost certainly a natural 
defence mechanism towards random deletion events. Redundancies in most 
biological pathways have been well characterised and are often compensated 
for by alternative signalling routes (Kitano, 2007). It has been suggested 
therefore that in some cases it may be necessary to target multiple “nodes” of a 
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Table 1. Advantages and disadvantages of forward / reverse chemical genetic 
screening approach towards drug discovery 
 
Strategy Advantages Disadvantages 
Forward 
chemical 
genetic 
screening 
 
- Allows for multiple target binding 
 
- Identifies promiscuous compounds  
 
- Optimisation of polypharmacological 
profile possible (Dar et al., 2012) 
 
- Identification of novel (multiple) 
targets or pathways in a disease 
 
- Contributed >50% of novel  
molecular mechanisms of action 
identified in approved small 
compounds over the past decade 
(Swinney and Anthony, 2011) 
 
 
- Difficult to optimise due to 
numerous targets involved 
 
- Mechanism of action may 
not always be known 
 
Reverse 
chemical 
genetic 
screening 
 
- Pipeline is geared towards 
generating target focused 
compounds 
 
- Single known target (simplifies 
mechanism of action) 
 
- Potential to be highly specific 
towards target (low off target 
toxicity)  
 
- Extremely difficult to make 
100% selective for single 
target 
 
- Does not take into account 
multiple targets / pathways 
involved in disease 
 
- Has a poor track record for 
drug development with high 
attrition rates 
 
- Requires extensive 
validation of biological target.  
 
- Potential for adverse drug – 
drug interactions when 
combined (Bucşa C, 2013) 
 
 
pathway (or pathways) before a phenotype may be induced (Zhao and Iyengar, 
2012). 
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This is particularly relevant for diseases in which the primary targets are also 
present in otherwise healthy cells (Tang and Aittokallio, 2014). The goal of 
target based drug discovery is to identify and exploit differentially expressed 
targets (such as BRAF in cancer) to treat the disease whilst minimalizing toxicity 
towards healthy cells (Cong et al., 2012; Hopkins, 2008; Joyce et al., 2012). 
However this is not always possible, as can be seen in many forms of 
chemotherapy where severe toxicity can be observed in patients due to the 
cytotoxicity of the dosed compounds inhibiting essential functions present in 
both healthy and cancerous cells simultaneously (Tang and Aittokallio, 2014). It 
has been suggested that a more prudent approach may be to better understand 
the subtle ways in which pathways are perturbed in cancer (Bhadriraju and 
Chen, 2002; Tang and Aittokallio, 2014). For example, two proteins that may be 
non-lethal to cancer when knocked down alone may be essential for survival 
when knocked down simultaneously due to their combined importance in a 
cancer specific pathway. These small fluctuations in endogenous pathway 
expression between cancerous and healthy cells, may explain the clear 
difference in their observed cell fate despite their common genetic lineage 
(Gascoigne and Taylor, 2008; Hopkins, 2008; Tang and Aittokallio, 2014).  
 
Phenotypic screening can be used as a powerful tool in developing this 
polypharmacological approach. Compounds screened can bind multiple targets 
to generate a phenotype (thereby having a desired polypharmacological profile). 
It is then possible using chemoinformatics to predict (and then biologically 
validate) any number of potential targets that only in combination elicit the 
observed effect (Feng et al., 2009; Liggi, 2013). In this way it is possible to 
generate a target profile of the disease and subsequently optimise the 
compound identified in the phenotypic screen towards each of those targets.  
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A study by Dar et al., (2012) provides an elegant example of how both target 
and phenotypic chemical genetic screening can be used in combination to 
discover numerous targets in cancer, which can be successfully antagonised 
simultaneously to develop a selectively promiscuous compound with a strong 
therapeutic effect. Dar et al., (2012) used a target based chemical genetic 
screen (utilising the Drosophila multiple endocrine neoplasia type 2 (MEN2B) 
model) to identify one compound (AD57) that rescued oncogenic Ret induced 
lethality (Read et al., 2005; Vidal et al., 2006). Structurally related Ret inhibitors 
showed reduced efficacy and increased toxicity when compared to AD57. 
Phenotypic compound screening using the Drosophila wing assay (where 
overexpressed Ret in the wing leads to over proliferation and abnormal cell 
migration), showed that optimal survival in the model occurred when Ret, Src, 
Raf and S6K were inhibited. It was also shown that inhibition of Tor led to 
increased toxicity (Read et al., 2005). Using this knowledge two compounds 
were synthesised (AD80 and AD81) based on the previous AD57 scaffold that 
were selectively potent for all three desired targets (whilst selectively avoiding 
Tor binding), resulting in lowered toxicity and improved efficacy in Drosophila 
and mammalian MEN2 models. This included mouse xenografts, which when 
compared to previously screened isomers (i.e. AD57) and even currently 
available drugs (such as vandetanib) showed improved inhibition of tumour 
growth (Dar et al., 2012). This screen highlighted the strong advantages of using 
chemical genetic screening to both identify lead compounds towards a specific 
target (through target based screening) and develop an optimal 
polypharmacological profile (though phenotypic screening) for optimised 
compound efficacy with minimal toxicity (Dar et al., 2012; Hopkins, 2008). This 
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study provided significant support for the role of phenotypic based screening 
and polypharmacology towards successful drug development.  
 
1.1.7 Models of phenotypic screening 
 
It is important to pick an appropriate model when developing a phenotypic 
screen as this often determines the throughput capacity. For example, over the 
past two decades cell based assays have been used to great effect in 
phenotypic screens due to significant advances in high throughput screening 
technology. Using in vitro model systems it is possible to screen vast numbers 
of compounds and/or end points over a short time period (summarised in Figure 
3 and reviewed in (Feng et al., 2009; Michelini et al., 2010)). As a model system, 
the practical advantages of using an in vitro assay (depending on the assay 
chosen) is unparalleled in its capacity for application towards high throughput 
screening (Feng et al., 2009). As such, cell based assays play an important role 
in early drug discovery by rapidly identifying lead compounds. All cell based 
assays however share one common flaw, their inability to accurately represent a 
fully functional three-dimensional model organism. This is significant, as failure 
to accurately predict efficacy and toxicity in humans has been well documented 
as a contributor to the currently high levels of compound development attrition 
(Hopkins, 2008; Kola and Landis, 2004).  
 
 
One alternative to in vitro screening is to use invertebrate models in the form of 
C. elegans and Drosophila melanogaster, which retain the capacity for high 
throughput screening with the advantages associated with using an in vivo  
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Figure 3. Current in vitro phenotypic screening assays. Throughput is defined 
by the number of compounds screened per week (Log10). Multiplicity is defined 
by the number of parameters (Log10) an assay format can assess. HTS 
represents HTS assays with a single output (and therefore producing the 
highest throughput). RGA and ELISA assays shown are considered to be 
multiplexed, (many HTS assays running simultaneously at lower throughput). 
Assay formats shown in orange are imaged based assays. Assay formats 
shown in blue are non-imaged based assays. Assay mulitplexity is inversely 
correlated with throughput. cDNA, (complementary DNA). ELISA, (enzyme-
linked immunosorbent assays). RGA, (reporter gene assays). FACS, 
(fluorescence-activated cell sorting). HTS, (high throughput screening). Adapted 
from (Feng et al., 2009) 
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system (Segalat, 2007). C. elegans was first introduced as a viable animal 
model by Sidney Brenner in the1960’s and has contributed greatly to our 
understanding of the molecular biology behind many critical biological events, 
such as senescence, early development, apoptosis and neuronal function 
(Brenner, 1974; Giacomotto and Segalat, 2010). Their short life cycle, low cost, 
ease of husbandry and small size (~50µM in length) make them highly 
amenable towards high-throughput phenotypic chemical genetic screening 
(Boyd et al., 2010a; Boyd et al., 2010b; Helmcke et al., 2010). However, C. 
elegans have several drawbacks towards their use as a model of a human 
system. For example, they are genetically distant from humans and as such 
cannot replicate a number of diseases. Also, whilst they have functioning organ 
systems their anatomy and physiology may be too different to reliably predict 
efficacy or toxicity in a human equivalent (Bier, 2004; Mushegian et al., 1998). 
The fruit fly model Drosophila melanogaster is similar in its advantages and 
disadvantages towards chemical genetic screening (Arias, 2008; Brenner, 1974; 
Manev and Dimitrijevic, 2004; Stilwell et al., 2006). Whilst both models have 
been shown to have potential in drug discovery (reviewed in (Artal-Sanz et al., 
2006), (Nichols, 2006) and (Segalat, 2007)), it remains that their physiology may 
be too different to humans to be a representative screening model (Wheeler, 
2012).  
 
Commonly used model of the human system is the mouse (Mus murinae) (West 
et al., 2000). However mice are large, have relatively low fecundity, long life 
spans and high husbandry costs. As such the mouse model is obviously not 
suited towards optimised medium to high throughput compound screening. A 
compromise between the evolutionary and physiological relevance of the mouse 
and the practical high though put screening advantages elicited by C. elegans 
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and D.melanogaster can be found in the form of Zebrafish and X. laevis. Both 
models are significantly more relevant towards human physiology than the 
invertebrate models whilst retaining their high fecundity and screening capacity 
(Brenner, 1974; Wheeler and Brandli, 2009; Zon and Peterson, 2010; Zon and 
Peterson, 2005). 
 
1.1.8 Chemical genetic screening using X. laevis and zebrafish  
 
Peterson et al. conducted the first successful HTS using the zebrafish vertebrate 
animal model (Peterson et al., 2000). The HTS was performed using a chemical 
genetic approach, screening 1100 small molecules selected randomly from a 
small molecular library. To maximise screening output, 4 organ systems were 
observed; the central nervous system, the cardiovascular system, pigmentation 
and ear development, which differ significantly from invertebrates. Visual 
examination of all four systems for abnormal phenotypic defects allowed a 
single experimenter to screen roughly 400 compounds per day. Around 1% of 
compounds screened affected a single feature of one of the organ systems 
observed (Peterson et al., 2000). Since then, in a screen conducted by 
Tomlinson et al., (2005), it has also been shown that the classical animal model 
X. laevis is equally amenable to HTS. The experiment subjected X. laevis 
embryo samples to much the same compounds and screening methods used 
upon zebrafish in the Peterson et al. (2000) HTS. Results revealed compounds 
that were shown to give a particular phenotype in zebrafish also gave a very 
similar phenotype in X. laevis (Tomlinson et al., 2005).  
 
The advantages to using both zebrafish and X. laevis as a screening animal 
model are highly comparable. The main practical advantage of using X. laevis is 
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that hundreds of eggs can be produced at a controlled time by a single female 
following hormone stimulation (zebrafish require no hormone stimulation but 
females produce fewer eggs). X. laevis eggs are easily fertilized via in vitro 
fertilization, which allows for the rapid generation of viable embryos in a 
relatively short amount of time. The embryos are also small enough to be 
arrayed out into 96 or 48 well plates as desired, but large enough so that 
development can be easily observed under a light microscope. As both of these 
organisms are aquatic, compounds can be dosed into the media and are 
passively or actively absorbed (Berger and Currie, 2007; Wheeler, 2012). These 
practical advantages make X. laevis highly suited towards HTS. Whilst these 
practical advantages are shared by both X. laevis and zebrafish, it is notable 
that X. laevis is evolutionary several hundred million years closer to humans 
(Kumar and Hedges, 1998). Also the X. laevis animal model contains organs 
that are more representative of the human system, such as lungs instead of 
gills, their immune system and a two chambered atrium which the zebrafish 
lacks (Wheeler and Brandli, 2009). As a genetic model X. laevis has proven to 
be inapplicable to techniques commonly utilised in the zebrafish due to its 
polytetraploid genome (Wheeler and Brandli, 2009). However, an evolutionary 
very close model to X. laevis, Xenopus tropicalis, has a diploid genome that was 
sequenced in 2012 (Hellsten et al., 2010). It is also worth noting that the X. 
laevis genome is currently being sequenced, the first draft of which has been 
published on Xenbase, the Xenopus model organism online data base 
(http://xenbase.org) (Bowes et al., 2013; Bowes et al., 2008; Bowes et al., 2010; 
James-Zorn et al., 2013). Both X. laevis and X. tropicalis have proven to give 
very similar results when screened with the same set of compounds, suggesting 
X. tropicalis in the future may be used instead of or in conjunction with X. laevis 
(Fort et al., 2004; Wheeler and Brandli, 2009).     
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1.1.9 X. laevis chemical genetic screening in practice  
 
The value of X. laevis as a HTS vertebrate animal model was emphasized in a 
highly successful HTS carried out by Tomlinson et al., (2009) (Figure 4) 
(Tomlinson et al., 2009b). The screen observed the phenotypic effects of 3000 
arrayed compounds (sourced from either the NCI Diversity I or the MicroSource 
Gen-Plus collection) placed in 96 well plates with five X. laevis embryos per 
well. The embryos were allowed to develop over 3 days until they reached stage 
38. Phenotypic abnormalities were primarily scored depending on pigmentation 
defects observed. Of the 3000 compounds screened 40 provided reproducible 
abnormal phenotypes considered to be a “hit” (Tomlinson et al., 2009b). The 40 
reported “hits” could be broken down into common abnormal phenotypic 
categories of which included edema (8%), general development (8%), 
melanophore morphology (12%), eye development (13%), melanophore 
migration (17%) and pigmentation (42%) (Tomlinson et al., 2005).  
 
Further analysis of the identified hit compound NCI 84093 (which was shown to 
cause marked inhibition of melanophore migration), showed it to be a matrix 
metalloproteinase (MMP) inhibitor (Tomlinson et al., 2009a). MMPs consist of a 
large family of zinc dependant endopeptidases that can cleave the vast majority 
of constituents in the extracellular matrix (Wang et al., 2011). They also have a 
number of other roles in human systems such as cell migration and have been 
heavily linked to cancer progression (Hofmann et al., 2000). Specifically 
NCI/84093 was shown to inhibit MMP-14 and MMP-2, which have been 
identified as being required for melanophore migration, an important factor in 
melanoma (Tomlinson et al., 2009a). Melanoma is a very aggressive and 
invasive form of cancer that shows poor prognosis on diagnosis  
25 
 
 
 
 
Figure 4. Flow diagram of a screen using X. laevis. Compounds are arrayed out 
into 96 well plates. Embryo’s are collected and arrayed out into well plates, 5 
embryos per well. Plates are incubated at 18oC for three days and phenotypes 
are subsequently scored. Those compounds that generate abnormal 
phenotypes are screened again using the same process to verify hits and/or to 
produce dose response data with a range of concentrations of the same 
compound. Adapted from (Tomlinson et al., 2009a).  
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(Eide et al., 2009). It has been suggested that its highly invasive qualities are 
due to the fact that the melanocytes from which the melanoma is derived are 
extremely migratory themselves. Thus previous results suggest that inhibiting 
melanophore migration could pose an effective treatment of melanoma, as was 
shown with a second hit compound NCI 210627. 
 
Using similarity searching chemoinformatical algorithms, further analysis of NCI 
210627 found it to be structurally highly related to the dihydrooroate 
dehydrogenase (DHODH) inhibitor Brequinar (Tomlinson et al., 2005; White et 
al., 2011). It was subsequently found that the anti-arthritic drug Leflunomide was 
also an inhibitor of DHODH despite being structurally unrelated to both NCI 
210627 and Brequinar. As Leflunomide was already an FDA approved drug it 
was quickly taken on for further testing as there is little chance of off target 
toxicity due to its already approved status. Since this discovery, Leflunomide 
has been shown to have very promising implications as an anti-melanoma 
chemotherapeutic (White et al., 2011). By inhibiting DHODH it is believed that 
Leflunomide causes the inhibition of transcriptional elongation in melanoma cells 
which was shown to cause a rapid reduction in primary melanoma tumor size, a 
mechanism of action that would not have been identified were it not for the 
original X. laevis screen (White et al., 2011). These results emphasize the 
potential of X. laevis HTS as a tool for identifying new drugs with novel 
mechanisms of action. It also goes someway to help validate X. laevis as a 
valuable asset to drug discovery.     
 
Since the initial Tomlinson screen a number of other successful chemical 
genetic screens have also contributed towards validating X. laevis as model for 
phenotypic chemical genetic screening (Adams et al., 2006; Dush et al., 2011; 
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Kalin et al., 2009). These assays focused upon different end points including 
angiogenesis, lymphangiogenesis, left right asymmetry and TGF-β signaling 
(Dush et al., 2011; Kalin et al., 2009). For the purpose of this thesis I will 
concentrate upon X. laevis melanocyte abnormalities as my primary screening 
endpoint. We hope to replicate the original success of the initial Tomlinson 
screen by identifying novel compounds for the treatment of melanoma, but also 
to expand the screens remit to better identify and validate the potentially novel 
targets involved. 
 
1.1.10 Xenopus melanogenesis 
 
Xenopus melanophores (known as melanocytes in higher vertebrates) are 
derived from pluripotent neural crest cells which arise in the developing neural 
tube. Neural crest cells can also differentiate into bone, cartilage, neurons and 
endocrine, adipose and connective tissue (Kumasaka et al., 2005). 
Melanophore migration begins as a wave, starting at the anterior of the embryo 
and ending at the posterior trunk. Between stages 26 and 30, Xenopus 
melanophores migrate from the dorsal side of the neural tube and finish 
migrating by stage 41, forming two distinctive lateral and dorsal pigment stripes 
(Figure 5) (Collazo et al., 1993). Melanophore development has been shown to 
play a role in a number of different disease states. For example, absence of the 
melanocytes in humans is indicative of piebaldism. Another example includes 
vitalingo, an autoimmune disease which leads to the destruction of melanocytes 
in patches of the patients skin (Granato et al., 1996). Perhaps more significantly, 
accumulated mutations in melanocytes promoting uncontrolled cell growth can 
give rise to the formation of melanoma. For example, the transcription factor Mitf 
has been shown to be essential towards melanocyte development, with Loss of 
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Mitf function leading to a total failure of melanocyte differentiation (Kumasaka et 
al., 2005). Mitf however has also been shown to play a significant role in the 
progression of human melanoma growth by promoting cell division and survival 
through CDK2 and BLC2 respectively (Garraway et al., 2005). The inhibition of 
the formation of melanophores and their subsequent migration in Xenopus has 
been used as an indicator of potential therapeutic compounds for the treatment 
of melanoma in humans (White et al., 2011). 
 
 
 
 
Figure 5. Xenopus melanophore migration schematic. The dorsal (red arrow) 
and lateral pigment (black arrow) stripes of a stage 38 wild type embryo.  
 
1.1.11 Melanoma 
 
Melanoma is a cancer of the skin, arising from melanocytes that have 
undergone numerous mutations to become cancerous (Figure 6). It is a 
particularly aggressive form of cancer with poor prognosis rates past stage 1 of 
tumour development (Braeuer, 2013; Garbe and Leiter, 2009). Melanocytes 
reside within the basal layer of the epidermis, which on occasion give rise to  
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Figure 6. Development of metastatic cancer. Summarises the various phases 
involved in the progression of a melanocyte to a malignant melanoma. Adapted 
from (Gaggioli and Sahai, 2007). 
 
naevi through abnormal increased proliferation. Not all naevi will become 
cancerous but some may show increasing signs of dysplasia, which begin to 
spread. The initial radial growth phase (RGP) tends to occur laterally and close 
to the epidermis and is still associated with good prognosis if diagnosed at this 
phase. As the melanoma begins to grow vertically (the vertical growth phase 
(VGP)), melanoma cells penetrate the basement membrane and invade the 
dermis, the majority of which still remaining in clusters. The VGP is often 
associated with the cancer possessing metastatic potential, which when 
accompanied by increasing vasculogenesis signals the cancer is now 
aggressive and will begin to spread to different sites (Gaggioli and Sahai, 2007). 
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Reported melanoma incident rates have risen over the past decade and this has 
recently been accompanied by a number of new treatment options that have 
successfully improved patient survival rates (Garbe and Leiter, 2009). It is now 
well established that a mutation in the B-Raf oncogene, which is present in 41% 
of melanomas, plays a significant role in the progression of the disease (Bis, 
2013; Lee, 2011). B-Raf activates the MAP kinase / ERK pathway thereby 
promoting uncontrolled cell division (Braeuer, 2013; Wan et al., 2004). The 
MAPK pathway has been shown to play a significant role in the proliferation and 
survival cancer cells, particualarly in melanoma (Figure 7). The activation of 
RAS GTPase promotes the activation of the ARAF, BRAF and CRAF kinases. 
RAF kinases promote the phosphorylation and activation of MEK, which 
subsequently phosphorylates and activates ERK. ERK proteins translocate into 
the nucleus where they begin to upregulate a number of cell survival proteins 
and transcription factors. This includes the upregulation of CCND1, which is 
known to promote cell proliferation and cell survival. In this way, the MEK 
pathway plays a significant role towards the promotion and survival of 
melanoma. This also explains why such great effort has been made into the 
development of inhibitors specific to this pathway, as clearly they have strong 
therapeutic potential. Current example inhibitors are shown in Figure 7. 
 
The significance of the MAPK pathway in melanoma is emphasised by the 
numerous studies and therapeutics that are targeted towards B-Raf in an 
attempt to inhibit its proliferative effects (Sabbatino et al., 2013). Two notable 
examples are Vermurafenib and Debrafenib, compounds that specifically 
interfere with the B-Raf/MEK pathway resulting in cell death (Chapman et al., 
2011). Whilst these compounds represent a significant step forward in our 
capacity to treat melanoma (replacing decarbazine as the front line treatment 
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option (Chapman et al., 2011)), they are only effective against tumours that 
contain the B-Raf mutation (Chapman et al., 2011). This is important as 41% of 
melanoma patients with wild type B-Raf must rely on less effective treatment 
options (Bis, 2013). Moreover, it is not uncommon for those patients possessing 
B-Raf mutant containing tumours to develop resistance within a year, resulting 
in remission (Fedorenko et al., 2011).  
 
 
Figure 7. MAPK signalling cascade. Example inhibitors of the RAF and MEK 
elements of the MAPK pathway are indicated. ARAF, v-raf murine sarcoma 
3611 viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene B1; 
CCND1, cyclin D1; CRAF, v-raf-1 murine leukemia viral oncogene homolog 1; 
ERK, extracellular signal-regulated kin‐ase; MEK mitogen-activated protein 
kinase kinase (adapted from (Siddiqui and Piperdi, 2010)). 
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This has led to numerous combinatorial studies in an attempt to target the 
cancer at multiple target sights to inhibit it rapidly via multiple pathways before it 
can acquire resistance (reviewed in (Kwong and Davies, 2014). 
 
It is evident that alternative targets need to be identified if melanoma is to be 
treated effectively, particularly for those patients who possess B-Raf wild type 
tumours. Whilst there are numerous candidates (such as the PI3K-AKT pathway 
or CDK4 (Davies, 2012; Kwong et al., 2012; Kwong and Davies, 2014)) for 
alternate targets acting independently to the MAP kinase / ERK pathway it has 
yet to be shown which targets in combination with B-RAF result in the best 
chance of survival (Kwong and Davies, 2014). Recent studies have shown that 
the addition of a MEK inhibitor combined with a B-Raf antagonist has promising 
effects in reducing melanoma tumour size and proliferation (Greger et al., 2012; 
Grimaldi et al., 2014). MEK inhibitors however have proven themselves to have 
significant toxic side effects in humans as their mechanism of action results in 
global cytotoxicity (Menzies and Long, 2013). It is likely that given the high 
variation of mutations observed between melanoma patients any combinatorial 
treatment will ultimately have to be personalised (Madureira and de Mello, 
2014).  
 
It is also worth noting the recent success of antibiotic treatments such as PD-1 
and MDX-101 (Ipilimumab). Ipilimumab activates the immune system by 
targeting CTLA-4. Inhibiting CTLA-4 allows cytotoxic T lymphocytes to recognise 
and destroy the melanoma cells. Novel treatments such as these in combination 
with small compound therapy may in the future prove to be an effective tool for 
the treatment of melanoma (Cha et al., 2014). 
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Whilst progress has been made in our capacity to treat melanoma, it is clear that 
both new drugs and novel targets (that are differentially expressed in cancer 
cells when compared to healthy cells) are required. One way to quickly identify 
novel therapeutic compounds is to predict them in silico by screening virtual 
compound libraries against a target of interest to predict binding potential 
(Kortagere et al., 2012; Vogt and Bajorath, 2012). By using known structural 
alerts and previous biological and chemical data it is also possible to predict 
those compounds that might be particularly toxic or difficult to optimise, as well 
as other important drug characteristics such as solubility, absorption and 
potential metabolic and excretory routes (Tan et al., 2013; Valerio and 
Choudhuri, 2012). Likewise, it is also possible to predict which targets might 
give rise to an exhibited phenotype by combining biological and structural data 
(Liggi, 2013). In this way in silico predictions (known as chemoinformatics) can 
refine the selection process by which screening compounds are chosen (Vogt 
and Bajorath, 2012).  
 
1.1.12 Chemoinformatics 
 
The field of chemoinformatics has shown great potential for the prediction of 
both compounds with good ‘drug like’ qualities and novel disease targets, 
thereby being of great use towards chemical genetic screening experimental 
design and analysis (Chen et al., 2012). Defined in 1998 by Brown, 
“Chemoinformatics is the mixing of those information resources to transform 
data into information and information into knowledge for the intended purpose of 
making better decisions faster in the area of drug lead identification and 
optimization” (Brown, 1998). In respect to drug discovery the value of 
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chemoinformatics increased in the 1990’s due to the use of HTS methods 
combined with the advent of click chemistry and the large number of ‘druggable’ 
targets’ identified as a consequence of the human genome project (Dobson, 
2004; Feher and Schmidt, 2003; Lander et al., 2001). The identification of 
thousands of new potential druggable targets widened the scope for drug 
screening, yet the majority of suspected targets have never been 
pharmacologically proven in their inferred disease pathway (Dobson, 2004). 
Indeed, hindsight has shown that care should be taken in the interpretation of 
this explosion of targets, which has led to the concept of a “druggable genome” 
(Cheng et al., 2007). This term, which is now commonly cited in literature, is 
misleading in the context of small molecule drug discovery as the target of such 
molecules is almost always a protein complex and not the genes themselves. 
When this is taken into account the number of potential druggable targets 
increases from ~30,000 genes to several hundred thousand proteins (when 
alternative splicing and post-translational modifications are also considered 
(Kubinyi, 2003)). It still remains today that the great majority of these proteins 
have very little information regarding their functions in the human system, let 
alone their potential role in disease pathways (Kola and Landis, 2004). It has 
been estimated that theory precedes empirical validation of new proposed drug 
targets by at least a decade (Hurko, 2010). 
 
It follows that despite a dramatic increase in available compounds and the 
capacity through which to screen them, the number of approved medicines has 
steadily declined over the past 30 years (Drews, 2003; Frantz, 2004; Weigelt, 
2009).  In 1998 it was estimated that of 7,000,000 compounds screened, just 
one will become a fully approved drug (Hurko, 2010) In Figure 8 compounds 
can clearly be seen to have significantly lower success rates at later clinical 
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stages, emphasizing the current rate of compounds attrition. In addition the drug 
discovery process takes between 8-12 years, costing $1.2 billion dollars (Hurko, 
2010). If it is also considered that only three in ten medicines that make it to 
market recover the original investment made into them, it becomes clear that 
such attrition is unacceptable and unsustainable (Kola and Landis, 2004).     
 
Compounds tend to fail at very late stages in the drug discovery pipeline, 
typically in phase 1 or phase 2 clinical trials (Kola and Landis, 2004). This has 
led to the belief that whilst high-throughput screening of compound libraries 
provides numerous "hit" lead compounds, the quality of these lead compounds 
must be drastically improved so as to not subject them to expensive clinical 
trailing that will inevitably fail (Kubinyi, 2003). This has promoted much research 
into the development of improved compound screening. Due primarily to the 
advent of combinational chemistry there has been a dramatic rise in the quantity 
 
Figure 8. Success rate as shown by development stage and therapeutic target 
area. App, approval; Reg, Registration. Adapted from (Kola and Landis, 2004). 
0
10
20
30
40
50
60
70
80
90
100
I II III Reg. App.
S
u
c
c
e
s
s
 r
a
te
 (
%
)
Stage of development
36 
 
 
 
of chemical information available (Kodadek, 2011; Lopez-Vallejo et al., 2011). 
Chemoinformatics are commonly employed as a computational solution to help 
organise and refine this data to make the most of the available information. The 
capacity to organise and segregate vast quantities of data based on defined 
chemical descriptors provides an opportunity to greatly refine compounds 
chosen for HTS (Bender, 2010; Bender et al., 2009; Xue and Bajorath, 2000). 
This therefore leads to the production of a higher quality “hit” that is more likely 
to progress through late stage clinical trialling where most compounds currently 
fail. There are four primary areas in which chemoinformatics can be applied to 
the design of a HTS experiment; compound library design, compound similarity 
searching and clustering, data modelling and the design of screening strategies 
(Parker and Schreyer, 2004).  Whilst all of these areas have significance in the 
design of successful HTS, library design and selection is particularly important 
(Goodnow et al., 2003).  
 
The failure of large newly synthesised compound libraries in the 1990’s to 
produce an increase in identified lead compounds suggests that such a method 
is inefficient (Feher and Schmidt, 2003; Goodnow et al., 2003). It is now widely 
accepted that this random synthesis approach failed because the compounds 
generated did not represent an appropriate area of chemical space (Feher and 
Schmidt, 2003; Ganesan, 2008; Lipinski and Hopkins, 2004; Lipinski et al., 
2001). Chemical space is a term intended to represent all possible (not 
necessarily existing) compounds, which is proposed to resemble the 
cosmological universe in its vastness. Figure 9 depicts a model representing all 
of chemical space. The light blue space represents all possible compounds. If it 
is assumed that within this model that proximity between compounds is 
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dependent upon similarity, so that the most similar compounds are adjacent to 
each other, it is possible to predict discrete areas of chemical space with 
particular properties. This is illustrated by the coloured areas (Lipinski and 
Hopkins, 2004). Such diversity makes screening compounds and compiling 
compound libraries randomly highly inefficient and may contribute greatly to the 
high attrition described in the later stages of the drug discovery process (Feher 
and Schmidt, 2003). In light of this, significant efforts have been made by 
pharmaceutical companies to create more focused screens and libraries. This 
can be achieved by using chemoinformatical algorithms to select discrete areas 
of chemical space to sample compounds from, which often depends on what  
 
Figure 9. Chemical space model. Blue space represents all possible 
compounds. Coloured regions represent chemical space oocupied by 
compounds sharing similar specified features. ADME; absorption, distribution, 
metabolism and excretion. Figure taken from (Lipinski and Hopkins, 2004). 
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characteristics or “descriptors” it is believed the molecule should have to be an 
effective drug for the target therapeutic area (Gedeck et al., 2006; Lipinski and 
Hopkins, 2004; Reymond et al., 2010). 
 
1.1.13 Molecular descriptors 
 
Lipinski’s rule of five is an example of a commonly applied general rule of thumb 
as to what characteristics (or descriptors) a molecule should have (Maldonado 
et al., 2006). These assumptions are based on past research that has shown 
that 90% of orally absorbed drugs have less than ten hydrogen-bond acceptors, 
less than five hydrogen-bond donors, a molecular weight of less than 500 Da 
and a log P (measure of hydrophilicity) of less than five (Lipinski et al., 2001). By 
disregarding all compounds that do not abide by these rules the experimenter is 
left with a chemical space containing compounds that are predicted to be more 
likely to become successful drug candidates. However, if one considers all the 
possible organic “drug-like” compounds below 500 Da (roughly 1060 compounds 
(Bohacek et al., 1996)), there would not be enough matter in the universe to 
synthesise just one of every molecule (Bender et al., 2006). Much research has 
been focused on the creation of more focused descriptors; however these 
typically depend on the desired therapeutic application (Bender, 2010; 
Maldonado et al., 2006). For example as an alternative to the Lipinski rules, oral 
absorption and blood brain barrier penetration can be partially predicted by 
observing the polar surface area (Bergstrom et al., 2003; Ertl et al., 2000) or 
VolSurf parameters (Cruciani et al., 2000; Ertl et al., 2000; Kubinyi, 2003). 
Certain properties are integral for an effective drug regardless of binding 
efficiency and are said to require acceptable ADME (absorption, distribution, 
metabolism and excretion) properties (Beresford et al., 2002; Geerts and 
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Vander Heyden, 2011; Tian et al., 2011). Positive ADME properties relate 
directly to effective drug efficacy. For example a compound must be hydrophilic 
enough so that it is efficiently absorbed and distributed around the body, but 
hydrophobic enough so that it can easily diffuse across the required cell 
membranes to reach the intended target (Tian et al., 2011).  
 
Appropriate descriptors are integral to effective chemoinformatic analysis and 
are determined by the desired use of the compound in question. Many drugs 
need to be metabolised to be transformed into their active form (also known as 
prodrugs) (Rautio et al., 2008). Prodrugs are designed like this because the 
parent compound may be more stable or easily administered than its active 
form, thereby making them more efficient as a therapeutic agent (Rautio et al., 
2008). For example the pain alleviating drug codeine is in fact an inactive parent 
compound which when metabolised creates the substrate morphine, a potent 
opiate analgesic (Solomon, 1974). The metabolic fate of the compound is 
particularly important factor in drug development. It is imperative that the 
compound can be metabolised and/or excreted easily from the system once it 
has achieved its intended goal (Boobis et al., 2002; Murphy, 2001). This 
requires the compound to be small enough and polar enough to be excreted in 
the urine or faeces. If the compound aggregates in a tissue and cannot be 
cleared, or produces toxic metabolites following its degradation then it cannot be 
used as an approved drug regardless of its efficacy (Caldwell et al., 2009). By 
using descriptors that indicate a compound will be broken down safely (or 
activate appropriately), chemoinformatic analytical descriptors are integral in 
directing this selection process (Boobis et al., 2002). 
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1.1.14 Chemoinformatic target prediction 
 
One disadvantage of utilising a phenotypic screen is the bottleneck that occurs 
when trying to understand the mechanism of action elicited by an identified lead 
(Kalin et al., 2009; Wheeler and Brandli, 2009). Given that compounds used in 
such screens often have little information regarding their biological (and 
potentially novel) targets, understanding the underlying root cause of the elicited 
phenotype is comparable to searching for a needle in haystack. This fact is 
compounded by the possibility that numerous pathways and targets may likely 
be involved (Kell, 2013). Target prediction methods use databases (such as 
CHEMBL (Gaulton et al., 2012), PUBCHEM (Wang et al., 2009) and WOMBAT 
(Schreiber, 2008)), to link small molecules to bioactivity data (Liggi, 2013). 
Molecules are selected and their known information are extrapolated onto those 
molecules whose biological activity in unknown (Liggi, 2013). Utilising 
chemoinformatical analysis combined with ligand data it is possible to predict 
targets for compounds in silico that have been proven to be accurate when 
validated in a biological system (Cortes-Ciriano, 2013; Liggi, 2013; Schreiber, 
2008). For example, a study by Lemieux et al., (2013) used chemoinformatics to 
predict targets for compounds shown to give abnormal feeding phenotypes in C. 
elegans. By using ligand binding data, numerous pathways were predicted and 
subsequently biologically validated in vitro. In total, four pathways that were 
previously unknown to effect feeding in C. elegans were predicted and validated 
(Lemieux et al., 2013).  
 
To predict mechanisms of action, compounds with known mechanisms of action 
are typically used as activity landmarks (to which it might be inferred that 
compounds of similar structure might elicit their phenotype via the same 
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mechanism of action). This approach is limited in that it relies on the availability 
of a relevant landmark compound that has a clear and specific mechanism of 
action. It also does not take into account phenotypes that arise through the 
inhibition of more than one target. One approach to circumvent this issue is to 
integrate chemical similarity comparisons with phenotypic data. Training 
statistical models (using compound structural information that are associated 
with known targets) can reveal new relationships between phenotypes and 
compounds. It is also possible to integrate relevant signalling pathways and 
disease information into the analysis. For example, compounds that perturb 
different targets in the same pathway are expected to generate a similar 
phenotype. A study by Loukine et al., (2012) constructed a bioactivity profile 
network by screening 656 FDA approved drugs in silico against 73 targets. By 
combining in silico target prediction, in vitro tests, adverse drug reaction 
annotation, phramacodynamic and pharmacokinetic properties a drug-target-
adverse effect network was created. This network predicted new off targets (247 
drug-target-side effect links) for the screened compounds that explained a 
number of side effects known to be elicited by the drugs. For example, tremors 
are known side effect of diphenhydramine, which was predicted to interfere with 
an off target dopamine transporter, and was subsequently biologically validated 
(Liggi, 2013; Lounkine et al., 2012). This study emphasises the power of 
chemoinformatic analysis as a tool for the prediction of novel targets using 
phenotypic screening data. It also demonstrates how such an approach can 
significantly reduce the bottle neck seen in phenotypic screening by rapidly 
predicting numerous novel targets to explain abnormal phenotypes which may 
be multi-targeted in nature (Liggi, 2013; Zhao and Iyengar, 2012). In 
collaboration with Andreas Bender I used the phenotypic data generated in our 
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X. laevis screen in conjunction with chemoinformatical analysis to predict novel 
targets and pathways for the potential treatment of melanoma.  
 
1.1.15 Summary 
 
It has been shown previously by Tomlinson et al., (2005) that X. laevis are 
highly amenable towards phenotypic chemical genetic screening having 
identified numerous hit compounds, one of which aiding in the discovery of a 
new drug for the treatment of melanoma that is currently undergoing human 
clinical trialling (Tomlinson et al., 2005; White et al., 2011). We aim to improve 
upon this process and further validate the use of X. laevis as a prominent model 
for phenotypic screening in drug discovery.  
 
We aim to screen the NCI diversity set II compound library and expand upon the 
previous Tomlinson screen by first utilising cell based assays to better 
understand the effect in vivo identified abnormal phenotype compounds might 
have towards melanoma cell viability. In collaboration with Andreas Bender 
(Unilever, Cambridge), we will then use a chemoinformatical approach to predict 
potential targets for each of the phenotypic hit compounds identified in vivo. 
These predicted targets will then be subsequently validated biologically by using 
known inhibitors in an attempt to replicate the original identified phenotype.  
 
A secondary aim of this thesis is to assess the value of X. laevis towards drug 
development. This was attempted by developing a novel toxicity assay for the 
early preclinical assessment of renal toxicity. The significance of drug 
development and the amenability of the X. laevis model towards improving its 
current capabilities are discussed in the next section. 
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1.2 Pharmaceutical drug development 
 
Toxicity testing in drug discovery is unavoidable both from a legal and ethical 
standpoint. It is illegal to market drugs that have not been approved by the 
regional safety regulatory body and therefore all pharmaceutical compounds 
must abide by the established safety parameter laws. Safety regulatory bodies 
are a necessity as they provide expert independent reviews of drug toxicity data 
and form the mediating barrier between profit seeking companies and the health 
of their patients.  
 
The importance of safety testing in pharmaceuticals is exemplified by the 1950s 
thalidomide tragedy. Between 1956-1962 pregnant women were prescribed 
thalidomide as an anti-emetic, resulting in over 9000 children in Europe and 
Africa being born with severe deformities (Franks et al., 2004). The USA 
escaped this tragedy because the Food and Drug Administration (the FDA) 
refused to approve the drug due to a lack of sufficient safety data (Weir, 2009). 
The United States FDA was formed in the early 19th century in response to 
deaths from dangerous formulations, and is integral in ensuring that clinical trials 
are conducted safely and provide safe and efficacious drugs. Whilst 
discrepancies do exist between what different countries regulatory bodies 
consider as permissible with regards to toxicity, it is hoped that such authorities 
have significantly reduced the chance of another event on the scale of 
thalidomide ever occurring again.  
 
Over the past two decades regularity body safety parameters have become 
increasingly stringent, making their standards of high efficacy and low levels of 
off target toxicity difficult to achieve (Lorman, 2001). This has contributed to the 
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documented decrease in pharmaceutical productivity and subsequent drop in 
the number of novel therapeutic compounds coming to market (Kola and Landis, 
2004). Increasingly compounds are failing at very late stages of drug 
development due to previously undiagnosed toxicity and/or lack of efficacy, 
resulting in great expenditure with little return (Kola and Landis, 2004; Swinney 
and Anthony, 2011). To combat this, pharmaceutical companies have 
incorporated a plethora of biochemical, in vivo and in vitro assays as standard 
practice within their pipelines that are critical for the prediction of toxicity and 
optimisation of prospective compounds. 
 
1.2.1 Biochemical and in vitro assays in preclinical toxicity testing  
 
A considerable amount of effort has been made in attempting to create 
economical, high-throughput pre-clinical assays that can be used to assess 
compound toxicity and ADME (absorption, distribution, metabolism and 
excretion) characteristics before they can progress further into development. 
The early prediction of whether a compound might exhibit toxic side effects 
(such as unwanted drug-drug interactions or off target effects), poses a 
significant challenge in drug development. In vitro biochemical based assays 
have been implemented as a method of predicting potential compound toxicity. 
In 1998, the number of serious adverse drug-drug interactions reported in the 
U.S.A. was estimated to be as high two million per year (Lazarou et al., 1998). It 
was proposed that many of the reported adverse drug-drug reactions were 
caused by one drug inhibiting the metabolism of the other, the first administered 
compound resulting in high plasma concentration levels of the second resulting 
in a subsequent toxic effect (Wienkers and Heath, 2005). To address this 
problem a simple biochemical assay was implemented that assessed the 
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inhibition of specific cytochrome P450 (CYP) function. Cytochrome P450s are a 
superfamily of enzymes that play an important role in the phase one metabolism 
of the majority of organic compounds in the body. Therefore by measuring their 
activity and production in the presence of a compound it is possible to assess 
metabolic state and potential toxicity. To achieve this, a probe substrate that 
produces a quantifiable product (such as fluorescence) when metabolised can 
be added to the desired isolated specific CYP (as well as the suspected CYP 
inhibitor compound). The measured rate of metabolism of the probe substrate 
(which can be assessed by a fluorometric or liquid chromatography-mass 
spectroscopy assay) indicated whether or not the suspected compound might 
be a toxic CYP inhibitor (Donato and Castell, 2003; Wienkers and Heath, 2005). 
This biochemical assay was an excellent example of current toxicity assay 
development, in that it provides a quick, simple and quantifiable assessment of 
a compounds toxicity that would typically only usually be observed at a much 
later stage in drug development. However, such biochemical assays are not 
without their disadvantages, mainly because by their very nature they do not 
adequately represent a functional biological system.  
 
This concern led to the implementation of cell based assays in early preclinical 
protocols, which have subsequently been used to assess toxicity, proliferation, 
activation of signalling pathways and morphological changes (Michelini et al., 
2010). For example, a simple high-throughput procedure that quantifies cell 
death (and therefore potential toxicity) is the terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay which accurately measures 
cell culture apoptosis by labelling the terminal end of nucleic acids to determine 
DNA fragmentation (Kasagi et al., 1994). As well as modelling toxicity, studies 
have shown that primary human cell systems can be manufactured to closely 
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represent a number of different disease states (Bhadriraju and Chen, 2002; 
Butcher, 2005). In addition, these prospective assays can be automated in 96 or 
384 well plates, and are therefore easily amenable to HTS (it was estimated that 
approximately 500 compounds a week can be tested in a fully automated 
system (Butcher, 2005)). Hence cell-based assays can be used as a screening 
tool to search for potential drug compounds at a previously unprecedented rate 
in a model that can replicate an extensive range of disease states (Michelini et 
al., 2010). They can also equally be used from a toxicological perspective to 
identify compounds that might also exacerbate or trigger a disease or condition. 
However, cell based assays are limited in a number of ways. For example, 
despite the wide variety of disease modelling cell lines available, this list is by no 
means comprehensive. The primary issue with all cell based assays however is 
that they are still inadequate as a model of a three dimensional organism. Such 
assays in practice are two dimensional and therefore cannot mimic the known 
complicated matrix of signals that comprise a three dimensional organ tissue. 
Similarly, cell based assays cannot replicate whole body or multiple tissue 
disease states that require a complete animal system, such as abnormal 
hormone regulation and neuronal disorders (Butcher, 2005). Despite these 
issues, cell based screening has an important place in early preclinical 
prediction of in vivo toxicity and represents an economical high-throughput 
option for initial compound screening.  
 
1.2.2 In vivo assays for drug development  
 
Many of the benefits ascribed to cell based assays arise because experimentally 
they are infeasible in more traditional animal models such as Rattus norvegicus 
(rats), mus musculus (mice), Canis lupus (dogs), sus scrota (pigs) and non-
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human primates (Hornberg et al., 2013). Such animal models are expensive, far 
from high-throughput and therefore restricted to late stage preclinical testing 
despite their in vivo relevance (Zbinden, 1991). This is unfortunate as such 
species are evolutionary the closest (easily available) experimental animal 
models of the human system. Invertebrate animal models (such as the classic 
nematode worm and Drosphila) can easily be incorporated into screening 
assays, but their protein divergence from humans results in a high rate of false 
negatives making them unsuitable despite their practical advantages (Segalat, 
2007). Zebrafish and X. laevis have proven themselves to be highly amenable 
to HTS (Peterson et al., 2000; Taylor et al., 2010; Tomlinson et al., 2005; 
Tomlinson et al., 2009a; White et al., 2011). Both also have also been used for 
toxicity testing, in particular X. laevis, which has a long history of use in the 
identification of toxic compounds.    
 
1.2.3 X. laevis as a toxicity assay 
 
X. laevis has historically been used as a toxicity assay for three decades. The 
‘Frog Embryo Teratogenesis Assay – Xenopus’ (FETAX) assay was originally 
developed by Dumont et al., (1983) and this protocol has been the basis of 
thousands of toxicity assays to date (Dumont, 1983). The majority of these 
experiments have focused upon using the FETAX assay as a model for 
environmental toxicity, using X. laevis as a surrogate model for other 
amphibians. This once again is due to the practical advantages of utilising the X. 
laevis model (such as year round fecundity and ease of husbandry), which 
would be extremely difficult if not impossible with other native amphibians.   
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The FETAX assay is a straightforward toxicity screen. Blastula (stage 12) 
embryos are subjected to compounds at varying concentrations (alongside 
appropriate negative, positive and vehicle controls) for 96 hours, subsequently 
fixed and observed using a light microscope for any overt signs of toxicity 
(Davies, 1995). The endpoint of the experiment is normally dependant on the 
hypothesis, but can include and is not limited to: mortality and malformation 
(Mouche et al., 2011), developmental stage, head-to-tail length (Hoke and 
Ankley, 2005), motility (behaviour), pigmentation (Dumont, 1983), malformations 
of the major organs (such as the gut, eyes and brain), and so on.  Other 
endpoints could also include chromosomal damage or RNA, DNA, protein 
synthesis and enzyme levels (Davies, 1995).  
 
The FETAX assay has great scope as a toxicity assay but is not without its 
caveats. The X. laevis model has been noted as being somewhat insensitive 
compared to other aquatic models (such as other amphibians, daphnia rosea, 
salmon, rainbow trout, etc.).  A study by Hoke and Ankley (2005) showed that 
these species when subjected to the same compound concentrations as X. 
laevis are less tolerant and therefore perhaps better environmental markers 
(Hoke and Ankley, 2005). This study however was primarily focused upon X. 
laevis as an environmental marker of toxicity and also only used lethality as an 
endpoint. This by no means discounts the FETAX assay as a viable 
pharmaceutical toxicity assay and instead suggests that species native to the 
environment containing the contaminant may be more viable models for 
environmental toxicity testing.  
 
One specific aim of this project is to develop a novel toxicity assay that would 
improve the development of compounds within a pharmaceutical pipeline. This 
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would ideally identify toxic compounds sooner and therefore permit them to be 
disregarded quicker, allowing resources to be spent on stronger candidates. The 
goal was to produce an in vivo, medium throughput, vertebrate toxicity assay 
using the X. laevis model that either meets an unmet current demand or 
improves upon an assay that is currently in place. The belief is that such an 
assay would begin to bridge the gap between preclinical in vitro and subsequent 
in vivo toxicity screening. This is important, as in vivo screening is extremely 
costly and relatively slow.  Previous chemical genetic screening in our laboratory 
has already shown that the X. laevis model is highly amenable to such a 
screening platform, whereby many compounds could be tested in quick 
succession (Tomlinson et al., 2005; Tomlinson et al., 2009a; White et al., 2011). 
The strong history of the FETAX assay is also evidence that X. laevis can 
successfully be used as a model for toxicity (albeit so far only primarily in an 
environmental context), utilising many different endpoints.  
 
It is important to note that, as mentioned above, if this assay is to be industrially 
relevant it must either meet an unmet demand or improve upon assays that are 
already in place. In collaboration with our part sponsors AstraZeneca we 
considered several suggestions for toxicity end points that were thought to be 
‘desirable’ (assuming my assay could determine them in an efficient and 
efficacious manner). These suggested toxicity end points included liver toxicity, 
structural cardio toxins, macrophage infiltration and finally renal toxicity. After 
searching the relevant literature coupled with preliminary assays I decided to 
focus on developing a X. laevis renal toxicity assay.  
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1.2.4 Renal toxicity 
 
Renal toxicity is a serious concern in the pharmaceutical industry, being 
responsible for 7% of preclinical compound failures (Desrochers et al., 2013; 
Fuchs and Hewitt, 2011). In addition, 30-50% of reported kidney failure in 
patients is due to adverse drug reactions (Desrochers et al., 2013; Fuchs and 
Hewitt, 2011; Pannu and Nadim, 2008). Clearly nephrotoxicity is a serious 
concern that has yet to be fully addressed using the current technology available 
(Desrochers et al., 2013).  Despite being less the 1% of the our total body 
weight, the kidney receives 20-25% of our total cardiac output making it highly 
susceptible to blood borne toxicants (such as drugs) due to overwhelming 
exposure (Choudhury and Ahmed, 2006). Given that the kidney is a specialised 
filtration organ, it also rapidly concentrates compounds to levels that were 
previously non-toxic when diluted by the blood. Proximal tubule deterioration is 
commonly associated with nephrotoxicity because it is the first section of the 
nephron to come into contact with the toxic filtrate (Lash, 2009). Furthermore, 
the kidney expresses many of the enzymes that are associated with toxic 
bioactvation of compounds more commonly associated with liver toxicity (such 
as members of the cytochrome P450 or glutathione families) (Lash, 2009). All of 
these factors contribute to a high level of nephrotoxicity during drug 
development. 
 
Nephrotoxicity can be broken down into two subtypes; acute renal failure and 
chronic renal failure. Acute renal failure occurs rapidly following toxicant 
exposure and can manifest itself through numerous mechanisms. For example, 
hypofiltration or hypoperfusion is a result of renal vasoconstriction or glomerular 
injury. Acute nebular necrosis arises from direct tubular injury and in some 
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cases intratubular obstruction causes rapid determination of renal function 
(Lash, 2009). Chronic renal failure arises gradually over time through prolonged 
low level toxicant exposure and can result in chronic tubuloinstitial fibrosis 
through immunological or inflammatory reactions, or papillary necrosis through 
chronic ischemia or cell injury (Lash, 2009). Whilst this list is by no means 
exhaustive it gives an insight into the many specific ways in which nephrotoxicity 
can manifest. 
 
1.2.5 Current in vivo and in vitro models of nephrotoxicity 
 
In an attempt to assess potential renal toxicity in prospective compounds a 
number of preclinical in vitro and in vivo assays have been generated. In vivo 
assays have a number of advantages over in vitro assays, the most obvious and 
important of which being that they represent a fully functioning organism and 
therefore are far more representative of human physiology. One typical in vivo 
assay for example is to observe the glomerular filtration rate (GFR) as a 
measure of renal function (National Kidney, 2002; Stevens et al., 2006). The 
GFR can be defined as the volume of blood removed substance per unit of time. 
One common indirect measure of the GFR is to observe creatinine 
concentration in the blood. Creatinine in normal healthy animals (including 
humans) is produced at a constant rate and it is excreted continually. Abnormal 
creatinine concentrations in the blood and/or urine would therefore imply 
abnormal renal function (National Kidney, 2002; Stevens et al., 2006). One 
significant limitation with this assay is its relative insensitivity whereby extensive 
damage often occurs before creatinine levels change at which point irreparable 
damage may have occurred (National Kidney, 2002). Other common in vivo 
assessments of renal function often included detection of abnormalities present 
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within the urine such as osmolality and overall volume, which are indicative of a 
disruption to normal fluid homeostasis. Other potential indicators in the urine 
that may signify abnormal renal function include acid/base balance, solute 
concentration and the presence of proteins/enzymes (Waring and Moonie, 
2011). 
 
The classic limitations associated with in vivo assays are their high expense and 
relatively low throughput when compared to in vitro capabilities (Zbinden, 1991). 
In an attempt to address this, a number of in vitro assays have been generated 
to increase the throughput of drug development whilst rapidly identifying 
potentially nephrotoxic compounds (Desrochers et al., 2013; Lash, 2009) 
(summarised in Table 2). 
 
A large number of in vitro assays have been generated which range greatly in 
complexity. The use of isolated perfused kidneys for example represent the best 
in vitro model available that can closely replicate in vivo conditions. Naturally 
however, this is an expensive and low throughput procedure when compared to 
primary and immortalised cell culture screening, which sacrifices in vivo 
relevance for high throughput potential. Both of these assays have relevance in 
the prediction of nephrotoxicity and their individual application is determined by 
the situation at hand. For example earlier in preclinical screening when 
significantly more compounds are being explored the high throughput capacity 
of cell based assays takes precedent over their respective lack of in vivo 
relevance. Later in preclinical testing when only a relatively few number of   
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Table 2. Advantages and disadvantages of in vitro assays used in the 
detection of renal toxicity 
 
In vitro assay Advantages Disadvantages 
Isolated 
perfused 
kidney 
- Highly representative of in 
vivo system 
- <2 hours viability 
 
- Limited amount of repeated 
use per sample 
 
- Incomplete structure 
 
- Expensive and low 
throughput 
Renal slices 
- Simple 
 
- Intact structure 
 
- High throughput 
- <2 hours viability 
 
- Lumen can collapse 
 
- Poor oxygenation can 
result in death of section 
Isolated 
perfused 
tubules 
- Intact tubules 
 
- Can determine site of action 
in tubules 
 
- Possible to quantitate viability 
- <2 hours viability 
 
- Can be difficult to isolate 
and set up 
Renal cell 
suspensions 
- Simple 
 
- High throughput 
- <4 hours viability 
 
- Loss of cell polarisation 
 
- Loss of extracellular 
transport mechanisms 
Primary cell 
lines 
- Similar to in vivo 
 
- Maintains cell polarity 
 
- Long time viability 
- Easily contaminated with 
other cell types 
 
- Dedifferentiation can occur 
 
- Tricky to maintain 
Renal cell 
cultures 
- Standardised protocol 
improves reproducibility 
 
- Immortalised 
 
- Easy to transfect and 
genetically manipulate 
 
- Simple to use 
- Dedifferentiation can occur 
 
- Can have an ill-defined 
origin 
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prospective compounds are remaining (but accurate prediction of 
nephrotoxicity is essential prior to in vivo screening), the isolated 
perfused kidney assay is more appropriate with its high relevance to an in 
vivo system (despite its low throughput capacity). 
 
1.2.6 The human kidney 
 
Mammalian kidneys are bilateral organs whose primary role is to regulate the 
composition and volume of bodily fluids, and remove metabolic waste products 
from the blood by filtration. All vertebrate kidney development undergoes three 
phases, starting as a pronephros, progressing into a mesonephros and finally 
the metanephros (a fully developed adult kidney) (Vize, 2003). Each phase 
increases in complexity in both the number and organisation of the nephrons. 
The pronephros is non-functioning in higher vertebrates and consists of a 6-10 
pairs of tubules in humans. These tubules lead into a pair of primary ducts that 
extend caudally into the cloaca. The structure completely disappears by the 
fourth week of human development to be replaced by the mesonephros. The 
mesonephros consists of mesonephric tubules derived from the mesoderm and 
is the primary excretory organ in the first 4-8 weeks of human development. 
Towards week 8, the structure degenerates and is replaced by the metanephros 
which begins developing at week 5. The metanephros is the permanent higher 
vertebrate kidney and is also derived from the intermediate mesoderm. The 
human metanephros is distinct from its previous incarnations in that it contains a 
much larger number of nephrons (around 300 million), and contains an 
extensively branched duct system (Vize, 2003).  
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Each nephron consists of a glomerulus (also known as the Bowman’s capsule) 
that is connected to a tubule, which is in turn connected to a collecting duct 
(Figure 10). The glomerulus is the first stage in the filtration process and is 
comprised of a capillary tuft surrounded by a group of specialised epithelial cells 
known as podocytes. The glomerulus is responsible for blood ultrafiltration in 
which podocytes play a critical role (Vize, 2003). 
 
The purpose of the tubule is to enable reabsorption of metabolically useful 
solutes as well as reuptake of water. The tubule can be divided into three 
segments known as the proximal, intermediate and distal tubule. Each tubule 
partition is unique unto each other in that they contain distinct cellular 
morphologies and express unique solute transporters (Vize, 2003).    
  
 
Figure 10. Schematic of the nephron.  
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1.2.7 X. laevis renal development and function 
 
As mentioned previously, the higher vertebrate kidney has three separate 
phases of development in which three structures are formed in sequence, with 
the preceding structure being superseded by the next (the pronephros to the 
mesonephros to finally the metanephros). In higher vertebrates the pronephros 
is non-functioning and is considered to be a vestigial organ (Vize, 2003). In X. 
laevis however the pronephros acts as a functioning organ from 6 days post 
fertilisation and is critical in maintaining blood solute levels (Jones, 2005). X. 
laevis, like most aquatic organisms, passively absorb water through their skin 
via their environment; thereby blood osmolality is an important concern even at 
early stages in development. The early X. laevis pronephros functions as any 
vertebrate kidney would by filtering and actively reabsorbing solutes to maintain 
acceptable blood solute levels and prevent ion depletion. The X. laevis 
pronephros is a relatively simple paired organ (with respect to the 
metanephros), in that it consists of only three major components: the glomus, 
the tubules and the duct. It is in essence, a single functioning nephron.  
 
In early development the mesodermally derived pronephros is formed between 
the lateral plate and the paraxial mesoderm ventral to somites three and five 
(Jones, 2005; Vize, 2003). The nephritic field is quickly established and final 
patterning occurs by stage 26 (tail bud) of development (Jones, 2005). At this 
point the specific structures of the pronephros begin to arise, with the glomus 
becoming distinct from the tubules and the duct and the intermediate mesoderm 
being separated into the somatic and splanchnic mesoderm via the formation of 
the coelom (Jones, 2005; Vize, 2003). By Stage 30, the lumen of the nephrons 
has formed and the pronephros is fully functional by stage 38 (Jones, 2005).  
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Blood is filtered via the glomus, entering the coelomic space and subsequently 
the nephron via the nephrostomes (ciliated funnels which push the urine into the 
tubules). The tubules actively reuptake salts by creating an electrochemical 
gradient by using a number of different transporters to efficiently reabsorb useful 
solutes.  
 
Despite the simplicity of the pronephros compared to the adult metanephros 
their primary function is analogous, making it an excellent model of renal 
development and also potentially renal function. 
 
1.2.8 X. laevis and human differences in nitrogen excretion 
 
Whilst the X. laevis renal system has many similarities to humans, one key 
difference is the primary urinary product. X. laevis being aquatic organisms 
excrete ammonia as opposed to urea in the case of terrestrial animals such as 
humans. Both products are essential in the removal of excess nitrogen, which is 
highly toxic if not disposed of effectively. 
 
Ammonia in animals is produced by dietary amino acids broken down by gut 
bacteria as well as the catabolism of amino acids, nucleic acids, and amines 
(etc.) in peripheral tissues. Ammonia in most tetrapod’s is highly toxic, and so 
the majority produced is rapidly converted into urea. Evolution has led to the 
synthesis of three different dominant nitrogen products in the pursuit of efficient 
nitrogen excretion in animals in the form of ammonia, urea and uric acid (Figure 
11).  
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The nitrogen product produced is dependent upon the environment in which the 
organism inhabits, the deciding factor commonly hinging on the organisms 
requirement for water retention. For example, most aquatic animals such as 
teleost fish, aquatic invertebrates and larval amphibians excrete ammonia 
(Wright, 1995). This is primarily due to the high solubility of ammonia allowing 
for easy excretion into the surrounding media, with some animals capable of 
excreting some ammonia passively through the skin as well as via the kidney 
(Cruz et al., 2013). Aquatic animals have subsequently evolved a much higher 
tolerance to ammonia blood levels then terrestrial animals (Wright, 1995). For 
example teleost fish are capable of tolerating between 0.05mM - 1mM ammonia 
plasma concentrations (Wright, 1995) when compared to most mammals, which 
exhibit central nervous damage at plasma concentrations as low as 0.05mM 
(Meijer et al., 1990). The ability to excrete ammonia easily into their environment 
is unique to aquatic animals, as due to its high solubility 1mg of ammonia 
requires 400ml of water to maintain ammonia below toxic levels. In contrast, 
urea excretion requires 10 times less water than ammonia excretion and uric 
acid excretion requires 50 times less water (Wright, 1995). This is significant for 
terrestrial animals that are far more dependent upon efficient water retention 
then their aquatic counterparts. It is for this reason that terrestrial animals  
 
Figure 11. Common forms of ammonia excretory products. A. Ammonia. B. 
Urea. C. Uric acid. (Wright, 1995) 
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convert ammonia to either urea or uric acid despite the respective increase in 
metabolic cost.  
 
X. laevis, despite technically belonging to a family of amphibians, only excrete 
ammonia. This is almost certainly due to a critical time point in their evolution in 
which X. laevis moved back to being wholly aquatic organisms, never venturing 
onto land (Balinsky, 1961; Underhay, 1955). This would explain why the primary 
X. laevis urinary metabolite is ammonia; whereas other closely related species 
of truly amphibious frogs in their adult form produce urea (Underhay, 1955). It is 
interesting that X. laevis retain the ability to produce urea but do so only in times 
of drought when water is scarce. This is presumably a defensive response in an 
attempt to preserve water under stressful environmental conditions (Balinsky, 
1961; Underhay, 1955). 
   
1.2.9 X. laevis as a model of renal function 
 
Whilst most nephrotoxicity typically concerns the adult metanephros, there is still 
great benefit to be had in studying the nephrotoxic effects of compounds on the 
X. laevis embryo pronephros. X. laevis have successfully been used to model 
kidney development and interrogate the complex developmental mechanisms 
that govern it (Jones, 2005). For example using the animal cap assay (where 
mesodermal cells are dissected from a blastula stage embryo), it is possible to 
differentiate mesodermal cells into pronephric tubules when treated with the 
growth factor activin and retinoic acid (Moriya, 1993). It is now also possible to 
differentiate these cells into the pronephric glomus and duct (Brennan et al., 
1999; Osafune et al., 2002). Such assays have been used to identify the exact 
time at which parts of the pronephros are formed (Seufert et al., 1999). 
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Morpholino  knock down experiments have also been used to identify a number 
of genes critical in pronephros development (Jones, 2005). Such interrogation of 
early kidney development is extremely difficult in other vertebrate amniotes and 
exemplifies X. laevis as an excellent model of early kidney development. Renal 
function as opposed to renal development however, is an area that has yet to be 
explored in X. laevis.  
 
1.2.10 Summary 
 
There is currently no literature in which renal function in X. laevis has been cited 
as a predictor for nephrotoxicity. This niche combined with the described 
advantages of using the X. laevis model suggest the proposed assay (if 
successfully developed) has the potential to be of significant benefit to the drug 
discovery process. It is known that the X. laevis pronephros is functional from as 
early as stage 38, actively excreting ammonia into the surrounding media. Using 
a simple biochemical assay we believe that it may be possible to quantify the 
amount of ammonia excreted into the media as an indirect measure of active 
renal function. Our hypothesis is that any nephrotoxic compounds introduced 
into the X. laevis system could result in a significant change in the amount of 
ammonia excreted thereby indicating abnormal renal function as a result of 
nephrotoxicity. 
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1.3 Thesis aims 
 
The primary goal of this thesis is to assess the applicability of X. laevis as a 
model for drug discovery and development (Summarised in Figure 1). The 
secondary aim of this thesis is to assess the value of X. laevis towards drug 
development in the form of a novel toxicity assay for the early preclinical 
assessment of renal toxicity. In collaboration with our part sponsors 
AstraZeneca, I have attempted to design a novel preclinical toxicity assay for the 
detection of renal toxicity. Using simple biochemical assays (utilising the salicylic 
acid and glutamate dehydrogenase assay methods of ammonia detection), I go 
on to show that it is possible to detect excreted ammonia in the X. laevis media. 
The assay however may not be sensitive enough to detect changes in renal 
function as an indicator of nephrotoxicity. Further refinement of the assay may 
lead to increased sensitivity. In summary, this thesis shows the potential of the 
X. laevis animal model across all phases of preclinical development towards 
drug discovery and development as a high throughput, high content, vertebrate 
screening model organism. 
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Chapter II 
2.0 Materials and Methods  
Table 3. List of reagents 
 
Reagents Supplier details 
L15  Sigma L5520 
Gentamycin sulphate Sigma G1397. 
 
Bovine serum albumin  Fisher Scientific BPE9703-100. 
Ethyl 3-aminobenzoate 
methane sulfonate  Sigma A5040-25G. 
Human Chorionic 
gonadotropin (HCG)  www.animeddirect.co.uk 804745. 
Pregnant mare serum 
gonadotrophin (PMSG)  
www.animeddirect.co.uk 859448. 
Poly-L-Lysine  Sigma P4832 
Cytochalasin D  Sigma C8273 
Penicillin Streptomycin 
(Pen Strep)  
Gibco 15070-063 
L-Glutamine  Gibco 25030-024 
0.25% Trypsin-EDTA (1X)  Gibco 25200-072 
Trypan blue solution  Fluka 93595 
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Dimethyl sulphoxide 
(DMSO) Hybri-Max  
Sigma D2650 
RPMI – 1640 Medium (1X)  Hyclone SH30096.01 
DMEM + GlutaMAX  
Gibco 21885-025 
CellTitre-glo Luminescent 
Cell Viability assay  
Promega G7572 
JBL NH4 Test  
JBL www.JBL.de 
Tetra Test NH3 / NH4  
Tetra www.miscota.co.uk 
API Ammonia Test Kit  
API www.apifishcare.co.uk 
Glutamate dehydrogenase 
(GDH) activity assay   
Sigma AA0100 
 
Table 4. List of solutions 
Solutions Formulation 
BSA solution 1% BSA in 1XMMR. 
1XMMR 100mM NaCl, 2mM KCL, 1mM MgCl2, 2mM CaCl2, 5mM 
HEPES. 
0.1XMMR 
 
10mM NaCl, 0.2mM KCL, 0.1mM MgCl2, 0.2mM CaCl2, 
0.5mM HEPES. 
0.05XMMR 
 
5mM NaCl, 0.1mM KCL, 0.05mM MgCl2, 0.1mM CaCl2, 
0.25mM HEPES. 
HCG 100U/ml  HCG was prepared in PBS and stored at 4oC. 
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Table 5. List of equipment used 
 
 
 
 
 
 
 
 
PMSG 
1000U/ml  
PMSG was prepared in PBS and stored at 4oC. 
X. laevis testis 
buffer 
 
80% fetal calf serum, 20% 1XMMR. 
X. tropicalis 
testis buffer  
 
L15 with 10% FBS. 
A375 media 
 
RPMI – 1640 Medium (1X) supplemented with 10%  FBS, 1% 
Pen strep and 1% L-Glutamate. 
HEK293 media 
DMEM + GlutaMAX supplemented with 10% FBS, 1% Pen 
Strep and 1% L-Glutamate. 
RD1 media 
 
DMEM + GlutaMAX supplemented with 10% FBS and 1% 
Pen Strep, 
Ammonia 
assay 
standards 
All solutions were prepared using 0.1 X MMR buffered with 
10mM TRIS 
 
Equipment Supplier 
Plate reader  
 
BMG LabTech Omega Series (Data 
analysed using OMEGA software) 
Spectrophotometer  
 
Biochrom WPA Biowave II 
UV/Visible Spectrophotometer 
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2.1 Generation of Xenopus laevis and Xenopus tropicalis embryos  
 
X. laevis and X. tropicalis adult frogs were kept at 18oC and 25oC in 40 litre and 
20 litre tanks (maximum of 15 frogs per tank) respectively, with 12:12 hour 
light:dark cycles.  
 
All experiments involving X. laevis and X. tropicalis were in compliance with the 
relevant laws and guidelines installed by the UEA. This research has been 
approved by an ethical review board in accordance with UK Home Office 
regulations under the project license number PPL 80/2499. X. laevis embryos 
were generated and staged according to Nieuwkoop and Faber (Nieuwkoop, 
1956).  
 
2.1.1 X. laevis egg generation and in vitro fertilisation 
 
2.1.1.1 Testes isolation 
 
A live X. laevis male was isolated and immersed in 0.5g of 1.6% ethyl 3-
aminobenzoate methane sulfonate dissolved in 300ml reverse osmosis water in 
a 500ml beaker. The beaker was wrapped in tin foil and placed in the dark at 
4oC for one hour. The testes were surgically removed and stored in X. laevis 
testes buffer at 4oC, remaining viable for a maximum of 1 week. The carcass 
was disposed of via incineration.   
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2.1.1.2 X. laevis egg generation and in vitro fertilization  
 
Female frogs were primed 4 days prior to the experiment by injecting 100U 
PMSG into one pericardial sac in an isolated priming tank. The female X. laevis 
were not fed and were isolated until the day of the experiment. 14 hours prior to 
the experiment pre-primed female X. laevis were induced with 500U human 
chorionic gonadotrophin (HCG) by injecting 250U into each pericardial sac and 
left overnight at RT. The following day X. laevis eggs were collected by gently 
squeezing the animals with a massaging action ensuring eggs were deposited 
into a 25ml Petri dish. Excess water was removed from the Petri dish prior to 
fertilization. In vitro fertilization was achieved when the pre-prepared male testes 
were finely sliced using a razor blade to produce a thin slice that could be 
rubbed over the eggs. The testis section was then placed in a 2ml Eppendorf 
tube containing 1ml of 1XMMR and macerated. The resulting solution was 
deposited over the embryos using a 3ml Pasteur pipette and left for five 
minutes. The embryos were then flooded with 0.1XMMR and left for 20 minutes. 
Eggs can be collected in this manner a total of 6 times in one day, with a 
minimum of one hour between each squeeze. 
 
2.1.1.3 Embryo dejellying   
 
Immediately following in vitro fertilization the 0.1XMMR solution was removed 
from the embryos and replaced with 2% cysteine dissolved in 1XMMR. The 
embryos were left for 7 minutes and were subjected to occasional manual 
swirling until they could be seen to visibly touch each other. The embryos were 
then washed twice in 1XMMR, then twice in 0.1XMMR and placed into a BSA 
pre-coated 140mm Petri dish in 0.1XMMR. Embryos were left to develop at the 
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desired incubation temperature and checked regularly to dispose of dead or 
abnormal samples. 
 
2.1.2 X. tropicalis egg generation and in vitro fertilisation 
 
2.1.2.1 Testes isolation 
 
A live X. tropicalis male was isolated and immersed in 0.5g of 1.6% ethyl 3-
aminobenzoate methane sulfonate dissolved in 300ml reverse osmosis water in 
a 500ml beaker. The beaker was wrapped in tin foil and placed in the dark at RT 
for one hour. The testes were surgically removed and stored in X. tropicalis 
testes buffer at 4oC, remaining viable for a maximum of 1 week. The carcass 
was disposed of via incineration.   
 
2.1.2.2 X. tropicalis egg generation and in vitro fertilization  
 
Female frogs were primed 1 to 2 days prior to the experiment by injecting 10U 
HCG into one pericardial sac and placed into an isolated priming tank. The 
female X. tropicalis were not fed until the day of the experiment. Four hours prior 
to the experiment pre-primed female X. tropicalis were induced with 200U HCG 
by injecting into one pericardial sac and incubated at 25oC. Four hours later (or 
when eggs were visible in the tank) X. tropicalis eggs were collected by gently 
squeezing the animals with a massaging action ensuring eggs were deposited 
into a 25ml Petri dish. In vitro fertilization was achieved when the pre-prepared 
male testes was finely sliced using a razor blade to produce a slither that was 
then placed in a 2ml Eppendorf tube containing 1ml of X. tropicalis testes buffer 
and macerated. The resulting solution was deposited over the embryos using a 
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3ml Pasteur pipette and left for five minutes. The embryos were then flooded 
with 0.05XMMR and left for 20 minutes. Unlike with X. laevis, egg collection 
should typically only occur once per frog, per day.  
 
2.1.2.3 Embryo dejellying   
 
140mm petri dishes were pre-coated in BSA solution to prevent the embryos 
from sticking to the plate during their development. Immediately following in vitro 
fertilization the 0.05XMMR solution was removed from the embryos and 
replaced with 2% cysteine dissolved in 1XMMR. The embryos were left for 7 
minutes and were subjected to occasional manual swirling until they could be 
seen to visibly touch each other. The embryos were then washed twice in 
1XMMR, then twice in 0.05XMMR and placed into a BSA pre-coated Petri dish 
in 0.05XMMR. Embryos were left to develop at 25oC and checked regularly to 
dispose of dead or abnormal samples.    
 
2.2 Chemical genetic screening 
 
Imaging equipment and software – Q imaging 01-MP3.3-RTV-CLR-10 camera 
mounted on a Zeiss Stemi 5V6 microscope and processed with the Q capture 
software package. 
 
2.2.1 Determining the optimal screening concentrations 
 
The optimal screening concentrations for chemical genetic screening using X. 
laevis was previously determined in the lab to be 20M and 40M (Tomlinson et 
al., 2005). For consistency these concentrations were also used when screening 
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the X. tropicalis. These concentrations were chosen following a dose response 
screen (1M - 100M) using a range of randomly selected bioactive compounds 
to determine which concentrations ensured a satisfactory discovery rate with low 
overall toxicity (Tomlinson et al., 2005). Two concentrations were chosen to 
account for some compounds being toxic at higher concentrations versus 
compounds whose phenotypes were less pronounced at lower concentrations. 
 
2.2.2 Chemical genetic screen using X. laevis or X. tropicalis 
 
Embryos were grown in a 140mm Petri dish containing 10ml of 0.1XMMR at 
180C until they reached stage 15. Compounds were arrayed into 48 or 96 well 
plates at double the desired final concentration in 500µl or 150µl respectively 
using a 12 channel Rannin multichannel pipette and an 8 well multichannel 
pipette. Embryos were then arrayed via pipette at 10 or 5 embryos per well into 
48 or 96 well plates respectively. Embryos were transferred in 500µl or 150µl of 
0.1XMMR (supplemented with gentamycin sulfate to 50mg/ml) making the final 
volume of each well 1000µl or 300µl in 48 or 96 well plates respectively. Plates 
were sealed using an O2 permeable plate seal. Arrayed X. laevis and X. 
tropicalis embryos were grown at 180C and examined visually with a dissecting 
microscope at 1, 2 and 3 days post fertilisation (approximately stage 25, 32 and 
38 respectively). Embryos were fixed at stage 38 in their respective wells by 
removing as much of the dosing solution as possible using a Pasteur pipette 
and fixed in 1000µl or 200µl of MEMFA in 48 or 96 well plates respectively. After 
2 hours at RT the MEMFA was replaced with PBST (Tomlinson, 2012).  
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2.2.3 Observing embryos 
 
Phenotypes were observed by transferring the desired embryos into a Petri dish 
coated with 2.5ml 1% agarose gel covered with PBS via Pasteur pipette. 
Embryos were observed using a Zeiss Stemi 5V6 microscope. Images were 
captured using a 01-MP3.3-RTV-CLR-10 camera mounted and processed with 
the Q capture software package. All images of embryos are orientated from left 
to right (anterior to posterior). To clarify the terminology used to describe the 
orientation of the X. laevis embryos in images taken, Figure 12 A Displays an 
annotated stage 38 Nieuwkoop and Faber embryo. This also indicates the 
positions of the lateral and dorsal pigmentation stripes that are referred to 
numerous times in this thesis. Also included are example images of a stage 38 
wild type X. laevis embryos, accompanied by two commonly observed 
phenotypes in the form of total pigmentation loss and abnormal melanophore 
migration (Figure 12 B i, ii and iii). 
 
2.2.4 Embryo Fixation 
 
For long term storage embryos were removed from their wells using a Pasteur 
pipette and transferred to a 5ml glass vial and covered with a PBST/methanol 
(50/50) solution, and left on a rocker for 5 minutes. This wash step was repeated 
once again using PBST/methanol (50/50) solution and finally left in 100% 
methanol. Fixed embryos were stored at 40C. 
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Figure 12. Example of X. laevis embryo image orientation. A. Typical stage 38 X. laevis embryo as defined by (Nieuwkoop, 1956). B. Example 
images of stage 38 X. laevis embryos displaying abnormal pigmentation phenotypes. i. Wild type embryo. ii. Embryo displaying a complete loss 
of pigmentation. iii. Embryo displaying abnormal melanophore morphology phenotype.     …................................................................................
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2.3 Small compounds used  
 
The National Cancer Institute (NCI) Diversity set I and Diversity set II compound 
libraries, plus subsequent individual NCI compounds requested following 
identification during the initial chemical genetic screen, were all sourced from 
the Synthesis and Chemistry Branch, Developmental Therapeutics program, 
Division of Cancer Treatment and Diagnosis, National Cancer Institute, USA. 
The NCI Diversity set I and NCI Diversity set II compound libraries consisted of 
1990 and 1363 compounds respectively and were supplied in a 96 well plate 
10mM (dissolved in DMSO), 100µl per compound, per well format. All additional 
individual compounds were supplied as solids and were dissolved in DMSO to 
make 10mM stocks. 
 
AstraZeneca organ specific toxic compounds were obtained from AstraZeneca, 
Alderley Park, Cheshire, UK. Compounds were obtained in a 96 well plate 
format in 10mM 100µl stock solutions (dissolved in DMSO). Compounds were 
selected and organised based on their specific organ toxicity (nephrotoxicity, 
hepatotoxicity, cardiotoxicity and non-toxic controls). AstraZeneca sourced 
compounds were chosen based on previously published information provided by 
(Lin and Will, 2012). 
 
2.4 Dose response assays 
 
Those compounds which were shown to give a repeatable phenotype were used 
in a dose response assay, Here compounds were added to stage 15 embryos 
(10 embryos per well, 1ml final volume) at either 0.1, 1, 10, 25, 50, 100µM. 
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Embryos were allowed to develop to stage 38 at which point they were fixed in 
MEMFA, and scored for abnormal phenotypes. 
 
2.5 Cell culture assays 
 
2.5.1 Cell lines used 
 
The A375 (BRAF mutant) human melanoma cell line was obtained from the 
Ribas laboratory (University of California, USA). The RD1 human 
rhabdomyosarcoma line and the HEK293 Human epithelial kidney cell line were 
both obtained from the Biomedical Research Centre (University of East Anglia, 
UK). All cell lines were first used at passage 2 and finished with at passage 21. 
All cell lines were incubated at 38oC, 95% humidity and 5% CO2 and were 
routinely tested for mycoplasma.  
 
2.5.2 Cell viability assays 
 
The Cell Titre Glo® (Promega) assay was used to determine cell viability in the 
cell lines used. First costar 96 well plates (Corning incorporated) were coated 
with poly-L-lysine (Sigma)  (40µl per well) to aid cells in sticking to the plate. 
After rocking at RT for one hour poly-L-lysine was removed and cell lines were 
seeded into wells. A375, RD1 and HEK293 cell lines were seeded at 2000, 7500 
and 15000 cells per well respectively in 100µl culture media. 
 
After 24 hours media was removed from the wells and replaced with fresh media 
plus compounds at the desired concentrations. This also included a positive 
control (100nM Cytochalasin D) and vehicle control (0.1% DMSO). All chosen 
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NCI compounds were prepared as serial dilutions at 1.56, 3.13, 6.25, 12.5, 25, 
50, 75 and 100µM. All concentrations (including controls) for all cell lines were 
run in triplicate within the same plate. Plates were then incubated at 37oC. 
 
On day 5 the plates were removed from the incubator. 50µl of media was 
removed and replaced with 50µl CellTitre-Glo reagent. The plates were left to 
rock at RT for 10 minutes then immediately read using a Plate reader.  
 
Cell viability was calculated using Microsoft Excel software, and was plotted as 
the average fluorescence of the three sample replicates as a percentage of the 
average fluorescence of the three DMSO control replicates found within the 
same plate. IC50’s were generated using Prism Graphpad software and 
calculated using a nonlinear regression model.    
 
2.6 Renal function toxicity assay 
 
2.6.1 Salicylic acid assay detection of ammonia NH3 
 
The salicylic acid method of NH3 detection was the first assay used first for the 
detection of ammonia in sample media. The JBL NH4 Test kit is a commercially 
available assay that rapidly determines the amount of NH4 / NH3 in sample 
media. The kit was used with the protocol provided with some alterations to 
achieve a higher throughput format. Embryos were grown from stage 38-45 in a 
96 deep well plate (five embryos per well, 2ml final volume, without experimental 
compounds). At stage 45, 1ml of media was removed from each well and placed 
in a fresh cuvette. Wells were only sampled once each as by removing media 
the final volume of the well would be changed, thereby altering the potential 
75 
 
 
concentration of ammonia present when sampling again at a later date. The 
assay protocol stipulates that 1ml of each sample is required per reaction. To 
this solution 33µl of JBL solution one, two and three (supplied with the assay kit) 
were added in sequence and mixed via inversion (with a 5 minute gap between 
each addition). Each sample was then left for 5 minutes at which point 300µl of 
each reaction solution was transferred to a 96 well plate and absorbance was 
subsequently read on a spectrophotometer at 695nm. A blank (media containing 
no embryos) was used as a negative control. 
 
Experiments involving compounds followed the same assay protocol, but with a 
different dosing regimen. Embryos were incubated with compounds at the 
desired concentration from embryonic stage 38 to stage 41 (roughly three days) 
at 18oC, at which point the compound was removed and fresh media added. 
Embryos were then incubated until they reached embryonic stage 45 (roughly 
another 3 days) at 18oC, at which point their media was sampled according to 
above protocol. The reason for this dosing regime is that it was unclear whether 
the compound would have an immediate effect, therefore residual excreted 
ammonia may be present in the media when read at day 45 despite recent 
nephrotoxicity and thereby bias results. To avoid this, compounds were dosed 
for a period of time and then removed with fresh media added to effectively 
standardise the base level of ammonia present. This ensures that that ammonia 
concentrations detected reflect the effect of the compound after its potential 
effects have taken place. 
 
The Tetra NH4  Ammonia assay was used in exactly the same way as the JBL 
kit. The API NH4 Ammonia assay contained two solutions instead of three, 
however the amount of each solution added remained the same. 
76 
 
 
 
It was not possible to continue to assess ammonia excretion in X. laevis 
embryos past embryonic stage 45. This is because UK law considers X. laevis 
embryos to be sentient past embryonic stage 45, requiring additional licensing 
not covered by our current agreement. It would significantly complicate the 
development of the assay if it were to progress past embryonic stage 45 due to 
the necessary government licensing involved and therefore any assay 
developed has to be sampled prior to this cut off. 
 
2.6.2 Glutamate dehydrogenase assay detection of ammonia NH3 
 
The GDH assay protocol provided was used exactly as instructed in the 
provided protocol (including compound dosing regimens. 1000µl of the ammonia 
assay reagent was added to a cuvette followed by 100µl of sample media. A 
blank sample was also run alongside the test sample by adding 100µl H2O to 
1000µl of the ammonia assay reagent.  The solution was inverted and incubated 
at RT for 5 minutes. The spectrophotometer was blanked using water as a 
reference. The absorbance of the solution was then read at 340nm.10µl of L-
glutamate dehydrogenase was then added to the solution which was inverted 
and then incubated at RT for 5 minutes. The solutions absorbance was then 
read every minute until it ceased decreasing. Using this data, the ΔA340 was 
calculated to determine the change in absorbance following the addition of the 
L-glutamate dehydrogenase enzyme. As the reaction is driven by the presence 
of ammonia, the larger the ΔA
340
, the more ammonia present in the sample. A 
blank ΔA340 was then subtracted from the sample ΔA340 to generate the sample 
Δ(ΔA340) so as to account for background levels of ammonia that may be 
present in the media. 
77 
 
 
 
 
 
 
 
 
2.7 Chemoinformatical prediction of compound targets 
 
All chemoinformatical analysis was performed by the Bender laboratory. For the 
full method of this analysis see (Liggi, 2013). The significant stages of the 
protocol are summarised below. 
 
2.7.1 Chemoinformatical analysis of compounds identified from the NCI 
Diversity set II chemical genetic screen 
 
The aim of this experiment was to predict targets for those 72 compounds 
identified to give abnormal phenotypes in the X. laevis chemical genetic screen 
by using both the chemical structures of the compounds and the specific 
phenotypic class to which they were allotted (based on the phenotype they 
gave).  
 
First the 72 identified compounds 2D structures were subjected to a pipeline 
(KNIME workflow) in which they were standardised (according to pre-set 
parameters) for consistency. Molprint 2D fingerprints (depth 3) were then 
generated and target prediction was run using the ChEMBL v10 training set 
(approximately 155,000 ligand pair covering 894 targets). A Laplacian-modified 
naïve Bayes classifier then calculated the relative class membership 
ΔA340 = 
= A
initial 
- A
Final
 
Δ(ΔA340) = 
     = ΔA340(Test or Standard) - ΔA340(Blank) 
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probabilities for each compound and returned a ranked list of targets with 
scores. Several visualisation/clustering methods were then employed (Multi-
Dimensional Scaling, network distance from k-nearest neighbour and 
hierarchical clustering) using Orange Canvas to assess bioactivity profile 
similarity amongst the different phenotypes. Inductive rules and classification 
trees (limited to depth = 5) were then generated to establish the best data splits 
for explaining each compounds relationship with its observed phenotype. Finally 
predicted targets were subjected to enrichment calculations in order to derive as 
much information as possible. 
 
2.8 Statistical analysis 
 
All statistical tests were carried out using Graph Pad Prism 6 software. Suitable 
statistical tests were chosen for each data set to suit the type of data analysed. 
Tests used in this thesis include Students T-test and IC50 generation. 
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Chapter III 
 
3.0 Xenopus laevis and Xenopus tropicalis as reliable 
models for chemical genetic screening 
 
3.1 Introduction 
 
3.1.1 Assessment of X. laevis chemical genetic screening reliability  
 
Previous research has already highlighted X. laevis as a robust model for 
chemical genetic screening capable of assessing a variety of end points 
(discussed in Chapter I) (Dush et al., 2011; Kalin et al., 2009; Tomlinson et al., 
2009a; Tomlinson et al., 2009b; White et al., 2011). The primary aim of this 
thesis was to further assess the role of X. laevis as a chemical genetic 
screening model for drug discovery. It is appropriate to first assess the models 
reproducibility in such screens. The original Wheeler laboratory NCI diversity set 
I compound screen was amongst the first of its kind to assess the application of 
X. laevis towards chemical genetic screening (Brandli, 2004; Kalin et al., 2009; 
Tomlinson et al., 2005; Tomlinson et al., 2009b). It was successful in identifying 
35 compounds that gave rise to a range of phenotypes (summarised in Figure 
13 A). I aimed to assess the reproducibility of the X. laevis chemical genetic 
assay by rescreening each of the 35 original hit compounds and observing if a 
similar phenotype was elicited. To achieve this, fresh compound stocks were 
ordered for each compound from the National Cancer Institute (USA), and were 
prepared, screened and analysed using exactly the same method as described 
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Figure 13. Phenotypic categories scored in the original Tomlinson et al., (2009) chemical genetic screen. A. Pie chart depicting the proportion 
of positive hits (n=35) in each category. B. Untreated control embryo, insert boxes show the eye (b1) and the melanophores on the lateral 
pigment stripe (b2). Categories include C. pigmentation, D. edema formation, E. melanophore migration, F. eye development (insert box shows 
disrupted eye development, black box shows magnified area f1), G. general development and H. melanophore morphology (insert box shows 
small melanophores on the lateral pigment stripe, h1). Coloured insert boxes relate to the coloured pie chart section. Embryos shown were 
screened at 40µM. Figure taken from (Tomlinson et al., 2009b). 
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in (Tomlinson et al., 2009b). Should a phenotype similar to that previously 
described be observed, this would suggest the X. laevis chemical genetic model 
system is both reliable and robust in its ability to reproduce previous findings, 
further supporting its use as a model for drug discovery and development.  
 
3.1.2 Assessment and comparison of X. tropicalis as a viable chemical 
genetic screening model 
 
One negative towards using X. laevis as a model organism is that its 
paleopolyploidy genome complicates genetic experimentation and analysis. It is 
believed that the X. laevis polyploidy genome arose due to a hybridisation event 
of two parent species approximately 40 million years ago (Evans et al., 2004; 
Hellsten et al., 2007). This resulted in the formation of gene duplicates (known 
as homeologs) resulting in functional redundancy. These gene duplicates may 
retain overlapping functions and redundancies, complicating the generation and 
interpretation of mutant phenotypes.   
 
All living Xenopus species possess a paleopolyploid genome with the exception 
of X. tropicalis, which possess a diploid genome. Retaining all of the practical 
advantages of the closely related species X. laevis (summarised in Table 6), X. 
tropicalis also has the advantage of being far more amenable towards genetic 
experimentation. In addition, X. tropicalis reaches sexual maturity in 
approximately four months whereas X. laevis takes approximately 12 to 24 
months. This is significant as it permits the rapid generation of inbred mutant 
lines, which is comparatively much more difficult when using X. laevis. Such 
advantages explain the prominent rise in popularity of X. tropicalis as an 
experimental model over the past two decades. To date however, little literature  
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Table 6. Differences exhibited between the X. laevis and X. tropicalis animal 
models 
 
 
  X. laevis X. tropicalis 
Ploidy allotetraploid diploid 
Haploid 18 chromosomes 10 chromosomes 
Genome size 3.1 x 109 bp 1.7 x 109 bp 
Optimal temp 16-22°C 25-30°C 
Adult size 10 cm 4-5 cm 
Egg size 1-1.3 mm 0.7-0.8 mm 
Brood size 300-1000 1000-3000 
Generation time 24 months 4 months 
 
 
exists as to whether X. tropicalis is amenable for chemical genetic screening. 
One exception is a study by Fort et al., (2004), who aimed to assess the 
applicability of X. tropicalis as an alternative test species for use in the traditional 
Frog Embryo Tertogenesis assay – Xenopus (FETAX) assay. Results showed 
that X. tropicalis was not only equally amenable towards FETAX screening as X. 
laevis, but also produced similar phenotypes under the same conditions (Fort et 
al., 2004).  
 
Given the clear practical advantages exhibited by the X. tropicalis model, it 
appeared prudent to investigate as to whether it could also be applied to our 
chemical genetic screening system. It was important to assess not only whether 
they were practically amenable towards the existing protocol, but also whether 
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the phenotypes elicited were comparable to those previously identified in X. 
laevis. To determine this I screened the NCI diversity set I hit compounds 
identified in the previous Tomlinson et al., (2005) screen using the same 
protocol described for X. laevis. 
 
3.2 Results 
 
3.2.1 Rescreening of the original NCI diversity set I compound library 
 
Fresh compound stocks for each of the 35 compounds identified in the 
Tomlinson et al., (2005) screen were requested from the NCI repository. Of 
these, six were not obtainable due to lack of availability (as summarised in 
Table 7). To ensure consistency, all compounds were screened following the X. 
laevis chemical genetic screening protocol described in (Tomlinson et al., 
2009b). A representative example of each of the six commonly identified 
phenotypes (pigmentation, melanophore morphology, melanophore migration, 
edema, morphological and eye development phenotypes), identified in the 
original Tomlinson et al., (2009) screen alongside the relative proportion of 
positive hits (n=35) for each phenotypic category are summarised in Figure 13.  
Of the 13 available abnormal pigmentation inducing phenotypic compounds 
rescreened, all reproduced their respective phenotypic effect in X. laevis (Figure 
14). Notably, NCI 30712, NCI 47938, NCI 49762, NCI 62406, NCI 86153, NCI 
99676, NCI 130830 and NCI 132230 (Figure 14 C-G and I-K respectively), 
showed a marked reduced pigmentation in both the lateral and dorsal stripe as 
well as in the head and eye. NCI 7734, NCI 158011 and NCI 164990 (Figure 14 
B, L and M respectively) also showed markedly reduced pigmentation in the 
lateral and dorsal stripe, however the head and eye pigment still remain, albeit it 
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Table 7. Hit compounds identified in the Tomlinson et al., (2005) NCI diversity 
set I chemical genetic screen, accompanied by their identified phenotype, 
molecular weight, formula, and structure. Also shown is their ability to be reliably 
replicated (n=3). E, (Edema phenotype).  ED, (eye development phenotype). M, 
(abnormal morphology phenotype). Mg, (Abnormal melanophore migration 
phenotype). MM, (abnormal melanophore morphology phenotype). P, (abnormal 
pigmentation phenotype).  *** Denotes those compounds for which new stocks 
were not available.  
 
NCI Hit 
Compounds 
Phenotype 
generated 
MW Formula Structure 
Phenotype 
replicated 
4972 P 166 C10H14O2 
 
✓ 
7734 P 216 
C11H17ClO
2 
 
✓ 
10470 E 346 C22H18O4 
 
✓ 
85 
 
 
17173 MM 230 
C8H10N2O4
S 
 
✓ 
22207 Mg 388 C9H4Cl6O4 
 
✓ 
25431 Mg 249 C17H15NO 
 
X 
30712 P 269 C17H19NO2 
 
✓ 
47938 P 345 C22H19NO3 
 
✓ 
62406 P 308 
C12H9ClN4
S2 
 
✓ 
86 
 
 
80126 MM 391 
C20H25NO5
S 
 
✓ 
84093 Mg 320 C23H20N2O 
 
✓ 
86153 P 316 
C15H12N2O
2S2 
 
✓ 
86374 P 493 
C19H15N2O
Se 
 
*** 
90737 M 332 
C19H12N2O
2S 
 
✓ 
95609 MM 1057 
C52H72N12
O8S2 
 
✓ 
99667 P 341 
C13H19N5O
2S2 
 
✓ 
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99676 P 346 
C16H18N4O
S2 
 
✓ 
101984 ED 289 C18H15N3O 
 
✓ 
130830 P 264 C17H16N2O 
 
✓ 
132230 P 434 
C28H22N2O
3 ✓ 
✓ 
143019 ED 214 C5H6N6S2 
 
✓ 
158011 P 309 C18H15NS2 
 
✓ 
164990 P 288 
C15H16N2O
2S 
 
✓ 
88 
 
 
177383 Mg 822 
C43H54N2O
14 
 
*** 
186066 P 386 
C21H26N2O
S2 
 
✓ 
210627 Mg 565 
C32H18Cl2
N2O4 
 
✓ 
227147 MM 513 
C20H38N8N
iS2 
 
✓ 
357777 M 329 C19H15N5O 
 
✓ 
372074 Mg 336 
C19H16N2O
4 
 
✓ 
373070 P 304 
C18H12N2O
3 
 
*** 
375985 ED 249 C16H11NO2 
 
*** 
89 
 
 
609699 MM 458 
C23H24ClN
3O5 
 
*** 
627512 Mg 356 C19H16O7 
 
✓ 
638432 ED 407 
C24H23ClN
2O2 
 
✓ 
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Figure 14. Abnormal pigmentation phenotypes replicated using compounds 
identified from the original Tomlinson NCI diversity set I compound screen. X. 
laevis embryos were assessed at stage 38 and compared to a corresponding 
DMSO vehicle control.  Embryos shown were screened at 40µM. A. DMSO 
solvent control. B. NCI 7734. C. NCI 30712. D. NCI 47938. E. NCI 49762. F. 
NCI 62406. G. NCI 86153. H. NCI 99667. I. NCI 99676. J. NCI 130830. K. NCI 
132230. L. NCI 158011. M. NCI 164990. N. NCI 186066. 
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at a reduced level when compared to the vehicle control. This is in fact still 
consistent with the phenotypes previously presented in the original Tomlinson et 
al., (2009) screen. Both NCI 99667 (11H) and NCI 186066 (11N) showed 
reduced pigmentation, however melanocytes are clearly present in the head, 
eye and lateral / dorsal stripe regions. It would appear in each of these cases 
that the head and eye are unaffected as regards to pigmentation defects 
whereas the lateral and dorsal stripes indicate a reduced number of 
melanocytes that appear to have abnormal rounded morphology when 
compared to the dendritic morphology clearly exhibited in the vehicle control.  
 
All five of the available melanophore morphology phenotype inducing 
compounds reproduced their previously prescribed phenotypic effect to varying 
degrees when compared to the vehicle control (Figure 15). NCI 17173, NCI 
80126, NCI 95609, NCI 227147 and NCI 609699 (Figure 15 B-F respectively), 
all presented melanocytes in the lateral stripe with a rounded morphology that 
was far less dendritic then that displayed in the vehicle controls. NCI 17173 and 
NCI 609699 also showed a reduced number of melanocytes in the lateral and 
dorsal stripe when compared to the vehicle control. NCI 609699 also displayed 
abnormal morphology in the form of an undeveloped tail region when compared 
to the control.  
 
Of the melanophore migration phenotype inducing compounds, all five 
reproduced their previously prescribed phenotypic effect to varying degrees 
when compared to the vehicle control (Figure 16). NCI 22207, NCI 84093, NCI 
210627 and NCI 627512 all presented abnormal melanophore migration 
patterns down either the lateral or dorsal stripe (as highlighted in Figure 16 B-D 
and F respectively). NCI 372074 (Figure 16 E) showed some signs of abnormal 
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Figure 15. Abnormal melanophore morphology phenotypes replicated using compounds identified from the original Tomlinson NCI diversity set 
I compound screen. X. laevis embryos were assessed at stage 38 and compared to a corresponding DMSO vehicle control. Embryos shown 
were screened at 40µM. A. DMSO solvent control. B. NCI 17173. C. NCI 80126. D. NCI 95609. E. NCI 227147. F. NCI 609699 
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Figure 16. Abnormal melanophore migration phenotypes replicated using compounds identified from the original Tomlinson NCI diversity set I 
compound screen. X. laevis embryos were assessed at stage 38 and compared to a corresponding DMSO vehicle control. Embryos shown 
were screened at 40µM. A. DMSO solvent control. B. NCI 22207. C. NCI 84093. D. NCI 210627. E. NCI 372074. F. NCI 627512 
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melanophore migration with melanocytes unusually situated in the dorsal region 
of the lateral stripe, however this was not as prominent as other examples 
identified in the same phenotypic category. I was also able to reproduce the 
previously described edema phenotype (Figure 17 B). Likewise, both of the 
abnormal morphology inducing compounds induced phenotypes similar to that 
described in the original Tomlinson et al., (2009) screen (Figure 18 B and C). 
For example, NCI 90737 presents an elongated trunk phenotype with a 
shortened tail exactly as described previously. Similarly, the enlarged forebrain 
displayed by NCI 357777 was also described in the original screen. 
 
All three of the previously described abnormal eye development inducing 
compounds identified in the original Tomlinson et al., (2009) screen induced 
abnormal eye development when rescreened to varying degrees (Figure 19 B-
D respectively).  NCI 101984 presented a malformed eye in which the size of 
the eye is not reduced when compared to the vehicle control as described in the 
Tomlinson et al., (2009) screen but instead suggests possible abnormal 
development in the retinal pigment epithelial layer. NCI 143019 displays a 
complete loss of eye structure consistent with anophthalmia. The original 
phenotype was described as generating a small eye (microphthalmia) when 
compared to the vehicle control as well as a dislocation of the lens. NCI 638432 
was previously described as having abnormal retinal epithelial layer, as 
indicated by a mottled pigmentation of the eye, which is also present in the 
replicate sample. The size of the eye presented in the replicated phenotype is 
smaller than that of the control, suggesting microphthalmia.
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Figure 17. Abnormal edema phenotype replicated using compounds identified from the original Tomlinson NCI diversity set I compound 
screen. X. laevis embryos were assessed at stage 38 and compared to a corresponding DMSO vehicle control. Embryos shown were screened 
at 40µM. A. DMSO solvent control. B. NCI 10470. 
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Figure 18. Abnormal morphology phenotypes replicated using compounds identified from the original Tomlinson NCI diversity set I compound 
screen. X. laevis embryos were assessed at stage 38 and compared to a corresponding DMSO vehicle control. Embryos shown were screened 
at 40µM. A. DMSO solvent control. B. NCI 90737. C. NCI 357777. 
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Figure 19. Abnormal eye development phenotypes replicated using compounds identified from the original Tomlinson NCI diversity set I 
compound screen. X. laevis embryos were assessed at stage 38 and compared to a corresponding DMSO vehicle control. Embryos shown 
were screened at 40µM.  A. DMSO solvent control. B. NCI 101984. C. NCI 143019. D. NCI 638432. 
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3.2.2 Assessment of X. tropicalis as a chemical genetic screening model 
 
To determine if the X. tropicalis model is amenable to chemical genetic 
screening, the same hit compounds identified by Tomlinson et al., (2009) were  
screened upon X. tropicalis using the same method and concentrations (40µM) 
as described previously for the X. laevis. Due to limited stock availability, only 25 
of the 29 original hit compounds in my possession were screened. This number 
was still a fair representation of all the six phenotypes identified, as the missing 
compounds (NCI 49762, NCI 99609, NCI 99676, NCI 372074 and NCI 627512) 
all came from phenotypic classes containing numerous alternative hit 
compounds. To allow for easy comparison of the similarities and differences 
exhibited between the phenotypes elicited in either the X. laevis or X. tropicalis 
models, all figures are presented with each compound induced phenotype side 
by side. As the majority of the compounds produced similar phenotypes in both 
models, the figures in this chapter have been condensed to show representative 
examples for each phenotypic class. For the complete collection of the 
phenotypes for all compounds in both models see to Appendix I.  
 
Of the abnormal pigmentation compounds screened, all gave rise to a similar 
phenotype in X. tropicalis as was displayed in X. laevis. For example, NCI 
47938 caused a significant loss in pigmentation in both the lateral and dorsal 
stripe in both the X. laevis and X. tropicalis embryos. Likewise NCI 62406 
causes a global reduction of pigmentation in the lateral and dorsal stripe and the 
head and eye in both models. One notable difference between the models for 
some compounds is displayed highlighted by NCI 99676 (Figure 20 Di and Dii), 
in which there is global pigment loss in the X. tropicalis embryo, whereas the  
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Figure 20. Side by side comparison of NCI compounds identified in the NCI 
diversity set I compound screen that gave rise to a similar prominent abnormal 
pigmentation phenotype when assessed at stage 38 (when compared to the 
DMSO vehicle control) in both X. laevis and X. tropicalis. Embryos shown were 
screened at 40µM. Ai. X. laevis DMSO solvent control. Aii. X. tropicalis DMSO 
solvent control. Bi. X. laevis NCI 7734. Bii. X. tropicalis NCI 7734. Ci. X. laevis 
NCI 30712. Cii. X. tropicalis NCI 30712. Di. X. laevis NCI 99676. Dii. X. 
tropicalis NCI 99676. 
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pigment is only lost in the dorsal and lateral stripe for the X. laevis embryo, but 
appears to still be present in the eye and head region. 
 
A similar pattern was seen in those compounds that gave rise to a melanophore 
morphology phenotype in the X. laevis embryos. Two of the four compounds 
gave rise to similar phenotypes in both models, as seen with NCI 17173 (Figure 
21 Bi and Bii). The remaining two compounds however, whilst presenting clear 
evidence of abnormal melanophore morphology also showed a greatly reduced 
number of melanocytes in general when compared to their X. laevis equivalent, 
as shown by NCI 80126 (Figure 21 Ci and Cii). Similarly, X. tropicalis embryos 
screened with all three of the compounds known to induce an abnormal 
melanophore migration phenotype in X. laevis appeared to produce an 
exaggerated phenotype in the X. tropicalis. For example NCI 22207 and NCI 
84093 both produced notable abnormal melanophore migration phenotypes in 
the X. tropicalis but also markedly reduced pigmentation in the lateral and dorsal 
stripe (Figure 22 Bi, Bii, Ci, and Cii). 
 
The one edema producing compound did appear to reproduce a phenotype in 
the X. tropicalis similar to the described in the X. laevis (Figure 23 Bi and Bii), 
although also presented a global reduction in pigmentation when compared to 
the X. laevis equivalent. Of the two abnormal morphology generating 
compounds screened, NCI 90737 produced a similar abnormally elongated 
trunk phenotype to that described in the X. laevis counterpart (Figure 24 Bi and 
Bii). NCI 357777 however produced an abnormal phenotype that was dissimilar 
to that induced in X. laevis (Figure 24 Ci and Cii). The X. tropicalis embryo 
presented a total lack of pigmentation accompanied by global developmental 
delay and embryos would typically not survive long past the stage presented  
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Figure 21. Side by side comparison of NCI compounds identified in the NCI 
diversity set I compound screen that gave rise to a similar prominent 
melanophore morphology phenotype when assessed at stage 38 (when 
compared to the DMSO vehicle control) in both X. laevis and X. tropicalis. 
Embryos shown were screened at 40µM. Ai. X. laevis DMSO solvent control. Aii. 
X. tropicalis DMSO solvent control. Bi. X. laevis NCI 17173. Bii. X. tropicalis NCI 
17173. Ci. X. laevis NCI 80126. Cii. X. tropicalis NCI 80126.  
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Figure 22. Side by side comparison of NCI compounds identified in the NCI 
diversity set I compound screen that gave rise to a similar prominent 
melanophore migration phenotype when assessed at stage 38 (when compared 
to the DMSO vehicle control) in both X. laevis and X. tropicalis. Embryos shown 
were screened at 40µM. Ai. X. laevis DMSO solvent control. Aii. X. tropicalis 
DMSO solvent control. Bi. X. laevis NCI 22207. Bii. X. tropicalis NCI 22207. Ci. 
X. laevis NCI 84093. Cii. X. tropicalis NCI 84093. 
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Figure 23. Side by side comparison of NCI compounds identified in the NCI 
diversity set I compound screen that gave rise to a similar prominent edema 
phenotype when assessed at stage 38 (when compared to the DMSO vehicle 
control) in both X. laevis and X. tropicalis. Embryos shown were screened at 
40µM. Ai. X. laevis DMSO solvent control. Aii. X. tropicalis DMSO solvent 
control. Bi. X. laevis NCI 10470. Bii. X. tropicalis NCI 10470.  
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Figure 24. Side by side comparison of NCI compounds identified in the NCI 
diversity set I compound screen that gave rise to a similar prominent 
morphological phenotype when assessed at stage 38 (when compared to the 
DMSO vehicle control) in both X. laevis and X. tropicalis. Embryos shown were 
screened at 40µM. Ai. X. laevis DMSO solvent control. Aii. X. tropicalis DMSO 
solvent control. Bi. X. laevis NCI 90737. Bii. X. tropicalis NCI 90737. Ci. X. laevis 
NCI 357777. Cii. X. tropicalis NCI 357777. 
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here. The X. laevis embryo showed a loss of pigmentation in the lateral and 
dorsal stripe, but melanocytes were clearly present in the head and eye. It also 
had an enlarged fore brain which the X. tropicalis samples lacked. Of the three 
abnormal eye development compounds screened, only NCI 143019 produced a 
similar phenotype as described in X. laevis (Figure 25 Bi, Bii, Ci and Cii). NCI 
143019 featured a very similar under developed eye in X. tropicalis as it did in X. 
laevis, with both also possessing a global lack of total pigment. NCI 101984 
however shows little abnormality in the eye structure or development in the X. 
tropicalis when compared to the X. laevis equivalent, although it did present a 
more prominent decrease of pigmentation seen in the lateral and dorsal stripe.  
 
3.3 Discussion 
 
The first aim of this chapter was to assess the reproducibility of X. laevis as a 
chemical genetic screening tool by rescreening the original Tomlinson et al., 
(2009) hit compounds. Using newly ordered stocks, this rescreening strategy 
resulted in the majority of the phenotypes previously described being replicated. 
For the edema, abnormal morphology, abnormal eye development, abnormal 
melanophore migration, abnormal melanophore morphology and the majority of 
the abnormal pigmentation phenotypes, the majority of compounds screened 
reproduced phenotypes that were very similar to those previously described. 
However, in a minority of cases it could be argued that whilst the phenotypic 
class allocated was clearly appropriate, the extent to which these phenotypes 
were expressed was not fully the same between the original and rescreened 
samples. For example both NCI 99667 and NCI 186066 showed reduced 
pigmentation, however the phenotype was not as clearly defined as it had been  
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Figure 25. Side by side comparison of NCI compounds identified in the NCI 
diversity set I compound screen that gave rise to a similar prominent eye 
development phenotype when assessed at stage 38 (when compared to the 
DMSO vehicle control) in both X. laevis and X. tropicalis. Embryos shown were 
screened at 40µM. Ai. X. laevis DMSO solvent control. Aii. X. tropicalis DMSO 
solvent control. Bi. X. laevis NCI 101984. Bii. X. tropicalis NCI 101984. Ci. X. 
laevis NCI 143019. Cii. X. tropicalis NCI 143019. 
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when compared to other phenotypes in the same category. Indeed it is 
reasonable to suggest that in the case of these compounds, based on the 
number of melanocytes present and their rounded morphology, a more 
appropriate phenotypic class for both compounds might have been abnormal 
melanophore morphology. Despite this small discrepancy the majority of the 
phenotypes were successfully reproduced, implying that the assay is 
reproducable and therefore reinforces the position of X. laevis as a robust model 
for chemical genetic screening. 
 
The second aim of this chapter was to assess the applicability of X. tropicalis 
towards chemical genetic screening. To determine this, the same hit compounds 
identified in the Tomlinson et al., (2005) were screened upon X. tropicalis 
embryos, utilising the same method and concentrations (40µM) as described 
previously for X. laevis.  
 
Of the 25 compounds screened, all gave a phenotype that resemble the 
phenotypic class ascribed previously to X. laevis. The extent to which some of 
these phenotypes presented themselves however did vary. In a number of 
cases (for example 99676 (Figure 20 Di and Dii)) the extent to which 
pigmentation was reduced in the embryo was increased. This also occurred for 
some compounds in which abnormal pigmentation had not previously been 
present in their X. laevis counterpart, as shown for NCI 10470 (Figure 23 Bi 
and Bii). All compounds however displayed high similarity between X. laevis 
and X. tropicalis phenotypes with three notable exceptions. 
 
Both NCI 357777 (Figure 24 Ci and Cii) and NCI 101984 (Figure 20 Bi and 
Bii) failed to reproduce the abnormal morphology and abnormal eye 
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development phenotypes described in their X. laevis counter parts respectively. 
NCI 101984 showed no indication of abnormal eye development although 
shared a similar abnormal pigmentation phenotype. As the phenotype was 
subtle in the X. laevis sample, this may simply not overtly present itself in the X. 
tropicalis model. NCI 357777 however led to the death of the embryos before 
they reached stage 38. This could suggest that the X. tropicalis model may in 
some cases be more sensitive than their X. laevis counter parts requiring a 
reduced concentration to allow the embryos to survive until they can be 
assessed. 
 
NCI 80126 (Figure 21 Ci and Cii) presented a phenotype in X. tropicalis that 
would be far better categorised as abnormal pigmentation, due to the distinct 
global absence of melanocytes presented by the samples. This may in fact be a 
reflection of the noticeable heightened reduction in pigmentation displayed by 
other compounds in the X. tropicalis when compared to the X. laevis, suggesting 
that the X. tropicalis melanocytes are either more prone to cease producing 
melanin or may simply fail to differentiate during neural crest specification when 
antagonised by a compound inhibitor. It is possible that due to their smaller size, 
the compound may penetrate the X. tropicalis system more readily, making 
them more sensitive than their X. laevis counterpart. It has been shown 
previously (unpublished data) that increasing the concentration of compounds 
that give rise to a melanophore morphology or migration in X. laevis can 
generate phenotypes that might more readily be categorised as abnormal 
pigmentation. Likewise, decreasing the concentration of those compounds that 
give rise to an abnormal pigmentation can sometimes generate phenotypes that 
would be better categorised as abnormal melanophore morphology or abnormal 
melanophore migration. The increased sensitivity of the X. tropicalis embryos 
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may explain why in some cases, phenotypes previously identified as abnormal 
melanophore morphology or abnormal melanophore migration phenotypes in X. 
laevis might present themselves as abnormal pigmentation in X. tropicalis. A 
future study might investigate whether lowering the concentration of such 
compounds when screening in X. tropicalis, reproduce the phenotypes 
described in X. laevis. This however does not explain why in some compounds 
that had no previous abnormal pigmentation phenotype pattern of any form 
when screened in X. laevis (such as the edema inducing compound NCI 10470 
(Figure 23 Bi and Bii) present themselves in X. tropicalis. This may suggest 
that the X. tropicalis model could generally be more sensitive. It is worth 
highlighting however that to increase the throughput of these typically medium 
throughput chemical genetic screens samples are tested at only a few 
concentrations to rapidly identify phenotypes of interest that might be worthy of 
further investigation. Whilst some of the X. tropicalis phenotypes may have 
differed in their intensity, interesting phenotypes were presented and therefore 
given the primary objective of the experiment the screen could be considered 
successful. 
 
It is apparent that the X. tropicalis model has high potential in its practical 
application towards chemical genetic screens. There were no practical 
difficulties in either plating the embryos or their tolerance to equivalent 
concentrations of solvent. One significant and unavoidable difference between 
the two models was the difference in incubation temperature. Whilst X. laevis 
embryos were incubated at 18oC during the course of the assay (and can 
tolerate a range of temperatures between 12oC and 22oC that can be used to 
regulate speed of development), X. tropicalis can only be incubated at 22oC. 
This however did not seem to have any effect on the compounds in question 
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with no change in solubility observed (no precipitation was observed). The 
difference in temperature is also reflected by the X. tropicalis embryos’ 
significantly faster development speed when compared to X. laevis (even when 
incubated at the same temperature). This allowed the X. tropicalis embryos to 
reach stage 38 a full day earlier then the X. laevis, thereby substantially 
reducing assay turnaround time. This is significant in the context of drug 
discovery where the reduction of protocol time by a full day would significantly 
increase throughput capacity.  
 
Temperature differences between the two models may affect the binding of the 
compound to a particular target once absorbed. An increase in temperature 
would lead to an increase in kinetic energy, potentially therefore leading to more 
rapid binding in the X. tropicalis  then the X. laevis  and subsequently generating 
a phenotype more rapidly or to a greater extent. This may therefore skew 
observed IC50s when comparing the two models against the same compounds. 
It is not possible using the current data to speculate whether or not this may or 
may not have had an effect on the phenotypes generated by either model. As 
human core body temperature is around 370C, the warmer incubation 
temperatures of the X. tropicalis may better represent a human model system. 
 
A further practical consideration is the relatively smaller size of the X. tropicalis 
embryos, potentially suggesting they may be capable of being incubated in less 
media and are therefore more suited to a 96 well plate format. A future 
experiment could investigate reducing the media volume X. tropicalis embryos 
are incubated in to thereby reduce the amount of compound used per assay. 
This would again be of benefit to medium through-put screens by potentially 
reducing the cost of the assay.  
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One disadvantage of using the X. tropicalis model is the reduced number of 
eggs produced per female. The 300-1000 eggs produced per female in X. 
tropicalis is significantly lower than the 1000-3000 eggs produced per female in 
the X. laevis, thereby increasing the amount of husbandry required to perform a 
screen on a similar scale. A further disadvantage is the relatively low amount of 
genetic material recoverable per embryo due to their smaller size, requiring 
larger embryo pools depending on the amount of material required. However the 
significantly shorter generation time and genetically tractable genome enjoyed 
by the X. tropicalis model would permit the rapid generation of isolated mutant 
lines which could be used in conjunction with chemical genetic screening to 
identify molecules that could be used for the treatment of specific diseases. 
Such an advantage coupled with the practical capacity demonstrated in this 
experiment would suggest that X. tropicalis is highly suitable as a model towards 
chemical genetics screening and may potentially be a more viable option then X. 
laevis. It has yet to be determined whether X. tropicalis can be used for a full 
scale chemical genetic screen. A planned future preliminary experiment is to 
screen three to four plates from a library previously screened using X. laevis 
embryos to assess whether results across a broad range of compounds 
produced similar effects (such as death, abnormal phenotypes or no effect) 
comparable to that observed when using X. laevis. 
 
To summarise this chapter I have shown that the use of X. laevis for chemical 
genetic screening is highly reproducible. This strengthens the value of the NCI 
diversity set II screen (which I out line in Chapter IV). Similarly, preliminary 
evidence would suggest that X. tropicalis is highly suited towards chemical 
genetic screening and the models genetic advantages may one day led to it 
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superseding X. laevis as the primary amphibian model for chemical genetic 
screening. However, further work is necessary to determine if the model is 
capable of a chemical genetic screen and further investigation is required as to 
the optimal screening concentrations required. 
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Chapter IV 
 
4.0 NCI diversity set II X. laevis chemical genetic screen 
followed by cell viability assay screening 
 
4.1 Introduction 
 
4.1.1 X. laevis as a chemical genetic screening model 
 
The practical utility of the X. laevis animal model towards forward chemical 
genetic screening has already been discussed in great length (see Chapter I), 
promoting its strengths as an ideal tool for medium throughput screening 
applications with a variety of potential endpoints at its disposal (Adams et al., 
2006; Dush et al., 2011; Kalin et al., 2009). Tomlinson et al., (2009) was one of 
the first to show this potential in X. laevis by screening the NCI diversity set I 
compound library on X. laevis embryos, focusing primarily on those compounds 
that gave rise to abnormal pigmentation phenotypes as a marker for interesting 
bioactivity of a screened molecule (Tomlinson et al., 2005; Tomlinson et al., 
2009b). This led to the discovery of NCI 210627, a compound that gave rise to a 
subtle abnormal melanophore migration phenotype. This work was then 
continued in the Zon laboratory (Harvard, USA), where subsequent 
chemoinformatical analysis of NCI 210627 identified brequinar as a compound 
with a very similar structure to NCI 210627. Brequinar is a known inhibitor of the 
enzyme dihydrooratate dehydrogenase (DHODH) and when screened upon X. 
laevis embryos (under the same conditions as used in the identification of NCI 
210627), produced a very similar phenotype. This suggested that the 
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mechanism of action of NCI 210627 in eliciting the observed phenotype may 
well also be through antagonising DHODH. Subsequent analysis led the 
identification of the anti-arthritis drug Leflunomide, a structurally dissimilar 
compound to both NCI 210627 and brequinar that was also a known inhibitor of 
DHODH. Leflunomide has since been shown to reduce spontaneous tumour 
growth in the BRAF V600E mutant Zebrafish line, and was also shown to 
significantly reduce the cell viability of melanoma cell lines when compared to 
non-melanoma controls (White et al., 2011). They subsequently showed 
leflunomide (in combination with the MEK inhibitor PLX4032) to significantly 
reduce melanoma tumour size and metastasis in mouse xenograft models. 
Leflunomide (in combination with PLX4032) is now undergoing human clinical 
trialling in the US with the hope that its will soon become a new novel 
therapeutic option for the treatment of melanoma (White et al., 2011).  
 
The discovery of leflunomide was only possible through the highly successful 
screen originally carried out by Tomlinson et al., (2009) and White et al., (2011), 
and highlights the potential of abnormal pigmentation phenotypes identified in X. 
laevis screens as potential indicators of either molecules with therapeutic 
potential towards the treatment of melanoma, or may lead to the discovery of 
novel therapeutic targets with similar therapeutic potential. We felt that the 
possibilities of the developed X. laevis screening system had not been saturated 
by the original screen and that the potential was there to find additional 
molecules with therapeutic potential. We therefore sought to replicate the 
success of this experiment by screening the NCI diversity set II compound 
library using a similar protocol to that utilised by Tomlinson et al., (2009). We 
then aim to expand upon this previous work by using a cell viability assay to 
assess either the therapeutic potential of hit compounds identified towards the 
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treatment of melanoma in house. By combining the X. laevis screening protocol 
with carefully selected follow up experiments (such as the melanoma cell 
viability assay), we aim to demonstrate (via the rapid identification of novel 
therapeutic compounds and targets) how the X. laevis model could be of value 
towards pharmaceutical drug discovery.  
 
4.1.2 The NCI diversity set II compound library 
 
The NCI diversity set II compound library consisted of 1363 compounds 
(supplied in 96 well, 100µl 10mM stocks), and was obtained from the NCI 
developmental therapeutic program. Formed as part of the NIH cancer initiative, 
the NCI diversity series was developed as an initiative to aid in the discovery 
and development of new drugs for the treatment of cancer. To date (March 
2014), the latest available version is the NCI diversity set IV. Whilst the previous 
libraries (including the NCI diversity set I and II used the Tomlinson et al., (2009) 
and this screen) are no longer available as libraries, the individual compounds 
may still be obtained (stock availability permitting).  
 
The NCI diversity series set II compound library was chosen for several 
reasons. The NCI diversity set compounds are selected from the far larger NCI 
complete library, which consists of over 140000 compounds. Compounds 
included in NCI Diversity libraries have been selected based on their previously 
demonstrated biochemical activity and structural information. Such information 
enables the prediction of those compounds that will likely prove to be bioactive, 
whilst possessing features that are frequently attributed to improving a 
compounds ‘druggability’ (i.e. they are not electrophilic, unstable, 
organometallic, polycyclic aromatic hydrocarbons, possess low molecular 
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weight, etc.). In addition, the compounds are also selected based upon their 
dissimilarity. As such all compounds in the NCI diversity set libraries should be 
structurally dissimilar, ensuring that a screen of any kind is sampling a larger 
area of chemical space with little redundancy and thereby increasing its 
efficiency. The structural diversity and predicted bioactivity of the NCI diversity 
series make it an extremely attractive option for a wide variety of screening 
experiments (Jorissen and Gilson, 2005; Kau et al., 2003; Li et al., 2004).  
 
A second reason for selecting the NCI diversity set II compound library (which 
was the latest edition available at the time of ordering), is that it is the direct 
sequel to that used in the Tomlinson et al., (2009) screen. The NCI diversity set 
II library contains only 10% of those represented in the NCI diversity set I library. 
This enables a direct comparison between screens in terms of the percentage 
hit rate of phenotypes identified and may potentially further assess the 
applicability of the NCI diversity series towards such screens. Any compounds 
that may have generated phenotypes in the original screen that appear in the 
both libraries could also be used as a positive control to assess our capacity to 
identify presented phenotypes.  
 
4.1.3 Screening of the NCI diversity set II compound library 
 
One of the primary aims of this thesis is to further investigate the benefits of 
using the X. laevis model as a tool in drug discovery, to the benefit of both 
industry and prospective patients. To help determine this, my colleague Kim 
Hanson and I both screened the NCI Diversity set II compound library using the 
X. laevis model. Of the 1363 compounds screened, 72 gave rise to repeatable 
phenotypes that could be categorised as ‘abnormal’. Many of the identified 
117 
 
 
phenotypes were involved in pigment loss, reduction or abnormal migration or 
melanophore morphology. It was previously observed that phenotypes such as 
these may be indicative of compounds with the potential to inhibit melanoma 
growth (Tomlinson et al., 2009b; White et al., 2011). To further investigate this 
potential, all 72 compounds were subjected to cell viability assays in which their 
ability to reduce the A375 melanoma cell line cell viability was observed in 
relation to two non-melanoma cell line controls (HEK293 and RD1). Of the 72 
compounds screened, for 13 compounds the IC50s of the A375 melanoma cell 
line were shown to be statistically significantly reduced when compared to the 
IC50s of their respective HEK293 and RD1 controls. The selective nature of 
these compounds against the A375 cell line, combined with the structural 
diversity inherent in the NCI diversity set II library suggests that each of these 13 
compounds may lead to novel targets for the treatment of melanoma or indeed 
be used as novel drugs themselves. This simple yet effective chemical genetic 
screening method once again highlights the benefits of using the X. laevis 
model. It also displays how (in conjunction with carefully chosen relevant 
assays) X. laevis chemical genetic screening assay can be used to rapidly 
generate promising lead compounds for the treatment of melanoma, thereby 
emphasising their potential towards improving drug discovery. 
 
4.2 Results 
 
4.2.1 Phenotype scoring 
 
This screen was primarily focused upon identifying phenotypes involving 
abnormal pigmentation defects (total or partial loss of pigmentation and/or 
abnormal melophore migration or morphology). It also permitted easy 
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visualisation of other areas of X. laevis development, such as abnormal eye 
development, abnormal general morphology, edema and blistering (summarised 
in Figure 26 A). The criteria by which these phenotypic categories were defined 
is outlined below.  
 
All compounds were screened at both 20µM and 40µM in 96 well plates and 
embryos were screened by eye for abnormal phenotypes at stage 38 using a 
light microscope. Each well consisted of 5 embryos, 80% of which must present 
a similar phenotype to be considered a phenotypic hit. To limit experimenter 
bias, all plates were screened blind by both my colleague Kim Hanson and 
myself. Many of the compounds elicited phenotypes that might fall into two or 
three separate categories (i.e. total pigmentation loss and abnormal 
morphology). During individual scoring of the plates we ranked the prominence 
of the phenotype observed on a scale of 1-3 (1 being clearly prominent, 3 
implying a subtle effect). In cases where two phenotypic categories might be 
apparent for the same embryo, a consensus was reached based on the ranking 
of phenotypic prominence given by each experimenter. All identified hit 
compounds were repeated in larger volume (1ml) with a higher sample number 
(n=10 per well) and screened according to the same criteria outlined above to 
ensure they could be replicated. All hit compounds subsequently identified were 
then subjected to a dose response screen across a range of doses (0.1, 1, 10, 
25, 50, 75 and 100 µM, 20 embryos per well 1 ml final volume) to evaluate the 
phenotypes over a range of concentrations.  
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Figure 26. A. Example images for phenotypic categories to which identified 
phenotypes were allocated i. Vehicle DMSO control. ii. Total pigmentation loss. 
iii. Partial pigment loss. iv. Abnormal melanophore migration. v. Abnormal 
melanophore morphology. vi. Abnormal general morphology. vii. Abnormal eye 
development. viii. Edema. ix. Blistering. B. Chart displaying percentage of hit 
compounds allocated to each phenotypic category (n = 72). C. Chart displaying 
percentage of the total number of times a phenotype was identified (n = 161). 
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4.2.2 Summary of phenotypes observed from hit compounds identified in 
the NCI diversity set II X. laevis chemical genetic screen 
 
The NCI diversity set II compound library was supplied as 100µl, 10mM stocks 
in 96 well plates that were transferred directly to the media upon plate set up. 
Phenotypes observed were broadly split into 8 phenotypic categories as 
summarised in Figure 26 A ii Total pigmentation loss (in which no or very little 
pigment is present in the entire embryo). iii. Partial pigment loss (in which 
obvious pigment loss has occurred (usually in the lateral and dorsal stripe) but 
some clearly remains (normally localised in the head and eye)). iv. Abnormal 
melanophore migration (in which melanocytes appear to present abnormal 
patterning (usually in the lateral and dorsal stripe)). v. Abnormal melanophore 
morphology (in which melanocytes fail to present the dendritic form that is 
consistent with healthy controls). vi. Abnormal general morphology (in which the 
embryo in any way appears to have a distinctive and consistent abnormal body 
shape or form not consistent with the corresponding control). vii. Abnormal eye 
development (in which the eye fails to form or where normal structures can be 
seen to have clear abnormal morphology). viii. Edema (in which the embryo 
presents an increase in fluid around the heart cavity). ix. Blistering (in which the 
embryo presents excessive fluid build-up beneath the skin that is irregularly 
located between samples subjected to the same conditions).  
 
The total number of hit NCI compounds identified (n = 72) and the phenotypic 
class to which they were allocated (based on the strongest or most prominent 
phenotype presented) are represented in Figure 26 B Total and partial pigment 
loss account for 39% of all hit compounds identified, highlighting their 
prominence in this screen. Abnormal melanophore migration and melanophore 
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morphology phenotypes were also well represented (accounting for 13% and 
10% of identified hits respectively), although they were less frequently observed 
then the total or partial pigment loss phenotypic categories. A high proportion of 
hits (17%) gave rise to phenotypes that could be characterised as having 
abnormal morphology. Similarly, abnormal eye development was also prominent 
and represented 14% of the hits. Both the blistering and edema phenotypic 
categories were less prominent, consisting of 7% and 1% of total hits identified 
respectively.  
 
More often than not, embryos that presented a strong phenotype of any 
phenotypic class often possess attributes suggesting they could also belong to a 
second or third phenotypic category. For example Figure 26 A ix presents a 
clear blistering phenotype, however the embryo also significantly lacks 
pigmentation when compared to the vehicle control and therefore might also be 
considered to belong to the ‘total pigmentation loss’ phenotypic category. This is 
emphasised in Figure 26 C which represents the total number of compounds 
identified for each phenotypic category (irrespective of the strength of the 
phenotypes elicited) (n = 161). As such, an identified hit compound may well be 
represented more than once in this graph depending on the total number of 
phenotypes elicited in the embryo. For example, the blistering phenotype 
presented in Figure 26 A ix is represented here twice in both the blistering and 
total pigmentation loss phenotypic categories. In Figure 26 C the total and 
partial pigmentation represent only 28% of phenotypes identified, whereas 
abnormal morphology and eye development represent 42%. This reflects how 
despite often being only slight, abnormal morphology and abnormal eye 
development phenotypes were often present in embryos that were considered to 
have stronger alternative phenotypes (as demonstrated in the blistering example 
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exhibited in Figure 26 A ix). In total however, pigmentation phenotypes are still 
the dominantly observed phenotypic categories observed, with total and partial 
pigmentation loss combined with abnormal melanophore migration and 
morphology accounting for 51% of all phenotypes observed. Abnormal 
melanophore migration and morphology accounted for 23% of the total 
phenotypes identified. Both the edema and blistering phenotypes were still 
poorly represented, accounting for a total 6% of all phenotypes identified.  
 
4.2.3 Summary of hit compounds identified in the NCI diversity set II X. 
laevis chemical genetic screen according to their allocated phenotypic 
categories 
 
In total, the NCI diversity set II X. laevis chemical genetic screen was successful 
in identifying 72 compounds that gave rise to reproducible phenotypes. As 
outlined above previously, these phenotypes were broadly split into eight 
phenotypic categories. Those hit compounds that were categorised as 
presenting a phenotype consistent with total pigmentation loss are displayed in 
Figure 27. Of these compounds, NCI 9358, NCI 20618, NCI 20619, NCI 99657, 
NCI 99660, NCI 131982, NCI 131986, NCI 164965 and NCI 515893 Figure 27 
B, D-I, K and N) all present a near total loss of pigmentation in the lateral and 
dorsal stripe as well as the head and eye when compared to their respective 
vehicle control. NCI 12588, NCI 135810, NCI 205913 and NCI 319034 (Figure 
124 
 
 
 
 
 
 
 
125 
 
 
Figure 27. NCI compounds identified in the NCI diversity set II compound 
screen that gave rise to an abnormal pigmentation phenotype, in which no 
pigment is present in the whole embryo when assessed at stage 38 (when 
compared to the DMSO vehicle control). Phenotypes are shown alongside 
associated compound structure and chemical information (NCI ID, molecular 
formula and MW). Embryos shown were screened at 40µM. A. DMSO solvent 
control. B. NCI 9358. C. NCI 12588. D. NCI 20618. E. NCI 20619. F. NCI 99657. 
G. NCI 99660. H. NCI 131982. I. NCI 131986. J. NCI 135810. K. NCI 164965. L. 
NCI 205913. M. NCI 319034. N. NCI 515893. MW; Molecular weight. 
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27 C, J, L and M) also show this phenotype however a very small amount of 
pigment remains in either the head or eye. Embryos determined to present a 
phenotype consistent with the partial loss of pigmentation phenotype were 
placed in the total loss of pigmentation phenotypic category as the amount of 
pigmentation remaining is relatively marginal.  
 
Compounds categorised as presenting a phenotype consistent with partial 
pigmentation loss are displayed in Figure 28. NCI 30712, NCI 42028, NCI 
45536, NCI 45545, NCI 59620, NCI 62609, NCI 62611, NCI 87084, NCI 
104993, NCI 106581, NCI 111848, NCI 117741, NCI 153792, NCI 154718 and 
NCI 319471 all show a significant loss of pigmentation in either the lateral or 
dorsal stripe (or both), whilst still possessing pigmentation in the head and/or 
eye (Figure 28 B-P). Interestingly, NCI 30712 and NCI 45536 appear to also 
possess abnormal eye development phenotypes in which structures of the eye 
are consistent with anophthalmia. NCI 104993 and NCI 154718 also display 
slight abnormal eye development as presented by a partial lack of pigmentation 
in the eye which may suggest a disruption to the retinal pigment epithelial layer. 
Finally, NCI 319471 presents a slight abnormal eye phenotype in which the eye 
appears bigger when compared to the control, indicating myopia. 
 
In total, seven hit compounds were categorised as presenting abnormal 
melanophore morphology in Stage 38 embryos (Figure 29). NCI4292, NCI 
117987, NCI 133002, NCI 204262 and NCI 275971 (Figure 29 B, D-E, G and 
H), All possess melanocytes in the lateral stripe which appear round and 
compacted in morphology when compared to the dendritic shape exhibited in 
their relevant vehicle controls. NCI 34871 and NCI 138398 (Figure 29 C and F) 
present melanocytes which appear enlarged and disorganised when compared 
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Figure 28. NCI compounds identified in the NCI diversity set II compound 
screen  that gave rise to a partial abnormal pigmentation phenotype, in which 
patches of normal pigmentation were either absent or not prominent when 
assessed at stage 38 (when compared to the DMSO vehicle control). 
Phenotypes are shown alongside associated compound structure and chemical 
information (NCI ID, molecular formula and MW). Embryos shown were 
screened at 40µM. A. DMSO solvent control. B. NCI 30712. C. NCI 42028. D. 
NCI 45536. E. NCI 45545. F. NCI 59620. G. NCI 62609. H. NCI 62611. I. NCI 
87084. J. NCI 104993. K. NCI 106581. L. NCI 111848. M. NCI 117741. N. NCI 
153792. O. NCI 154718. P. NCI 319471. MW; Molecular weight. 
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Figure 29. NCI compounds identified in the NCI diversity set II compound screen that gave rise to a prominent abnormal melanophore 
morphology phenotype when assessed at stage 38 (when compared to the DMSO vehicle control). Phenotypes are shown alongside 
associated compound structure and chemical information (NCI ID, molecular formula and MW). Embryos shown were screened at 40µM. A. 
DMSO solvent control. B. NCI 4292. C. NCI 34871. D. NCI 117987. E. NCI 133002. F. NCI 138398. G. NCI 204262. H. NCI 275971. MW; 
Molecular weight. 
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to the DMSO control. NCI 34871 and NCI 204262 appear to also present an 
abnormal eye development phenotype in which a distinct patch of pigmentation 
appears to be missing from the retinal epithelial layer. In addition, NCI 275971 
also appears to present abnormal eye development in the form of a smaller eye 
then that of the vehicle control, suggesting microphthalmia. 
 
Of the 72 hit compounds identified, nine were categorised as presenting a 
phenotype constituent with abnormal melanophore migration (Figure 30). Of 
these compounds NCI 11624 and NCI 13156 (Figure 30 B and C) presented 
phenotypes in which the melanocytes appeared to be abnormally patterned in 
both the dorsal and lateral stripe (See Figure 12). In NCI 11624 the phenotype 
is slight but consistent between samples. NCI 13156 by far presents the most 
prominent example of abnormal melanophore migration whereby abnormal 
patterning down the lateral stripe can clearly be observed when compared to the 
vehicle control. It is also notable that melanocytes do not appear to be able to 
migrate down to the lateral stripe region suggesting this compound has severely 
interrupted normal melanocyte migration. NCI 13653, NCI 125197 and NCI 
139021 all present abnormal melanophore migration phenotypes in which the 
condition is most prominent in the lateral stripe. In each example melanophores 
appear to have failed to migrate successfully in this specific region whereas the 
dorsal stripe remains relatively normal when compared to the vehicle control. In 
contrast however NCI 36525, NCI 92794, NCI 150982 and NCI 246415 (Figure 
30 E, F, I and J) present abnormal melanophore migration phenotypes that 
appear primarily localised to the lateral stripe, whereas the dorsal stripe appears 
to be relatively normal. NCI 246415 appears to present several other 
phenotypes, with the relative lack of pigment in the head and eye indicative of 
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Figure 30. NCI compounds identified in the NCI diversity set II compound screen  that gave rise to a prominent abnormal melanophore 
migration phenotype, in which melanocytes have not progressed normally down either the lateral and/or dorsal stripe when assessed at stage 
38 (when compared to the DMSO vehicle control). Phenotypes are shown alongside associated compound structure and chemical information 
(NCI ID, molecular formula and MW). Embryos shown were screened at 40µM. A. DMSO solvent control. B. NCI 11624. C. NCI 13156. D. NCI 
13653. E. NCI 36525. F. NCI 92794. G. NCI 125197. H. NCI 139021. I. NCI150982. J. NCI246415. MW; Molecular weight. 
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total pigment loss and the rounded morphology of the melanocytes present in 
the lateral stripe being consistent with abnormal melanophore morphology.  
 
Only NCI 205832 presented a phenotype consistent with the edema phenotypic 
category (Figure 31 B). Five compounds in the form of NCI 14380, NCI 68971, 
NCI 246415, NCI 308847 and NCI 343557 (Figure 32 B-F), gave rise to 
phenotypes consistent with the blistering phenotypic category. NCI 14380 and 
NCI 343557 also gave rise to a stunted abnormal morphology phenotype, 
whereas NCI 246415 also gave rise to a phenotype consistent with that 
observed with a total loss of pigmentation. 
 
Of the 72 hit compounds identified, 12 gave rise to a phenotype that could be 
considered to be abnormal morphology (Figure 33). NCI 21683, NCI 30390, 
NCI 31762, NCI 43013, NCI 79253, NCI 85326, NCI 88916, NCI 151262, NCI 
377384, NCI 402590, NCI 645987 and NCI 667251 (Figure 33 B-M), all gave 
rise to phenotypes that presented consistent abnormal morphology when 
compared to the vehicle control. Of these compounds all generated an 
additional phenotype that could be attributed to either total or partial loss of 
pigmentation, with the exception of NCI 31762. NCI 21683, NCI 30390, NCI 
79253, NCI 151262, NCI 377384, NCI 402590, NCI 645987 and NCI 667251 all 
additionally presented abnormal eye development phenotypes in the form of 
anophtalmia. NCI 31762, NCI 43013, NCI 85326 and NCI 88916 also present 
abnormal eye phenotypes that suggest abnormal development of the retinal 
pigment epithelial layer. 
 
Of those NCI hit compounds identified 10 were recognised as giving an 
abnormal eye development phenotype (Figure 34). Of these compounds, NCI 
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Figure 31. NCI compounds identified in the NCI diversity set II compound screen  that gave rise to a prominent edema phenotype when 
assessed at stage 38 (when compared to the DMSO vehicle control). Phenotypes are shown alongside associated compound structure and 
chemical information (NCI ID, molecular formula and MW). Embryos shown were screened at 40µM. A. DMSO solvent control. B. NCI 205832. 
MW; Molecular weight. 
 
 
 
 
 
 
136 
 
 
 
137 
 
 
Figure 32. NCI compounds identified in the NCI diversity set II compound screen  that gave rise to a prominent blistering phenotype when 
assessed at stage 38 (when compared to the DMSO vehicle control). Phenotypes are shown alongside associated compound structure and 
chemical information (NCI ID, molecular formula and MW). Embryos shown were screened at 40µM. A. DMSO solvent control. B. NCI 14380. 
C. NCI 68971. D. NCI 246415. E. NCI 308847. F. NCI 343557. MW; Molecular weight. 
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Figure 33. NCI compounds identified in the NCI diversity set II compound 
screen  that gave rise to a prominent abnormal morphological phenotype when 
assessed at stage 38 (when compared to the DMSO vehicle control). 
Phenotypes are shown alongside associated compound structure and chemical 
information (NCI ID, molecular formula and MW). Embryos shown were 
screened at 40µM. A. DMSO solvent control. B. NCI 21683. C. NCI 30390. D. 
NCI 31762. E. NCI 43013. F. NCI 79253. G. NCI 85326. H. NCI 88916. I. NCI 
151262. J. NCI 377384. K. NCI 402590. L. NCI 645987. M. NCI 667251. MW; 
Molecular weight. 
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Figure 34. NCI compounds identified in the NCI diversity set II compound 
screen that gave rise to a prominent abnormal eye phenotype when assessed at 
stage 38 (when compared to the DMSO vehicle control). Phenotypes are shown 
alongside associated compound structure and chemical information (NCI ID, 
molecular formula and MW). Embryos shown were screened at 40µM. A. DMSO 
solvent control. B. NCI 3001. C. NCI 5907. D. NCI 19219. E. NCI 31703. F. NCI 
45572. G. NCI 66020. H. NCI 130872. I. NCI 211490. J. NCI 340852. K. NCI 
378719. MW; Molecular weight. 
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5907, NCI 19219, NCI 45572, NCI 66020, NCI 130872, NCI 211490, NCI 
340852 and NCI 378719 (Figure 34 C-D and F-K) gave rise to abnormal eye 
development phenotypes that suggested abnormal development of the retinal 
pigment epithelial layer. NCI 3001 (Figure 34 B) appears to present a 
phenotype in which the lens is dislocated from its normal position, whereas NCI 
31703 displays an eye phenotype in which the eye morphology is misshapen 
and larger than its vehicle control counterpart, possibly consistent with myopia. 
NCI 19219, NCI 31703 and NCI 340852 also present phenotypes consistent 
with that described for total or partial loss of pigmentation. NCI 340852 also 
appears to be exhibiting an abnormal morphology phenotype. NCI 130872 
exhibits a slight abnormal melanophore migration phenotype in which 
melanophores do not appear to have migrated successfully along the lateral and 
dorsal stripe. 
 
To further characterise the 72 phenotypes established, each compound was 
subject to a dose response assay (0.1, 1, 10, 25, 50, 75 and 100µM, 1ml final 
volume 20 embryos per well). Table 8 provides an example of two compounds 
in which the phenotype that was previously recorded was replicated. For 
example NCI 4292 was recorded as producing a melanophore morphology 
phenotype which was replicated at high doses but appeared to not be apparent 
around lower concentrations. NCI 12588 also appears to replicate the described 
phenotype of abnormal pigmentation, whilst at lower concentration this 
phenotype is lost. Interestingly, there appears to be a transition period at 25 – 
10µM in which the pigmentation loss phenotype is lost and an abnormal 
melanophore morphology/abnormal melanophore migration phenotype is 
presented. This may suggest in some cases at lower concentrations that those 
compounds that give rise to a total or partial loss of pigmentation may transitio
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Table 8. Collated dose response data in which embryos were exposed to hit 
compounds identified over a range of concentrations. 20 embyros were initially 
plated in each well. Percentage of embryos that showed a prominent phenotype 
at each concentration are displayed as a percentage of total embryos alive 
when assessed at stage 38 (1 = 100%). B, (blistering). E, (Edema).  ED, (eye 
development). P, (abnormal pigmentation). M, (abnormal morphology). Mg, 
(Abnormal melanophore migration). MM, (abnormal melanophore morphology). 
PD, (Percentage death). S, (stunted growth). 
 
 
Conc (μM) M S P MM MG E ED B PD 
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 4292 
10 0 0 0 1 0 0 0 0 0 
25 0 0 0 1 0 0 0 0 0 
 
50 0 0 0 1 0 0 0 0 0 
 
100 0 0 0 1 0 0 0 0 0 
           
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 12588 
10 0 0 0 0 1 0 0 0 0 
25 0 0 1 1 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
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into other pigment related phenotypes as part of a spectrum. The majority of 
compounds however showed a consistent phenotype across the range of doses. 
A complete list of dose response results can be found in Appendix II. 
 
4.2.4 Melanoma cell viability screen in response to the 72 identified hit 
NCI diversity set II compounds 
 
To identify those compounds with potential therapeutic applications towards the 
treatment of melanoma, the 72 hit compounds identified in the NCI diversity set 
II compound screen were subjected to cell viability screening using the A375 
melanoma cell line and the HEK293 and RD1 non-melanoma control cell lines. 
Of the 72 hit compounds screened, preliminary experiments found that 40 
compounds did not decrease A375 cell viability at 100µM and were 
subsequently disregarded (data not shown). The remaining 32 compounds 
which did preliminarily reduce A375 cell viability were screened 3 times each 
over a range of concentrations (from 1.56E-06 to 1.00E-04 M) on the A375, 
HEK293 and RD1 cell lines. The resultant data was used to generate growth 
inhibitory IC50s to compare the relevant ability of each NCI hit compound to 
reduce A375 cell viability in relation to the respective HEK293 and RD1 control. 
Of the 32 compounds screened, 13 gave rise to IC50s in the A375 cell lines that 
were statistically significantly lower than that displayed in their respective 
HEK293 and RD1 controls (Table 9).  Figure 35 displays dose response graphs 
in which the cell viability of the A375, HEK293 and RD1 cell line is displayed 
against an increasing concentration of each compound. NCI 13653 and NCI 
20619 (Figure 35 A and B) are presented as examples of those compounds 
that did not give rise to IC50s that were statistically significantly lower in the 
A375 cell lines when compared to their respective HEK293 and RD1 controls. 
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Table 9. IC50s generated screening NCI hit compounds on the A375, HEK293 
and RD1 cell lines. Highlighted cells indicate those compounds which gave rise 
to IC50s in the A375 melanoma lines that were statistically significantly lower 
than that produced when screened on the HEK293 and RD1 control. 
 
NCI 
Compound A375 HEK293 RD1 
3001 1.487E-05 1.191E-04 6.828E-05 
13653 2.504E-05 4.397E-05 5.074E-05 
19219 1.152E-05 7.070E-05 6.685E-05 
20619 1.137E-05 1.429E-05 2.258E-05 
30712 4.397E-06 3.311E-06 9.185E-06 
34871 2.724E-05 1.916E-05 1.081E-05 
36525 9.710E-06 6.538E-06 2.646E-05 
43013 3.947E-05 1.146E-04 7.887E-05 
45536 1.616E-05 3.640E-05 3.423E-05 
59620 3.975E-05 1.273E-05 2.881E-05 
79253 2.996E-05 5.976E-05 4.509E-05 
87084 1.115E-05 1.105E-05 2.895E-05 
88916 3.630E-06 2.764E-06 1.248E-05 
92794 8.391E-06 2.190E-05 2.829E-05 
99660 4.357E-05 6.735E-05 3.860E-05 
111848 5.431E-06 2.706E-05 3.128E-05 
117987 1.911E-05 2.395E-05 1.703E-05 
125197 7.423E-05 1.244E-04 7.737E-05 
130872 2.788E-05 2.199E-05 3.402E-05 
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131982 1.904E-05 6.320E-05 4.424E-05 
131986 1.505E-05 3.494E-05 4.020E-05 
133002 4.502E-05 8.511E-05 7.336E-05 
138398 2.738E-05 1.029E-04 8.174E-05 
151262 2.340E-05 1.591E-05 3.512E-05 
153792 2.365E-05 6.322E-05 6.194E-05 
205832 1.533E-05 4.757E-05 2.506E-05 
205913 3.791E-05 5.273E-05 5.731E-05 
246415 2.588E-05 6.767E-05 3.826E-05 
275971 4.539E-06 1.920E-05 7.897E-06 
319471 2.958E-05 6.924E-05 6.866E-05 
343557 1.855E-05 1.753E-05 2.952E-05 
378719 3.652E-06 ~1.238e-005 1.012E-05 
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Figure 35. Dose response graphs displaying cell viability (%) of A375, HEK293 
and RD1 cell lines in response to the designated NCI compound over an 
increasing concentration range (LOG10 M). Error bars represent standard error 
(n=3). All graphs shown (with the exception of NCI 13653 and NCI 20619 gave 
rise to IC50s in the A375 cell line which were statistically different to those 
obtained in both corresponding HEK293 and RD1 control cell lines. A. NCI 
13653. B. NCI 20619. C. NCI 3001. D. NCI 19219. E. NCI 43013. F. NCI 45536. 
G. NCI 79253. H. NCI 92794. I. NCI 111848. J. NCI 131982. K. NCI 131986. L. 
NCI 133002. M. NCI 138398. N. NCI 153792. O. NCI 319471.  
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The remaining compounds (NCI 3001, NCI 19219, NCI 43013, NCI 45536, NCI 
79253, NCI 92794, NCI 111848, NCI 131982, NCI 131986, NCI 133002, NCI 
138398, NCI 153792 and NCI 319471 (Figure 35 C-O)), all presented IC50s 
that were statistically significantly lower in the A375 cell lines when compared to 
their respective HEK293 and RD1 controls. A complete figure summarising 
compiled dose response cell viability data for all 32 screened hit compounds can 
be found in Appendix III.  
 
When the cell viability data was originally generated, we did not include a very 
low dose control. This made graphs difficult to interpret as in some cases it was 
hard to determine where the top of the graph plateaued, which also complicated 
IC50 generation. To correct for this a subset of the compounds assayed were 
rescreened at 1X10-9 M in the A375, HEK293 and RD1 cell lines to compare the 
cell viabilities detected between the 1X10-9 treated sample and the vehicle 
controls (Figure 36). For all compounds across all three cell lines the 1X10-9 
treated samples were shown via T-test to have no significant difference in cell 
viability when compared to their respective vehicle control. As such a 1X10-9 
data point was included on each graph (as shown in Figure 35) to aid in the 
interpretation of the data and IC50 generation.  
 
It was not possible to calculate statistical differences between IC50s generated 
in the compiled graphs displayed in Figure 35. This is because for each cell 
viability assay, each concentration contained three replicates within each plate 
that were averaged when normalised to the in plate vehicle control (to calculate 
percentage cell viability). Each data point of the dose response compiled graphs 
shown in Figure 35 is representative of three separate experimental repeats 
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Figure 36. Summary of statistical difference of 11 hit NCI compounds cell viability when screened at log10-9 M using the A375, HEK293 and 
RD1 cell lines to their respective in plate vehicle DMSO controls. A. Percentage A375 cell viability of hit NCI compounds when compared to 
their respective vehicle DMSO control (n = 6). B. Percentage HEK293 cell viability of hit NCI compounds when compared to their respective 
vehicle DMSO control (n = 6). C. Percentage RD1 cell viability of hit NCI compounds when compared to their respective vehicle DMSO control 
(n = 6). D. Statistical student T-test comparison of each NCI compound towards its in plate vehicle DMSO control (p = ≤ 0.05). 
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 (each replicate having already been averaged to generate percentage cell 
viability). It is not possible to statistically analyse data that has been averaged 
twice and therefore the IC50s generated using these compiled graphs is not 
appropriate for this application. Instead it was necessary to generate IC50s for 
each of the cell line replicates (n=3) for each compound, which would enable the 
statistical comparison of each cell lines IC50s via T-test (Figure 37). For 
example Figure 37 C displays three dose response graphs for NCI 43013, each 
one representing each of the three replicates for each of the three cell lines 
screened (Figure 37 C i, ii and iii). For each replicate for each cell line, 
individual IC50s were generated (Figure 37 C iv). Using a student T-test it was 
then possible to statistically compare the IC50 values of each of the three 
replicates between two different cell lines (Figure 37 C v). In Figure 37 C v for 
example, the t-test p-value when comparing the A375 and HEK293 is 0.007, 
therefore stating the IC50s between these lines are statistically significantly 
different (this is also true when comparing the A375 and RD1 cell lines IC50s for 
this compound). Based on the previously obtained IC50s in the compiled graph 
(in which the A375 IC50 is lower than that of the HEK293 and RD1 IC50s), this 
data therefore states that the hit compound NCI 43013 generates an IC50 in the 
A375 cell line that is statistically significantly lower than that obtained in either 
the HEK293 or RD1 control cell line. Also included in this Figure 37 is an 
example of a compound (NCI 20619) which did not give rise to a significant 
difference in the IC50 between the A375 cell line and either the HEK293 or RD1 
cell line (Figure 37 A). Another example is provided for NCI 36525 in which the 
IC50 between the A375 cell line and either the HEK293 cell line was not 
significantly different, but was between the A375 and RD1 cell lines (Figure 37  
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Figure 37.  Data used to calculate statistical differences between IC50s 
generated for each of the 32 tested NCI ‘hit’ compounds screened upon three 
cell lines (A375, HEK293 and RD1). i. Graphs displaying A375 percentage cell 
viability (%) in response to the designated NCI compound over an increasing 
concentration range (LOG10 M), and were used to generate the IC50s for each 
of the 3 replicates (error bars represent standard error). ii. Graphs displaying 
HEK293 percentage cell viability (%) in response to the designated NCI 
compound over an increasing concentration range (LOG10 M), and were used 
to generate the IC50s for each of the 3 replicates (error bars represent standard 
error). iii. Graphs displaying RD1 percentage cell viability (%) in response to the 
designated NCI compound over an increasing concentration range (LOG10 M), 
and were used to generate the IC50s for each of the 3 replicates (error bars 
represent standard error). iv. IC50 values generated from the corresponding NCI 
‘hit’ compound dose response graphs for each of the three replicates for the 
A375, HEK293 and RD1 cell lines respectively. v. P-values (P-value = ≤ 0.05) 
generated using a student’s T-test to statistically compare IC50 values 
generated using the corresponding NCI ‘hit’ compound dose response graphs 
for the A375, HEK293 and RD1 cell lines. Those p-values highlighted in bold 
indicate those cell lines whose IC50 values can be considered statistically 
different from one another. A. NCI 20619. B. NCI 36525. C. NCI 43013.  
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B). A complete figure summarising IC50 statistical analysis for all 32 screened 
hit compounds can be found in Appendix IV. 
 
4.3 Discussion 
 
The NCI diversity set II chemical genetic screen was a success. Of the 1363 
compounds screened, 72 were identified as giving reproducible phenotypes. 
This suggests a hit rate of 5%, which represents a three percent increase from 
that exhibited in the previous Tomlinson et al., (2005) NCI diversity set I 
compound screen (2%). This may reflect a refinement in the compound 
selection process employed by the NCI when designing the NCI diversity set II 
library when compared to the NCI diversity set I. It might also reflect the fact that 
the significant labour such screens require was split between a colleague and 
myself, whereas the original screen was carried out by a single person. This 
may have enabled us to be more stringent in our general experimental practice 
as phenotype screening is time consuming and tiring requiring focus over long 
periods of time, thereby potentially reducing errors we may have made 
screening alone. Interestingly, the only hit compound that was identified in the 
original Tomlinson screen that was also present in the NCI diversity set II library 
(NCI 30712) was also identified as giving an abnormal phenotype in our screen. 
This suggests that we were efficient in identifying abnormal phenotypes and 
gives us some confidence that the majority of possible phenotypes were 
identified. All identified hit compounds were replicated later to minimise the risk 
of false positives. However, there is a possibility that in some cases embryos 
may have died through natural causes which would have otherwise presented a 
phenotype. Such false negatives are difficult to account for giving the scale of 
the task at hand. However, all compounds were initially screened at two 
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separate concentrations and it is unlikely that in both instances the embryos 
were to have died of natural causes. Whilst this does not eliminate the possibility 
of false negatives, it does reduce the possibility to what we perceive to be an 
acceptable level given the high success rate of phenotypic hit identified.  
 
It is clear that in many cases embryos presented phenotypes that could easily 
have been allocated into two or more separate phenotypic categories (the 
criteria for phenotypic classification and allocation is outlined above). For the 
purpose of this experiment it is not strictly important as to what phenotypic 
category they were assigned (this is covered in more detail in Chapter V), 
especially as all 72 of the compounds were preliminarily screened in the A375 
cell viability assay. It is noticeable however that many phenotypes regardless of 
their category often present an additional abnormal eye or abnormal general 
morphology phenotype. Given the broad appearance of these phenotypes 
(which were often subtle) and the structural diversity inherent in the compounds 
screened, this was considered to be representative of general toxicity in the 
embryos. As such, as these additional phenotypes were often marginal, their 
importance with regards to the mechanism of action of the compound itself was 
considered less interesting than the mechanism of action responsible for 
generating the more interesting multiple abnormal pigmentation phenotypes. 
 
As was the case in the original Tomlinson screen, the majority of phenotypes 
identified were pigmentation related. Total and partial pigment loss account for 
39% of all hit compounds identified, highlighting their prominence in this screen. 
Abnormal melanophore migration and melanophore morphology phenotypes 
were also well represented (accounting for 13% and 10% of identified hits 
respectively). Melanocytes are the cells which give rise to melanoma in humans, 
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therefore any compound (such as those identified here) that can inhibit 
migration, inhibit growth or induce apoptosis in those cells could well have 
therapeutic potential (as was previously shown in the Tomlinson et al., (2009) 
and White et al., (2011) screen with the discovery of leflunomide). During early 
development, the migratory neural crest cells differentiate into the melanocytes 
which are present in the X. laevis embryo dorsal and lateral stripe. Interestingly, 
the pigment producing cells observed in the eye are not derived from these 
neural crest cells. This may suggest that of those compounds shown which 
generate a phenotype consistent with a total loss of pigment, some may in fact 
simply inhibit the synthesis of the melanin pigment as opposed specifically 
promoting apoptosis or abnormal migration of the cells themselves. To address 
this we aim to screen all such compounds using the mushroom tyrosinase 
assay. The tyrosinase enzyme is critical in the synthesis of the melanin pigment 
and therefore its interference would indicate a loss of melanin. As numerous 
tyrosinase inhibitors have already been characterised and their therapeutic 
potential is low, such an assay would aid in refining the 72 hits compounds 
identified by highlighting those that may be acting through a potential novel 
therapeutic target or pathway. 
 
The cell viability assays have also been successful in identifying 13 compounds 
with significantly reduced the IC50 of the A375 cell line when compared to the 
respective HEK293 and RD1 controls. Of these compounds, five gave rise to 
abnormal melanophore migration phenotypes, 7 abnormal total or partial 
pigmentation loss phenotypes and one abnormal melanophore morphology 
phenotype in the X. laevis screen. This provides further evidence that those 
phenotypes identified as giving abnormal pigmentation defects are indicative of 
compounds that may have therapeutic potential towards the treatment of 
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melanoma. The cell viability assay was chosen for its practical considerations 
(high-throughput potential, short run time and high reproducibility). It could be 
argued however that cell viability as an end point does not reliably inform as to 
whether the decrease in viability observed is due to apoptosis or a decrease in 
proliferation. Such information would aid in understanding the compounds 
mechanism of action. As such, in the future we aim to support the cell viability 
data with both migration assays (such as the scratch assay (Liang et al., 2007)) 
and apoptosis assays (such as the well documented TUNEL assay (Kasagi et 
al., 1994)) to further understand the mechanism of action of the compounds in 
question. However the cell viability assays in this instance have been successful 
in reducing the number of hit compounds from 72 to 13. An additional note is 
that due to the genetic variability inherent in cancers (especially melanoma), it 
will be necessary in the future to carry out these screens using additional 
melanoma and control cell lines so as to further support the extent to which 
these compounds might be considered to have therapeutic value. 
 
The NCI diversity set II chemical genetic screen was a success. Of the 1363 
compounds screened, 72 were identified as giving reproducible phenotypes. Of 
these, 13 were shown to statistically significantly reduce the IC50 of the A375 
melanoma cell line when compared to their HEK293 and RD1 controls, 
suggesting they may have therapeutic potential towards the treatment of 
melanoma. This strongly promotes the use of X. laevis as a forward chemical 
genetic screening model, which in combination with cell based assays has 
rapidly generated 13 structurally diverse lead compounds. This again highlights 
the potential of X. laevis as a tool for drug discovery. The benefit of a forward 
chemical genetic screening strategy is the rapid generation of hit compounds 
with potentially novel mechanisms of action. The traditional bottle neck of this 
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strategy however is the identification of the targets involved, particularly if little 
biological data is known about the compounds in question (as is the case with 
the NCI diversity set II compound library). This has led to the development of in 
silico chemoinformatical algorithms which are now used to predict potential 
binding targets. The application of chemoinformatics towards the identification of 
targets for compounds identified in this screen is discussed in Chapter V.  
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Chapter V 
 
5.0 Chemoinformatical analysis of the X. laevis NCI 
diversity set II compound screen 
 
5.1 Introduction 
 
Forward chemical genetic screening excels in rapidly identifying compound 
bioactivity through the generation of interesting phenotypes. A critical bottleneck 
in forward chemical genetic screening arises when attempting to determine the 
identified compounds mechanism of action. Often compounds screened have 
ambiguous or no previous biological information, providing little help in 
identifying any potential target(s) involved. Chemoinformatical algorithms can be 
used to compare screened compound chemical information with known 
biological information from similar structural isoforms to predict potential targets. 
This provides a platform from which experimenters are able to begin 
investigating a compounds mechanism of action. Traditionally, mechanism of 
action has been predicted by comparing the screened libraries chemical 
information (such as two dimensional or three dimensional structures) with 
training sets consisting of compounds with known mechanism of action, which 
act as activity landmarks. This approach can be effective but is also limited, as it 
relies upon the availability of a relevant landmark compound that has a clear 
and specific mechanism of action, and often only accounts for the inhibition of a 
single target (whereas a phenotype may be produced by many). One approach 
to circumvent this issue is to integrate chemical similarity comparisons with 
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phenotypic data. Training statistical models (using compound structural 
information that are associated with known targets) can reveal new relationships 
between phenotypes and compounds. It is also possible to integrate relevant 
signalling pathways and disease information into the analysis.  
 
5.2 Results 
 
5.2.1 Bender laboratory chemoinformatical analysis of the NCI diversity 
set II chemical genetic screen 
 
During my PhD we formed a collaboration with the Bender laboratory (Unilever, 
Cambridge), who specialise in chemoinformatical compound target prediction. 
The Bender laboratory utilised the data generated in my X. laevis chemical 
genetic screen (described in Chapter IV) to produce a list of targets for each 
phenotypic category, each of which being statistically strongly predicted to have 
not been associated by chance (Liggi, 2013). To achieve this, each of the 
compounds two dimensional structures from the NCI diversity set II compound 
library were pre-processed according to the Bender laboratories specific criteria 
(to enable consistent analysis). The compounds were then cross referenced 
with the ChEMBL v10 training set (approximately 155,000 ligand pair covering 
894 targets) to predict potential targets for the entire NCI diversity set II 
compound library. The NCI diversity set II 72 identified hit compounds then 
isolated and processed using several visualisation and clustering methods so as 
their bioactivity profile similarity might be assessed. Similarities and 
dissimilarities between predicted targets for compounds belonging to each 
phenotypic category were then compared. Compounds were then further 
classified to establish the best data splits. This determined which predicted 
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targets were predicted to give rise to which phenotype. Predicted targets for 
each phenotypic category were then ranked statistically by calculating the 
probability that a particular prediction is relevant as opposed to occurring by 
chance. This was achieved by generating an estimation score for each target as 
a measure of the probability that a particular event (in this case: target 
predicted) might have occurred by chance (or is in fact actually relevant). 
Estimation scores were generated by first calculating the frequency of each 
predicted target (each of which having been predicted to generate a specific 
phenotype) in 10000 separate random control datasets. The "total frequency" of 
a target obtained in the NCI data set was then divided by the total frequency 
obtained by the same target in the random datasets, generating a value 
between 0 (enriched) and 1 (random). For example, let us consider the case of 
target A, which has a frequency of 3 in the NCI dataset, and is also found 
150/10000 times with a frequency smaller than 3 in the random datasets. Its 
estimation score would be 150/10000 = 0.015, and the target would be considered 
enriched - it is unlikely to obtain the same frequency by chance. Vice versa, 
target B has a frequency of 8, but its frequency is bigger in 7000 random 
datasets, having an estimation score of 7000/10000 = 0.7. Targets with an 
Estimation score less than 0.01 were considered to be enriched. The result of 
the Bender group analysis was the generation of predicted targets for each 
phenotypic category that were statistically highly unlikely to have occurred by 
chance (Liggi, 2013). 
 
The generation of predicted targets for each phenotype gives us a platform from 
which to begin exploring the NCI hit compounds mechanism of action, however 
their involvement requires biological validation. To achieve this, compound 
antagonists for ten of the abnormal melanophore migration predicted targets 
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were obtained and screened on X. laevis embryos (under the same conditions 
and concentrations used in the NCI screen), to observe if the abnormal 
melanophore migration phenotypes could be replicated (Table 10). Abnormal 
melanophore migration predicted targets were chosen as the phenotype in X. 
laevis has been shown before to be indicative of compounds that might have 
therapeutic potential towards the treatment of melanoma (as was the case for 
leflunomide and is also supported by data presented in this thesis). Therefore 
these predicted targets if validated may have therapeutic potential as novel drug 
targets for the treatment of melanoma. Successful validation would also go 
some way towards providing confidence in such chemoinformatical predictions, 
thereby promoting this system as a potentially powerful tool for novel target 
discovery in forward chemical genetic screens.  
 
5.2.2 Summary of targets predicted to give rise to abnormal melanophore 
migration phenotypes when antagonised 
 
The Bender report listed a number of targets predicted to give rise to each of the 
phenotypic categories listed previously. Table 11 summarises those targets 
predicted to be involved in generating an abnormal melanophore migration 
phenotype. The targets are listed in order of p value significance, so that those 
targets with the lowest p-value (and therefore predicted to statistically have the 
highest probability of being involved in generating an abnormal melanophore 
migration phenotype) are listed at the top, and those with the highest estimation 
scores (and therefore are predicted to be less statistically significantly likely to 
be involved in generating an abnormal melanophore migration phenotype) are at 
the bottom. It should be noted that all targets shown are predicted to be
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Table 10. Complete list of those compounds predicted to give rise to an 
abnormal melanophore migration phenotype (p = ≤ 0.01). 
 
 
 
 
 
 
 
Predicted target Gene name p-value 
Urokinase-type plasminogen activator PLAU 0 
Serine/threonine-protein kinase WEE1 WEE1 0.0001 
Estrogen-related receptor beta ER-β 0.0002 
3-phosphoinositide dependent protein kinase-1 PDK1 0.0004 
MAP kinase-activated protein kinase 2 MAPKAPK2 0.0009 
Monoamine oxidase A MAO 0.0011 
Estradiol 17-beta-dehydrogenase 2 HSD17B2 0.0027 
Cytochrome P450 1A2 CYP1A1 0.0029 
Protein-tyrosine phosphatase LC-PTP PTPN7 0.0031 
Induced myeloid leukemia cell differentiation protein MCL-1 0.0033 
Serine/threonine-protein kinase c-RAF 0.0061 
Vascular endothelial growth factor receptor 3 VEGF-C 0.008 
cGMP-inhibited 3',5'-cyclic phosphodiesterase B PDE3B 0.0091 
Ribosomal protein S6 kinase 1 RSK3 0.0092 
Tyrosine-protein kinase SRC c-SRC 0.0093 
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Table 11. Summary of abnormal melanophore migration predictedtargets, 
alongside their respective compound antagonists. The compound structure and 
source of the antagonists are also provided 
 
Predicted 
target 
Compound 
name 
Source Structure 
Wee1 PD407824 Tocris Bioscience 
 
ER-β PHTPP 
Santa Cruz 
Biotechnology 
 
MAO 
Bifemelane 
hydrochloride 
Tocris Bioscience 
 
MCL-1 MIM1 Tocris Bioscience 
 
c-Raf1 GW 5074 
Santa Cruz 
Biotechnology 
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VEGF-C AAL-993 
Santa Cruz 
Biotechnology 
 
PDE3B 
 
Anagrelide 
hydrochloride 
 
Santa Cruz 
Biotechnology 
 
RSK2 SB203580 
Santa Cruz 
Biotechnology 
 
RSK3 BRD 7389 Tocris Bioscience 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
167 
 
 
Table 12. NCI hit compounds shown to statisically significantly reduce the A357 
melanoma line when compared to their respecitve non melanoma controls 
versus the abnormal melanophore migration predicted targets. X indicates those 
targets an NCI compound is directly predicted to bind to. NCI compounds are 
shown with there associated X. laevis phenotypes. Mg. Abnormal melanophore 
migration. P. Total or partial pigment loss 
 
 
 
19219 43013 45536 79253 92794 111848 133002 153792 319471 
 Mg P P P Mg P Mg P P 
ER-β X X X 
 
X X 
   
MAO X 
        
PLAU 
      
X 
  
c-Raf1 X 
      
X 
 
VEGF-C 
     
X 
 
X X 
RSK2 X 
        
RSK3 X 
        
Mcl-1 
 
X 
 
X X 
  
X X 
WEE1 
    
X X 
   
PDE3B 
  
X 
  
X 
 
X 
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statistically significantly likely to generate the abnormal melanophore migration 
phenotype, only the extent of this significance varies. Of those potential targets 
listed in Table 8, 10 were predicted to be targeted by nine of the 13 hit NCI 
compounds previously identified to generate a statistically lower IC50 in the 
A375 melanoma cell line when compared to its respective non-melanoma 
controls (Table 9). The remaining four NCI compounds previously identified to 
generate a statistically lower IC50 in the A375 melanoma cell line when 
compared to its respective non-melanoma controls were not predicted to interact 
with any of the abnormal melanophore migration predicted targets.  
 
Of the nine NCI compounds that were predicted to interact with the abnormal 
melanophore migration predicted targets, three generated abnormal 
melanophore migration phenotypes in the X. laevis embryos whereas the  
remaining six generated phenotypes consistent with total or partial pigmentation 
loss (Table 9) when screened at 40µM. Of the nine NCI compounds listed, three 
(NCI 19219, NCI 92794 and NCI 153792) were predicted to interact with 4 or 
more of the abnormal melanophore morphology predicted targets. Only NCI 
79253 and NCI 133002 were predicted to bind to a single target. Of the 10 
predicted abnormal melanophore migration targets shown, MAO, PLAU, RSK2 
and RSK3 were the only targets predicted to bind to a single NCI compound. 
NCI 133002 was the only example of an NCI compound to be predicted to 
interact with a single target, of which that single target (PLAU) was also only 
predicted to interact with that specific NCI compound. 
 
As abnormal melanophore migration phenotypes in X. laevis may potentially be 
indicative of novel compounds or targets with possible therapeutic value towards 
the treatment of melanoma, each of the 10 predicted abnormal melanophore 
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migration targets predicted were looked at in more detail. It was determined as 
to whether these predicted targets had any previous evidence linking their 
involvement to the disease. Table 13 provides a summary of this information. Of 
the 10 targets predicted, six (ER-β, PLAU, c_Raf1, VEGF-C, Mcl-1, MAO, RSK2 
and WEE1) were found to have literature evidence linking them to being 
involved in melanoma. The remaining four (RSK3 and PDE3B) had no literature 
evidence linking their involvement towards melanoma.  
 
5.2.3 Validation of abnormal melanophore migration predicted 
phenotypes 
 
To validate the targets predicted to be involved in the generation of abnormal 
melanophore migration phenotypes, a compound antagonist was ordered for 
each of the 9 predicted targets Table 10. A compound antagonist for the 
predicted target PLAU has so far not been obtainable. Of the nine compounds 
ordered, six (GW5074, MIM1, Bifemelane hydrochloride, AAL993, BRD7389 
and PHTPP).gave rise to abnormal pigmentation phenotypes in X. laevis 
embryos at stage 38 (40µM) (Figure 38).. Embryos subjected to the remaining 
four compounds (PD407824, anagrelide hydrochloride, SB203580) at the same 
concentration did not survive. Due to time constraints, dose response assays 
analysing the effects of these antagonists have not yet been completed. All six 
phenotypes generated by the predicted target antagonists affected pigmentation 
in some way. The C-Raf1 antagonist GW5074 can be seen to give a clear loss 
of pigmentation in the lateral stripe and eye, and also presents what appears to 
be abnormal melanophore migration in the lateral and dorsal stripe (Figure 39 
B). Of the hit NCI compounds listed above as being predicted to interact with C- 
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Table 13. Predicted abnormal melanophore migration targets are highlighted 
according to whether or not current literature has linked their involvement to 
melanoma. Example literature sources are provided for all positive examples. 
 
 
 
 
 
Target Involvement Supporting literature  
ER-β Yes (de Giorgi et al., 2011)  
MAO Yes (Pietrangeli and Mondovi, 2004)  
PLAU Yes (Besch et al., 2007; Marconi et al., 2008) 
c-Raf1 Yes (Karreth et al., 2009) 
VEGF-C Yes 
(Peppicelli et al., 2013; Rinderknecht and Detmar, 
2008) 
RSK2 Yes (Cho et al., 2012) 
RSK3 No 
 Mcl-1 Yes (Jiang et al., 2008) 
WEE1 Yes (Magnussen et al., 2012) 
PDE3B No 
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Raf1 (NCI 19219 and NCI 153792) (Figure 39 C and D), NCI 19219 would 
appear to present a phenotype that is very similar in appearance to that 
described for GW5074. The NCI 153792 phenotype is less similar in 
appearance, possessing near full normal pigmentation in the lateral stripe and 
eye when compared to GW5074, but is still similar in that it also presents a 
slight abnormal melanophore migration phenotype. 
 
The Mcl-1 antagonist MIM1 appears to have generated a severely stunted 
embryonic phenotype that is devoid of pigment (Figure 40 B). Based on this 
image, it is not possible to determine whether the loss of pigment observed is 
due to a direct effect of the compound itself or the significantly delayed growth 
exhibited by the sample in question. Of the NCI compounds predicted to interact 
with Mcl-1 (NCI 43013, NCI 45536, NCI 79253, NCI 92794, NCI 111848, NCI 
153792 and NCI 319472), all presented phenotypes that exhibit a similar loss of  
pigmentation to varying degrees (Figure 40 C-I). Of these, NCI 43013 and NCI 
79253 appear to also display a similar stunted phenotype to that presented by 
MIM1. 
 
The MAO antagonist bifemelane hydrochloride presented a phenotype in which 
rounded melanophores can be seen in the lateral, stripe suggesting abnormal 
melanophore morphology (Figure 41 B). In addition, slight abnormal patterning 
of melanocytes along the dorsal stripe can be observed suggesting abnormal 
melanophore migration. Also, an abnormal eye phenotype is visible as a loss of 
pigmentation in the retinal epithelial pigment layer. Only NCI 19219 was 
predicted to interact with MAO, and the phenotype exhibited is similar to that 
presented by bifemelane hydrochloride (Figure 41 C). The abnormal eye  
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Figure 38. Sourced compound antagonists for potential melanophore migration phenotype giving targets identified the chemoinformatics report 
that gave rise to prominent phenotypes when assessed at stage 38 (when compared to the DMSO vehicle control). Embryos shown were 
screened at 40µM. A. DMSO solvent control. B. GW5074. C. MIM1. D. Bifemelane hydrochloride. E. AAL993. F. BRD7389.  G. PHTPP. 
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Figure 39. Stage 38 phenotype generated in response to GW5074 antagonist for predicted melanophore migration target c-Raf-1, alongside 
stage 38 hit NCI diversity set II compound phenotypes that were also predicted to antagonize the c-Raf-1 target. All NCI compounds shown 
have also previously been seen to give IC50s in the A375 melanoma cell line that were significantly different to their respective HEK293 and 
RD1 non-melanoma cell line controls. Embryos shown were screened at 40µM. A. DMSO solvent control. B. GW5074. C. NCI 19219. D. NCI 
153792.  
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Figure 40. Stage 38 phenotype generated in response to MIM1 antagonist for predicted melanophore migration target Mcl-1, alongside stage 
38 hit NCI diversity set II compound phenotypes that were also predicted to antagonize the Mcl-1 target. All NCI compounds shown have also 
previously been seen to give IC50s in the A375 melanoma cell line that were significantly different to their respective HEK293 and RD1 non-
melanoma cell line controls. Embryos shown were screened at 40µM. A. DMSO solvent control. B. MIM1. C. NCI 43013. D. NCI 45536. E. NCI 
79253. F. NCI 92794. G. NCI 111848. H. NCI 153792. I. NCI 319472.  
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Figure 41. Stage 38 phenotype generated in response to bifemelane hydrochloride antagonist for predicted melanophore migration target 
MAO, alongside stage 38 hit NCI diversity set II compound phenotypes that were also predicted to antagonize the MAO target. All NCI 
compounds shown have also previously been seen to give IC50s in the A375 melanoma cell line that were significantly different to their 
respective HEK293 and RD1 non-melanoma cell line controls. Embryos shown were screened at 40µM. A. DMSO solvent control. B. 
Bifemelane hydrochloride. C. NCI 19219.  
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development and abnormal melanophore morphology and migration can be 
observed as described for the bifemelane hydrochloride phenotype. 
 
The VEGF-C antagonist AAL993 generated a clear melanophore migration 
phenotype in both the lateral and dorsal stripe of the embryo (Figure 42 B). Of 
the NCI compounds predicted to interact with VEGF-C (NCI 111848, NCI 
153792 and NCI 319472), all presented phenotypes that exhibit a similar loss of 
pigmentation and abnormal melanophore migration to varying degrees (Figure 
42 C-E), although none were as prominent as the phenotype displayed by 
AAL993. 
 
The phenotype generated by BRD7389 (the RSK3 antagonist) was severely 
stunted, and presented a total lack of pigmentation, a complete lack of eye 
structure and blistering (Figure 43 B). As with MIM1 it is difficult to ascertain 
from this example the loss of pigment observed is due to a direct effect of the 
compound itself or the significantly delayed growth exhibited by the sample in 
question. The NCI compounds predicted to interact with RSK3 also present a 
loss of pigmentation in the lateral stripe (Figure 43 C). 
 
The PHTPP (ER-β antagonist) phenotype presented a loss of pigmentation in 
the lateral stripe and eye, and also demonstrated abnormal slight melanophore 
migration in the dorsal and lateral stripe (Figure 44 B). Also, an abnormal eye 
phenotype is visible as a loss of pigmentation in the retinal epithelial pigment 
layer. Of the NCI compounds predicted to interact with ER-β (NCI 19219, NCI 
43013, NCI 45536, NCI 92794 and NCI 111848), all demonstrated a loss of 
pigmentation similar to that generated by PHTPP to varying degrees (Figure 44 
C-G). In particular, NCI 19219 presents a very similar loss of lateral stripe.
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Figure 42. Stage 38 phenotype generated in response to AAL993 antagonist for predicted melanophore migration target VEGF-C, alongside 
stage 38 hit NCI diversity set II compound phenotypes that were also predicted to antagonize the VEGF-C target. All NCI compounds shown 
have also previously been seen to give IC50s in the A375 melanoma cell line that were significantly different to their respective HEK293 and 
RD1 non-melanoma cell line controls. Embryos shown were screened at 40µM. A. DMSO solvent control. B. AAL993. C. NCI 111848. D. NCI 
153792. E. NCI 319472.  
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Figure 43. Stage 38 phenotype generated in response to BRD7389 antagonist for predicted melanophore migration target RSK, alongside 
stage 38 hit NCI diversity set II compound phenotypes that were also predicted to antagonize the RSK target. All NCI compounds shown have 
also previously been seen to give IC50s in the A375 melanoma cell line that were significantly different to their respective HEK293 and RD1 
non-melanoma cell line controls. Embryos shown were screened at 40µM. A. DMSO solvent control. B. BRD7389. C. NCI 19219. 
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Figure 44. Stage 38 phenotype generated in response to PHTPP antagonist for predicted melanophore migration target ER-β, alongside stage 
38 hit NCI diversity set II compound phenotypes that were also predicted to antagonize the ER-β target. All NCI compounds shown have also 
previously been seen to give IC50s in the A375 melanoma cell line that were significantly different to their respective HEK293 and RD1 non-
melanoma cell line controls. Embryos shown were screened at 40µM. A. DMSO solvent control. B. PHTPP. C. NCI 19219. D. NCI 43013. E. 
NCI 45536. F. NCI 92794. G. NCI 111848. 
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pigmentation when compared to its PHTPP phenotypic counterpart. NCI 43013 
is the only NCI compound to exhibit and abnormal eye phenotype similar to that 
observed in the PHTPP phenotype. NCI 45536 also exhibits and eye phenotype 
in which the eye lacks structure and is larger than its corresponding controls, 
however it is not similar in appearance to that observed in the PHTPP 
phenotype.  
 
5.3 Discussion 
 
Using the structural data of the NCI diversity set II compound library combined 
with the phenotypic data generated from the X. laevis chemical genetic screen 
(as described in Chapter IV), the Bender laboratory produced a report in which 
many targets were predicted for each phenotypic category described in our X. 
laevis chemical genetic screen. Each of these targets were predicted to give rise 
to a similar phenotype in X. laevis embryos to that presented by its allocated 
phenotypic category (i.e. a target predicted to be associated with generating a 
total loss of pigmentation should generate this phenotype when antagonised in 
X. laevis embryos). All of the identified protein targets shared greater than 70% 
homology between Xenopus and human. This would suggest a high degree of 
conservation and suggest that these targets would be relevant with regards to a 
human system. 
 
Many of the abnormal melanophore migration predicted targets were also 
predicted to be targeted by nine out of 13 of the identified NCI compounds 
(shown previously to produce statistically significantly lower IC50 cell viabilities 
in the A375 melanoma cell line when compared to their respective non-
melanoma controls). NCI 19219, NCI 92794, NCI 111848 and NCI 153792 were 
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predicted to bind to three or more of the targets predicted to give rise to 
abnormal melanophore migration. This may suggest that these compounds are 
more promiscuous. It may also indicate that some of the abnormal melanophore 
migration predicated targets may only elicit the described predicted phenotype 
in combination, however this cannot be said with certainty until each of the 
targets phenotype is assessed by inhibiting their expression individually. One 
point of note is that the structural diversity inherent in the NCI diversity set II 
compound library means that even if two or more of the hit NCI compounds do 
interact with the same target, it is likely they do so through different binding 
mechanisms. That is to say, the NCI hit compounds may potentially have the 
same predicted target(s) but almost certainly interact with them through very 
different mechanisms. MAO and PLAU were the only example whereby one 
target was predicted to bind to a single NCI compound (NCI 133002 and NCI 
79253 respectively). Each of these NCI compounds are also both predicted to 
bind one single target. This may strongly suggest that the phenotypes elicited by 
NCI 133002 and NCI 79253 may well be acting through the inhibition of MAO 
and PLAU respectively, thereby potentially predicting their mechanism of action.  
 
One benefit of using a chemoinformatical approach is that novel targets might 
be identified that were previously not associated with a disease or condition (in 
this case melanoma). Alternatively it may indicate that compounds screened 
might pose an alternative inhibitor of a target that is well characterised in its role 
within a disease. This is significant because alternative structures may bind 
more efficiently or present lower off target effects, and as such may potentially 
be a more preferable therapeutic option than alternative compounds already on 
the market. Two of the 10 predicted abnormal melanophore migration 
phenotype targets (RSK3 and PDE3B) had no literature as regards to their 
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involvement in melanoma, suggesting that they may prove to be novel and thus 
far unexplored targets for its treatment. 
 
Of those predicted abnormal migration phenotype targets, the hormone ER-β 
has some evidence implicating its involvement towards melanoma progression. 
De Giorgi et al., (2009) used qPCR to determine that thicker more invasive 
melanoma tumours are correlated with a decrease in expressed ER-β and ER-β 
when compared to controls and non-invasive melanoma tumours (de Giorgi et 
al., 2009). As such, they go on to propose that the expression of ERs in 
melanoma tissue has the potential to be used as a prognostic indicator of 
invasive melanoma (de Giorgi et al., 2009). More evidence is required to better 
understand the role of ER-β in melanoma progression, however it would appear 
to have potential as a therapeutic target. The ER-β antagonist (PHTPP) 
presents a phenotype that displays a clear loss of pigmentation in the lateral 
stripe and eye, as well abnormal melanophore migration in the dorsal stripe. The 
phenotype bears a strong resemblance to all five of the hit NCI compounds 
predicted to bind to it. Given the similarity between the phenotypes observed, 
this may possibly represent the mechanism of action through which they 
operate. However as not all of the phenotypes are identical, this may also 
suggest that other targets may also be involved. 
 
Of those predicted abnormal migration phenotype targets, MAO was shown to 
have a link to melanoma. The primary function of the amine oxidase family is the 
deamination of oxidases, and are critical for the metabolism of amines. MAO is 
situated in the mitochondria and consists of two subtypes in the form of MAO-A 
and MAO-B. Only the MAO-A subtype has been implicated in melanoma 
progression (MacDonald and Lerer, 1994; Pietrangeli and Mondovi, 2004). The 
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MAO-A inhibitor clorgyline was shown to reduce apoptosis in A375 melanoma 
cells through a reduction in the production of free radicals (Pietrangeli and 
Mondovi, 2004). MAO-B has also been implicated to reduce the production of 
free radicals in cancerous cell lines, however its effects on melanoma survival 
have not yet been assessed (Marcocci et al., 2001). The target prediction does 
not appear to distinguish between the MAO subtypes and so a general inhibitor 
was obtained in order to observe if the predicted abnormal melanophore 
migration phenotype was replicated in X. laevis. Given that a slight melanophore 
migration/abnormal pigmentation phenotype was produced in the X. laevis 
embryo when exposed to the MAO antagonist (bifemelane hydrochloride) this 
suggests that the prediction was in fact accurate, in that compound interference 
with the MAO target produced the predicted phenotype. In the future it may be 
interesting to obtain inhibitors specific to each MAO subtype, so as to further 
assess their individual ability to produce an abnormal melanophore migration 
phenotype and begin to further evaluate their potential as targets for the 
treatment of melanoma. 
 
PLAU was also linked to melanoma progression. PLAU is involved in a range of 
biological processes including adhesion, migration and inflammation. Its 
increase in expression has been associated with numerous forms of cancer 
(including melanoma) and is believed to be a promoter of metastasis. A study by 
Besch et al., (2006) found that its inhibition in a range of melanoma cell lines 
induced apoptosis and mass death, implicating it as having strong potential as a 
therapeutic target towards the treatment of melanoma (Besch et al., 2007). A 
PLAU antagonist has been ordered but not yet screened on X. laevis embryos.  
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c-Raf1 has also already been well characterised in its role in melanoma. The b-
Raf subtype is mutated in 41% of melanomas and has already been exploited 
as a promising target for the treatment of melanoma with several effective 
inhibitors on the market (e.g. Vermurafenib and Debrafenib). It is not uncommon 
for patients to rapidly develop resistance to these drugs, in which activation of c-
Raf has been shown to play a critical role (Montagut et al., 2008). Activation of 
c-Raf has been shown to compensate for the inhibition of b-Raf in human 
melanoma cell lines by continuing to drive cell proliferation through the 
activation of the MAP kinase / ERK pathway (Karreth et al., 2009; Montagut et 
al., 2008). The c-Raf1 antagonist GW5074 produced a very pronounced 
melanophore migration phenotype in the X. laevis embryo, suggesting that the 
prediction of its role in generating an abnormal melanophore migration 
phenotype was accurate. Due to its role in b-Raf inhibitor resistance, c-Raf 
inhibition may well pose a potential route by which resistance can be avoided. 
As such the suggested NCI inhibitors of c-Raf shown here (NCI 19219 and NCI 
153792) may have potential implications towards the treatment of melanoma. 
 
Of those predicted abnormal migration phenotype targets, VEGF-C was also 
shown to be linked to melanoma in the literature. The VEGF family are well 
known for their role in promoting angiogeneisis to increase oxygen levels in 
tissues suffering from an anoxic environment. Through promoting angiogeneisis 
VEGF-C permits tumour growth allowing it to survive. VEGF-C has been 
implicated in melanoma by increasing tumour induced lymphangiogeneisis and 
promoting metastasis by the A375 melanoma cell line (Papoutsi et al., 2000). 
However despite promising in vivo data of VEGF inhibitors in cancer mouse 
models, their ability to treat cancer has so far not been successfully replicated in 
humans (Bergers and Hanahan, 2008). The VEGF-C inhibitor (AAL993) 
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produced a pronounced abnormal melanophore migration phenotype thereby 
validating its prediction. The AAL993 generated phenotype would suggest 
VEGF-C to be a possible target of the NCI compounds predicted to interact with 
it (NCI 111848, NCI 153792 and NCI 319472). However, great effort has been 
made into developing VEGF inhibitors for the treatment of cancer with little 
success, suggesting that other identified targets may present a more attractive 
option to pursue.  
 
The list of abnormal melanophore migration targets predicted two ribosomal s6 
kinase subtypes in the form of RSK2 and RSK3. The ribosomal s6 kinase (RSK) 
family are well known for their role in signal transduction. RSK2 has been 
previously associated with melanoma. Phosphorylated RSK2 expression has 
been shown to be significantly enhanced in human cancer cell lines when 
compared to non-cancerous controls, and is hypothesised to play a role in 
tolerance to ultraviolet stress (a known cause of melanoma) (Cho et al., 2012). 
Preliminary experiments with the RSK2 compound antagonist has led to the 
death of the embryos, however further experimentation by reducing the 
concentration of the compound may reveal further information as to its ability to 
replicate its predicted phenotype. RSK3 currently has no known implication 
towards melanoma development or progression. Its predication in the 
chemoinformatical analysis followed by subsequent replication of predicted 
phenotype in X. laevis embryos suggest that NCI compounds which were 
effective in reducing A375 melanoma IC50s (in this case NCI 19219), may be 
operating through a mechanism that has as of yet not been explored. However, 
NCI 19219 also is predicted to interact with four other targets, and therefore 
each of these targets needs to be further characterised individually (potentially 
via individual knock down experiments), to further understand their role in 
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generating the abnormal melanophore migration phenotype, and therefore their 
potential role as a therapeutic target in melanoma. 
 
Mcl-1 is well established in many cancers for promoting cell survival. Mcl-1 in 
melanoma has been previously shown to be critical for survival of human 
melanoma cell lines upon endoplasmic reticulum stress (Jiang et al., 2008), and 
its degradation has been shown to induce apoptosis in melanoma cells (Pandey 
et al., 2013). As such, it potentially poses an attractive target towards the 
treatment of melanoma. The phenotype generated by the Mcl-1 antagonist 
(MIM1) caused a severe delay in global development. It is hard to determine if 
the pigmentation phenotype observed is due to a direct effect of the compound 
antagonist or a result of the global toxicity observed. As such, it will be 
necessary in the future to screen using a lower concentration to see if the 
predicted abnormal phenotype can be validated in vivo. However, an abnormal 
pigmentation phenotype is still clearly visable, suggesting the chemoinformatical 
prediction may be correct. Another point of note is the large amount of hit NCI 
compounds predicted to interact with Mcl-1. This may suggest it represents a 
generic target and therefore possibly that all these NCI compounds may be 
acting through the same target. This would seem to be unlikely however as the 
original NCI phenotypes (for each of the hit compound predicted to bind to Mcl-
1), do not all look the same in appearance thereby suggesting additional 
variables may be involved. 
 
WEE1 has been strongly linked to melanoma and its expression is in fact a 
marker of prognosis (Magnussen et al., 2012). WEE1 plays a critical role in cell 
cycle regulation and has been implicated as a promoter of metastasis in 
melanoma (Magnussen et al., 2012). WEE1 therefore presents itself as an 
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attractive potential target towards the treatment of melanoma. The WEE1 
antagonist (PD407824) has so far lead to the death of the embryos, and as such 
a phenotype has not been detectable to validate its chemoinformatical prediction 
of generating an abnormal melanophore morphology phenotype. By refining the 
concentration administered it may be possible to validate this particular target in 
the near future. Two hit NCI compounds (NCI 92794 and NCI 111848) were 
predicted to interact with WEE1, thereby suggesting that should WEE1 be 
successfully biologically validated they may potentially be novel inhibitors. 
 
PDE3 enzymes are involved in the regulation of cardiac and vascular smooth 
muscle contractility. Whilst PDE3B has been implicated as having a genetic role 
in obesity, as of yet it has no known link towards the progression or promotion of 
melanoma. The PDE3B antagonist (anagrelide hydrochloride) led to the death of 
the embryos when screened. In the near future we aim to lower the 
concentration of the antagonist screened so as to assess whether a phenotype 
might be presented, or whether the compound is just generally toxic. PDE3B 
poses an interesting example of a compound which may potentially represent a 
novel target for the treatment of melanoma. However the prediction must be 
validated in vivo before we can hypothesise further. 
 
Two of the predicted targets (RSK3 and PDE3B) are particularly interesting, in 
that neither of them have been previously linked directly to melanoma 
progression. This may suggest their role in melanoma development may either 
operate through an unknown pathway or through a known pathway via a novel 
mechanism. Additional chemotherapeutics targeting different targets offers 
additional lines of defence when treating aggressive cancers such as 
melanoma. As such the identification of two potentially novel targets for the 
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treatment of melanoma is significant and warrants further investigation. It 
remains to be shown whether these targets have abnormal expression in patient 
tumour samples. 
 
The remaining eight compounds which were linked to melanoma can act as 
positive controls. It is to be expected that some compounds that generate 
abnormal melanophore migration phenotypes may well operate through targets 
known to be implicated in melanoma. Those predicted targets that were known 
to be associated with melanoma and also produced a pigmentation phenotype 
when antagonised in the X. laevis embryos go some way to supporting our 
belief that the X. laevis screening system is an excellent model for the 
identification of targets and/or compounds that have therapeutic potential 
towards the treatment of melanoma. That many of the hit NCI compounds 
identified reduce A375 cell viability were also predicted to interact with these 
predicted abnormal melanophore migration targets further strengthens our faith 
in the X. laevis screening assay we have developed but also in the predictive 
power of the chemoinformatical analysis itself. The six predicted target 
antagonists that produced an abnormal pigmentation phenotype support the 
predictive power of the assay. With adjustments to the dosing concentrations 
already discussed we hope to soon validate the remaining four predicted targets 
as well.  
 
There is a chance that the small compound antagonists ordered may be eliciting 
their respective phenotypes (whether they produced their predicted phenotype 
or not) via additional targets. Whilst these antagonists were selected based on 
their strong affinity towards each of the identified abnormal melanophore 
migration targets predicted, it is not possible to guarantee that the phenotypes 
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observed occur only through that mechanism with no off target effects. To fully 
validate these target predictions it will be necessary in the future to knock down 
the expression of each target via morpholino injection so as to then assess the 
specific effects the predicted target has towards generating its predicted 
phenotype. For the time being however, the compound antagonists have served 
their purpose by giving promising signs that the chemoinformatical predictions 
are in fact accurate.  
 
Through the combination of forward chemical genetic screening, appropriate cell 
based assays and chemoinformatical analysis we have developed an efficient 
and effective screening strategy for the rapid identification of numerous hit 
compounds that are likely to be acting through either well known or novel targets 
that may have possible implications towards the treatment of melanoma. As 
such, this strongly supports our argument that X. laevis screening systems such 
as this would be of great benefit to drug discovery. 
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Chapter VI 
 
6.0 Development of the X. laevis renal function toxicity 
assay 
 
6.1 Introduction 
 
Work presented in this thesis so far has focused on the X. laevis model system 
towards its application as a tool for drug discovery. It is yet to be established if 
the model can match its potential in its application towards drug development, 
specifically as a toxicity assay for the early detection of toxic compounds. To 
address this, I have designed (in collaboration with AstraZeneca) an X. laevis 
renal toxicity assay. Renal toxicity is a serious concern for the pharmaceutical 
industry, being responsible for 7% of preclinical compound dropouts 
(Desrochers et al., 2013; Fuchs and Hewitt, 2011). In addition, 30-50% of 
reported kidney failure in patients is due to adverse drug reactions (Desrochers 
et al., 2013; Fuchs and Hewitt, 2011; Pannu and Nadim, 2008). As such, there 
is a clear demand for an improved capacity for renal toxicity detection, as our 
current capabilities are insufficient. This thesis has already outlined the 
significant practical advantages of utilising the X. laevis animal model towards 
drug discovery. Combined with the strong history of the FETAX assay, this 
suggests that if the assay development is successful the X. laevis model has the 
potential to contribute towards the prediction of renal toxicity to the benefit of 
industrial drug development.  
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Whilst X. laevis has already been successfully used for the study of renal 
development (Brennan et al., 1999; Osafune et al., 2002; Seufert et al., 1999), it 
has not yet been used as a model for renal function. It is known that the X. 
laevis pronephros is functional from as early as stage 38, actively excreting 
ammonia into the surrounding media. Using a simple biochemical assay we 
believe that it is possible to detect ammonia excreted into the media and use 
this as an indirect measure of active renal function. The hypothesis was that 
nephrotoxic compounds introduced into the X. laevis system would result in a 
significant change in the amount of ammonia excreted, thereby indicating 
abnormal renal function as a result of nephrotoxicity. To aid in the validation of 
the assay, AstraZeneca provided a library of compounds which were known to 
be either non-toxic or nephrotoxic in humans (Table 14). Many of these 
nephrotoxic compounds were known to act via different mechanisms, therefore 
if they were detected in this assay and gave rise to abnormal ammonia excretion 
this would have gone some way to validating the assay as a measure of renal 
function. Some of these mechanisms include  
 
We have evaluated two possible assays for the detection of ammonia 
concentration in X. laevis media samples in the form of the salicylic acid assay 
and the glutamate dehydrogenase assay (outlined below). 
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Table 14. List of AstraZeneca supplied nephrotoxic and non-toxic compounds. 
 
 
 
Designated ID Compound name Known biological function 
NT1 Beclomethasone dipropionate Non-Toxic 
NT2 Fluoxetine Non-Toxic 
NT3 Diphenhydramine hydrochloride Non-Toxic 
NT4 S-(−)-Carbidopa Non-Toxic 
NT5 Gemfibrozil Non-Toxic 
NT6 Raloxifene hydrochloride Non-Toxic 
NT7 Zomepirac sodium salt Non-Toxic 
NT8 Loperamide hydrochloride Non-Toxic 
NT9 Rifapentine Non-Toxic 
NT10 Fexofenadine hydrochloride Non-Toxic 
NT11 Amiloride hydrochloride hydrate Non-Toxic 
NT12 Acarbose Non-Toxic 
Ne1 Vancomycin Nephrotoxic 
Ne2 Doxorubicin Nephrotoxic 
Ne3 Tobramycin Nephrotoxic 
Ne4 Leflunomide Nephrotoxic 
Ne5 Bithionol Nephrotoxic 
Ne6 Lisinopril Nephrotoxic 
Ne7 Amiodarone Nephrotoxic 
Ne8 Clindamycin hydrochloride Nephrotoxic 
Ne9 Zileuton Nephrotoxic 
Ne10 Rifabutin Nephrotoxic 
Ne11 Cefaclor Nephrotoxic 
Ne12 Idarubicin hydrochloride Nephrotoxic 
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6.2 Results 
 
6.2.1 Salicylic acid method of ammonia detection 
 
The salicylic acid method of ammonia detection was originally selected due to 
its simplicity and potential capacity towards high-throughput screening. It 
represents a modified version of the original Berthelot reaction, in which 
ammonium ions and phenol react to form an indophenol dye which absorbs 
strongly between 630nm and 720nm. The salicylic acid method of ammonia 
detection occurs via a reaction between ammonium ions present with 
hypochlorous acid and salicylate ions in the presence of nitroferricyanide ions to 
form the salicylic acid analogue of indeophenol blue (see reaction below).  
 
 
 
The absorption maximum of salicylic acid is 665nm. The amount of salicylic acid 
produced is indicative of the amount of ammonia present, i.e. the higher the 
absorbance measured, the higher the concentration of ammonia present in the 
media.  Initial experiments using the salicylic acid method of ammonia detection 
appeared to be promising. Initial optimisation experiments indicated that it was 
possible to detect an increase in detectable absorbance at 695nm with 
increasing concentration of ammonia, and that it was also possible to the 
observe an increase in absorbance in incubated embryo media from stage 38 
onwards (the stage at which the pronephros is believed to be functioning), 
NaOH, hypochlorite 
                NH4+ + salicylate                                                            indophenol (blue-green) 
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suggesting excreted ammonia was detectable with this assay. However, the 
DMSO solvent in which the AstraZeneca compounds were dissolved was later 
shown to inhibit the salicylic acid reaction from taking place (which was 
supported by (T. T. Ngo 1982))). As the majority of small molecules in 
compound libraries such as AstraZeneca’s are dissolved in DMSO, this problem 
was found to be unavoidable and necessitated the evaluation of a different 
biochemical assay for the detection of ammonia that could function in the 
presence of DMSO.  
  
6.2.2 Evaluation of the salicylic acid method of ammonia detection 
 
Initial optimisation experiments using the salicylic acid method of ammonia 
detection presented positive results. Using the JBL salicylic acid ammonia 
detection kit, it was shown that media obtained from embryos incubated in 0.1 X 
MMR (five embryos per well) from developmental stage 15, showed absorbance 
that was similar to that displayed by the negative control (Figure 45 A). When 
the same embryos were allowed to continue to develop to stage 45, the media 
showed a large increase in absorbance detected. This supports published data 
suggesting the X. laevis pronephros is only functional post embryonic stage 38 
and also suggests that little to no ammonia is excreted passively prior to this. In 
an attempt to standardise the JBL salicylic acid ammonia detection assay, 
standard curves were generated that showed a positive correlation between 
measured optical density at 695nm and increasing ammonia standard 
concentrations (6µM, 10µM, 20µM, 40µM, 60µM, 120µM, 160µM, 340µM and 
560µM) (Figure 45 B). This suggests that the JBL ammonia assay kit is 
sensitive enough to detect varying levels of ammonia present in solution, which 
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is necessary to identify fluctuating ammonia excretion levels in embryos as a 
surrogate marker for renal function. 
 
A time course assay was carried out to determine whether ammonia could be 
detected in the media of X. laevis embryos over increasing incubation time. X. 
laevis embryos were plated five embryos per well at stage 38 in 0.1 X MMR (2ml 
final volume). At each time point (12 hour intervals) X. laevis embryo media was 
sampled to measure absorbence at 695nm. In an attempt to refine the X. laevis 
ammonia assay protocol, this experiment was carried out using either a 1000µl 
or 200µl media sample protocol (Figure 45 C). For each time point recorded, 
the 1000µl protocol was carried out according to the same protocol outlined for 
the original X. laevis salicylic acid assay. The 200µl protocol sampled 200µl of 
media per well (the same well as each sample taken for the 1000µl protocol to 
ensure consistency) and deposited directly into a 96 well plate, to which 6.6µl of 
reagent one, two and three were added and mixed via multichannel pipette. 
Each solutions absorbance was subsequently read in a plate reader. Also 
included in the graph is a negative control (fresh media with no embryos) and a 
positive control (560µM NH3 standard solution). Both the 1000µl and 200µl 
protocols showed a steady increase in absorbance over time. The 200µl 
protocol samples detected higher absorbance at each time point than the 1000µl 
protocol samples, although (with the exception of time point 72 hours) all of the 
time points between the 1000µl or 200µl media sample protocols have over 
lapping standard error. The negative and positive control show little change in 
adsorption over time, suggesting passive environmental ammonia diffusion was 
not occurring. 
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Figure 45. Optimization of the X. laevis salicylic acid ammonia detection assay. 
A. Assessment of ammonia detectable in X. laevis media at different 
developmental stages (having been incubated in sample media from stage 15). 
The positive control represents a 560µM ammonium sulphate stock solution. 
The negative control represents fresh media containing no embryos. Error bars 
represent standard error (n=3). * denotes ST38 and ST45 significant difference 
(P=<0.01).  B. Standard curve generated using increasing concentrations of 
ammonium sulphate solution. Error bars represent standard error (n=3). C. Time 
course assay in which embryo media absorbance was read every 12 hours for 
72 hours. The two protocols tested in this assay are represented as either the 
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200µl or 1000µl protocol. The positive control represents a 560µM ammonium 
sulphate stock solution. The negative control represents fresh media containing 
no embryos. Error bars represent standard error (n=3). D. Time course assay in 
which two types of negative control media absorbance were read every 12 
hours for 72 hours. The two protocols tested in this assay are represented as 
either the NCC (Negative Control ‘Clean’) or NCD (Negative Control ‘Dirty’). The 
positive control represents a 560µM ammonium sulphate stock solution. Error 
bars represent standard error (n=3). E. Absorption in response to number of 
embryos per well (1, 2, 3, 4 or 5 embryos per well, incubated at stage 38 and 
assayed at stage 45). – C, Negative Control (Fresh media containing no 
embryos). + C, Positive control (560µM ammonium sulphate stock solution). 
Error bars represent standard error (n=3) 
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In a separate time course experiment (Figure 45 D), two different negative 
controls were compared using the 1000µl media sample protocol in the form of 
‘dirty’ and ‘clean’ controls. Both controls represent media in which no embryos 
have been incubated (and are both therefore negative controls). The ‘clean’ 
control indicates media that has come from a fresh stock of 0.1 X MMR whereas 
the ‘dirty’ control represents media that has come from incubated embryos 
before the pronephros was functional (prior to stage 38). The purpose of the 
‘dirty’ control is to evaluate whether residual ammonia is being transferred to the 
sample wells during the experiment set up, and to see if this ‘dirty’ media has 
any effect on absorption over time. As the embryos have to be transferred in 
media, there is a possibility that ammonia in the incubated media may 
contaminate the experiment. The ‘dirty’ control can therefore be directly 
compared to the ‘clean’ control to assess this possibility. At no point during the 
time course assay did the ‘dirty’ negative control absorption appear to differ from 
the ‘clean’ control absorption.   
 
The potential effect of number of embryos per well may have on detected 
absorption in the JBL ammonia assay was assessed by plating embryos as 
stipulated in the original protocol  with either one, two, three, four or five 
embryos per well (Figure 45 E). Embryos were incubated for 72 hours (until 
embryonic stage 45) at which point their media absorbance was read. A positive 
correlation can be observed between number of embryos per well and 
absorbance detected at 695nm. 
 
To assess the predictive capacity of the X. laevis salicylic acid ammonia renal 
function toxicity assay, embryos were incubated from ST38 with one of either 10 
nephrotoxic or 5 nontoxic AstraZeneca compounds (40µM) (Figure 46 A). 
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Embryo media was then analysed according to the original protocol (out lined 
previously). For all 10 nephrotoxic and 5 nontoxic compounds screened, none 
presented an absorbance that was significantly different from the negative 
control. The positive control however recorded an absorbance consistent with 
that detected from previous experiments, suggesting that the lack of detectable 
absorbance in each test sample may be due to the addition of the AstraZeneca 
compounds to the assay. It is unlikely that 15 structurally diverse compounds 
would independently interfere with the salicylic acid assay reaction. The only 
common factor between these compounds is that they were all dissolved in the 
solvent DMSO. As such, the role of DMSO and its effect on the salicylic acid 
assay reaction was investigated.  
 
A literature search discovered that the salicylic acid reaction is inhibited by the 
presence of DMSO (T. T. Ngo 1982). This is supported by follow up studies 
using different salicylic acid ammonia detection assay brands (the API and 
TETRA ammonia detection kits) which also found in each case that the 
presence of DMSO at a variety of concentrations when using 560µM NH3 
standard solutions resulted in absorbance levels consistent with that of the 
negative control (across all three test kits) (Figure 46 B). The positive control 
(which contained no DMSO) gave absorption levels similar to those observed in 
previous assays for the same stock NH3 concentration (560µM) and was 
consistent across all three test kits. 
 
A final assay was conducted to determine if other solvents also inhibit the 
salicylic acid ammonia assay reaction (Figure 46 C). Of the solvents screened, 
DMF, EtOH and MeOH all appeared to have no effect on the absorbance 
detected when compared to the positive control. DMSO showed almost no 
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measurable absorbance detected (similar to that displayed by the negative 
control) suggesting that the reaction had been inhibited. 
 
6.2.3 Glutamate dehydrogenase assay method of detection 
 
The glutamate dehydrogenase assay was obtained in the form of an ammonia 
assay kit supplied by Sigma-Aldrich (AA0100). In this reaction, ammonia present 
in a sample solution (such as embryo media) reacts with α-ketoglutaric acid 
(KGA) and reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 
the presence of L-glutamate dehydrogenase (GDH) to from L- glutamate and 
oxidised nicotinamide adenine dinucleotide phosphate (NADP+), as depicted in 
the reaction below. 
 
The oxidation of NADPH to NADP+ results in a decrease in absorbance at 
340nm that is directly proportional to the concentration of ammonia present in 
the sample. By subtracting initial absorbance (before addition of GDH enzyme) 
from final absorption (five minutes prior to GDH enzyme addition), the Delta 
A340 was calculated. The larger the Delta A340, the more ammonia is present 
in the sample solution.  
                                                                             GDH 
KGA + NH4+ + NADPH                    L-glutamate + NADP+ + H2O 
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Figure 46. Assessment of AstraZeneca compounds on X. laevis renal function using the X. laevis salicylic acid ammonia detection assay. A. 
Absorption detected following addition of 10 AstraZeneca nephrotoxic (Ne) compounds and five AstraZeneca non-toxic compounds (NT) (40µM 
final concentration). Positive control represents absorption of media containing five embryos with no compound present. Negative control 
represents absorption of fresh media containing no embryos. Error bars represent standard error (n=3). B. Assessment of differing 
concentrations of DMSO effect upon absorption detected from media containing 560µM ammonium sulphate using three different salicylic acid 
ammonia detection assay kits (represented as the API, TETRA and JBL test kits). The positive control represents absorption of media contain 
560µM ammonium sulphate with no DMSO present. The Negative control represents absorption of fresh media containing no embryos. Error 
bars represent standard error (n=3). C. Assessment of different solvents and their effects on detectable absorbance when using the salicylic 
acid ammonia detection assay. Each solvent sample contained (1/1000) solvent concentration in a 560µM ammonium sulphate stock solution. 
The positive control represents absorption of media containing 560µM ammonium sulfate with no solvent present. The Negative control 
represents absorption of fresh media containing no embryos. (N=1). 
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6.2.4 Evaluation of the glutamate dehydrogenase assay method of 
ammonia detection 
 
Due to the unavoidable DMSO inhibition of the salicylic acid reaction, the 
glutamate dehydrogenase assay was adopted as a potential alternative 
biochemical assay. Data for the GDH assay had to be generated using a 
spectrophotometer, as plate reader samples generated uninterpretable results 
(data not shown). A standard curve was created to ensure that the assay was 
sensitive to a range of ammonia concentrations (Figure 47 A). A preliminary 
range of ammonia concentrations were trialed using this method with DMSO 
which showed no sign of interference as experienced when using the salicylic 
acid assay method of ammonia detection (data not shown). Due to time 
constraints, it was necessary to begin testing AstraZeneca compounds as soon 
as possible to assess their effect upon X. laevis renal function. 
 
To assess the predictive capacity of the X. laevis GDH ammonia renal function 
toxicity assay (and to ensure the assay functioned in the presence of DMSO), 
embryos were incubated from St38 with one of either 12 nephrotoxic or 12 
nontoxic AstraZeneca compounds (100µM) (Figure 47 B). Embryo media was 
then analysed according to the outlined protocol. A vehicle control was also 
included alongside a positive control (embryo media without DMSO) to ensure 
the DMSO solvent was having no effect on the assay. For all 12 nephrotoxic and 
12 nontoxic compounds screened, none generated a Delta(A430) that appeared 
significantly different to the vehicle control (Table 15). One possible exception is 
for the non-toxic compounds NT1 and NT7, which give rise to a significantly 
higher Delta(A430) suggesting an increase in ammonia excretion compared to 
the positive control. Nephrotoxic compounds NE5 and NE7 killed the embryos  
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Table 15. T-test comparison of AstraZeneca compound dosed embryo media 
generated Delta(A340) versus vehicle control Delta(A340). Significant values 
are highlighted in bold. Neg Con. Negative Control (P = 0.05) (n = 4). 
  
AstraZeneca compound P Value 
Pos Con 0.131 
Ne1 0.142 
Ne2 0.493 
Ne3 0.561 
Ne4 0.626 
Ne6 0.635 
Ne8 0.885 
Ne9 0.501 
Ne10 0.711 
Ne11 0.239 
Ne12 0.641 
NT1 0.028 
NT2 0.289 
NT3 0.406 
NT4 0.602 
NT5 0.958 
NT6 0.492 
NT7 0.019 
NT8 0.886 
NT9 0.738 
NT10 0.237 
NT11 0.859 
NT12 1 
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Figure 47. Assessment of the X. laevis GDH ammonia detection assay. A. Standard curve egenerated using increasing concentrations of 
ammonium sulphate solution. Error bars represent standard error (n=3). B. Delta A340 detected following addition of 10 AstraZeneca 
nephrotoxic (Ne) compounds and five AstraZeneca non-toxic compounds (NT) (100µM final concentration). Vehicle control (V Con) represents 
absorption of media containing five embryos with no compound present. Negative control represents absorption of fresh media containing no 
embryos. Pos Con represents embryo media without DMSO present. Error bars represent standard error (n=3). 
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before their media could be sampled. Phenotypes exhibited before death 
displayed no visible signs associated with X. laevis renal toxicity (such as 
edema formation). No significant difference was recorded between the vehicle 
and positive controls.  The lack of identifiable change in Delta(A340) between 
the test samples and the positive control suggests either the assay is not 
sensitive enough to detect a change in ammonia excretion (and therefore renal 
function), or that the AstraZeneca compounds are not toxic in the X. laevis 
system.  
 
6.3 Discussion 
 
Our initial aim was to develop a renal function assay using the X. laevis animal 
model to rapidly and accurately identify nephrotoxic compounds during 
preclinical drug development. Results suggest that neither the salicylic acid nor 
the GDH biochemical detection of ammonia assays were capable of determining 
abnormal renal function in the X. laevis model. Despite promising preliminary 
data from the initial assessment of the salicylic acid method of ammonia 
detection, its application towards drug development is not feasible due to its 
inhibition in the presence of DMSO. Many compounds are dissolved as standard 
in the DMSO solvent (including the majority of the compounds stocked and 
supplied by our AstraZeneca collaborators), severely diminishing the value of 
the assay. This is unfortunate as optimisation assays showed it to be consistent 
and sensitive. Importantly, initial experiments using the salicylic acid method of 
ammonia detection suggested that it is indeed possible to detect excreted 
ammonia as absorbance increased in incubated media samples when 
compared to negative controls. Embryos incubated from embryonic stages 15 to 
38 also showed no indication of ammonia present when compared to embryos 
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incubated from embryonic stages 15 to 45. This supports the literature which 
stipulates that the X. laevis pronephros is non-functional until after stage 38 
(Jones, 2005).  
 
The comparison between the original 1000µl and altered 200µl media sample 
salicylic acid assay methods suggested that the protocol could also be refined to 
improve throughput, another important concern in assay design. Another reason 
for comparing these two protocols was to assess whether or not the assay could 
be developed to reduce the quantity of reagents required (thereby making the 
assay more cost effective per reaction). Preliminary experiments suggest that 
utilising the 200µl protocol had potential, and thereby both the amount of 
reagents used and the assay throughput time could be reduced. This would 
have been worth investigating further had the assay not failed due to inhibition 
by DMSO. The increase in absorbance shown in the 200µl protocol may be due 
to it being transferred and mixed directly in the 96 well plates allowing each 
sample to be read in the plate reader faster than is possible in the 1000µl.  
 
Standard curves generated for both the salicylic assay and GDH assay could 
have been used to calculate the concentration of the ammonia in the solution of 
other samples. This was not done for the preliminary assays as it was only of 
concern that the absorbance in test samples was higher to that of the negative 
controls. Had the assays progressed further this would have been implemented 
as standard practice for each experiment to enable accurate calculation of 
sample ammonia concentration. Whilst this could have been easily implemented 
for the salicylic acid assay, the significant increase in samples per experiment 
would be problematic for the GDH assay which would only function in the 
spectrophotometer at this stage. This significant increase in throughput time 
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would have been unacceptable, and therefore a future experiment would have 
been to investigate how the GDH assay could be adapted into a plate reader 
format. 
 
The GDH assay was selected as the only remaining viable option for the 
biochemical detection of ammonia in solution. The original Berthelot reaction 
biochemical method of ammonia detection (from which the salicylic acid reaction 
is adapted), has also been shown to be inhibited by DMSO (Searle, 1984). 
Another alterative was the Nessler reaction, which functions through an entirely 
different reaction pathway (and therefore may not be inhibited by DMSO). 
However this was avoided as it produced large quantities of hot mercury as a 
side product and was considered unsuitable for use in a large scale industrial 
context. Ammonia electrochemical probes were also considered, however none 
could be sourced that would fit into the individual 96 wells in which the embryos 
were incubated. Further investigation would have required significant time and 
financial investment, leaving the GDH assay as the only viable remaining option.  
 
The GDH original protocol (despite numerous attempts) could not be 
successfully adapted towards a 96 well plate to plate reader format. Data 
generated was consistently uninterpretable and was not consistent with the 
standard curves that could be generated using the original protocol (data not 
shown). Here the major issue was most likely a failure to mix the reagents 
thoroughly in the smaller volumes necessary when working with 96 well plates. 
The original protocol necessitates that the reagents be mixed and their 
absorbance read quickly and in unison, presenting a challenge when faced with 
large samples numbers (96 compounds per plate) which are to be expected 
when developing assays based on industrial throughput expectations. One 
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suggestion might be to dialyse the GDH enzyme from the glycerol in which it is 
stored and reconstitute it in water. The reduction in viscosity would enable for 
easier and rapid mixing. Additionally, it may be possible to increase the volume 
of GDH added to enable easier pipette mixing.  
 
Addition of AstraZeneca compounds suggest that ammonia excreted by 
embryos is detectable by the GDH assay (in the form of elevated Delta(A340) 
measurements when compared to negative controls) and therefore DMSO was 
not inhibiting the reaction. However, Delta(A340) levels were not significantly 
different from that displayed by the vehicle control (with the exception of NT1 
and NT7). The lack of identifiable change in Delta(A340) between the test 
samples and the positive control suggests either the assay is not sensitive 
enough to detect a change in ammonia excretion (and therefore renal function), 
or that the AstraZeneca compounds are not toxic in the X. laevis system. NT1 
and NT7 did give significantly different Delta(A340) readings when compared 
with vehicle controls, despite these compounds having been shown to be 
previously non-toxic in humans (hence there should be no change in renal 
function). Also, in both cases the Delta(A340) of NT1 and NT7 are significantly 
higher than the vehicle control, suggesting an increase in ammonia excretion 
and therefore an increase in renal function. These findings suggest that the 
AstraZeneca compounds may not be eliciting the same effect in the embryos as 
they are known to elicit in humans.  
 
One possible future experiment is to further investigate the AstraZeneca 
nephrotoxic compounds Ne5 and Ne7, which lead to the death of the embryos 
before they could be sampled at embryonic stage 45. The phenotypes elicited 
before death displayed no visible signs of renal failure (such as edema) however 
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they may still have possibly arisen through nephrotoxicity. Screening these 
compounds on embryos at lower concentrations should improve survivability 
and potentially give rise to a detectable change in renal function. Unfortunately 
however even if this were shown to be the case failure to identify any change in 
renal function for 10 out of the 12 known nephrotoxic compounds is 
unacceptable for an assay of this nature, as it would imply the assays specificity 
is insufficient and would lead to the generation of numerous false negatives. The 
detection of the two non-toxic compound that were significantly different to the 
vehicle control also suggests that the assay also has the potential to generate 
false positive results. In summary, the X. laevis GDH ammonia detection renal 
function assay in its current from is not capable of detecting abnormal changes 
in renal function.  
 
A possible reason for the failure to detect a change in renal function may be due 
to a fault in the model itself. Cruz et al., (2013) noted that X. laevis excrete 
around 50% of ammonia via the skin and that both the ventral and dorsal skin 
were capable of generating an ammonia efflux (Cruz et al., 2013). This could 
lead to a situation whereby ammonia levels in the media are maintained by 
diffusion through the skin despite renal function impairment. This may potentially 
explain the observations in which there is no reduction in ammonia 
concentrations and consequently can claim no reduction in renal function 
regardless of the actual functionality of the embryo pronephros. However Cruz 
et al., (2013) conducted this research using adult X. laevis post metamorphosis 
frogs and it is not known to what extent X. laevis embryos at stage 45 excrete 
ammonia through their skin (as used in the renal function assay). This may 
require further investigation to determine if there is indeed a difference between 
adult and juvenile ammonia excretion via the skin before a conclusion can be 
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drawn in regards to its contribution towards the inability of the renal function 
assay to detect significant difference in ammonia excretion in renal functionally 
impaired embryos. 
 
Another possible flaw with the X. laevis model and its application towards 
prediction of renal toxicity is that the pronephros is essentially a single nephron, 
whereas the adult human kidney is comprised of millions of nephrons (Vize, 
2003). This suggests that the chronic toxic effects often associated with human 
renal toxicity cannot necessarily be replicated in the X. laevis embryos, as any 
toxicity directed towards the X. laevis pronephros may immediately generate 
renal failure. As such, the X. laevis renal function assay would only have been 
able to identify nephrotoxic compounds as being acute renal function inhibitors 
and would not be able to predict the possible chronic effects that might be 
elicited in humans. However as this assay would have been implemented early 
in preclinical trialling in drug development, it could act as an early warning 
system identifying those compounds that are potentially nephrotoxic and 
highlighting them as necessary of further investigation. The assay would avoid 
false negatives (a significant problem in drug development) and allow potentially 
nephrotoxic compounds to be screened in other renal toxicity assay systems 
much sooner than they would have if the assay were not available, saving time 
and financial investment.  
 
A novel toxicity assay must be proven to be both specific and efficient if it is to 
be successful. In being specific it must be able to determine its endpoint 
accurately with minimal false positives or false negatives. In being efficient it 
must be able to make such specific measurements in a timely manner with 
minimal labour. The extent to which these two factors can be achieved with 
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maximum effectiveness is dependent on factors such as the endpoint 
determined by the assay, the availability of other competing assays and the 
phase in development in which it is implemented. Evidence provided here 
suggests that the proposed X. laevis renal function assay cannot reliably 
achieve either of these goals. Whilst this may be disappointing, the assay was 
shown to be functional and ammonia excreted could be detected. Further 
investigation through other ammonia detection methods in the future (such as 
using an ammonium electrode) may yield better results. 
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Chapter VII 
 
7.0 Final conclusions and future directions 
 
7.1 Final Conclusions 
 
One of the primary aims of this thesis was to assess the applicability of the X. 
laevis model towards pharmaceutical drug development. The X. laevis model 
has proven itself to be a reliable and robust chemical genetic screening model, 
capable of rapidly identifying numerous hit compounds with potentially novel 
mechanisms of action. The NCI diversity set II compound screen was a 
success. Of the 1363 compounds screened, 72 hit compounds were identified 
that gave rise to numerous phenotypes of which the majority involved 
pigmentation abnormalities. Compounds that generate abnormal phenotypes 
involving pigmentation in X. laevis embryos such as those presented in this 
thesis have previously been suggested to indicate potential therapeutic 
applications towards melanoma (Tomlinson et al., 2009b; White et al., 2011), 
either directly through the compound itself or the target or pathway through 
which it was acting. The NCI diversity set II screen would appear to support this 
as 13 compounds identified in the NCI diversity set II compound screen 
presented statistically significantly lower percentage cell viability IC50s in the 
A375  melanoma cell line when compared to the non-melanoma controls. These 
compounds strongly support the capability of our screening strategies to rapidly 
identify compounds with potentially novel therapeutic applications towards the 
treatment of melanoma. In addition, due to the structural diversity inherent in the 
NCI diversity set II compound library it is likely that all compounds identified 
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operate through different targets or pathways thereby further increasing the 
value of those compounds identified.  
 
The addition of chemoinformatic analysis also significantly improved the value of 
the screen. Forward chemical genetic screens such as these typically stall when 
attempting to identify a hit compounds mechanism of action, particularly when 
the screened compounds have little or no known previous biological information. 
In silico predictions such as those generated by the Bender group (in 
collaboration with ourselves) have enabled us to rapidly identify both known and 
potentially novel predicted targets that may pose as novel therapeutic targets for 
the treatment of melanoma. Importantly these predictions do not only suggest 
targets for each of the individual hit compounds identified, but go further by 
predicting those targets which are commonly associated with a particular X. 
laevis phenotype generated. The replication of abnormal pigmentation and 
abnormal melanophore migration phenotypes (by screening alternative 
compound antagonists) validated 6 of the 10 abnormal melanophore migration 
phenotype predicted targets. This supports the accuracy of the 
chemoinformatical analysis and gives us encouragement that other predicted 
targets for both individual compounds and phenotypic categories have value 
and are worth exploring. The identification of two targets that have no known 
previous link to melanoma (RSK3 and PD3EB) suggest that this 
chemoinformatical prediction strategy is an effective method for identifying 
potentially novel targets with therapeutic applications towards the treatment of 
melanoma. Importantly, the majority of NCI compounds shown to give a 
statistically significantly lower IC50 in the A375 melanoma cell line when 
compared to non-melanoma controls have also been predicted to interact with 
the abnormal melanophore migration predicted targets, suggesting that these 
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compounds may be eliciting their phenotypes through these same predicted 
targets. This suggests that not only have we predicted potentially novel targets 
with therapeutic application towards melanoma (which have already begun to be 
validated biologically), but also we have identified several structurally diverse 
compounds that have been shown to reduce melanoma cell viability that are 
likely to be acting through these same targets. By effectively developing both the 
prediction of targets and the assessment of hit compounds on melanoma cell 
viability simultaneously, we have rapidly generated nine structurally diverse 
compounds that reduce melanoma cell viability through potentially novel targets 
or have the potential to be acting through known targets with as of yet undefined 
efficacy (which may potentially be better than other inhibitors currently 
available).  
 
In conclusion, the X. laevis chemical genetic screening model system we have 
implemented has proven itself to be capable of rapidly identifying numerous hit 
compounds, that in combination with appropriate cell based assays and 
chemoinformatics have generated several compounds and targets with 
potentially novel therapeutic applications towards the treatment of melanoma. 
As such the X. laevis chemical genetic system has proven itself to excel as a 
robust screening model, which in combination with appropriate supporting 
assays and chemoinformatical analysis has strong potential to contribute 
towards drug discovery.  
 
The second primary aim of my thesis was to assess the applicability of the X. 
laevis model towards drug development by developing a renal function toxicity 
assay. Preliminary experiments with the renal function assay were initially 
promising. Unfortunately however recent data suggests that it is not capable of 
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detecting abnormal renal function in X. laevis embryos. Ammonia excreted from 
the embryos was detectable from embryonic stage 38 onwards and therefore 
supported the literature as being the stage in development at which the 
pronephros becomes functional (Jones, 2005). However significant setbacks 
such as the inhibition of the salicylic acid assay by DMSO and the failure to 
detect any change in renal function when exposed to nephrotoxic compounds in 
the GDH assay have severely stunted the development of this assay. It may be 
that the GDH was not sensitive enough to detect a significant change in renal 
function or that the compounds did not exhibit the same effects in the X. laevis 
model as they have been shown to in humans. The specific mechanism of 
action for each of the nephrotoxic compounds is not known, and so it is difficult 
to determine whether the lack of toxicity is due to specific inter-species 
differences.  
 
Further work is required (as discussed previously) before the assay can 
progress further towards implementation in larger scale experiments. At this 
moment in time, whilst the assay remains an interesting and a potentially 
promising concept, it is not yet capable of contributing towards drug 
development.  
 
7.2 Future considerations 
 
The X. laevis screening strategy has proven itself to be highly amenable in its 
application towards drug discovery. However there are numerous areas in which 
further investigation would aid in validating the model as a chemical genetic 
screening organism. One particular concern when screening with aquatic 
organisms is that whilst it is convenient to simply add dosed compounds into the 
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embryos media as the primary route of exposure, it is not clear exactly what 
dose of the compound actually enters the X. laevis system. In adult organisms a 
primary route of exposure to xenobiotics is either orally or through uptake in the 
lungs or gut. The X. laevis embryos do not start feeding until embryonic stage 
45 (at which point they are considered to be sentient) and therefore all uptake of 
xenobiotics must come through either passive diffusion or active uptake until the 
gills open at embryonic stage 40. It is unlikely that all compounds administered 
enter the X. laevis system at the same rate. Therefore it is difficult to say with 
certainty at what concentration a phenotype may be elicited. For the same 
reasons, penetration and distribution of the compounds around the X. laevis 
embryos system are equally unknown. A possible solution to this (if accurate 
embryonic system compound concentrations are required) may be to take 
embryo samples and analyse them using mass spectrometry. Further work into 
this may help in further understanding how capable different compounds are 
taken up by X. laevis embryos from the media, allowing us to make educated 
predictions based on compound structure as to whether a compound is likely to 
penetrate the embryo system or whether it will struggle to be taken up. 
 
A further consideration with dosing embryos via media is that some compounds 
precipitate when administered. This is particularly relevant, as often some 
compounds in a library will precipitate and often this is unavoidable. Many of 
these compounds still elicit a phenotype, however it is not yet known what effect 
this has on X. laevis embryo uptake or what influences it might have on the 
phenotype presented. Personal observation suggests that precipitated 
compounds may lead to blistering in embryos. By developing the mass 
spectrometry technique suggested previously it may be possible to better 
understand the role precipitation has towards generating phenotypes.  
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In the future, visual scoring of the embryos phenotypes during the Xenopus 
screen may benefit from adopting approaches used during histopathology 
scoring. Terms used in the description of phenotypes during our screen included 
“mild, moderate and severe”. Such terms can reduce inter-observer repeatability 
over time, as their use is dependent on the observer’s opinion (Gibson-Corley et 
al., 2013). A better system would include a more quantitative approach. This 
could be achieved by described the percentage of pigmentation missing (when 
compared to a control) as a more specific measure of pigmentation loss. Such a 
process would increase throughput time of observing the embryos but would 
lead to more robust characterisation of phenotypes observed. 
 
To improve the scoring system further we have begun to implement automated 
X. laevis phenotype recognition software. In collaboration with the Bender 
laboratory, we have developed a programme that is capable of detecting and 
categorising specific abnormal pigmentation phenotypes from images of X. 
laevis embryos (Drakakis, 2014) (see attached publication). The development of 
such an automated system enables the standardisation of identified phenotypes 
and removes any potential experimenter bias when screening by eye. 
Implementation of this programme may improve the hit rate of identified 
phenotypes in future screens. 
 
Future work concerning those hit compounds from our screen that statistically 
significantly lowered IC50 cell viabilities in the A375 melanoma cell line when 
compared to controls will include the further assessment of their effect on 
different melanoma and control cell lines. This is important, as many cancers 
show large genetic variability (particularly melanoma) and as such it is important 
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that a potential therapeutic compound presents a desirable effect in several 
lines to predict its potential towards treating the wider population. As mentioned 
previously it will be necessary to assess these compounds using additional 
assays (such as the scratch or TUNEL assay) to better understand whether the 
decrease in observed cell viability is due to an increase in apoptosis or a 
decrease in proliferation.  
 
Additional future characterisation of the identified compounds might include the 
use of three dimensional cell culture modelling. Such assays are more relevant 
towards in vivo systems as they attempt to replicate the three dimensional 
environment of a tissue or organ. For example, 3D invasion assays culture 
cancer cells on a layer of Matrigel in the presence of a compound. The ability of 
the compound to reduce metastasis is measured by the cells ability to migrate 
through the gel. This is particularly relevant to cancers such as melanoma given 
its aggressive metastatic nature. This assay would therefore help greatly in the 
characterisation of the identified hit compounds identified in the Xenopus screen 
and evaluate their therapeutic potential. Should the compounds give positive 
results in these additional assays, the next stage would be to assess the 
compounds using xenograft models (White et al., 2011). In these in vivo assays, 
immune compromised mice are transplanted with human melanoma cells. The 
mice subsequently grow humanised melanomas, and the ability of the identified 
lead compound to treat the tumours are assessed. Compounds are 
administered for a set number of doses at different concentrations. Success of 
the compound in treating the tumour is assessed by measuring the reduction of 
tumour size or inhibition of growth (White et al., 2011). If the compounds give 
promising results in both the in vitro and in vivo assays it would then be worth 
approaching a pharmaceutical company to continue the evaluation of the 
223 
 
 
compounds on an industrial scale and begin pushing the compounds towards 
clinical trials and ultimately regulatory approval.  
 
It is notable that a large number of the phenotypes observed during the screen 
involve pigmentation. This may represent an inherent bias in the screen itself, 
whereby pigmentation is the most easily characterised and observed phenotype 
when embryos are scored visually. This may mean that less easily observed 
phenotypes (such as those involving specific organ function or development) 
may be missed under the current screening regime. As the primary focus of this 
screen has been directed towards identifying potential lead compounds for 
melanoma treatment, which derives from the melanocytes observed, this bias 
should not affect the assay in a detrimental way. As a screening system for 
identifying compounds for the treatment of melanoma, the current format has 
been shown to have a decent success rate (as shown by the discovery of 
leflunamide and potentially those compounds identified in this screen) (White et 
al., 2011).  
 
It may be that the melanocytes themselves however are more sensitive to this 
screening assay system then other cell types. The neural crest cells begin 
specifying at around embryonic stage 15, the same stage at which the 
compounds are dosed. This may mean that they are at a more sensitive time 
during their development and compound exposure may make it more likely that 
they fail to differentiate into the melanocytes. This possibility could be 
investigated by whole mount in situ hybridisation. By staining for neural crest 
cell/melanocyte specific markers it will be possible to detect the presence of 
either the neural crest cell or the melanocytes, allowing us to comment further 
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on the likelihood that the neural crest cells are more sensitive to this form of 
screening assay.  
 
The phenotypes described in this assay are developmental in nature. It could be 
asked as to whether a developmentally derived phenotype is translatable to a 
disease phenotype setting. Given the success of this screening strategy in the 
past with the discovery of Leflunomide, and the large number of pigmentation 
effecting compounds identified in this screen that were predicted to interact with 
therapeutic targets previously identified in melanoma, it would appear that our 
Xenopus screening system is relevant towards melanoma development. 
 
Concerning the chemoinformatical predictions, experiments looking to further 
validate abnormal melanophore migration predicted targets by genetic knock 
down are currently being planned using a CRISPR/Cas9 system (Auer et al., 
2014). If the same phenotype is observed in the Xenopus knockdowns as had 
been previously with the NCI compounds, this would suggest that the predicted 
target is correct. This will go some way to validating the original predictions and 
give us faith in the accuracy of other predictions in this analysis that have not yet 
been investigated. We also hope to investigate targets predicted for other 
phenotypic categories involving pigmentation, in the hope that they might also 
present promising novel targets for the treatment of melanoma.  
 
The specificity of the compounds themselves may also be assessed by 
ectopically expressing their targets. This would be particularly useful for those 
compounds that are predicted to bind to multiple targets. For example, a 
compound is predicted to bind to targets A and B. If target A is ectopically 
expressed in the presence of the compound and the phenotype is present, this 
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would suggest that target A is not responsible for generating the phenotype and 
therefore imply target B is the correct target. If target B is then ectopically 
expressed in the presence of the compound and no phenotype is presented, this 
would further imply target B is responsible for the observed effect. It is likely 
however that some compounds may be eliciting their phenotype through several 
targets. In this instance, careful planning will be required to elucidate which 
targets in combination generate the observed effect (Dar et al., 2012).  
 
There are few mutant lines available from which to explore the predicted target 
compounds identified. Interestingly, the MOA mutant zebrafish line 
(macott261/tt261) has been shown to induce abnormal melanocyte development. As 
of yet, no Xenopus mutant lines are available from which to further explore any 
of the predicted targets. 
 
A final future experiment concerning the X. laevis application towards drug 
discovery is to repeat the screen using different endpoints (I.e. not focusing on 
pigmentation), and see whether appropriate follow up assays and similar 
chemoninformatical analysis can identify promising lead compounds and targets 
in a similar manner to those discovered in this screen (Brandli, 2004; Kalin et al., 
2009). Developing the X. laevis system to encompass different endpoints may 
require the generation of mutant lines to create specific disease models. Whilst 
X. laevis may not be easily amenable to genetic manipulation, the closely 
related model X. tropicalis already has numerous mutant lines readily available. 
As the application of X. tropicalis towards chemical genetic screening has been 
shown in this thesis to be promising, it may be prudent to begin evaluating their 
further use in drug discovery chemical genetic screens.  
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As discussed previously, the X. laevis renal function toxicity assay does not in 
its current form appear to be capable of accurately detecting change in renal 
function in response to nephrotoxic compounds. This is unfortunate as clearly 
ammonia excretion could be detected. It may be possible to use the assay 
however as a model for renal function outside of the context of drug 
development. For example, it has been shown through in situ hybridisation that 
megalin, LRP2 and cublin are highly expressed in the Xenopus proximal tubule. 
By genetic knock out it would be possible using the renal function toxicity assay 
to determine if any of these proteins impair renal function once removed 
(Christensen et al., 2008). If the assay can detect a change in renal function 
then its use as an assay for the detection of renal function impairment may have 
use in an academic setting. 
 
In the future it may be prudent to consider other toxicity assays using the 
Xenopus focusing on alternative organ systems. Other possible assays include 
exploring liver toxicity, structural cardio toxicity and macrophage infiltration. All 
of these suggestions would require the development of a system in the X. laevis 
whereby an endpoint could be measured as a marker of toxicity. The assay 
would have to both reliable and high throughput and would requiring significant 
trialling and development time, but may one day potentially be of benefit towards 
drug development.   
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Appendix I Figure 1. Side by side comparison of NCI compounds identified in 
the NCI diversity set I compound screen that gave rise to a similar prominent 
abnormal pigmentation phenotype when assessed at stage 38 (when compared 
to the DMSO vehicle control) in both X. laevis and X. tropicalis. Ai. X. laevis 
DMSO solvent control. Aii. X. tropicalis DMSO solvent control. Bi. X. laevis NCI 
7734. Bii. X. tropicalis NCI 7734. Ci. X. laevis NCI 30712. Cii. X. tropicalis NCI 
30712. Di. X. laevis NCI 47938. Dii. X. tropicalis NCI 47938. Ei. X. laevis NCI 
62406. Eii. X. tropicalis NCI 62406. Fi. X. laevis NCI 86153. Fii. X. tropicalis NCI 
86153. Gi. X. laevis NCI 99676. Gii. X. tropicalis NCI 99676. Hi. X. laevis NCI 
130830. Hii. X. tropicalis NCI 130830. Ii. X. laevis NCI 132230. Iii. X. tropicalis 
NCI 132230. Ji. X. laevis NCI 158011. Jii. X. tropicalis NCI 158011. Ki. X. laevis 
NCI 164990. Kii. X. tropicalis NCI 164990. Li. X. laevis NCI 186066. Lii. X. 
tropicalis NCI 186066.  
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Appendix I Figure 2. Side by side comparison of NCI compounds identified in 
the NCI diversity set I compound screen that gave rise to a similar prominent 
melanophore morphology phenotype when assessed at stage 38 (when 
compared to the DMSO vehicle control) in both X. laevis and X. tropicalis. Ai. X. 
laevis DMSO solvent control. Aii. X. tropicalis DMSO solvent control. Bi. X. 
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laevis NCI 17173. Bii. X. tropicalis NCI 17173. Ci. X. laevis NCI 80126. Cii. X. 
tropicalis NCI 80126. Di. X. laevis NCI 227147. Dii. X. tropicalis NCI 227147. Ei. 
X. laevis NCI 609699. Eii. X. tropicalis NCI 609699. 
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Appendix I Figure 3. Side by side comparison of NCI compounds identified in 
the NCI diversity set I compound screen that gave rise to a similar prominent 
melanophore migration phenotype when assessed at stage 38 (when compared 
to the DMSO vehicle control) in both X. laevis and X. tropicalis. Ai. X. laevis 
DMSO solvent control. Aii. X. tropicalis DMSO solvent control. Bi. X. laevis NCI 
22207. Bii. X. tropicalis NCI 22207. Ci. X. laevis NCI 84093. Cii. X. tropicalis NCI 
84093. Di. X. laevis NCI 210627. Dii. X. tropicalis NCI 210627.  
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Appendix I Figure 4. Side by side comparison of NCI compounds identified in 
the NCI diversity set I compound screen that gave rise to a similar prominent 
eye development phenotype when assessed at stage 38 (when compared to the 
DMSO vehicle control) in both X. laevis and X. tropicalis. Ai. X. laevis DMSO 
solvent control. Aii. X. tropicalis DMSO solvent control. Bi. X. laevis NCI 101984. 
Bii. X. tropicalis NCI 101984. Ci. X. laevis NCI 143019. Cii. X. tropicalis NCI 
143019. Di. X. laevis NCI 638432. Dii. X. tropicalis NCI 638432. 
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Appendix II 
 
Appendix II Table 1. Collated dose response data in which embryos were 
exposed to hit compounds identified in the NCI diversity set II compound screen 
over a range of concentrations. Amount of embryos per well (n=20) which 
displayed a prominent phenotype at each concentration are displayed as a 
percentage of total embryos alive when assessed at stage 38 (1 = 100%). B, 
(blistering phenotype). E, (Edema phenotype).  ED, (eye development 
phenotype). P, (abnormal pigmentation phenotype). M, (abnormal morphology 
phenotype). Mg, (Abnormal melanophore migration phenotype). MM, (abnormal 
melanophore morphology phenotype). PD, (Percentage death). S, (stunted 
growth). 
 
 
Conc (μM) M S P MM MG E ED B PD 
  
                  
 
0.1 0.05 0 0 0 0 0 0.05 0 0 
 
1 0.05 0 0 0 0 0 0.05 0 0 
NCI 3001 
10 0.05 0 0 0 0 0 0.05 0 0 
25 0.2 0 0 0 0 0 0.1 0 0 
 
50 0.15 0 0 0 0 0 0.1 0 0 
 
100 0 0 0 0 0 0 0.15 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 4292 
10 0 0 0 1 0 0 0 0 0 
25 0 0 0 1 0 0 0 0 0 
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50 0 0 0 1 0 0 0 0 0 
 
100 0 0 0 1 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 5907 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0 0 0 0.25 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 9358 
10 0 0 1 0 0 0 0 0 0 
25 1 0 1 0 0 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 11624 
10 0 0 1 0 0 0 0 0 0 
25 0 1 0 0 0 1 0 0 0 
 
50 0 1 0 0 0 1 0 0 0 
 
100 0 1 0 0 0 1 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
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NCI 12588 
10 0 0 0 0 1 0 0 0 0 
25 0 0 1 1 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0.85 0 0 0.85 0 0.15 
 
1 0.1 0 0 1 1 0 1 0 0 
NCI 13156 
10 0 0 0 1 1 0 1 0 0 
25 0 0 0 1 1 0 1 0 0 
 
50 0.2 0 0 1 1 0 1 0 0 
 
100 0 0 0 0 1 1 0 0 0 
  
                  
           
 
0.1 0 0 0 1 0 0 0 0 0 
 
1 0 0 0 1 0 0 0 0 0 
NCI 13653 
10 1 0 0 1 0 0 0 0 0 
25 1 0 0 1 0 0 0 0 0 
 
50 1 0 1 1 0 0 1 0 0 
 
100 0 1 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 1 0 0 0 0 0 
 
1 1 0 0 1 1 0 0 0 0 
NCI 14380 
10 1 0 0 1 0 1 0 0 0 
25 0 0 0 0 0 0 0 0 1 
 
50 0 0 0 0 0 0 0 0 1 
 
100 0 0 0 0 0 0 0 0 1 
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0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 1 0 0 0 0 
NCI 19219 
10 0 0 0 0 1 0 0 0 0 
25 0 1 0 0 0 0 0 0 0 
 
50 0 1 0 0 0 0 0 0 0 
 
100 0 1 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 20618 
10 0 0 1 0 0 0 0 0 0 
25 1 0 1 0 0 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 0.8 0 0 0 0 0 0.2 
  
                  
           
 
0.1 0 0 0 0 0 0 0.05 0 0 
 
1 0 0 0 1 0 0 0 0 0 
NCI 20619 
10 0 0 0 1 0 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 0.95 0 0.05 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 21683 
10 1 0 0 0 0 0 0 1 0 
25 0 1 0 0 0 0 0 1 0 
 
50 0 1 0 0 0 0 0 1 0 
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100 0 1 0 0 0 0 0 1 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 30930 
10 0 0 0 0.7 0.5 0 0 0 0 
25 0 0 0 1 1 0 0.75 0 0 
 
50 0 0.3 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 1 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 31703 
10 0 0 0 1 1 0 0 0 0 
25 0 0 0 1 1 0 0 0 0 
 
50 0 0 0 1 1 0 0 0 0 
 
100 0 0 0 1 1 0 0 0 0 
  
                  
           
 
0.1 0 0 1 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 31762 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 1 0 0 0 0 
 
50 0 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 1 0 0 0 0 0 
NCI 34871 10 0 0 0 0.5 0 0 0 0 0 
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25 0 0 0 1 0 0 0 0 0 
 
50 0 0 0 1 0 0 0 0 0 
 
100 0 0 0 1 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 1 1 1 0 0 0 
 
1 0 0 0 1 1 0 0 0 0 
NCI 36525 
10 1 0 1 0 0 0 1 0 0 
25 1 0 1 0 0 0 1 0 0 
 
50 1 0 1 0 0 0 1 0 0 
 
100 0 0 1 0 0 0 1 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0.05 0 0 0 0 0 0 0 0 
NCI 42028 
10 0.05 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 1 0 0 0 0 0 0 
 
1 0 0 1 0 0 0 0 0 0 
NCI 43013 
10 0 0 1 0 0 0 0 0 0 
25 1 0 1 0 0 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
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1 0 0 0 0 0 0 0 0 0 
NCI 45536 
10 0 0 0 0 0 0 0.05 0 0 
25 0 0 0 1 0 0 0 0 0 
 
50 0.05 0 0 1 0 0 0 0 0 
 
100 0 0 0 1 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 45545 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0 0 0 0.3 0 0 0 0 0 
 
100 0 0 0 0.8 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 1 0 0 0 0 
 
1 0 0 0 0 1 0 0 0 0 
NCI 45572 
10 0 0 0 0 1 0 0 0 0 
25 0 0 0 0 1 0 0 0 0 
 
50 0 0 0 0 1 0 0 0 0 
 
100 0 0 0 0 1 0 0 0 0 
  
                  
           
 
0.1 0.1 0 0 0 0 0 0 0 0 
 
1 0.05 0 0.05 0 0 0 0 0 0 
NCI 59620 
10 0 0 0.05 0 0.05 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0.1 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
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0.1 1 0 0 0 0 1 0 0 0 
 
1 0.05 0 0 0 0 0 0 0 0 
NCI 62609 
10 0 0 0 0 0 0.05 0 0 0 
25 1 0 0 1 0 0.1 1 0 0 
 
50 1 0 0 1 0 1 1 1 0 
 
100 0 0 1 0 0 1 1 1 0 
  
                  
           
 
0.1 0 0 0 0.1 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 62611 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0.35 0 0 0 0 0 
 
50 0 0 0 1 0 0 0 0 0 
 
100 0 0 0 0.95 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0.85 0 0 0 0 0 
 
1 0 0 0 0 1 0 0 0 0 
NCI 66020 
10 1 0 0 0 1 0 1 0 0 
25 1 0 0 1 1 0 1 0 0 
 
50 1 0 0 1 1 0 1 0 0 
 
100 0 0 1 1 1 0 1 0 0 
  
                  
           
 
0.1 0.05 0 0 0.05 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 68971 
10 0 0 0 0.05 0 0 0 0 0 
25 0 0 0 0.1 0 0 0 0 0 
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50 1 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 1 0 0 0 0 0 0 
 
1 0 0 0 1 0 0 0 0 0 
NCI 79253 
10 0 0 0 1 0 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 85326 
10 0 0 0 0 0 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 1 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 87084 10 0 0 0 0 0 0 0 0 0 
 
25 0 0 0 1 0 0 0 0 0 
 
50 0 0 0 1 1 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 1 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
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NCI 88916 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0 0 0 0 1 0 0 0 0 
 
100 0 0 0 1 1 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 1 0 0 0 0 
NCI 92784 
10 0 0 0 0 1 0 0 0 0 
25 0 0 0 1 1 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 99657 
10 0.05 0 1 0 0 0 0 0 0 
25 0.1 0 1 0 0 0 0 0 0 
 
50 0.1 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0.1 0 0 0 0.2 0 0 0 0 
 
1 0 0 0.2 0 0 0 0 0 0 
NCI 99660 
10 0 0 0 0 1 0 0 0 0 
25 0 0 0.95 0.95 0.95 0 0 0 0.05 
 
50 0.1 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
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0.1 0.05 0 0 0 0.7 0 0 0 0 
 
1 0 0 0 1 1 0 0 0 0 
NCI 104993 
10 0 0 0 1 1 0 0 0 0 
25 1 0 0 1 1 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0.05 0 0 0 0 0 0 0 0 
 
1 0.1 0 0 0 0 0 0 0 0 
NCI 106581 
10 0.05 0 0 0 0 0 0 0 0 
25 0.15 0 0 0 0 0 0 0 0 
 
50 0.1 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 1 1 1 0 0 0 0 
 
1 0 0 1 1 1 0 0 0 0 
NCI 111848 
10 0 0 1 1 1 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0.15 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 117741 
10 0.1 0 0 0 0.2 0 0 0 0 
25 0.05 0 1 0 1 0 0 0 0 
 
50 0 0 1 1 1 0 0 0 0 
245 
 
 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 1 0 0 0 0 
NCI 130872 
10 0 0 0 0 1 0 0 0 0 
25 1 0 1 0 0 0 0 0 0 
 
50 1 0 1 1 1 0 0 0 0 
 
100 0 0 1 0 0 0 1 0 0 
  
                  
           
 
0.1 0.05 0 0 0 0 0 0 0 0 
 
1 0.05 0 0 0 0 0 0 0 0 
NCI 131982 
10 0 0 1 1 0 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0.15 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 131986 
10 0 0 1 1 0 0 0 0 0 
25 0.05 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 133002 10 0 0 0 0 0 0 0 0 0 
246 
 
 
25 0 0 0 1 0 0 0 0 0 
 
50 0 0 0 1 0 0 0 0 0 
 
100 0 0 0 1 1 0 0 0 0 
  
                  
           
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 135810 
10 0 0 0 0 1 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
          
  
  
        
 
 
0.1 0 0 0 0 1 0 0 0 0 
 
1 0 0 0 0 1 0 0 0 0 
NCI 138398 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 1 0 0 0 0 
 
50 0 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 1 1 0 0 0 0 
 
1 0 0 0 1 1 0 0 0 0 
NCI 139021 
10 1 0 0 0 0 0 1 0 0 
25 1 0 1 0 0 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
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0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 1 1 0 0 0 0 
NCI 150982 
10 1 0 0 0 0 0 0 0 0 
25 1 0 0 0 0 0 0 0 0 
 
50 0 0 0 0 0 0 0 0 1 
 
100 0 0 0 0 0 0 0 0 1 
  
                  
  
                
 
 
0.1 0 0 0 1 0 0 0 0 0 
 
1 0 0 0 1 0 0 0 0 0 
NCI 151262 
10 0 0 0 0 1 0 0 0 0 
25 0 1 0 0 0 0 0 0 0 
 
50 0 1 0 0 0 0 0 0 0 
 
100 0 1 0 0 0 0 0 0 0 
  
                  
  
                  
 
0.1 0.05 0 0.6 0 0 0 0 0 0 
 
1 0.3 0 0 0 0 0 0 0 0 
NCI 153792 
10 0.2 0 0 1 0 0 0 0 0 
25 0.15 0 0 1 0 0 0 0 0 
 
50 0 0 0 1 0 0.15 0 0 0 
 
100 0 0 0 1 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
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1 0 0 0 0 0 0 0 0 0 
NCI 154718 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 1 0 0 0 0 0 
 
50 1 0 0 1 1 0 0 0 0 
 
100 0 1 1 0 0 0 0 1 0 
  
                  
  
                
 
 
0.1 0 0 1 1 0 0 0 0 0 
 
1 0 0 1 1 0 0 0 0 0 
NCI 164965 
10 0 0 1 0 0 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 204262 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0 0 1 1 1 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 205832 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 1 0 0 0 0 0 
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50 1 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 1 0 0.65 0 0 0 0 0 0 
 
1 1 0 0.45 0.35 0 0 0 0 0 
NCI 205913 
10 1 0 0.4 0.55 0.55 0 0 0 0 
25 1 0 1 1 1 0 0 0 0 
 
50 1 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 308847 
10 0.05 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 
 
50 0 0 0 0 0 0 0 0 0 
 
100 0 0 0 0 0 0 1 1 0 
  
                  
  
                
 
 
0.1 0.05 0 0 0.05 0 0 0 0 0 
 
1 0.1 0 0 0.25 0 0.05 0 0 0 
NCI 319034 
10 0 0 0.95 0.4 0 0 0 0 0 
25 0.05 0 0.35 0.05 0.15 0 0 0 0 
 
50 0 0 1 0 0 0 0.05 0 0 
 
100 0 0 1 0 0 0 0 0 0 
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0.1 0 0 0 0 0 0 0 0 0 
 
1 0.05 0 0 0 0 0 0 0 0 
NCI 319741 
10 0 0 0 0 0.3 0.05 0 0 0 
25 0 0 0 0 0.2 0.05 0 0 0 
 
50 0 0 0 0 0 0 0.1 0 0 
 
100 0 0 0 0 0.1 0.05 0 0.05 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 340852 
10 0 0 0 0 0 0 0 0 0 
25 0 0 0 1 1 0 0 0 0 
 
50 0 0 0 1 1 0 0 0 0 
 
100 0 0 0 1 1 0 0 0 0 
  
                  
  
                
 
 
0.1 0.1 0 0 0 0.05 0 0 0 0 
 
1 0.05 0 0 0 0 0.05 0 0 0 
NCI 343557 
10 1 0 1 0 1 0 0 0 0 
25 1 0 1 0 1 0 0 0 0 
 
50 1 0 1 0 1 0 0 0 0 
 
100 0 0 1 0 1 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0.5 0 0 0 0 0 
 
1 0 0.2 0 1 0 0 0 0 0 
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NCI 377384 
10 0 1 0 0 1 0 0 0 0 
25 0 1 1 0 0 0 0 0 0 
 
50 0 1 0 0 1 0 1 0 0 
 
100 0 0 0 0 0 0 0 0 1 
  
                  
           
 
0.1 0 0 0 1 1 0 0 0 0 
 
1 0 0 0 1 0 0 0 0 0 
NCI 378719 
10 0 0 0 1 0 0 0 0 0 
25 0 0 0 1 1 0 0 0 0 
 
50 0 0 0 1 1 0 0 0 0 
 
100 0 0 0 1 0 0 0 0 0 
          
  
  
        
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 402590 
10 0 1 0 0 1 0 0 0 0 
25 0 1 0 0 1 0 0 0 0 
 
50 0 1 0 0 1 0 0 0 0 
 
100 0 1 0 0 1 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 515893 
10 1 0 1 0 0 1 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
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100 0 0 1 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 1 0 0 0 0 0 0 
NCI 645987 
10 0 0 1 0 0 0 0 0 0 
25 0 0 1 0 0 0 0 0 0 
 
50 0 0 1 0 0 0 0 0 0 
 
100 0 0 1 0 0 0 0 0 0 
  
                  
  
                
 
 
0.1 0 0 0 0 0 0 0 0 0 
 
1 0 0 0 0 0 0 0 0 0 
NCI 667251 
10 0 1 0 1 1 0 0 0 0 
25 0 1 0 1 1 0 0 0 0 
 
50 0 1 0 1 1 0 0 0 0 
 
100 0 1 0 0 0 0 0 0 0 
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Appendix III Figure 1. Dose response graphs displaying cell viability (%) of 
A375, HEK293 and RD1 cell lines in response to the designated NCI compound 
over an increasing concentration range (LOG10 M). Error bars represent 
standard error (n=3). Asterisks (*) indicate those compounds which gave rise to 
IC50s in the A375 cell line which were statistically different to those obtained in 
both corresponding HEK293 and RD1 control cell lines. A. NCI 3001. B. NCI 
13563. C. NCI 19219. D. NCI 20619. E. NCI 30712. F. NCI 34871. G. NCI 
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36525. H. NCI 43013. I. NCI 45536. J. NCI 59620. K. NCI 79253. L. NCI 87084. 
M. NCI 88916. N. NCI 92794. O. NCI 99660. P. NCI 111848. Q. NCI 117987. R. 
NCI 125197. S. NCI 130872. T. NCI 131982. U. NCI 131986. V. NCI 133002. W. 
NCI 138398. X. NCI 151262. Y. NCI 153792. Z. NCI 205832. AA. NCI 205913. 
AB. NCI 246415. AC. NCI 275971. AD. NCI 319471. AE. NCI 343557. AF. NCI 
378719.   
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Appendix IV Figure 1. Data used to calculate statistical differences between 
IC50s generated for each of the 32 tested NCI ‘hit’ compounds screened upon 
three cell lines (A375, HEK293 and RD1). i. Graphs displaying A375 percentage 
cell viability (%) in response to the designated NCI compound over an 
increasing concentration range (LOG10 M), and were used to generate the 
IC50s for each of the 3 replicates (error bars represent standard error). ii. 
Graphs displaying HEK293 percentage cell viability (%) in response to the 
designated NCI compound over an increasing concentration range (LOG10 M), 
and were used to generate the IC50s for each of the 3 replicates (error bars 
represent standard error). iii. Graphs displaying RD1 percentage cell viability 
(%) in response to the designated NCI compound over an increasing 
concentration range (LOG10 M), and were used to generate the IC50s for each 
of the 3 replicates (error bars represent standard error). iv. IC50 values 
generated from the corresponding NCI ‘hit’ compound dose response graphs for 
each of the three replicates for the A375, HEK293 and RD1 cell lines 
respectively. v. P-values (P-value = ≤ 0.05) generated using a student’s T-test to 
statistically compare IC50 values generated using the corresponding NCI ‘hit’ 
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compound dose response graphs for the A375, HEK293 and RD1 cell lines. 
Those p-values highlighted in bold indicate those cell lines whose IC50 values 
can be considered statistically different from one another. *** indicates those p-
values that could not be generated due to ambiguous IC50 data. A. NCI 3001. 
B. NCI 13563. C. NCI 19219. D. NCI 20619. E. NCI 30712. F. NCI 34871. G. 
NCI 36525. H. NCI 43013. I. NCI 45536. J. NCI 59620. K. NCI 79253. L. NCI 
87084. M. NCI 88916. N. NCI 92794. O. NCI 99660. P. NCI 111848. Q. NCI 
117987. R. NCI 125197. S. NCI 130872. T. NCI 131982. U. NCI 131986. V. NCI 
133002. W. NCI 138398. X. NCI 151262. Y. NCI 153792. Z. NCI 205832. AA. 
NCI 205913. AB. NCI 246415. AC. NCI 275971. AD. NCI 319471. AE. NCI 
343557. AF. NCI 378719.   
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Abbreviations 
 
2D: Two dimensional 
3D: Three dimensional 
ADME: Adsorption, distribution, 
metabolism and excretion 
DMSO: Dimethyl sulphoxide 
DNA: Deoxyribonucleic acid 
DMF: Dimethylformamide 
FBS: Foetal bovine serum 
FCS: Foetal calf serum 
FDA: USA Food and Drug 
Administration 
GDH: Glutamate dehydrogenase 
HCG: Human chorionic 
gonadotrophin 
HTS: High throughput screening 
 
 
 
 
 
 
 
 
 
 
µ: Micro 
m: Milli 
M: Molar 
MEMFA: Fix (MEM salts + 
formaldehyde) 
MOA: Mechanism of action 
NA: Not applicable 
NME: New molecular entity 
P: Probability 
PMSG: Serum gonadotrophin 
RT: Room temperature 
R&D: Research and development 
SAR: Structure activity relationship 
UV:ultraviolet 
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 Chapter 9 
 Chemical Genetics and Drug Discovery in  Xenopus 
 Matthew  L.  Tomlinson ,  Adam E.  Hendry , and  Grant  N.  Wheeler 
 Abstract 
 Chemical genetics uses small molecules to modulate protein function and has the potential to perturb any 
biochemical event in a complex cellular context. The application of chemical genetics to dissect biological 
processes has become an attractive alternative to mutagenesis screens due to its technical simplicity, inex-
pensive reagents, and low-startup costs.  Xenopus embryos are particularly amenable to whole organism 
chemical genetic screens. Here we describe the basic protocols we have developed to screen small 
compound libraries on  Xenopus laevis embryos. We score embryos either by observing phenotypic 
changes in the whole tadpole or by changes in gene expression pattern using automated wholemount in 
situ hybridization. 
 Key words:  Xenopus laevis ,  Chemical genetics ,  Small molecule screens ,  Drug discovery ,  Embryo 
development ,  Tadpole ,  Wholemount in situ hybridization 
 
 In recent years a great amount of effort has been focused upon the 
identi fi cation of novel molecular compounds with the capacity to 
modulate speci fi c protein functions for drug development and new 
biological tools. The range of new drug targets needs to expand as 
it is getting harder to discover new novel drugs with conventional 
techniques. The recent discovery of a compound that can inhibit 
melanoma growth  ( 1 ) is a good example of the power of chemical 
genetic approaches in  Xenopus and zebra fi sh to discover new novel 
drug targets, unlikely to have been discovered with more conven-
tional drug discovery approaches. 
 The advent of high-throughput chemical genetic screening has 
allowed researchers to quantitatively assess the phenotypic effects 
of hundreds of compounds in a short period of time. The bene fi ts 
of screening in a whole organism such as  Xenopus include being 
able to study cell to cell interactions, developmental processes, 
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toxicology, penetrance, and drug metabolism. In particular, assays 
such as the frog embryo teratogenesis assay— Xenopus (FETAX) 
are well-established methods for developmental toxicity hazard 
assessment  ( 2,  3 ) . 
 Xenopus laevis and  Xenopus tropicalis are highly amenable to 
medium–high-throughput screening  ( 4– 8 ) . Forward chemical 
genetic approaches using  X. laevis can be used to identify and 
investigate speci fi c developmental abnormalities  ( 7,  9 ) . There 
are more speci fi c bene fi ts to using  Xenopus such as its well-
characterized fate map, ability to regenerate, and the possibility 
to do high-throughput in situ screening. Using  X. tropicalis will 
also allow the linking of genetics and small molecule screening 
as is currently done with zebra fi sh. For instance, to perform 
enhancer/suppressor screens and assist in molecular target 
identi fi cation. 
 Xenopus was  fi rst established as a chemical genetic model in a 
proof of principle study looking at its utility with a set of com-
pounds used in an earlier zebra fi sh chemical genetic screen  ( 5 ) . In 
the past few years a number of screens using  Xenopus have been 
published looking at the vasculature, lymphangiogenesis, left/
right asymmetry, neural crest, and pigment cell development  ( 1,  5, 
 9– 11 ) . A study conducted by Tomlinson et al .  ( 6 ) was designed to 
screen 2,990 compounds to observe the developmental abnormal-
ities the compounds may cause. The initial screen identi fi ed 41 
compounds displaying various phenotypes affecting general devel-
opment, edema, eye development, melanophore migration, mel-
anophore morphology, and overall pigmentation  ( 6 ) . Using the 
chemoinformatic Discoverygate algorithm upon the pigmentation 
altering compound NSC210627 (originally identi fi ed in  Xenopus ) 
demonstrated strong structural similarities to the DHODH inhibi-
tor brequinar. Further chemoinformatic analysis and testing com-
pounds cross species with zebra fi sh and human melanoma cells 
(Xenografts) ultimately led to the discovery of le fl unomide, an 
arthritic drug now shown to have great promise in reducing mela-
noma growth in vitro and in vivo  ( 1 ) . These studies highlight the 
potential for forward chemical genetics in  Xenopus to identify new 
therapeutic compounds using readily available compound libraries 
( see  Note 1 ). 
 Here we will describe in detail the methods used in our lab 
for screening large libraries of small molecules. We shall describe 
two methods. One is the visual screen used in Tomlinson et al. 
 ( 6 ) . The other involves using high-throughput wholemount in 
situ hybridization to look for phenotypes associated with changes 
in gene expression patterns or cellular behavior with cell speci fi c 
markers. 
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  1.  1.6% Ethyl 3-aminobenzoate methane sulfonate (to euthanize 
male) : 0.5 g dissolved in 300 mL 0.1× MMR in a 500 mL 
beaker. 
  2.  2% Cysteine (250 mL) : This needs to be made fresh on the day 
of use. Keep at room temperature and discard at the end of the 
day. 5 g  l -cysteine dissolved in 250 mL 1× MMR. Adjusted to 
pH 8 with NaOH. 
  3.  10× MEM salts (1 L) : Add 209.3 g MOPS, 76.08 g 20 mM 
EGTA, and 2.46 g 10 mM MgSO 4 to a 2 L beaker and make 
up to 1 L with deionized H 2 O. pH to 7.4 with NaOH and 
sterilize via autoclave. Store at 4 °C protected from light/
wrapped in foil. 
  4.  MEMFA (10 mL) : 1 mL of 10× MEM salts and 1 mL of 37% 
Formaldehyde dissolved in 8 mL H 2 O ( see  Note 2 ). 
  5.  10× MMR (1 L) : Add 58.45 g 1 M NaCL, 1.5 g 20 mM KCl, 
2.0 g 10 mM MgCl 2 , 2.7 g CaCl 2 , and 11.9 g 50 mM HEPES 
to a 2 L beaker. Make up to 1 L with deionized H 2 O. pH to 
7.5 using NaOH ( see  Note 3 ) and sterilize via autoclave. 
  1.  0.1% PBST : Add 5 mL 10% Tween detergent to 495 mL DEPC 
PBS and mix well ( see  Note 4 ). 
  2.  Proteinase K : Add 1  μ L stock proteinase K to 1 mL of PBST 
( see  Note 5 ). Stock Proteinase K at 10 mg/mL is stored at 
−20 °C. 
  3.  Hybridization buffer (Hyb Buffer) : 50% formamide, 5× SSC, 
1 mg/mL Torula RNA, 100  μ g/mL Heparin, 1× Denharts 
solution, 0.1% Tween 20, 0.1% CHAPS, 10 mM EDTA. 
  4.  20× SSC : 175.3 g NaCl, 88.2 g Sodium citrate. pH adjusted to 
7.0 and volume to 1 L with DEPC H 2 O. 
  5.  1× MAB (Maleic acid buffer) : 100 mM Maleic acid; 150 mM 
NaCl (pH 7.5). 
  6.  10% BMB (Boehringer Mannheim blocking agent) : 10% (w/v) 
Boehringer Mannheim blocking agent in preheated (50 °C) 1× 
MAB, stirred until dissolved and then autoclaved, aliquoted, 
and stored at −20 °C. 
  7.  Blocking solution : 2% BMB in 1× MAB. 
  8.  Antibody solution : 2% BMB, 20% goat serum, anti-DIG Fab 
fragment (Roche, 1:2,000 dilution) in 1× MAB. This can be 
reused, if stored at 4°C. 
  9.  Alkaline phosphatase buffer : 100 mM Tris (pH 9.5), 50 mM 
MgCl 2 , 100 mM NaCl, 0.1% Tween 20. 
 2.  Materials
 2.1.  Components 
Needed for Generating 
 Xenopus Embryos
 2.2.  Wholemount In 
Situ Hybridization 
Components
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  10.  NBT (nitro blue tetrazolium) : 75 mg/mL in 70% dimethylfor-
mamide (DMF). 
  11.  BCIP (5-Bromo-4chloro-3-indolyl-phosphate) : 50 mg/mL in 
100% DMF. 
  1.  Synthetic compound libraries can be sourced from many dif-
ferent companies ( see  Note 6 ). The synthetic compounds were 
obtained either prealiquoted in microtiter plates at 20 mM in 
dimethyl sulfoxide (DMSO) for screening or in powdered 
form and subsequently prepared as 10 mg/mL stock solutions 
in DMSO ( see  Note 7 ). 
 
 Carry out all procedures at room temperature unless otherwise 
speci fi ed.
  1.  Before beginning a chemical genetic screen the optimal screen-
ing concentration needs to be determined, to ensure a good 
discovery rate and low toxicity. This is achieved by randomly 
selecting a plate from the library, then assaying at serial dilu-
tions, e.g., from 1 to 50  μ M. 
  2.  Each well is assayed and scored for the following effects on the 
 fi ve developing embryos: lethality, stunted growth and devel-
opment, toxicity, and positive hits (effecting normal develop-
ment)  ( 5 ) . The concentration which gives low toxicity but a 
good discovery rate should be used. 
  1.  Embryos were grown in a Petri dish containing 10 mL of 0.1× 
MMR (supplemented with gentamycin sulfate to 50 mg/mL) 
at 18 °C until they reached stage 15 ( see  Notes 8 and  9 ). 
  2.  Embryos were then arrayed by Pasteur pipette at 5 embryos 
per well ( see  Note 10 ) into 48 or 96 well plates, containing 
the compound in 1,000 or 200  μ L of 0.1× MMR (supple-
mented with gentamycin sulfate to 100 mg/mL) respectively 
( see  Note 11 ). Figure  1 shows a schematic plan of our screen-
ing strategy. 
  3.  Arrayed embryos were grown at 18 °C ( see  Note 12 ) and 
examined visually with a dissecting microscope at 1, 2, and 3 
days post fertilization (approximately stage 25, 32, and 38 
respectively) ( see  Note 13 and Fig.  2 , e.g., how the embryos 
might look). 
  4.  Embryos were  fi xed at stage 38 ( see  Note 14 ) in their respec-
tive wells by removing as much of the dosing solution as pos-
sible using a Pasteur pipette and replacing with 1,000 or 
200  μ L MEMFA in 48 or 96 well plates respectively. 
 2.3.  Small Compounds 
Used
 3.  Methods
 3.1.  Determining 
Optimal Screening 
Concentrations
 3.2.  Screening 
Compounds
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 Fig. 1.  Chemical genetic screening strategy with developing  Xenopus embryos. Compound libraries are arrayed in 96 well 
format at 20 and 40  μ M ( a ). Embryos are generated by in vitro fertilization ( b ) then arrayed post gastrulation at stage 15, 
5 per well ( c +  c1 ). Plates are left to develop for 3 days at 18 °C. Once the embryos are post melanophore migration (stage 
38) they are then visually scored ( d 1–4 ) (Tomlinson et al.  ( 6 ) , Reproduced by permission of The Royal Society of 
Chemistry). 
 Fig. 2.  Closer view of a range of pigmentation phenotypes. Embryos are shown in the screening plates, as they would be 
scored by the observer. ( a ) shows wild type embryos and typical pigmentation patterns. ( b ) shows a partial disruption 
( stripes ) to the dorsal pigment stripe. ( c ) shows a complete loss of pigmentation. ( d ) shows a complete loss of pigment cell 
migration. All are at stage 38. 
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  5.  After  fi xation for a minimum of 2 h at room temperature the 
solution was replaced with PBST ( see  Note 15 ). 
  6.  All positive hits need to be screened again in 5 cm Petri dishes 
with 20 embryos and 10 mL of 0.1× MMR with a serial dilu-
tion of the compound of interest. This will give statistical 
con fi dence and a dose response, revealing compound toxicity 
and ef fi cacy. 
  1.  Phenotypes were observed directly in the microtitre plate or 
by transferring the embryos identi fi ed in the primary screen 
( see Subheading  3.2 ,  step 3 ) into a Petri dish containing a 
2.5 mL 1% agar solution covered with PBS via Pasteur pipette 
( see  Note 16 ). 
  2.  Embryos were observed using a Q imaging 01-MP3.3-RTV-
CLR-10 camera mounted on a Zeiss Stemi 5V6 microscope 
and processed with the Q capture software package ( see 
 Note 17 ). 
  1.  For long term storage, embryos in wells had as much PBST 
solution removed as possible using a Pasteur pipette and trans-
ferred to a 5 mL glass vial and covered with a PBST/methanol 
(50/50) solution, and left on a rocker for 5 min. 
  2.  This wash step was repeated once again and twice using 100% 
methanol. Fixed embryos are labeled and stored at 4  ° C 
( see  Note 18 ). 
 The wholemount in situ hybridization technique (WISH) for 
localizing gene expression can be successfully coupled with chemi-
cal genetics to speci fi cally identify compounds targeting individual 
cells or speci fi c organs. An overview of the protocol is given in 
Fig.  3 . We have developed a combined chemical genetic WISH 
screen to test small molecule compound libraries for their potential 
effects on embryonic macrophage migration with the aid of an 
automated in situ machine. 
  1.  Developing embryos were applied to compounds at stage 15, 
as previously described and allowed to develop to the stage 
required for the WISH (in this case stage 25). 
  2.  The embryos were then transferred to 96 well nylon net well 
plates, by Pasteur pipette, and assayed by in situ hybridization 
with the Intavis Biolane HT1 automated in situ machine, using 
a shortened WISH protocol. 
  3.  The following steps were omitted from the standard WISH 
protocol used in the lab ( see  Note 19 ). The 0.1 M trietha-
nolamine washing steps were removed. A 4-h incubation at 
room temperature with antibody solution may be suf fi cient to 
give a reproducible strong signal depending on the probe used. 
 3.3.  Observing 
Embryos
 3.4.  Embryo Fixation
 3.5.  High Throughput 
Combined In Situ 
Hybridization and 
Chemical Genetic 
Screen
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A last MAB wash (4 °C overnight) was omitted to increase the 
throughput of the screen. Typically four 96 well plates every 5 
days were routinely assayed. A representative result is shown in 
Fig.  4  ( 12 ) and Tomlinson and Wheeler (unpublished 
results). 
  4.  Fixation process—Day 1. Add MEMFA for 1 h with agitation 
at 20 °C. EtOH wash for 5 min with agitation at 20 °C, repeat 
three times. EtOH for 1 h with no agitation at 4 °C. Plates left 
at 4 °C to next day. 
  5.  Rehydration and hybridization process—Day 2 (Start at mid-
day) Initial Drain step. Wash with 100% MeOH for 5 min with 
agitation at 20 °C. The following steps are all for 5 min, 75% 
MeOH/25% H 2 O with agitation at 20 °C. 50% MeOH/50% H 2 0 
with agitation at 20 °C. 25% MeOH/75% PBST with agitation 
at 20 °C. PBST with agitation for 5 min at 20 °C, repeat again. 
Proteinase K/PBST for 10 min with agitation at 20 °C ( see 
 Note 20 ). PBST with agitation for 5 min at 20 °C, repeat twice 
more. 3.7% formaldehyde/PBST with agitation for 5 min at 
20 °C. PBST with agitation for 5 min at 20 °C, repeat twice 
 Fig. 3.  Schematic overview of our automated in situ protocol. The different WISH stages 
are shown.  Numbers indicate the days on which these stages are performed. 
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more. Hyb buffer with agitation for 5 min at 20 °C. Hyb/
probe step at 60 °C with agitation for 2 h, then in hyb buffer 
for 17 h at 4 °C (will  fi nish at 10 a.m. next day). 
  6.  Washing process and antibody incubation stage—Day 3 initial 
drain step. Hyb Buffer for 10 min with agitation at 60  ° C. 2× 
SSC for 20 min with agitation at 60  ° C, repeat twice. 0.2× SSC 
for 30 min with agitation at 60  ° C, repeat once. MAB for 5 min 
with agitation at 20  ° C, repeat twice. Blocking with blocking 
solution was then done for 60 min with agitation at 20  ° C. Add 
Antibody solution for 22 h with agitation at 4  ° C or 4 h at 
room temperature. 
  7.  Antibody washing process—Day 3 Initial drain step. Wash 
with MAB for 30 min with agitation at 20  ° C, repeat three 
times more. Final MAB wash with agitation at 4  ° C until ready 
for color development. Color development (with NBT and 
BCIP) should be done manually, in microtitre plates (nylon 
mesh can cause precipitation), and tracked carefully by the 
observer (see Note 21). Wash several times in PBST then visu-
ally score (see Note 22). Embryos can be  fi xed again and stored 
in ethanol as previously described 
 Fig. 4.  A chemical genetic screen using the Biolane HTI in situ machine and the mac-
rophage marker  mpo . Five stage 25 embryos can be seen with stained macrophages 
migrating away from the ventral blood island. Insert shows a closer view of an embryo, 
 white arrows highlight individual macrophages. 
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  1.  The two critical factors in performing a successful forward 
chemical genetic screen are selecting an appropriate compound 
library to source from and the biological question posed. This 
problem is illustrated by the vastness of chemical space (a rep-
resentation of all the possible organic molecules below 500 Da 
that are believed to be biologically relevant to drug discovery), 
which is estimated to contain at least 10 60 molecules, and has 
generated dif fi cult questions as to which compounds should be 
chosen for experimentation  ( 12 ) . The comparison of drug 
properties and descriptors has led to the emergent  fi eld of 
chemoinformatics, and there are many different established 
methods in place that use a variety of molecular descriptors to 
screen whole compound libraries to assess which compounds 
have the highest potential for successful screening. The 
uni fi cation of chemoinformatics and high-throughput chemi-
cal genetic screening has provided a powerful tool for identify-
ing and screening hundreds of drug like compounds in a 
vertebrate model. Conversely the NCI diversity set library, 
used in our study, has been screened successfully many times 
using different cells/organisms and appears to have not yet 
reached saturation  ( 6,  13 ) . This suggests that not only is chem-
ical diversity important but also the biological question being 
addressed. With a complex organism like  Xenopus undergoing 
a wide range of developmental process a rich resource is there 
to be mined. 
  2.  MEMFA should be made fresh each day and stored at 4 °C 
with light excluded by aluminum foil. 
  3.  10× MMR has a high buffering capacity, the use of 10 M 
NaOH will help speed up the pH process. 
  4.  The use of DEPC is only necessary to eliminate RNase con-
tamination from a solution where this could be a concern such 
as with WISH, elsewhere it is not necessary. 
  5.  Only make up proteinase K solution just before it is needed 
and keep at 4 °C until then. Each new batch of proteinase K 
has to be optimized for its activity by varying the amount of 
time embryos are treated in a control WISH. This becomes 
more critical when netwells are used. 
  6.  As mentioned in  Note 1 there are numerous and extensive 
chemical libraries to obtain compounds from and it is likely 
that only a select few will be appropriate for an individual 
experiment. They can contain collections chosen for their 
diversity or for known biological activity, such as patent expired 
 4.  Notes
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drug compounds. It is therefore important to take careful 
consideration as to which compound libraries are selected for 
each individual experiment. The author refers you to Bender 
et al.  ( 14 ) for a detailed review on choosing appropriate com-
pound libraries  ( 13 ) and to Wheeler and Brandli which con-
tains an extensive list of libraries used to date in zebra fi sh and 
 X. laevis screens  ( 8 ) . 
  7.  Xenopus has been shown to have a DMSO EC 50 (malforma-
tion) of 1.92%  ( 15 ) . To improve solubility of some compounds 
either PBST or MeOH could be used instead of DMSO, these 
should be kept below 1% concentration when assaying embryos 
to avoid direct toxicity and use vehicle only controls as with 
DMSO. 
  8.  Prior to stage 15 is the gastrulation phase of development. It is 
best to avoid screening during gastrulation as this stage of 
development is particularly sensitive to many compounds. 
  9.  If by stage 15 more than 20% of embryos are dead or deformed 
than the screen should be abandoned as it is likely the embryos 
will not be robust enough to develop under the potential stress 
of a chemical genetic screen. 
  10.  We  fi nd 5 embryos to be optimal in 96 well plates. In 48 well 
plates either 10 embryos can be cultured to stage 40 or 5 
embryos to stage 44. 
  11.  The Volume of 0.1% MMR transferred needs to be calculated 
and allowed for when determining compound concentration 
in the screen. Typically only 20  μ L is transferred with the 
embryos. 
  12.  Xenopus embryos will develop at different rates depending 
upon the incubation temperature. A  X. laevis and  X. tropicalis 
developmental timetable can be found in Xenbase ( http://
www.xenbase.org/other/methods.do ). It is therefore particu-
larly important to ensure that incubation temperatures remain 
consistent throughout the protocol. 
  13.  Developmental effects can be noted at these stages which may 
be less obvious at later stages. Interesting effects can be reas-
sayed and returned to later. 
  14.  The stage at which to  fi x is dependent on what the phenotype 
is that is being screened for, i.e., stage 38 for pigment and 
stage 42 for vasculogenesis. A smaller developmental win-
dow in the screen may give more speci fi c phenotypes. For 
example in looking at pigment cell migration, applying com-
pounds at stage 24 to stage 38 will decrease the chance of 
nonspeci fi c binding to other proteins or the same molecular 
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target at different developmental stages (e.g., the matrix 
metalloproteinases)  ( 7 ) . 
  15.  If required embryos can be stored in PBST at 4 °C for up to 1 
week with the addition of 0.5% sodium azide as an 
antimicrobial. 
  16.  We have found that embryos are much easier to orientate under 
the microscope when using a hair loop. A glass pipette (with a 
rubber bulb), which has been  fl amed smooth may be prefera-
ble to a plastic Pasteur pipette for transferring fragile treated 
embryos as it has a larger bore and a smoother surface. For 
viewing the  fi xed embryos in dorsal or ventral views a shallow 
indent can be made into the agar surface. 
  17.  Pictures can be further processed using software such as Adobe 
Photoshop. 
  18.  A reverse of this procedure will rehydrate the embryos for fur-
ther manipulation. 
  19.  Optimization may be needed for each in situ probe used as to 
which steps in the protocol can be omitted or reduced. The 
Macrophage speci fi c marker mpo/XPOX2 probe gives a high 
signal to background and can be reused eight times before 
signi fi cant loss of signal  ( 16 ) . 
  20.  Optimization and care will be needed in the length and tem-
perature of the proteinase K permeabilization stage as the 
nylon netwells can be abrasive to the embryos. 
  21.  NBT/BCIP color development solution can be added to plas-
tic trays slightly bigger than a netwell microtiter plate, these 
are then immersed. The whole tray and lid covered in alumi-
num foil to exclude light and rocked gently. 
  22.  False positive hits were detected in our macrophage chemical 
genetic screen due to a number of compounds developmen-
tally stunting the embryos. The screen was stopped and assayed 
when the control vehicle only embryos were at stage 25. 
Positive hits then have to be rescreened when the treated 
embryos have also reached stage 25. 
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Extensions to In Silico Bioactivity Predictions Using
Pathway Annotations and Differential Pharmacology
Analysis: Application to Xenopus laevis Phenotypic
Readouts
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1 Introduction
Computational methods play an important role in the drug
discovery process, providing the expensive and time-con-
suming pharmaceutical research with established ways of
support.[1–4] In particular, with the increase of computational
power and available small-molecule bioactivity data, ligand
based computational methods such as in silico target pre-
diction allow the identification of potential drug targets (re-
lating to both efficacy and off-target effects) as well as dis-
covery of new applications for known compounds.[3,5–9]
Their ability to rationalise the Mechanism of Action (MoA)
and toxicity of a compound potentially reduces the
number of compounds to subject to biological testing,
making them a useful tool to support experimental tech-
niques. Indeed, it has been shown that in silico methods
can complement in vitro screening[10] and therefore, with
the information being stored in public databases (see
Table 1), have become increasingly important in current
drug discovery protocols.
Target prediction allows us to “fill in the gaps” between
chemical and biological knowledge (shown in Figure 1),
linking the 3 principal data components commonly ana-
lysed in work of this type, namely the chemical structure of
compounds, the proteins they interact with, and the phe-
notype they modulate/cause on a cellular, tissue, or organ-
ism level.[11,12] These three components are strongly inter-
connected, and hence cannot be considered in isolation. A
drug indeed interacts with one or more proteins expressed
in an elaborate biological pathways network, leading to
a particular observed phenotype, which in turn also de-
pends on factors such as cell state, compound concentra-
tion and time point. Thus, the final result of the administra-
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Abstract : The simultaneous increase of computational
power and the availability of chemical and biological data
have contributed to the recent popularity of in silico bioac-
tivity prediction algorithms. Such methods are commonly
used to infer the ‘Mechanism of Action’ of small molecules
and they can also be employed in cases where full bioactiv-
ity profiles have not been established experimentally. How-
ever, protein target predictions by themselves do not nec-
essarily capture information about the effect of a compound
on a biological system, and hence merging their output
with a systems biology approach can help to better under-
stand the complex network modulation which leads to
a particular phenotype. In this work, we review approaches
and applications of target prediction, as well as their short-
comings, and demonstrate two extensions of this concept
which are exemplified using phenotypic readouts from
a chemical genetic screen in Xenopus laevis. In particular,
the experimental observations are linked to their predicted
bioactivity profiles. Predicted targets are annotated with
pathways, which lead to further biological insight. More-
over, we subject the prediction to further machine learning
algorithms, namely decision trees, to capture the differen-
tial pharmacology of ligand-target interactions in biological
systems. Both methodologies hence provide new insight
into understanding the Mechanism of Action of compound
activities from phenotypic screens.
Keywords: In silico bioactivity prediction · Cheminformatics · Mechanism of action · Xenopus laevis · Pigmentation
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Table 1. List of main databases available, the data contained within them and their respective web addresses (data as of 25/03/2013).
Database Content Web address
ChEMBL[13] 9570 Targets; 1434432 compound records; 1254575 distinct
compounds; 10509572 activities
https://www.ebi.ac.uk/chembl/
PubChem[14,15] Pcsubstance contains about 93 million records; Pccompound
contains nearly 33 million unique structures. PCBioAssay con-
tains more than 621000 BioAssays. Each BioAssay contains a var-
ious number of data points.
http://pubchem.ncbi.nlm.nih.gov/
DrugBank[16] 6712 drug entries, 4233 non-redundant protein http://www.drugbank.ca/
Chemspider[17] Over 28 million structures from hundreds of data sources. http://www.chemspider.com/
ZINC[18] Over 21 million purchasable compounds in ready-to-dock, 3D
formats.
http://zinc.docking.org/
WOMBAT[19] WOMBAT-PK 2010 contains 1260 entries (1260 unique SMILES),
totaling over 9450 clinical pharmacokinetic measurements; it
further includes 2316 physico-chemical properties; 932 toxicity
endpoints, and 2186 annotated drug-target bioactivities.
http://www.sunsetmolecular.com/index.php?option= -
com_content&view=article&id=16&Itemid=11
Cerep BioPrint
database[20]
2D and 3D descriptors, in vitro data and collected and curated
in vivo data
http://www.cerep.fr/cerep/users/pages/ProductsServices/
bioprintservices.asp
PDSP Ki Data-
base[21]
55524 Pubblished and internally derived affinity values for
a large number of molecules on GPCRs, Ion channels, transport-
ers and enzymes
http://pdsp.med.unc.edu/kidb.php
Figure 1. Visualisation of the links between compound, bioactivity and phenotypic data: the molecular structure of drugs, the biological
target(s) they interact with and the organism where the protein is expressed are strongly interconnected between each other. Figure was
obtained from Bender et al. 2007[22] with permission.
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tion of a compound is a rather complex system modula-
tion, which needs to be properly understood in order to
fully elucidate its effects related to both efficacy and poten-
tial toxicity. In the next section we will review the main
fields where in silico target prediction approaches have
been applied, and some essential applications will be de-
scribed.
1.1 Applicability of In Silico Bioactivity Prediction
1.1.1 Polypharmacology
Target prediction algorithms can help the MoA analysis by
understanding important targets responsible for an effect
and their connection. One of the main areas where in silico
techniques are increasingly being utilised in linking chemis-
try and biology is polypharmacology. The idea of “magic
bullets” introduced by Ehrlich[23,24] has been challenged in
the case of complex diseases such as Central Nervous
System (CNS) disorders, in which the therapeutic effect is
exerted by modulating multiple targets.[23,25,26] The limita-
tions of the approach contribute (together with other fac-
tors such as Pharmacokinetic/Pharmacodynamic properties
which are not discussed in detail in this paper) to the
number of drugs failing late-stage clinical trials. According
to a study conducted by the Centre for Medicines Research
(CMR), the number of drugs that between 2008 and 2009
has been promoted from Phase II to Phase III has fallen by
approximately 10% compared to the preceding two years,
2006–2007,[27] while only ~50% of them succeed from
Phase III to launch.[28] The alternative solution of “magic
shotguns” (selectively non-selective drugs)[29] is also not
without flaws since these drugs are often too promiscuous
and exhibit undesired secondary activities.[30–32] An example
of such a drug is the atypical antipsychotic (and rather pro-
miscuous compound) clozapine. Despite its high efficacy in
the treatment of schizophrenia, it is infrequently adminis-
tered because of the plethora of side effects associated
with its use.[33] The most important adverse reaction is the
life-threatening agranulocitosis, which is most probably
due to oxidoreductive stress/damage caused from the in-
teraction of clozapine with proteins implicated in the anti-
oxidant processes (such as NQO2, alpha-tocopherol transfer
protein and glutathione-related enzymes). Ideally however,
we can derive (or design) desired profiles for drugs based
on existing knowledge between ligand-protein interactions,
knowledge that can be derived from both experiments and
target prediction.
1.1.2 Synergistic Effects of Compound Combinations
The modulation of multiple targets is not necessarily elicit-
ed by a single compound, but may in fact be due to the
administration of multiple drugs in parallel. This can make
MoA analysis more challenging, as additional parameters
such as drugdrug interactions must also be taken into ac-
count. However, it has been suggested that the use of
drug combinations can also help us understand the com-
plexity of biological networks and signalling pathways in
those systems.[34] To this end, the effects of pairwise com-
pound combinations were recently assessed with the use
of a systematic high-throughput screening method.[35] An
interesting outcome of this study is the synergistic effect of
the antipsychotic drug chlorpromazine and the antiproto-
zoal agent pentamidine. Both compounds showed mild an-
tiproliferative activity on A549 lung carcinoma cells when
separately tested, but the concentration required is too
high to be considered clinically applicable on cancer treat-
ment. They were later subjected to synergistic testing,
where the combination performed better than the anti-
cancer drug paclitaxel in inhibiting growth of A549 lung
carcinoma cells in vitro and in vivo (human tumour xeno-
graft assay in mice). Understanding the biological processes
involved in the antiproliferative effect of the combination
of the two drugs is not trivial, but literature support as well
as the combination of the two compounds with other
agents suggests that it might be elicited via DNA binding,
calmoduline inhibition andregulation of polyamine levels.[35]
Hence, the unexpected phenotypes emerging from combi-
nations of compounds can be attributed not only to inter-
action with the proteins involved, but also to their connec-
tivity in biological pathways. Modulations of complex sys-
tems are thus possible via the interaction of multiple drugs
with multiple targets, and computationally predicted bioac-
tivity spectra could possibly facilitate in finding such syner-
gistic drug combinations.
1.1.3 Repositioning
A practical application of multi-target bioactivity profiles of
compounds is drug repositioning, which is the discovery of
a new purpose for an already approved drug. This process
can be driven by the same modulated target (and identify-
ing another disease indication for the approved drug), or
by taking advantage of secondary effects of a drug on the
market. Drug repositioning is becoming increasingly popu-
lar due to the opportunity for pharmaceutical companies
to expand their market by covering new disease areas with
already marketed drugs in a fast and cost-effective manner,
as these have already been subjected to clinical trials and
have well-established safety profiles for humans.[36,37] There-
fore, an additional observation-based trial would (in theory)
progress significantly faster than one for a novel compound
with an unknown profile. Drug repositioning historically
used to occur mainly by chance, by discovering unpredict-
ed therapeutic effects in human. A classic example is the
antipsychotic drug chlorpromazine: it was designed to
have antihistaminic properties, but the strong sedative
effect led to its use in psychosis,[38,39] where it elicits its ther-
apeutic effect thanks to the effect through multiple neuro-
transmitter receptors (most importantly dopaminergic and
serotoninergic). However, nowadays repositioning is also
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being explored on a more rational and systematic level.[40]
When a drug has a desired multi-target profile (is known to
modulate multiple targets of interest), it is suggested that
it may elicit therapeutic effects on disease(s) different from
the one for which it was originally intended, provided that
the targets implicated are also relevant for the second
pathology. The drug can therefore be proposed for reposi-
tioning and be tested in efficacy models in clinical trials
straightaway, skipping the time consuming and expensive
toxicological profiling tests. In silico target prediction can
also be used to reposition drugs by predicting unknown
biological targets, and it could be a viable solution for find-
ing a therapeutic approach against neglected and orphan
diseases.[41]
1.1.4 Current Applications
Target prediction algorithms have been applied in a wide
variety of applications. In a recent study, two machine
learning algorithms were implemented and compared
based on their performance in predicting activity, namely
a Laplacian-modified Nave Bayes classifier and a Parzen-
Rosenblatt Window classifier.[5] In particular, the predicted
targets from the application of the Parzen-Rosenblatt
Window method to a phospholipidosis dataset suggested
that phospholipidosis can be instigated via two different
mechanisms, namely inhibition of phospholipase activity
and enhanced cholesterol biosynthesis, initiated by interac-
tion of the compounds with several targets (Sphingomyelin
phosphodiesterase, phospholipase A2 and lysosomal phos-
pholipase A1 for the former, and lanosterol synthase for
the latter).[6] The aforementioned Bayesian classifier was
used to predict protein targets on a cytotoxicity dataset.[42]
The predicted mechanism of action was tested and validat-
ed in vitro, whereas synergistic effects caused by combina-
tions of compounds were also partially validated. A differ-
ent implementation of the Laplacian-modified Nave Bayesi-
an method[43] was used to derive predicted bioactivity pro-
files for a set of compounds sharing the same toxicity re-
sponse.[44] Predicted proteins were linked to their relevant
pathways, and by comparing them to pathways annotated
to non-toxic compounds it was possible to rationalise
ADRs. On a larger scale, a recent application[9] of in silico
bioactivity profiles was carried out using the Similarity En-
semble Approach (SEA),[45] which was used to predict drug-
target interactions in 3665 approved and investigational
drugs. 23 novel drug-target associations were uncovered,
and 14 out of the 23 pairs were experimentally confirmed
in binding assays. This is one of the few prospective valida-
tions of target prediction algorithms to date which shows
how target prediction can be used in understanding poly-
pharmacology and hence suggest new therapeutic applica-
tion and propose off-target associations responsible for
side effects. An extension to target prediction was attempt-
ed by shifting from structure-activity relationships to struc-
ture-selectivity relationships (SSR), with the use of “selectivi-
ty cliffs” instead of activity cliffs.[46] Models built later how-
ever showed that SSR models currently work considerably
worse for multi-target predictions relative to single target
predictions[47] and are therefore out of the scope of this
work. Predicted bioactivity profiles can also be used as
a measure of diversity, as target-based diverse compound
selection has been shown to outperform conventional fin-
gerprint diversity selection.[48]
Hence, as this short overview illustrates, in silico methods
play an important role in the drug discovery process as
they are used to infer the MoA of compounds in toto, from
therapeutic to off-targets. However, these methods are not
without limitations, which are discussed in the next section.
1.2 Limitations of Target Prediction Methods
All computational methods have limitations and pitfalls,[49]
both on data and methodological levels. Only a deep un-
derstanding and critical analysis of these capabilities and
deficiencies can lead to reliable results.[50] Some of the
most important aspects that have to be taken into consid-
eration when applying in silico models in the area of chem-
ical biology and drug design are discussed in the following
sections, such as quality and reliability of data used.
1.2.1 Data Sources
Target prediction methods are based on databases which
link small molecules (ligands) to bioactivity data (bioassays
and target, see Table 1). These data are then used to ex-
trapolate information about query molecules whose biolog-
ical activity is unknown or incomplete. There is a considera-
ble number of available biological and chemical data sour-
ces, both publicly available[51] and commercial, however the
essential limitations are shared between them. The main
limitation for activity prediction tools is the lack of com-
plete data matrices of a large number of compounds which
have been experimentally measured against a broad panel
of protein targets. Some bioactivity matrices have been
made available, however the public ones are small in size
and cover only specific subsets of pharmacological space
(such as DrugMatrix,[52] recently integrated into ChEMBL,
containing toxicogenomics profiles for 638 compounds
tested on rats and rat hepatocytes, and PDSP Ki Database,
see Table 1), while more comprehensive ones are commer-
cial (for instance the Cerep BioPrint database). Since
models make predictions based on knowledge (similarity
measures are used to assess relationships between mole-
cules), such incomplete data matrices could introduce bias
into the predictive models. This topic has also been dis-
cussed in more detail recently.[2,53,54] One way to increase
coverage of chemical space is to link all available non-over-
lapping data sources; however one of the limitations of
this approach is the inconsistency between databases. In
a recent study,[55] several commercial and public sources
(namely PubChem,[14,15] WOMBAT,[19] ChEMBL,[13] Evolvus,[56]
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and PDSP Ki Database
[21]) were merged with the aim to
create a joined relational database. In this process it was
found that only 34% of the compounds were consistently
annotated, with discrepancies spanning from UniProt
names to doses for the remainder. Each source was found
to contain unique molecules (from different bibliographic
sources), the percentage of which varied considerably be-
tween databases – from 94.7% of unique molecules found
in PubChem to 24.7% in PDSP Ki Database. Hence, this
work highlighted the inconsistency between data sources
already stated in previous studies,[57–63] as well as their com-
plementarities with respect to the information they con-
tain.
Biological databases are affected by a number of limita-
tions as well. A study attempting to connect small mole-
cules acting on the Nuclear receptor family with biological
pathways exposed the lack of data uniformity in these da-
tabases.[64] 20 biological pathways involving 18 nuclear re-
ceptors were extracted from BioCarta,[65] Cell Signalling
Technology,[66] ExPASy Biochemical Pathways Map,[67] KEGG,
Signal Transduction Knowledge Environment[68] and Path-
way Studio (PathwayAssist).[69] The issues observed are due
to both errors and literature information not yet integrated
into the knowledge base, and span from the same process
represented with different pathway schemes in different
databases, to inconsistency in protein nomenclature. An ex-
ample is the ‘Estrogen receptor pathway’ from BioCarta,
which presents two inconsistencies. Firstly, the protein
GRIP1 is linked to the Glutamate receptor interacting pro-
tein 1 instead of the glucocorticoid receptor interacting
protein 1. Secondly, the nuclear receptor interacting protein
1 is defined as positive (instead of negative) regulator of
ER-a. In a related study[70] on transcription factors, poor cor-
respondence between experimental data and pathway da-
tabases was also demonstrated. Seven transcription factors
important in oncogenesis (MYC, NOTCH1, BCL6, TP53, AR,
STAT1, and RELA) were associated with 84 pathways ex-
tracted from public (BioCarta,[65] KEGG,[71] WikiPathways[72]
and Cell Signalling Technology[66]) and commercial (Meta-
Core,[73] Ingenuity Pathway Analysis,[74] BKL TRANSPATH[75]
and TRANSFAC,[76] Pathway Studio[69] and GeneSpring Path-
ways[77]) pathways databases. Pairwise comparison between
the different databases was estimated by calculation of the
Jaccard index, which has an average grand value equal to
0.0533: only ~5% of targets were in common between 2
pathways. Hence, the coverage and reliability of life science
data is often questionable, and this appears to apply to
both the chemical and biological information domain.
The limitation of data sources just described has to be
taken into consideration and properly addressed by data
curation.[78] Data curation is a task prone to human error in
which information is extracted manually from literature. For
this reason, it was recently proposed that journals impose
formatting requirements regarding how data should be in-
cluded in papers, meaning that all the important informa-
tion would be provided in a easily accessible way, such as
a machine readable file in the Supplementary Informa-
tion.[51] This file would include all the key data, such as
SMILES of the compounds, way of synthesis, list of protein
targets, in vitro/in vivo tests, etc. and it would allow a com-
parison between, for instance, different molecules that
share the same bioactivity, leaving “nothing open to inter-
pretation”.[79] While currently few journals require submis-
sion of data in this consistent format, acceptance of this
model is likely to increase database quality.
Moreover, users of these sources have to follow a stand-
ardisation process to (virtually) eliminate the consequences
that an imprecise dataset can cause on their computational
model. Ambiguities should be filtered using a cleaning/
standardising pipeline[80] in order to remove mixtures, inor-
ganic and organometallic compounds (not all descriptors
and cheminformatics programs are able to deal with them),
convert structures from SMILES to 2D (easier visualisation
and error checking), strip salt and neutralise, normalise
mesomers, tautomers and aromatic rings, removal of dupli-
cates, and last but not least manual checking. This cleaning
procedure can be easily done with freely available pro-
grams (such as KNIME,[81] Standardizer,[82] etc.), and commer-
cial ones (Sybyl,[83] MOE,[84]Pipeline Pilot,[85] etc.)
1.2.2 Parameter Choice
A large number of machine learning algorithms are avail-
able,[86] but only few of them have been extensively ex-
plored in the target prediction domain. Popular examples
include the similarity-based SEA,[45] the probabilistic (usually
multi-class) Naive Bayes,[5,43,87,88] the distance-based Parzen-
Rosenblatt Window,[5,6] and Support Vector Machines[87,89]
which use hyperplanes to separate data points. Apart from
the choice of algorithm, the descriptors utilised to repre-
sent molecules significantly influence the outcome of the
prediction. A number of molecular descriptors have been
developed, but there is not one able to consistently outper-
form the others, as they are all able to capture different
characteristics of molecules.[90] Similar to the area of ligand-
based virtual screening,[91] it appears that 2D molecular de-
scriptors outperform their 3D counterparts when it comes
to target prediction.[91,92]
1.2.3 Pharmacokinetic and Pharmacodynamic Properties
While ligand-target interactions are often responsible for an
observed biological effect, this is not a one-to-one associa-
tion and questions of dose, time, distribution, metabolism
and associated properties often make the difference wheth-
er an effect is observed in practice or not. Hence, an evalu-
ation of ADMET (Adsorption, Distribution, Metabolism, Ex-
cretion and Toxicity) properties of the compound under in-
vestigation needs to be coupled with its pure target inter-
action profile. It is indeed important to estimate in advance
whether the compound will be absorbed by the organism
and transported to the target organ/tissue in order to expli-
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cate its therapeutic effect, its binding to plasma proteins,
whether it accumulates in particular tissues, the kind of
metabolic modification the molecule undergoes (and the
potential production of active/toxic metabolites), etc. In
silico ADMET prediction plays an important role in the drug
discovery process, because it provides a (relatively) fast,
cheap and efficient way to understand pharmacokinetics
and pharmacodynamics properties,[93–96] but it must be ac-
companied by experimental tests[97] in a controlled and
well organised workflow, in order to avoid misleading re-
sults.[98] Current target prediction methods do not take
ADMET into consideration explicitly (although they can be
applied iteratively on the metabolites generated using e.g.
other computational approaches, or those determined from
experimental measurements), and in order to progress
from qualitative to quantitative predictions this still remains
to be addressed in the future.
1.3 Extensions to Bioactivity Prediction
A system biology approach provides the drug discovery
field with a link between chemistry and biology, which is
fundamental in assisting the development of tools to pre-
dict targets, and therefore side effects and efficacy of new
drugs. A thorough understanding of biological conditions
is possible only by integrating all the relevant data avail-
able.[11,99,100] By providing researchers with – once unavaila-
ble or undecipherable – additional information via chemin-
formatics approaches, we can aid the polypharmacological
paradigm in rationally developing drugs with increased effi-
cacy.[101] It is evident that the combination of network biol-
ogy and polypharmacology can benefit from the use of
target prediction algorithms. An example of bioactivity pro-
files network was constructed in a recent study,[9] where in
silico target prediction, in vitro tests, ADRs annotation and
pharmacodynamics and pharmacokinetic properties were
connected to build a drug-target-adverse effect network.
656 FDA approved drugs were screened in silico against 73
targets(belonging to the Novartis safety panel assays) using
SEA.[45] 48% of the of the predicted target-ligand pairs
where confirmed by either databases search (~33%, found
in ChEMBL, GeneGo Metabase, Thompson Reuters Integrity,
Drugbank and GVKBio) or in vitro test, while only ~46%
where confuted. The new predicted off targets where then
annotated with the observed side effects, obtaining a total
of 247 drug-target-side effect links. Calculation of enrich-
ment factors for these triplets allowed the explanation of
side effects via the new predicted targets. Finally, pharma-
cokinetic and pharmacodynamic properties were taken into
consideration to understand if the link between drug,
target and side effect was plausible, i.e. if the compound
was able to reach an area under the curve (AUC) significant
enough for the interaction with the target. A successful
result of this study is, for example, the explanation of
tremor for the drug diphenhydramine via interaction with
the dopamine transporter. Networks can be also used for
the prediction itself, not only meta-analysis, as demonstrat-
ed by Yamanishi et al.[102] In particular, new drug-target in-
teractions were predicted by combining chemical, genomic
and pharmacological data using supervised bipartite graph
inference. Novel interactions for enzymes, ion channels,
GPCRs and nuclear receptors were derived, suggesting that
bioactivity similarity is more important than chemical simi-
larity when predicting drug-target interaction.
In this work we will illustrate two extensions to in silico
target prediction to phenotypic datasets, namely the uti-
lization of pathway annotations and the differential phar-
macology analysis of the resulting bioactivity spectra. With
regard to the phenotypic nature of the datasets used, this
screening paradigm has recently been highlighted as an
important step in early drug discovery[12,103,104] in order to
uncover insights into small molecule MoA and possibly
identify lead compounds more likely to show efficacy in
the clinic.[12,105] In particular, we present its application on
a chemical genetic screen to identify small molecules that
affect aspects of development of the Xenopus leavis tad-
pole.[106,107] With respect to the extensions to in silico bioac-
tivity prediction presented here, the resulting bioactivity
profiles are annotated with the pathways they map to,
leading to further biological insights into the system modu-
lated. Furthermore, classification trees are generated on the
aforementioned bioactivity profiles to establish the differ-
ences in compound MoA and thus explain different pheno-
types. Both approaches are generally applicable to pheno-
typic datasets and we will illustrate their use for the first
time in this work.
2 Materials and Methods
2.1 Xenopus laevis Phenotypic Screening Dataset
All experiments were performed in compliance with the rel-
evant laws and institutional guidelines at the University of
East Anglia. The research has been approved by the local
ethical review committee according to UK Home Office reg-
ulations.
Compounds used in the study were obtained from the
Diversity Set II compound library (comprised of 1394 com-
pounds), provided by the Drug Synthesis and Chemistry
Branch, Developmental Therapeutics Program, Division of
Cancer Treatment and Diagnosis, National Cancer Insti-
tute.[108] Compounds were prepared as 10 mM stock solu-
tions in dimethyl sulfoxide. The library screens were carried
out as previously described by Tomlinson et al.[106,107] Com-
pounds were defrosted overnight and arrayed into 96 well
plates at either 40 mM or 80 mM in 150 mL 0.1 X MMR solu-
tion. At stage 15, Xenopus laevis embryos were added to
the plates (5 embryos per well in 150 mL 0.1 X MMR, 300 mL
final volume, final respective concentrations 20 and 40 mM),
sealed with an oxygen permeable plate seal and incubated
for 3 days (until stage 38) at 18 8C. Embryos were screened
manually for the described phenotypes using a light micro-
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scope. To reduce experimental bias each plate was
screened separately by two individuals. Identified pheno-
types were photographed using a light microscope mount-
ed with a Micropublisher 3.3 RTV camera and processed
using Qcapture and Adobe Photoshop.
2.2 Computational Methods
2.2.1 Compound Preprocessing
The 1364 compounds from the NCI Diversity Set Library II
were subjected to a KNIME pipeline in which they were
pre-processed (standardised) according to the following
procedure: structures were converted to 2D, neutralised,
salts are stripped and tautomers are normalised using MOE
nodes. Molprint2D[109] circular fingerprints of depth 3 were
then generated using OpenBabel.[110]
2.2.2 Target Prediction
A Laplacian-modified Nave Bayes classifier[5] was used for
bioactivity profile prediction. The training set consists of
approximately 190k ligandprotein pairs extracted from
ChEMBL version 14 covering 477 targets. The criteria used
for building the training set were similar to those described
by Koutsoukas et al.[5] with the exception of the binding af-
finity threshold (1 mM) and the minimum number of instan-
ces per class (50). Information on agonism/antagonism is
not retained, as only the ligand-protein interaction is con-
sidered. The model outputs a confidence score for each
target on a per-compound basis. It is common in such anal-
yses to use an empirical global score cut-off.[111,112] However,
the difference in score distribution among the target
classes suggested our analysis could benefit from calculat-
ing class-specific confidence score cut-offs. The disparity in
score distribution might be due to the different number of
instances in each class, the diversity of molecules repre-
senting a particular class or the average number of features
(fingerprints) used to describe these molecules. The class-
specific thresholds were derived by calculating the optimal
balanced accuracy (precision and recall trade-off) on a per
target class basis, and were used to associate ligands with
putative targets.
2.2.3 Pathway Annotations
Proteinpathway annotations were extracted from the
KEGG[71] (release 58.1) database and all predicted targets
were annotated with the full set of pathway annotations
from KEGG.
2.2.4 Enrichment Calculation
A background distribution was assembled in order to
create a diverse library of compounds covering large chem-
ical space. Approved drugs from DrugBank, drug-like mole-
cules from PubChem, human metabolites from HDMB, nat-
ural products from ZINC and computationally generated
compounds from GDB13 were randomly extracted, yielding
a dataset of 194 849 molecules with a molecular weight
ranging from 100 to 900.
The background distribution was used in the enrichment
calculations to randomly select 10 000 datasets having the
same number of compounds of the test set. Several enrich-
ment calculations were performed as outlined in the fol-
lowing, where the frequency of prediction/annotation was
calculated as the number of times a given target/pathway
was predicted/annotated in the test set.
The Average Ratio for a given target/pathway was calcu-
lated by comparing the frequency of prediction/annotation
in each random dataset with the frequency of prediction/
annotation in the test dataset:
Frandom set1
Ftest set
þ Frandom set2Ftest set þ  þ
Frandom set10000
Ftest set
 
10000
ð1Þ
The Estimation Score was calculated by counting how
many times the frequency of prediction/annotation for
a given target/pathway in the random datasets is larger or
equal to the one in the test dataset. The absolute frequen-
cy (C in Equation 2) obtained is then divided by the total
number of random dataset, giving a value between 0 (en-
riched) and 1 (random).
Targets and pathways with Estimation Score= <0.01 are
considered enriched. In case of targets or pathways having
the same Estimation Score, the Average Ratio value is used
to further discriminate them: the lower the value, the more
enriched the target is.
C=10 000 ð2Þ
Where C=no. of times FrandomsetsFtest set.
2.2.5 Classification
The machine learning method chosen for establishing the
differences in mechanism of action responsible for a particu-
lar phenotype was the WEKA[113] implementation of Quin-
lan’s C4.5 classification tree.[114] In particular, active mole-
cules (showing at least one phenotype) were separated
into those altering Pigmentation and not. The predicted
targets (bioactivity profile) for each active molecule were
used as attributes (features) for the decision tree. The mini-
mum number of instances in leaves was set to 3 and the
criterion for determining the best splits was Information
gain. Due to the small number of instances in the dataset,
leave-one-out cross-validation was used to assess the per-
formance of the decision tree. Furthermore, pruning (confi-
dence factor 0.5, 10-fold) was used to shorten the length of
the tree.
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3 Results and Discussion
A chemical genetic screen was carried out on Xenopus
laevis embryos as described previously.[106,107] Phenotypes
were scored for their effects on Pigmentation, Morphology
(general), Edema, Melanophore morphology, Melanophore
migration, Eye development and Blistering (Table 2). 72 of
the 1364 NCI diversity set II compounds showed one or
more of the phenotypes listed (Figure 2), 70 of which suc-
cessfully made it through our computational pipeline (pre-
processing as described in Materials and Methods, and at
least one predicted target). A query of the ChEMBL data-
base revealed that only one of these compounds is anno-
tated with a single target (2 measurements) according to
the criteria used for the compilation of the in silico bioac-
tivity method training file. This highlights the importance
of bioactivity profile predictions in elucidating the MoA of
compounds. It is interesting to observe that the majority
(59/70) of the active compounds elicit more than one phe-
notype (Figure 3), suggesting the need to distinguish not
only between the targets/pathways involved between ac-
tives and inactives but also amongst the individual pheno-
types. In this work we will be focussing on the Pigmenta-
tion phenotype as it is the one most frequently observed
in this screen, with 45 compounds causing it. These 45
compounds are associated with a total of 236 predicted
targets, where each of these targets was predicted for at
least one compound in the active subset.
3.1 Enrichment Calculation for Targets and Pathways
3.1.1 Enriched Targets
Out of the 236 predicted targets, 33 have been found to
be enriched. The top ten enriched targets are shown in
Table 3 (see Supporting Information Table S1 containing all
enriched targets for further information). The only target
with an Estimation Score=0 is the Platelet-derived growth
factor receptor alpha (PDGFRa) which is important in Xeno-
pus laevis development[115] since its impairment causes de-
velopmental defects[116] such as alterations in pigmenta-
tion.[117] The second most significantly enriched target is
the Mast/stem cell growth factor receptor Kit, important in
Figure 2. Summary of phenotypes observed in Xenopus laevis tadpoles against vehicle control (A). Categories include Pigmentation (B),
Melanophore morphology (C), Melanophore migration (D), Eye development (E), General morphology (F), Blistering (G) and Edema (H). Col-
ored insert boxes correspond with Figure 3. All embryos are shown in lateral view, with anterior to the left. In this work, we analysed com-
pounds causing a Pigmentation phenotype, and to this end applied both pathway annotations and classification trees to further annotate
in silico target predictions.
Table 2. Summary of phenotypes observed in Xenopus after treat-
ment with compounds from the NCI Diversity Set II, along with
their abbreviation and a brief description. In this work, we focused
on the analysis of the Pigmentation (P) phenotype.
Phenotype Abbre-
viation
Description
Pigmentation phenotype P Absence of common pigmen-
tation
Morphology phenotype M Impaired tadpole physiological
development
Edema phenotype E Significant swelling
Melanophore morpholo-
gy phenotype
MM Pigment cells appear rounded
rather than dendritic
Melanophore migration
phenotype
MG Pigment cells have not migrat-
ed to their normal positions
Eye development pheno-
type
ED Eye underdeveloped and al-
tered retinal pigmentation
Blistering B Localised blistering
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melanocyte development, migration and survival.[118] It is re-
sponsible for apoptosis of melanocytes in zebrafish,[119] and
its mutation has been reported to lead to abnormal pig-
mentation such as piebaldism in human[120] which also links
it to the phenotype observed here. A number of enriched
targets are related to melanoma, confirming our analysis
since proteins implicated in human melanoma are found to
be important in Xenopus pigmentation (such as Dimeriza-
tion co-factor of hepatocyte nuclear factor 1 (HNF1)/pterin-
4a-carbinolamine dehydratase).[121] These are the Induced
myeloid leukemia cell differentiation protein Mcl-1,[122]
Cyclin-dependent kinases (CDKs)[123,124] (moreover CDK-1 ac-
tivation, along with JNK, triggers apoptosis in Xenopus un-
fertilised eggs[125]), RAF proto-oncogene serine/threonine-
protein kinase (RAF1)[126] (whose defects are also responsi-
ble for hyperpigmentation in Noonan and Leopard syn-
drome,[127,128] as well as altered pigmentation in Xeno-
pus[129]). A further enriched protein target is Glycogen syn-
thase kinase-3 beta (GSK-3b), implicated in energy metabo-
lism, neuronal cell development, and body pattern forma-
tion in Xenopus and other vertebrates.[130] Loss of GSK-3b
signalling is moreover associated with delayed pigmenta-
tion as observed in zebrafish treated with the lethal factor
component of Bacillus anthracis lethal toxin.[131] Overexpres-
sion of GSK-3b also leads to alterations in neuroectodermal
cell fates through activation of Xotx2 in Xenopus.[132] Thus,
this target is particularly relevant in both Pigmentation and
development, in agreement with our analysis. Finally, en-
richment of the b2 adrenergic receptor is justified by its
known involvement in pigmentation in humans,[133] zebra-
fish[134,135] and several other fish species.[136] The remaining 3
targets in the top 10 positions in our analysis are High af-
finity cAMP-specific 3’,5’-cyclic phosphodiesterase 7A, Tyro-
sine-protein phosphatase non-receptor type 7 (PTPN7) and
Receptor-type tyrosine-protein kinase FLT3. No literature
was found linking them to Pigmentation. However, PTPN7
is known to regulate a variety of cellular processes includ-
ing cell growth, differentiation, mitotic cycle, and oncogen-
ic transformation.[137] Receptor-type tyrosine-protein kinase
FLT3 also regulates differentiation and other processes such
as, proliferation and survival of hematopoietic progenitor
cells and of dendritic cells. implicated in hematopoietic ma-
lignancies.[138] Overall the validity of our method in identify-
ing targets implicated in either Pigmentation or develop-
Figure 3. Distribution of phenotypes on a per-active-compound basis. The colour scale for each phenotype is shown on the right-hand
side. Pigmentation is the most frequently observed phenotype in this dataset and also the only phenotype caused individually by 11 out
of the 45 compounds in the set. Compound numbers do not correspond to library IDs.
Table 3. Top ten targets from the enrichment calculations against
background distribution, along with Frequency of Prediction, Aver-
age Ratio and Estimation Score. Targets are ranked first by Estima-
tion Score then by Average Ratio. The only target with an Estima-
tion Score of zero is the Platelet-derived growth factor receptor
alpha.
Target Frequency
of Predic-
tion
Average
Ratio
Estimation
Score
Platelet-derived growth factor
receptor alpha
7 0.0684 0
Mast/stem cell growth factor re-
ceptor Kit
5 0.0868 0.0001
Tyrosine-protein phosphatase
non-receptor type 7
9 0.2105 0.0001
Induced myeloid leukemia cell
differentiation protein Mcl-1
18 0.3803 0.0001
High affinity cAMP-specific 3’,5’-
cyclic phosphodiesterase 7A
2 0.0098 0.0002
Cyclin-dependent kinase 1 6 0.1220 0.0002
RAF proto-oncogene serine/
threonine-protein kinase
6 0.1500 0.0002
Beta-2 adrenergic receptor 8 0.2232 0.0002
Glycogen synthase kinase-3 beta 12 0.3511 0.0002
Receptor-type tyrosine-protein
kinase FLT3
4 0.1097 0.0004
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ment is confirmed by the literature analysis, with the re-
maining targets enriched in our analysis being those where
involvement in Pigmentation is implicated statistically, and
where further mechanistic experimental studies would be
warranted.
3.1.2 Enriched Pathways
In our analysis 44 out of 150 KEGG pathways have been
found to be enriched. In Table 4 the top ten enriched path-
ways are shown (for further information giving the com-
plete list of enriched pathways see Supporting Information
Table S2). The enriched pathways can be classified in sever-
al clusters according to the biological function they modu-
late: development and cell migration (“Axon guidance”,
“Focal adhesion”, “Adherens junction”), cancer (“Melano-
ma”, “Acute myeloid leukemia”, “Cell cycle”, “MAPK cas-
cade”, ”Basal cell carcinoma”, “Pathways in cancer”, etc.),
cellular proliferation (“Neurotrophins”, “Hematopoietic cell
lineage”, “Melanogenesis”, etc.) and immune response/in-
flammation (“Cytokine-cytokine receptor interaction”, “Che-
mokine signalling pathway”, “T cell receptor signalling path-
way”, “B cell receptor signalling pathway”, “Hepatitis”,
“Masles”, etc.).
Amongst the most enriched pathways is “Axon guid-
ance”, fundamental in the CNS development,[139] but impli-
cated also in vascular system development,[140] in retinal
pigmentation in mouse[141] and eye development in Droso-
phila,[142] thus important for both the specific animal model
(development) and the phenotype observed. Also interest-
ing is the enrichment of the “Endocytosis” process, which is
implicated in the mechanism of melanosomes transfer into
surrounding cells in Xenopus,[143] in Drosophila wing pig-
mentation,[144] and Loeys-Dietz syndrome (one of the symp-
toms is thin and translucent skin, caused by mutation on
the TGF betareceptor gene,[145] which is expressed in this
pathway) and hence clearly related to our phenotype of in-
terest. Several cancer-related pathways are enriched. Their
enrichment is expected since pigment cells are derived em-
bryonic neural crest cells which have many properties in
common with cancer cells.[146] An important enriched path-
way in the cancer-related category is the “MAPK signalling
pathway”. Alterations of the MAPK cascade are responsible
for several malignancies,[147] skin abnormalities such as
Noonan, Costello and Cardio-facio-cutaneous syn-
dromes.[148] Moreover, cAMP activation of the MAPK signal-
ling pathway inhibits melanogenesis,[149] suggesting a direct
implication of this cascade in the observed phenotype. The
next enriched pathway is “Cell cycle”, where the micro-
phthalmia-associated transcription factor Mitf can act as an-
tiproliferative factor by inducing a G1 cell-cycle arrest in
melanocytes-mutation of its genes, and thus impaired func-
tion of the protein, leading to melanoma.[150] Overall, the
enrichment of pathways implicated in tumour development
could be mostly confirmed by literature. The enrichment of
immune system pathways could be due not only due to
their implication in cancer development. Cytokines are im-
portant in cell growth, immune response, angiogenesis, as
well as neurodevelopment.[151] They are implicated in sever-
al diseases whose symptomatology involves skin related
problems, such as Familial progressive hyper- and hypopig-
mentation (caused by mutation of KITLG gene,[152] ex-
pressed in the “Cytokine-cytokine receptor interaction”), Pri-
mary localized cutaneous amyloidosis (PLCA, caused by
mutations of cytokine receptors[153]) and Loeys-Dietz syn-
drome (where one of the symptoms is thin and translucent
skin, caused by mutation on the TGF beta receptor
gene,[145] which is expressed in this pathway). This is evi-
dence of a solid link to the phenotype studied. The next
enriched pathway from the immunomodulation category is
the “B cell receptor signalling pathway”. The B cell receptor
is an intramembrane protein complex whose activation is
triggered by extracellular antigens and causes a cascade
that leads to cellular response to stimulus, production of
kinases, B cell proliferation and Immunoglobulin produc-
tion. Its link to the phenotype studied is confirmed via its
involvement in MAPKinase activation, (whose pathway is
also enriched),[154] as well as Incontinentia pigmenti, a dis-
ease characterised by several symptoms such as hyperpig-
mentation.[155]
Hence, we conclude that overall, although at a first
glance most of the pathways do not appear to be directly
implicated in Pigmentation, a deeper literature analysis
shows their link with the phenotype, confirming the validity
of the pathways analysis in obtaining new insight into the
biological mechanism of the studied phenotype. As with
the enriched targets, the pathways not yet linked to the
Table 4. Top ten pathways from the enrichment calculations
against background distribution, along with Frequency of Annota-
tion, Average Ratio and Estimation Score Pathways are ranked first
by Estimation Score then by Average Ratio. We can observe that
the top 10 enriched pathways have an Estimation Score equal to
zero.
Pathway Frequency
of Annota-
tion
Average
Ratio
Estimation
Score
hsa04060 Cytokine-cytokine re-
ceptor interaction
47 0.2715 0
hsa05221 Acute myeloid leuke-
mia
41 0.2996 0
hsa04662 B cell receptor signal-
ling pathway
41 0.3362 0
hsa04360 Axon guidance 40 0.3603 0
hsa04510 Focal adhesion 85 0.4407 0
hsa04144 Endocytosis 58 0.4444 0
hsa04110 Cell cycle 46 0.4573 0
hsa05218 Melanoma 50 0.4637 0
hsa05200 Pathways in cancer 128 0.5835 0
hsa04010 MAPK signalling path-
way
87 0.5859 0
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phenotype under consideration warrant further mechanistic
study. In this particular case though, most hypotheses
could already be confirmed by literature analysis.
3.2 Classification of Differential Pharmacology for the
Pigmentation Phenotype
So far, we have presented the analysis of enriched targets
and pathways among compound causing the phenotype of
interest, compared to a background distribution. However,
many of the compounds found to be active in the current
study cause multiple phenotypes (Figure 3) which may be
due to similar MoA of the active compounds. From Table 5
(listing the targets with a higher raw frequency) we can ob-
serve that the former hypothesis is in accordance with our
bioactivity predictions, namely that the most frequently
predicted targets for the phenotype studied show consider-
able overlap for the remaining phenotypes. In particular,
the targets most frequently predicted for the Pigmentation
phenotype are the Induced myeloid leukemia cell differen-
tiation protein Mcl-1 and the G-protein coupled receptor
55, which are also the two most predicted targets for the
remaining phenotypes and therefore difficult to separate.
Even from a polypharmacological point of view, simultane-
ous activity on both these targets is predicted 10 out of 45
times for the Pigmentation phenotype vs. 8 out of 25 times
for the remainder of the compounds.
In the next step the C4.5 classification algorithm was em-
ployed to distinguish amongst the different phenotypes.
Each node contains a target used to split the data based
on whether a compound was predicted to be active (“1”)
or inactive (“0”) against it, whereas leaves contain the final
classification. Figure 4 shows a classification tree for differ-
entiating the active compounds causing the Pigmentation
phenotype (Leaf Node outcome= “Yes”) from those causing
any of the remaining phenotypes (Leaf Node outcome=
“No”). For this particular tree we can observe that each leaf
node (outcome) is preceded by predicted activity on
a single target, and inactivity on the remaining target-
nodes leading up to it. From an initial observation, it be-
comes evident that distinguishing between the compounds
Table 5. Top 10 ranked targets predicted for all active compounds,
the number of times they were predicted globally and the number
of times they were predicted for compounds showing the Pigmen-
tation phenotype. We can see that there is significant overlap be-
tween bioactivity predictions for compounds showing the Pigmen-
tation phenotype and total active compounds.
Top-10 targets predicted for active
compounds
Times pre-
dicted in
active com-
pounds (70)
Times predict-
ed for Pig-
mentation
phenotype
(45)
Induced myeloid leukemia cell differ-
entiation protein Mcl-1
32 18
G-protein coupled receptor 55 32 19
Amine oxidase [flavin-containing] B 21 14
Glycogen synthase kinase-3 beta 19 12
E3 ubiquitin-protein ligase Mdm2 18 9
Cytochrome P450 1A2 16 12
Estrogen receptor beta 16 12
Amine oxidase [flavin-containing] A 16 7
Tyrosine-protein phosphatase non-re-
ceptor type 7
16 9
Carbonic anhydrase 5A, mitochondrial 16 12
Figure 4. C4.5 classification tree for active compound set on Pigmentation phenotype against the 6 others. At each node activity (“1”) on
a protein target leads to phenotype classification, whereas inactivity (“0”) proceeds deeper into the tree. In other words, starting from the
root of the classification tree (top row), predicted activity on this target will lead to an outcome (indicated by the “pipes” leading down to
the target name). On the other hand, inactivity will lead to the assessment of predicted activity on the next (indented) protein target.
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that cause the Pigmentation phenotype from the others is
difficult (indicated by the decision tree depth), as many of
the molecules in our active dataset have very similar
modes of action (the phenotype overlap has been high-
lighted in Figure 3). The difficulty is also reflected by the
low classification accuracy (55.7% using leave-one-out
cross-validation) obtained for the decision tree.
The targets of particular interest in the classification tree
are the Carbonic Anhydrase 2 receptor and the Adenosine
A2a receptor, as predicted activity on them points to the
phenotype studied (Pigmentation=Yes) with the largest
coverage (10 compounds). However, the predicted activity
on these targets is not independent as each target de-
pends on those preceding it. The tree is best read/inter-
preted in the form of predicted profiles. This means that ac-
tivity/inactivity for all nodes are equally important from the
root of the tree to each leaf. For example, we can observe
that no activity on the Cystic fibrosis transmembrane con-
ductance regulator (root of the tree) and activity on the Ad-
enosine A2a receptor (leaf) is one complete predicted pro-
file/path. Any compound that follows this rule is therefore
predicted to show the Pigmentation phenotype.
Particularly in outer photoreceptor segments, CTFR acti-
vation helped with their elimination, whereas inhibition
slowed lysosomal degradation. In this case study, predicted
activity on CFTR was linked to absence of the phenotype,
whereas inactivity would forward the compound being an-
alysed to the next node in the classification tree, the Ade-
nosine A2a receptor (A2a). A2a is also expressed in the RPE
and is suggested to play a key role in sustaining its func-
tion.[157] The A2a receptor (as well as its homologues, the
A1, A2b and A3 receptors) is present in the human malig-
nant melanoma A375 cell line.[158]
Our classification indicates that 10 out of 45 compounds
with predicted A2a activity (and simultaneous inactivity on
CFTR) elicit the desired phenotype, suggesting this target is
important for pigmentation modulation. The same number
of compounds (10) is linked to activity on Carbonic anhy-
drase 2 (CA-II) and inactivity on the target-nodes leading to
it. Yoshiura et al.[159] have demonstrated that CA-II is
a target antigen in various types of cancer including mela-
noma.[159] CA-II has also been suggested to play a role in
the regeneration of RPE,[160] hence supporting the relevance
of the target in the Pigmentation phenotype considered
here. Next on the list of receptors expressed in the RPE (in
this case in rat) is the 5-hydroxytryptamine 2A receptor
(5HT2A),[161] predicted activity against which is not meant
to cause the Pigmentation phenotype according to our
classification tree. Furthermore, the serotonin 2A receptor
has been reported to interact with the Melanoma-associat-
ed antigen,[162] therefore indicating a possible role in pig-
mentation. Activity on 3-oxo-5-alpha-steroid 4-dehydrogen-
ase 2 (and inactivity on the target-nodes leading to it) is
also classified as not altering pigmentation. 5-alpha reduc-
tase types 1 and 2 mRNA has been found in various ocular
cells including RPE cells suggesting that they could be in-
volved in androgen action.[163] However, predicted activity
on Serine/threonine-protein kinase D1 (Protein kinase C m-
type) and Protein kinase C (PKC) a-type does modulate the
phenotype. cAMP production in rat and chick RPE cells has
been shown to be mediated by the activation of protein
kinase C[164,165] . Furthermore, melatonin-induced pigment
aggregation was reversed by treating melanophores of
Xenopus laevis with PKC activators,[166] hence lending sup-
port to this rule derived in our analysis. The hepatocyte
growth factor receptor (HGFR) was also confirmed to be ex-
pressed in RPE cells and is suggested to be involved in
both RPE normal function and disease.[167] For arachidonate
5-lipoxygenase however, Sakamoto et al.[168] demonstrated
that non-pigmented epithelial cells have the potential to
synthesize 5-lipoxygenase 5-fold more that pigmented
cells.
The remaining targets used for classification, namely the
alpha-2a adrenergic receptor, delta-type opioid receptor
metabotropic glutamate receptor 1 and tyrosine-protein
kinase Fyn(p59Fyn) were found to have a more specific in-
volvement in pigmentation and modulation of melanocyte
function. Alpha-2 adrenergic receptors were suggested as
mediators for melanophore pigment migration and later
confirmed as melanosome aggregation mediators.[169] In
a recent patent, opioid receptor antagonists were suggest-
ed for the suppression of melanin formation on the human
skin[170] whereas the metabotropic glutamate receptor
1 has been linked to melanoma development[171] in mice
due to its abnormal expression in melanocytes.[172] Finally,
p59Fyn plays an important role in suppressing melanocyte
differentiation by down-regulating mitogen-activated pro-
tein kinase 1 expression[173] in agreement with our analysis.
The targets used in the classification tree along with the
number of times they were predicted for the 45 com-
pounds showing the Pigmentation phenotype are listed in
Table 6. Interestingly, the predicted targets with a higher
raw frequency (shown in Table 5) are not used in the tree.
This is because the tree is designed to distinguish between
Pigmentation and the other 6 observed phenotypes, mean-
ing that targets predicted more frequently may indeed be
relevant in causing a particular phenotype, but do not dis-
criminate it from the other phenotypes observed in the
study. Overall we can conclude that the targets used by the
classification tree to separate the Pigmentation phenotype
from the other phenotypes can give further insight into
ligand-target-phenotype relationships, in addition to the
pathway-based analysis presented above.
4 Conclusions
In silico target prediction is a commonly used approach to
infer ligand-protein interactions for new small mole-
cules,[102] relating to both therapeutic target identification
and also side-effect and “off-target” prediction.[9] However,
target annotations alone are not sufficient to observe bio-
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logical effects observed in a system, and hence in this work
we extended previous approach both by pathway annota-
tions, and subjecting the targets predicted to a classification
tree analysis. For this purpose we used phenotypic screen-
ing data in Xenopus laevis and were able to show that the
enrichment calculations for both targets and pathways indi-
cated significant correlation with the phenotype studied,
highlighting the underlying biological mechanism. While in
most cases literature evidence could be found (in support
of our analysis), the remaining cases form testable mode-
of-action hypotheses which can be followed up experimen-
tally in a protocol similar to the one described by Tomlin-
son et al.[174] Furthermore, the classification analysis provid-
ed insight into differentiating amongst phenotypes with
overlapping predicted bioactivity profiles, and therefore
very similar modes of action. Hence we conclude that while
in silico mode of action analysis has progressed a long way
since its inception, system biology and polypharmacology
extensions are likely to provide further insights into pheno-
typic screening data analyses in the future.
Conflict of interest
None declared.
Acknowledgements
This research was supported by Unilever (SL and AB), Eli
Lilly (GD), EPSRC (GD), University of East Anglia (AH, KH),
John Innes Centre (AH), AstraZeneca (AH), John Jarrold Trust
studentship (KH).
References
[1] M. Glick, E. Jacoby, Curr. Opin. Chem. Biol. 2011, 15, 540–546.
[2] E. Jacoby, Wiley Interdiscip. Rev. : Comput. Mol. Sci. 2011, 1,
57–67.
[3] A. Koutsoukas, B. Simms, J. Kirchmair, P. J. Bond, A. V. Whit-
more, S. Zimmer, M. P. Young, J. L. Jenkins, M. Glick, R. C.
Glen, et al. , J. Proteomics 2011, 74, 2554–2574.
[4] L. Mak, S. Liggi, L. Tan, K. Kusonmano, J. M. Rollinger, A. Kout-
soukas, R. C. Glen, J. Kirchmair, Curr. Pharm. Des. 2013, 19,
532–577.
[5] A. Koutsoukas, R. Lowe, Y. Kalantar-Motamedi, H. Y. Mussa,
J. B. O. Mitchell, R. Glen, A. Bender, J. Chem. Inf. Model. 2013,
53, 1957–1966.
[6] R. Lowe, H. Y. Mussa, F. Nigsch, R. C. Glen, J. B. Mitchell, J.
Cheminf. 2012, 4, 2.
[7] J. L. Jenkins, Mol. Inf. 2012, 31, 508–514.
[8] M. J. Keiser, V. Setola, J. J. Irwin, C. Laggner, A. I. Abbas, S. J.
Hufeisen, N. H. Jensen, M. B. Kuijer, R. C. Matos, T. B. Tran,
et al. , Nature 2009, 462, 175–181.
[9] E. Lounkine, M. J. Keiser, S. Whitebread, D. Mikhailov, J.
Hamon, J. L. Jenkins, P. Lavan, E. Weber, A. K. Doak, S. Ct,
et al. , Nature 2012, 486, 361–367.
[10] D. Vidal, J. Mestres, Mol. Inf. 2010, 29, 543–551.
[11] T. I. Oprea, A. Tropsha, Drug Discov. Today: Technol. 2006, 3,
357–365.
[12] Y. Feng, T. J. Mitchison, A. Bender, D. W. Young, J. A. Tallarico,
Nat. Rev. Drug Discov. 2009, 8, 567–578.
[13] A. Gaulton, L. J. Bellis, A. P. Bento, J. Chambers, M. Davies, A.
Hersey, Y. Light, S. McGlinchey, D. Michalovich, B. Al-Lazikani,
et al. , Nucleic Acids Res. 2011, 44, 1–8.
[14] E. E. Bolton, Y. Wang, P. A. Thiessen, Annu. Rep. Comput.
Chem. 2008, 4, 217–241.
[15] Y. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang, Z. Zhou, L.
Han, K. Karapetyan, S. Dracheva, B. A. Shoemaker, et al. , Nu-
cleic Acids Res. 2012, 40, D400–D412.
[16] C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K.
Banco, C. Mak, V. Neveu, et al. , Nucleic Acids Res. 2011, 39,
D1035–D1041.
[17] H. Pence, A. Williams, J. Chem. Edu. 2010, 87, 1123–1124.
[18] J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad, R. G. Cole-
man, J. Chem. Inf. Model. 2012, 52, 1757–1768.
[19] M. Olah, R. Rad, L. Ostopovici, A. Bora, N. Hadaruga, D. Ha-
daruga, R. Moldovan, A. Fulias, M. Mractc, T. Oprea,
“WOMBAT and WOMBAT-PK: Bioactivity Databases for Lead
and Drug Discovery”, in Chemical Biology: From Small Mole-
cules to Systems Biology and Drug Design, Vol. 1–3 (Eds: S.
Schreiber, T. Kapoor, G. Wess), Wiley-VCH, Weinheim, Germa-
ny, 2008.
[20] C. Krejsa, D. Horvath, S. Rogalski, J. Penzotti, B. Mao, F. Barbo-
sa, J. Migeon, Curr. Opin. Drug Discov. Dev. 2003, 6, 470–480.
[21] B. L. Roth, E. Lopez, S. Patel, W. K. Kroeze, Neuroscientist
2000, 6, 252–262.
[22] A. Bender, J. Scheiber, M. Glick, ChemMedChem 2007, 2, 861–
873.
[23] J. Drews, Nat. Rev. Drug Discov. 2006, 5, 635–640.
[24] J. Drews, Science 2000, 287, 1960–1964.
[25] A. L. Hopkins, Nat. Chem. Biol. 2008, 4, 682–690.
[26] M. T. Bianchi, E. J. Botzolakis, BMC Pharmacol. 2010, 10, 3.
[27] J. Arrowsmith, Nat. Rev. Drug Discov. 2011, 10, 328–329.
[28] J. Arrowsmith, Nat. Rev. Drug Discov. 2011, 10, 87.
[29] B. Roth, D. Sheffler, W. K. Kroeze, Nat. Rev. Drug Discov. 2004,
3, 353–359.
[30] R. Morphy, Z. Rankovic, J. Med. Chem. 2005, 48, 6523–6543.
Table 6. Ordered (from root to leaves) list of targets used in clas-
sification tree and the times they were predicted for compounds
showing Pigmentation phenotype. These targets do not represent
the MoA but may highlight the difference in MoA leading to differ-
ent phenotypes.
Target Names used in classification tree (ordered) Times pre-
dicted in
pigmenta-
tion
Cystic fibrosis transmembrane conductance regulator 0
Adenosine A2a receptor 9
5-Hydroxytryptamine 2A receptor 2
Carbonic anhydrase 2 8
3-Oxo-5-alpha-steroid 4-dehydrogenase 2 2
Serine/threonine-protein kinase D1 6
Protein kinase C alpha type 5
Alpha-2A adrenergic receptor 2
Metabotropic glutamate receptor 1 8
Delta-type opioid receptor 2
Tyrosine-protein kinase Fyn 3
Arachidonate 5-lipoxygenase 3
Hepatocyte growth factor receptor 4
S
p
e
c
ia
l
Issu
e
C
h
e
m
o
g
e
n
o
m
ic
s
Mol. Inf. 2013, 32, 1009 – 1024  2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.molinf.com 1021
In Silico Bioactivity Predictions Using Pathway Annotations
[31] R. Morphy, Z. Rankovic, J. Med. Chem. 2006, 49, 4961–4970.
[32] R. Morphy, C. Kay, Z. Rankovic, Drug Discov. Today 2004, 9,
641–651.
[33] J. Tiihonen, J. Lçnnqvist, K. Wahlbeck, T. Klaukka, L. Niskanen,
A. Tanskanen, J. Haukka, Lancet 2009, 374, 620–627.
[34] J. Lehr, A. Krueger, G. Zimmermann, A. Borisy, Mol. Syst. Biol.
2008, 4, 1–6.
[35] A. A. Borisy, P. J. Elliott, N. W. Hurst, M. S. Lee, J. Lehar, E. R.
Price, G. Serbedzija, G. R. Zimmermann, M. A. Foley, B. R.
Stockwell, et al. , Proc. Natl. Acad. Sci. USA 2003, 100, 7977–
7982.
[36] J. Aube, ACS Med. Chem. Lett. 2012, 3, 442–444.
[37] T. T. Ashburn, K. B. Thor, Nat. Rev. Drug Discov. 2004, 3, 673–
683.
[38] F. Lpez-MuÇoz, C. Alamo, E. Cuenca, W. Shen, P. Clervoy, G.
Rubio, Ann. Clin. Psychiatry 2005, 17, 113–135.
[39] T. A. Ban, Neuropsychiatric Disease and Treatment 2007, 3,
495–500.
[40] J. L. Medina-Franco, M. A. Giulianotti, G. S. Welmaker, R. A.
Houghten, Drug Discov. Today 2013, 18, 495–501.
[41] S. Ekins, A. J. Williams, M. D. Krasowski, J. S. Freundlich, Drug
Discov. Today 2011, 16, 298–310.
[42] I. Cortes-Ciriano, A. Koutsoukas, O. Abian, R. C. Glen, A. Velaz-
quez-Campoy, A. Bender, Med. Chem. Commun. 2013, 4,
278–288.
[43] Nidhi, M. Glick, J. W. Davies, J. L. Jenkins, J. Chem. Inf. Model.
2006, 46, 1124–1133.
[44] J. Scheiber, B. Chen, M. Milik, S. C. K. Sukuru, A. Bender, D. Mi-
khailov, S. Whitebread, J. Hamon, K. Azzaoui, L. Urban, et al. ,
J. Chem. Inf. Model. 2009, 49, 308–317.
[45] M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J.
Irwin, B. K. Shoichet, Nat. Biotechnol. 2007, 25, 197–206.
[46] L. Peltason, Y. Hu, J. Bajorath, ChemMedChem 2009, 4, 1864–
1873.
[47] X. Ning, M. Walters, G. Karypis, G. Karypisxy, J. Chem. Inf.
Model. 2012, 52, 38–50.
[48] H. P. Nguyen, A. Koutsoukas, F. Mohd Fauzi, G. Drakakis, M.
Maciejewski, R. C. Glen, A. Bender, Chem. Biol. Drug Des.
2013, 82, 252–266.
[49] T. Scior, A. Bender, G. Tresadern, J. L. Medina-Franco, K. Mart-
nez-Mayorga, T. Langer, K. Cuanalo-Contreras, D. K. Agrafiotis,
J. Chem. Inf. Model. 2012, 52, 867–881.
[50] S. Kortagere, S. Ekins, J. Pharmacol. Toxicol. Meth. 2010, 61,
67–75.
[51] G. Nicola, T. Liu, M. K. Gilson, J. Med. Chem. 2012, 55, 6987–
7002.
[52] B. Ganter, R. D. Snyder, D. N. Halbert, D. M. Lee, Pharmacoge-
nomics 2006, 7, 1025–1044.
[53] F. Lpez-Vallejo, M. A. Giulianotti, R. A. Houghten, J. L.
Medina-Franco, Drug Discov. Today 2012, 17, 718–726.
[54] J. Mestres, E. Gregori-Puigjan, S. Valverde, R. V. Sol, Nat.
Biotechnol. 2008, 26, 983–984.
[55] P. Tiikkainen, L. Franke, J. Chem. Inf. Model. 2012, 52, 319–
326.
[56] Evolvus, Discov. Informatics, http://www.evolvus.com/, (ac-
cessed 30/05/2013).
[57] C. Southan, P. Vrkonyi, S. Muresan, J. Cheminf. 2009, 1, 10.
[58] Y. Zhou, B. Zhou, K. Chen, S. F. Yan, F. J. King, S. Jiang, E. A.
Winzeler, J. Chem. Inf. Model. 2007, 47, 1386–94.
[59] D. Stumpfe, J. Bajorath, J. Chem. Inf. Model. 2011, 51, 3131–
3137.
[60] P. Gedeck, C. Kramer, P. Ertl, Prog. Med. Chem. 2010, 49, 113–
160.
[61] M. Baker, Nat. Rev. Drug Discov. 2006, 5, 707–708.
[62] G. Schneider, Mol. Inf. 2011, 30, 759–763.
[63] A. J. Williams, S. Ekins, V. Tkachenko, Drug Discov. Today
2012, 17, 685–701.
[64] K. Hettne, M. Cases, S. Boyer, J. Mestres, Curr. Top. Med.
Chem. 2007, 7, 1530–1536.
[65] D. Nishimura, Biotech. Softw. Internet Rep. 2001, 2, 117–120.
[66] Cell Signaling Technology, http://www.cellsignal.com, (ac-
cessed 30/05/2013).
[67] P. Artimo, M. Jonnalagedda, K. Arnold, D. Baratin, G. Csardi, E.
de Castro, S. Duvaud, V. Flegel, A. Fortier, E. Gasteiger, et al. ,
Nucleic Acids Res. 2012, 40, W597–W603.
[68] N. R. Gough, Ann. N.Y. Acad. Sci. 2002, 971, 585–587.
[69] A. Nikitin, S. Egorov, N. Daraselia, I. Mazo, Bioinformatics
2003, 19, 2155–2157.
[70] E. Shmelkov, Z. Tang, I. Aifantis, A. Statnikov, Biol. Direct 2011,
6, 15.
[71] M. Kanehisa, S. Goto, Nucleic Acids Res. 2000, 28, 27–30.
[72] WikiPathways, http://www.wikipathways.org, (accessed 30/
05/2013).
[73] S. Ekins, Y. Nikolsky, A. Bugrim, E. Kirillov, T. Nikolskaya, Meth-
ods Mol. Biol. 2007, 356, 319–350.
[74] Ingenuity Pathway Analysis, Ingenuity Systems Inc. , www.in-
genuity.com, (accessed 30/05/2013).
[75] M. Krull, S. Pistor, N. Voss, A. Kel, I. Reuter, D. Kronenberg, H.
Michael, K. Schwarzer, A. Potapov, C. Choi, et al. , Nucleic
Acids Res 2006, 34, D546–D551.
[76] V. Matys, O. V. Kel-Margoulis, E. Fricke, I. Liebich, S. Land, A.
Barre-Dirrie, I. Reuter, D. Chekmenev, M. Krull, K. Hornischer,
et al. , Nucleic Acids Res. 2006, 34, D108–D110.
[77] GeneSpring, Agilent Technologies, http://www.genomics.
agilent.com/CollectionSubpage.aspx?PageType=Product
&SubPageType=ProductDetail&PageID=1675, (accessed 30/
05/2013).
[78] A. J. Williams, S. Ekins, Drug Discov. Today 2011, 16, 747–750.
[79] S. Orchard, B. Al-Lazikani, S. Bryant, D. Clark, E. Calder, I. Dix,
O. Engkvist, M. Forster, A. Gaulton, M. Gilson, et al. , Nat. Rev.
Drug Discov. 2011, 10, 661–669.
[80] D. Fourches, E. Muratov, A. Tropsha, J. Chem. Inf. Model.
2010, 50, 1189–1204.
[81] M. R. Berthold, N. Cebron, F. Dill, T. R. Gabriel, “KNIME: The
Konstanz information miner”, in Studies in Classification, Data
Analysis, and Knowledge Organization (GfKL 2007), Springer,
Heidelberg, 2007, pp. 319–326.
[82] Standardizer, ChemAxon, http://www.chemaxon.com, (ac-
cessed 30/05/2013).
[83] SYBYL, Tripos International, 1699 South Hanley Rd., St. Louis,
Missouri, 63144, USA.
[84] Molecular Operating Environment (MOE), Chemical Comput-
ing Group, 1010 Sherbooke St. West, Suite #910, Montreal,
QC, Canada, H3A 2R7.
[85] Pipeline Pilot, Accelrys, 10188 Telesis Court, Suite 100, San
Diego, CA 92121, USA.
[86] A. Varnek, I. Baskin, J. Chem. Inf. Model. 2012, 52, 1413–1437.
[87] M. Glick, J. L. Jenkins, J. H. Nettles, H. Hitchings, J. W. Davies,
J. Chem. Inf. Model. 2006, 46, 193–200.
[88] F. Nigsch, A. Bender, J. L. Jenkins, J. B. O. Mitchell, J. Chem Inf
Model 2008, 48, 2313–25.
[89] B.-H. Su, Y.-S. Tu, E. X. Esposito, Y. J. Tseng, J. Chem. Inf. Model.
2012, 52, 1660–1673.
[90] A. Bender, J. L. Jenkins, J. Scheiber, S. C. K. Sukuru, M. Glick,
J. W. Davies, J. Chem. Inf. Model. 2009, 49, 108–119.
[91] G. Hu, G. Kuang, W. Xiao, W. Li, G. Liu, Y. Tang, J. Chem. Inf.
Model. 2012, 52, 1103–1113.
S
p
e
c
ia
l
Is
su
e
C
h
e
m
o
g
e
n
o
m
ic
s
1022 www.molinf.com  2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Mol. Inf. 2013, 32, 1009 – 1024
Full Paper S. Liggi et al.
[92] J. H. Nettles, J. L. Jenkins, A. Bender, Z. Deng, J. W. Davies, M.
Glick, J. Med. Chem. 2006, 49, 6802–6810.
[93] J. Kirchmair, A. Howlett, J. E. Peironcely, D. S. Murrell, M. J.
Williamson, S. E. Adams, T. Hankemeier, L. van Buren, G.
Duchateau, W. Klaffke, et al. , J. Chem. Inf. Model. 2013, 53,
354–367.
[94] P. Zhao, L. Zhang, J. A. Grillo, Q. Liu, J. M. Bullock, Y. J. Moon,
P. Song, S. S. Brar, R. Madabushi, T. C. Wu, et al. , Clin. Pharma-
col. Ther. 2011, 89, 259–267.
[95] D. F. Ortwine, I. Aliagas, Mol. Pharmaceutics 2013, 10, 1153–
1161.
[96] G. Moroy, V. Y. Martiny, P. Vayer, B. O. Villoutreix, M. A. Miteva,
Drug Discov. Today 2012, 17, 44–55.
[97] K. H. Grime, P. Barton, D. F. McGinnity, Mol. Pharmaceutics
2013, 10, 1191–1206.
[98] D. A. Smith, Mol. Pharmaceutics 2013, 10, 1162–1170.
[99] M. Iskar, G. Zeller, X.-M. Zhao, V. van Noort, P. Bork, Curr. Opin.
Biotechnol. 2011, 23, 609–616.
[100] T. I. Oprea, S. K. Nielsen, O. Ursu, J. J. Yang, O. Taboureau, S. L.
Mathias, I. Kouskoumvekaki, L. A. Sklar, C. G. Bologa, Mol. Inf.
2011, 30, 100–111.
[101] A. L. Hopkins, J. S. Mason, J. P. Overington, Curr. Opin. Struct.
Biol. 2006, 16, 127–136.
[102] Y. Yamanishi, M. Kotera, M. Kanehisa, S. Goto, Bioinformatics
2010, 26, 246–254.
[103] M. Schenone, V. Dancˇk, B. K. Wagner, P. A. Clemons, Nat.
Chem. Biol. 2013, 9, 232–240.
[104] U. S. Eggert, Nat. Chem. Biol. 2013, 9, 206–209.
[105] J. Besnard, G. F. Ruda, V. Setola, K. Abecassis, R. M. Rodriguiz,
X.-P. Huang, S. Norval, M. F. Sassano, A. I. Shin, L. A. Webster,
et al. , Nature 2012, 492, 215–220.
[106] M. L. Tomlinson, A. E. Hendry, G. N. Wheeler, Meth. Mol. Biol.
2012, 917, 155–166.
[107] M. L. Tomlinson, M. Rejzek, M. Fidock, R. A. Field, G. N. Wheel-
er, Mol. BioSyst. 2009, 5, 376–384.
[108] Diversity Set Information, NCI Repositories, http://dtp.nci.nih.-
gov/branches/dscb/div2_explanation.html, (accessed 30/05/
2013).
[109] A. Bender, H. Y. Mussa, R. C. Glen, S. Reiling, J. Chem. Inf.
Comput. Sci. 2004, 44, 1708–1718.
[110] N. M. O’Boyle, M. Banck, C. A. James, C. Morley, T. Vander-
meersch, G. R. Hutchison, J. Cheminf. 2011, 3, 33.
[111] G. V. Paolini, R. H. B. Shapland, W. P. Van Hoorn, J. S. Mason,
A. L. Hopkins, Nat. Biotechnol. 2006, 24, 805–815.
[112] F. Mohd Fauzi, A. Koutsoukas, R. Lowe, K. Joshi, T.-P. Fan, R. C.
Glen, A. Bender, J. Chem. Inf. Model. 2013, 53, 661–673.
[113] M. Hall, E. Frank, G. Holmes, B. Pfahringer, P. Reutemann, I.
Witten, SIGKDD Explor. Newsl. 2009, 11, 10–18.
[114] J. R. Quinlan, C4.5: Programs for Machine Learning, Morgan
Kaufmann, San Mateo CA, 1993.
[115] E. W. Damm, R. Winklbauer, Development 2011, 138, 565–
575.
[116] C. Betsholtz, L. Karlsson, P. Lindahl, BioEssays 2001, 23, 494–
507.
[117] P. Soriano, Development 1997, 124, 2691–2700.
[118] A. Uong, L. I. Zon, J. Cell. Physiol. 2010, 222, 38–41.
[119] D. M. Parichy, J. F. Rawls, S. J. Pratt, T. T. Whitfield, S. L. John-
son, Development 1999, 126, 3425–3436.
[120] L. B. Giebel, R. A. Spritz, Proc. Natl. Acad. Sci. USA 1991, 88,
8696–8699.
[121] E. P. v. Strandmann, S. Senkel, G. Ryffel, U. R. Hengge, Am. J.
Pathol. 2001, 158, 2021–2029.
[122] L. Zhuang, C. S. Lee, R. A. Scolyer, S. W. McCarthy, X. D.
Zhang, J. F. Thompson, P. Hersey, Mod. Pathol. 2007, 20, 416–
426.
[123] J. Du, H. R. Widlund, M. A. Horstmann, S. Ramaswamy, K.
Ross, W. E. Huber, E. K. Nishimura, T. R. Golub, D. E. Fisher,
Cancer Cell 2004, 6, 565–576.
[124] C. Abdullah, X. Wang, D. Becker, Cell Cycle 2011, 10, 977–
988.
[125] D. Du Pasquier, A. Dupr, C. Jessus, PloS One 2011, 6, e23672.
[126] G. Maurer, B. Tarkowski, M. Baccarini, Oncogene 2011, 30,
3477–3488.
[127] M. Longoni, S. Moncini, M. Cisternino, I. M. Morella, S. Fer-
raiuolo, S. Russo, S. Mannarino, V. Brazzelli, P. Coi, R. Zippel,
et al. , Am. J. Med. Genet. , Part A 2010, 152A, 2176–2184.
[128] B. Pandit, A. Sarkozy, L. A. Pennacchio, C. Carta, K. Oishi, S.
Martinelli, E. A. Pogna, W. Schackwitz, A. Ustaszewska, A.
Landstrom, et al. , Nat. Genet. 2007, 39, 1007–1012.
[129] S. Lebreton, L. Boissel, N. Iouzalen, J. Moreau, Mech. Dev.
2004, 121, 1481–1494.
[130] I. Dominguez, J. Green, Development 2000, 127, 861–868.
[131] A. E. Tucker, I. I. Salles, D. E. Voth, W. Ortiz-Leduc, H. Wang, I.
Dozmorov, M. Centola, J. D. Ballard, Cell. Microbiol. 2003, 5,
523–532.
[132] K. Itoh, T. L. Tang, B. G. Neel, S. Y. Sokol, Development 1995,
121, 3979–3988.
[133] S. A. Grando, M. R. Pittelkow, K. U. Schallreuter, J. Invest. Der-
matol. 2006, 126, 1948–1965.
[134] Z. Wang, Y. Nishimura, Y. Shimada, N. Umemoto, M. Hirano, L.
Zang, T. Oka, C. Sakamoto, J. Kuroyanagi, T. Tanaka, Gene
2009, 446, 18–27.
[135] J. Xu, F. Xie, Biochem. Biophys. Res. Commun. 2011, 405, 250–
255.
[136] R. Fujii, Pigm. Cell Res. 2000, 13, 300–319.
[137] E. Legius, C. Schrander-Stumpel, E. Schollen, C. Pulles-Heintz-
berger, M. Gewillig, J.-P. Fryns, J. Med. Genet. 2002, 39, 571–
574.
[138] D. L. Stirewalt, J. P. Radich, Nat. Rev. Cancer 2003, 3, 650–655.
[139] B. J. Dickson, Science 2002, 298, 1959–1964.
[140] M. Klagsbrun, A. Eichmann, Cytokine Growth Factor Rev.
2005, 16, 535–548.
[141] M. S. Deiner, T. E. Kennedy, A. Fazeli, T. Serafini, M. Tessier-Lav-
igne, D. W. Sretavan, Neuron 1997, 19, 575–589.
[142] T. P. Newsome, B. Asling, B. J. Dickson, Development 2000,
127, 851–860.
[143] S. Aspengren, D. Hedberg, M. Wallin, Pigm. Cell Res. 2006, 19,
136–145.
[144] F. Riedel, D. Vorkel, S. Eaton, Development 2011, 138, 149–
158.
[145] B. L. Loeys, J. Chen, E. R. Neptune, D. P. Judge, M. Podowski,
T. Holm, J. Meyers, C. C. Leitch, N. Katsanis, N. Sharifi, et al. ,
Nat. Genet. 2005, 37, 275–281.
[146] R. M. White, J. Cech, S. Ratanasirintrawoot, C. Y. Lin, P. B. Rahl,
C. J. Burke, E. Langdon, M. L. Tomlinson, J. Mosher, C. Kauf-
man, et al. , Nature 2011, 471, 518–522.
[147] A. S. Dhillon, S. Hagan, O. Rath, W. Kolch, Oncogene 2007, 26,
3279–3290.
[148] C. Nava, N. Hanna, C. Michot, S. Pereira, N. Pouvreau, T. Nii-
hori, Y. Aoki, Y. Matsubara, B. Arveiler, D. Lacombe, et al. , J.
Med. Genet. 2007, 44, 763–771.
[149] R. Busc	, R. Ballotti, Pigm. Cell Res. 2000, 13, 60–69.
[150] S. Carreira, J. Goodall, I. Aksan, S. A. La Rocca, Nature 2005,
433, 764–769.
[151] B. E. Deverman, P. H. Patterson, Neuron 2009, 64, 61–78.
S
p
e
c
ia
l
Issu
e
C
h
e
m
o
g
e
n
o
m
ic
s
Mol. Inf. 2013, 32, 1009 – 1024  2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.molinf.com 1023
In Silico Bioactivity Predictions Using Pathway Annotations
[152] M. Amyere, T. Vogt, J. Hoo, F. Brandrup, A. Bygum, L. Boon,
M. Vikkula, J. Invest. Dermatol. 2011, 131, 1234–1239.
[153] A. Tanaka, J. E. Lai-Cheong, P. C. van den Akker, N. Nagy, G.
Millington, G. F. H. Diercks, P. C. van Voorst Vader, S. E. Clem-
ents, N. Almaani, T. Techanukul, et al. , Exp. Dermatol. 2010,
19, 416–423.
[154] J. M. Dal Porto, S. B. Gauld, K. T. Merrell, D. Mills, A. E. Pugh-
Bernard, J. Cambier, Mol. Immunol. 2004, 41, 599–613.
[155] A. L. Berlin, A. S. Paller, L. S. Chan, J. Am. Acad. Dermatol.
2002, 47, 169–190.
[156] J. Liu, W. Lu, S. Guha, G. C. Baltazar, E. E. Coffey, A. M. Laties,
R. C. Rubenstein, W. W. Reenstra, C. H. Mitchell, Am. J. Physiol.
Cell Physiol. 2012, 303, C160–C169.
[157] F. Dong, J. An, Chin. J. Ophthalmol. 2007, 43, 1110–1113.
[158] S. Merighi, K. Varani, S. Gessi, E. Cattabriga, V. Iannotta, C.
Ulouglu, E. Leung, P. A. Borea, Br. J. Pharmacol. 2001, 134,
1215–1226.
[159] K. Yoshiura, T. Nakaoka, T. Nishishita, K. Sato, A. Yamamoto, S.
Shimada, T. Saida, Y. Kawakami, T. A. Takahashi, H. Fukuda,
et al. , Clin. Cancer Res. 2005, 11, 8201–8207.
[160] G. E. Korte, J. Smith, Experientia 1993, 49, 789–791.
[161] M. Nash, T. Flanigan, R. Leslie, N. N. Osborne, Ophthalmic Res.
1999, 31, 1–4.
[162] I. Raote, A. Bhattacharya, M. Panicker, “Serotonin 2A (5-HT2A)
Receptor Function: Ligand-Dependent Mechanisms and
Pathways”, in Serotonin Receptors in Neurobiology (Ed: A.
Chattopadhyay), CRC Press, Boca Raton, FL, 2007.
[163] E. M. Rocha, L. A. Wickham, L. A.da Silveira, K. L. Krenzer, F. S.
Yu, I. Toda, B. D. Sullivan, D. A. Sullivan, Br. J. Ophthalmol.
2000, 84, 76–84.
[164] M. S. Nash, J. P. Wood, N. N. Osborne, Exp. Eye Res. 1997, 64,
249–255.
[165] A. Hirota, J. Jpn. Ophthalmol. Soc. 1992, 96, 1412–1417.
[166] D. Sudgen, J. Cell. Biol. 1992, 119, 1515–1521.
[167] K. Lashkari, N. Rahimi, A. Kazlauskas, Invest. Ophthalmol.
Visual Sci. 1999, 40, 149–156.
[168] S. Sakamoto, H. Shichi, J. Ocul. Pharmacol. 1991, 7, 141–145.
[169] J. O. Karlsson, R. G. Andersson, N. Grundstrçm, Br. J. Pharma-
col. 1989, 97, 222–228.
[170] R. Beumer, J. Klock, “Use of Opioid Receptor Antagonists”,
WO Patent 2007/039058 A2 2007.
[171] Y. E. Marn, S. Chen, J. Mol. Med. 2004, 82, 735–749.
[172] S.-S. Shin, B. A. Wall, J. S. Goydos, S. Chen, Pigm. Cell Melano-
ma Res. 2010, 23, 103–111.
[173] C. Wellbrock, C. Weisser, E. Geissinger, J. Troppmair, M.
Schartl, J. Biol. Chem. 2002, 277, 6443–6454.
[174] M. L. Tomlinson, P. Guan, R. J. Morris, M. D. Fidock, M. Rejzek,
C. Garcia-Morales, R. A. Field, G. N. Wheeler, Chem. Biol. 2009,
16, 93–104.
Received: May 31, 2013
Accepted: August 6, 2013
Published online: October 18, 2013
S
p
e
c
ia
l
Is
su
e
C
h
e
m
o
g
e
n
o
m
ic
s
1024 www.molinf.com  2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Mol. Inf. 2013, 32, 1009 – 1024
Full Paper S. Liggi et al.
MedChemComm
CONCISE ARTICLE
Pu
bl
ish
ed
 o
n 
29
 Ja
nu
ar
y 
20
14
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
as
t A
ng
lia
 L
ib
ra
ry
 o
n 
07
/0
4/
20
14
 1
4:
34
:3
9.
 
View Article Online
View Journal  | View IssueaUnilever Centre for Molecular Science
University of Cambridge, Lenseld Road, Ca
cam.ac.uk; Fax: +44 (0)1223 763076; Tel: +
bSchool of Biological Sciences, University
Norwich, NR4 7TJ, UK
cEli Lilly U.K., Erl Wood Manor, Windlesham
† Electronic supplementary informa
10.1039/c3md00313b
Cite this:Med. Chem. Commun., 2014,
5, 386
Received 23rd October 2013
Accepted 28th January 2014
DOI: 10.1039/c3md00313b
www.rsc.org/medchemcomm
386 | Med. Chem. Commun., 2014, 5,Comparative mode-of-action analysis following
manual and automated phenotype detection in
Xenopus laevis†
Georgios Drakakis,a Adam E. Hendry,b Kimberley Hanson,b Suzanne C. Brewerton,c
Michael J. Bodkin,c David A. Evans,c Grant N. Wheelerb and Andreas Bender*a
Given the increasing utilization of phenotypic screens in drug discovery also the subsequent mechanism-
of-action analysis gains increased attention. Such analyses frequently use in silico methods, which have
become signiﬁcantly more popular in recent years. However, identifying phenotype-speciﬁc mechanisms
of action depends heavily on suitable phenotype identiﬁcation in the ﬁrst place, many of which rely on
human input and are therefore inconsistent. In this work, we aimed at analysing the impact that human
phenotype classiﬁcation has on subsequent in silico mechanism-of-action analysis. To this end, an
image analysis application was implemented for the rapid identiﬁcation of seven high-level phenotypes
in Xenopus laevis tadpoles treated with compounds from the National Cancer Institute Diversity Set II. It
was found that manual and automated phenotype classiﬁcations were in agreement with some of the
phenotypes (e.g. 73.9% agreement observed for general morphology abnormality), while this was not the
case in others (e.g. melanophore migration with 37.6% agreement between both annotations). Based on
both annotations, protein targets of active compounds were predicted in silico, and decision trees were
generated to understand mechanisms-of-action behind every phenotype while also taking
polypharmacology (combinations of targets) into account. It was found that the automated phenotype
categorisation greatly increased the accuracy of the results of the mechanism-of-action model, where it
improved the classiﬁcation accuracy by 9.4%, as well as reducing the tree size by eight nodes and the
number of leaves and the depth by three levels. Overall we conclude that consistent phenotype
annotations seem to be generally crucial for successful subsequent mechanism-of-action analysis, and
this is what we have shown here in Xenopus laevis screens in combination with in silico mechanism-of-
action analysis.Introduction
In recent years phenotypic screening has experienced a come-
back,1–3 both due to technological advances and the realization
that single-target based screens appear to oversimplify the drug
discovery process in many cases. However, two questions that
need to be addressed in this approach are a solid choice of
phenotype denitions (many initiatives have recently been
started4,5 to address this question), as well as the subsequent
mode-of-action analysis6,7 to understand compound action also
on a mechanistic level. In this work we attempt to resolve bothInformatics, Department of Chemistry,
mbridge CB2 1EW, UK. E-mail: ab454@
44 (0)1223 762983
of East Anglia, Norwich Research Park,
, Surrey GU206PH, UK
tion (ESI) available. See DOI:
386–396these issues by introducing an automated phenotype classi-
cation soware application followed by an in silico bioactivity
prole analysis.
Phenotype annotation is not always a straightforward
process, especially when it relies heavily on human input and
involves large datasets.8–11 For this reason and being heavily
dependent on recent developments in IT data storage and
processing abilities, automated image processing has recently
been introduced for the analysis of high content screening
(HCS) data, which also has been a major technology driver
behind the recent trend towards phenotypic screening.12 Cell-
Proler,13 one of the rst open-source applications for detecting
cell phenotypes, is able to process cell images for simple read-
outs such as cell count/size, as well as more complicated read-
outs such as protein staining. The CellProler image processing
workow includes image illumination correction and iterative
object detection, before assessing the image for the desired
measures. However, this is not easily transferable to the current
work as the focus is whole-organism readouts and the resulting
detection of very diﬀerent features. The importance ofThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinepre-processing and feature extraction was also highlighted by
Bayraktar et al.,14 who proposed that the physiological state of
cells could be analysed using moment invariants (image prop-
erties which remain unchanged aer the application of a
particular transformation such as rotation). This is because
noisy images may compromise classication. In order to
improve the detection quality also in cases of noisy images,
recently an image segmentationmethodology was introduced to
aid object detection for improved classication of bipolar and
monoaster cells using Laplacian of Gaussian edge detection on
grayscale images, which sharpened important features.15 The
sharpening and detection of objects in an image is commonly
performed by assessing colour values of neighbouring pixels.
For simpler/faster calculations images are usually converted to
the greyscale, leaving the developer to have to deal with only one
colour channel. This can, however, result in the loss of impor-
tant information. An example of using diﬀerent colour channels
for object detection highlighted the potential of image analysis
in siRNA screens,16 where by overlapping the same image using
the values of two diﬀerent colour channels (diﬀerent cells were
highlighted in each colour channel) the authors were able to
successfully identify VSV-GFP infected cells. Given that biolog-
ical eﬀects oen change as a function of time, temporal reso-
lution also becomes important as shown by Neumann et al.,17
who used time-lapse in a high-throughput RNAi screen to detect
phenotypes such as mitosis and apoptosis. A number of similar
cellular readouts such as changes in morphology and cycle
progression can be easily computed with KineticScan® HCS
Reader BioApplications.12 As one can see, diﬀerent approaches
for automated image processing and feature extraction exist,
the correct selection of which depends on the nature of the
readout and experiment conducted.
Related to the particular system considered in this study,
Xenopus laevis phenotypic readouts and also several imaging
studies have been reported recently. Time-lapse imaging has
been employed for developmental readouts on a tissue level, as
embryo cells are larger compared to other vertebrate models.18
Alternative approaches to exploring morphogenesis in Xenopus
laevis include kymographs and 3D image projections which
allow the in-depth investigation and monitoring of cell and
tissue.19 Moving to higher dimensions, 3D imaging was used for
the visualisation of the diﬀerences in cardiac microstructures in
normal and abnormal Xenopus laevis tadpoles.20 Higher-level
phenotype identication aided with pinpointing heritable
developmental abnormalities in Xenopus tropicalis screens with
chemically induced mutations.21 Similarly, early stage X. tropi-
calis development phenotypes were studied by inhibiting the
function of 202 diﬀerent genes via the injection of morpholino
oligonucleotides, and corresponding ‘synphenotype groups’ of
genes which cause similar phenotypes were identied.22 This
seems to be one of the few systematic and consistent classi-
cations of phenotypes available today for Xenopus. However, no
algorithms have been described as of yet for an automated and
hence consistent feature extraction and hence phenotype clas-
sication in these studies.
Automated image analysis for phenotype detection has been
employed in zebrash though, which is one of the prototypicThis journal is © The Royal Society of Chemistry 2014model organisms employed for developmental analysis.23 A
comparison of two stages of zebrash development was recently
carried out using images derived from a Cellomics® ArrayScan®
II high-content reader on uorescent embryos.24 A more exible
approach, ZebIAT, allows comparisons not only between indi-
vidual zebrash, but across diﬀerent embryos under varying
conditions by detecting regions of interest using reference
landmarks,25 similar to the IN Cell Investigator Zebrash
Analysis Plug-In for the commercially available IN Cell Analyzer
System developed by GE Healthcare Life Sciences. (For further
image processing methods in zebrash the reader is referred to
extensive recent reviews.26,27) Hence it seems that automated
high-level phenotype detection has been explored to a higher
degree in zebrash than Xenopus.
We believe that the introduction of human input into
phenotype identication and annotation may incur inconsis-
tencies similar to those which occur during compound assess-
ment and prioritisation by medicinal chemists.28,29 This may
arise from large datasets (image series), the quality of the
images themselves, or merely the diﬃculty in pinpointing the
subtle details in particular regions of interest. Therefore,
the introduction of an algorithm with consistent phenotype
denitions in Xenopus phenotypic screens would provide
researchers with a classicationmethod that is at the same time
more objective, as well as faster. The results of such an appli-
cation signicantly depend on the quality of the images used as
input and therefore the quality needs to be regulated on a
systematic level in order to become consistent. Related open
source quality control metrics have already been introduced
into HCS applications by Bray et al.30 for discarding low quality
images which would have a negative eﬀect on the output of an
experiment. They proceeded to evaluate these metrics on a
series of 2154 images of which 910 were manually considered
blurry, yielding only 81 false positives and 28 false negatives
with an overall F-score of 0.975 and the algorithm was hence
found to be rather successful. Since soware applications
become error-prone when dealing with noisy images, we addi-
tionally aimed in our work to ensure that objective pre-pro-
cessing metrics are incorporated into our analysis algorithms.
The reason why a solid phenotypic denition of readouts is
crucial becomes even more evident in the next step, when the
mode of action of compounds needs to be elucidated. This is
true on a case-by-case basis, given that there are a limited
number of mechanisms that can achieve the same phenotype,
also when grouping compounds per phenotypic class and
considering which targets are more frequently present in this
class than others.31,32 (This principle is similar to ‘Gene Set
Enrichment Analysis’, which has become commonplace when
analyzing transcriptomics data.33) In case phenotype denitions
are inconsistent, the signal given by a shared mode-of-action by
compounds causing a given phenotype will be weakened or, in
the worst case, disappear completely. In our work, we will
employ in silico target predictions to suggest possible modes of
action related to particular phenotypes of interest.34 The most
commonly used methods in the eld are the similarity
ensemble approach (SEA),35,36 pharmacophores,37,38 support
vector machines (SVM)39 and the multinomial Na¨ıve Bayes.40–42Med. Chem. Commun., 2014, 5, 386–396 | 387
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View Article OnlineIt should be noted that diﬀerent methods use diﬀerent
descriptors, such as 2D/3D or binding site descriptors. Vali-
dating in silico approaches due to incomplete data has been
highlighted as a major problem in the eld, at times leading to
non-representative network analyses.43 However, when dealing
with complete data, in silico screening has been shown by Vidal
et al.44 to be a rather accurate alternative to in vitro screening,
where an ensemble approach of three descriptors resulted in
70% aﬃnity predictions on a complete ligand–protein interac-
tion matrix for antipsychotic drugs. In a recent study we have
demonstrated how such bioactivity predictions can be utilised
to gain biological insights, namely by annotating predicted
targets with pathways on the one hand, and by generating
polypharmacological bioactivity proles that diﬀerentiate
between phenotypes on the other.31 However, what has not
been paid attention to before – and this is the aim of the current
study – is the impact that phenotype annotations have
on subsequent mode-of-action analyses, here in the form of
in silico activity proles. In particular, we introduce a method-
ology for automated phenotype classication of Xenopus laevis
tadpoles treated with compounds from the National Cancer
Institute Diversity Set II.45 Bioactivity proles are then predicted
in silico for the molecules in this dataset which show an eﬀect
in vivo, and these are used for training decision trees to identify
underlying common modes of action. We will show that mode-Fig. 1 Workﬂow of the algorithm for automated phenotype categorisatio
by the user on a single image assuming that the environment (lighting
detection of regions of interest and phenotype annotation, based on the
388 | Med. Chem. Commun., 2014, 5, 386–396of-action analyses depend heavily on phenotype classications,
hence suggesting that an automated and consistent approach
appears to be benecial.Materials and methods
Compound screening
Compounds from the NCI Diversity Set II45 library were
screened as described by Tomlinson et al.10,11 Xenopus laevis
embryos (stage 15) were added to 96 well plates (5 embryos per
well) at two diﬀerent concentrations (20 and 40 mM) for 3 days
(until stage 38) at 18 C. Images of the tadpoles were reproduced
using a light microscope mounted with a Micropublisher
3.3 RTV camera. The original phenotype annotation was per-
formed manually using the consensus observation from two
individuals to decrease experimenter bias.Automated phenotype analysis
An image analysis soware application (the algorithm is
described below; all steps are outlined in Fig. 1 and parameters
summarized in Table 1) was developed in Microso® Visual C++
Express 2010 using the OpenCV46 2.45 library for Xenopus image
processing named ‘XePhIAS’ (Xenopus Phenotypic Imaging
Analysis Soware). While the primary aim of the application isn in Xenopus laevis image series. Part 1 refers to the two thresholds set
, background) will be similar throughout the series. Part 2 details the
deﬁnitions given in Table 1.
This journal is © The Royal Society of Chemistry 2014
Table 1 Deﬁnition of phenotypes in the automated image analysis software for chemical genetics Xenopus laevis screens. Fig. 2 gives examples
of all phenotypes, and Fig. 1 the workﬂow of the algorithm
Phenotype Description Strict denitions for application Method
Pigmentation Absence of common pigmentation Pigmented cells/all cells < 10% Count number of black pixels in the
binary image region of interest)
General morphology Impaired physiological
development
Tadpole length/height < 3 From global max (Xmax  Xmin) and
largest hYmax Ymini value (from the
21 points on the X-axis)
Melanophore morphology Pigment cells rounded, not
dendritic
Rounded pigmentation
occurrences > 10
Locate circles in the blurred image
with maximum radius of 3 pixels
using HoughCircles51–53
Melanophore migration Pigment cells have not migrated to
normal positions
Pigmented cells in the top half
excluding head/pigmented cells in
the bottom half excluding head >
3/2 and reverse
Draw lines between all average Y-
values and remove the head region.
Count black cells
Eye development Eye underdeveloped Eye detectable (circle in the blurred
image) in the tadpole head region
Locate the circle in the blurred
image with a minimum radius ¼
1/10 head region using
HoughCircles51–53
Blistering or edema (merged) Localised blistering or signicant
swelling
Diﬀerence in height values in
neighbouring X-axis values
excluding the head region > 5/4
(sudden height increase)
Check hYmax  Ymini values in
neighbouring X-axis points (from
the 21 points on the X-axis)
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View Article Onlinethe rapid and objective classication of consistently dened
phenotypes, it at the same time needs to remain exible for
varying environmental parameters/circumstances such as
lighting or background noise. For the latter reason we have
inserted a pre-processing step into the application which
requires minimal human input prompting for two thresholds to
apply to a control image in the form of slide bars which
dynamically show the outcome on the screen. These thresholds
are for performing Canny47 edge detection to locate the tadpole
and for dilating (using the Dilate48 function) the image so that all
edges of the tadpole are connected. From this point onwards the
application is able to automatically process the image series.
In the second step, all images are processed and the
phenotypes detected are written to a text le. The images areFig. 2 Illustration of phenotypes derived from the Xenopus laevis chemic
in image A. Phenotypes observed in order from image B to H: pigment
opment, general morphology, blistering, edema. We compare the impact
in our work, and the impact on the subsequent mode-of-action analysis
This journal is © The Royal Society of Chemistry 2014subjected to Canny47 edge detection and are then dilated
according to the user-dened thresholds. Objects are detected,
retaining only the largest object (in this case the tadpole).
Erosion (using the OpenCV Erode48 function) transformed the
object back to its original size. Bounding points were then set
around the tadpole in our image, allowing the denition of
regions of interest (eye location, for instance) as well as metrics
such as the relative length of the tadpole. A binary copy of each
image was used to search for pigmented cells and a blurred copy
helped locate rounded pigmented cells without too many false
positives. From the derived regions of interest in each image,
the algorithm classied each tadpole according to the pheno-
type denitions. The phenotypes annotated are pigmentation,
melanophore morphology, melanophore migration, eyeal genetics screen using the NCI diversity set II. Control tadpole shown
ation, melanophore morphology, melanophore migration, eye devel-
of manual and automated annotations of images into those categories
. (Reproduced with permission from Liggi et al.31)
Med. Chem. Commun., 2014, 5, 386–396 | 389
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View Article Onlinedevelopment, general morphology, blistering and edema, which
are visualised in Fig. 2 against a control tadpole. The pheno-
types are described in detail in Table 1 both qualitatively and
quantitatively, along with the method used by the soware
application for automated detection. Based on the denitions
in Table 1, the algorithm follows the steps detailed in Fig. 1.Data analysis
Active compounds (72 of 1398 in total) were pre-processed using
a KNIME54 pipeline as described in a recent study31 and then
subjected to an in silico bioactivity prediction method (Lap-
lacian-modied Na¨ıve Bayes classier) described by Koutsoukas
et al.40 The predictions were rened with the use of per-class
condence score thresholds.31 The 70 compounds with at least
one bioactivity prediction were linked to both the manually and
automatically annotated phenotypes (where only 69 readouts
could be used; snapshots of inactive compounds were not
provided and one image le was found to be corrupted). Pre-
dicted bioactivities proved key for this analysis as a ChEMBL55
search for ligand–protein pairs based on the same criteria as the
training set40 resulted in a single datapoint. Finally, decision
trees were built for mode-of-action analysis in the melanophore
migration phenotype. We usedWEKA56 to derive unpruned C4.5
(ref. 57) classication trees with a minimum number of
instances in each leaf equal to 20% of the instances of the
smallest class (those causing and not causing the melanophore
migration phenotype, respectively).Fig. 3 Impact of parameter choice on the automated phenotype classiﬁc
the 2 user-deﬁned thresholds for the program, the resulting image af
Column 2 shows the same three resulting images on an image being au
largest object (top), eroding (middle) and selection of regions of interest
annotated as pigmented (top) and detection of those with rounded pigm
390 | Med. Chem. Commun., 2014, 5, 386–396Results and discussion
The chemical genetic screening of Xenopus laevis embryos
described in the Materials and methods section gave rise to 72
compounds manually annotated as belonging to the pigmen-
tation, general morphology, melanophore morphology, mela-
nophore migration, eye development, blistering or edema
phenotypes (illustrated in Fig. 2), 70 of which had at least one
predicted protein target (see Materials and methods for details;
compounds were also allowed to have multiple phenotypic class
labels). 69 of the 70 embryos had an accompanying image
(one image failed to be parsed since the le was found to be
corrupted), and those were also automatically annotated with
their corresponding phenotypes.
We will now rstly explore the impact of parameter choice on
the image analysis algorithm, followed by a detailed analysis of
the consistency of manual and automated phenotype annota-
tion methods, and the resulting impact on the mode-of-action
analysis.Impact of parameter choice on image analysis
One of the main goals set for the soware was exibility for
application to similar image series in the future. For this
reason, the soware application prompts the user for two
thresholds on a “control” image (untreated Xenopus tadpole),
which should have a similar environment to the image series
being analysed, and which are used for Canny47 edge detectionation algorithm. Column 1 shows the raw image (top) used for deriving
ter Canny47 edge detection (middle) and the dilated image (bottom).
tomatically processed. Column 3 shows the image after selecting the
along with eye detection (bottom). Finally, Column 4 shows the cells
ented cells.
This journal is © The Royal Society of Chemistry 2014
Fig. 4 Contradicting melanophore migration phenotype annotations
between manual and automated classiﬁcations. Tadpoles on the left
were annotated automatically to belong to this phenotype (but not
manually), and those on the right were annotated manually (but not
automatically). The two images at the top are an indicator of more
subtle diﬀerences which may lead to classiﬁcation diﬀerences (and
where it is not clearly apparent whether automatic or manual anno-
tation would be more appropriate to be used), while those on the
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View Article Onlineand object dilation for locating the tadpole in each image. The
resulting images from applying these thresholds change
dynamically on the screen and are shown in the rst column
(top: original image, middle: image aer edge detection,
bottom: image aer dilation) in Fig. 3. Based on the steps out-
lined in Fig. 1, the algorithm applies the denitions from Table
1 to the 69 images in our dataset. In Column 2 of Fig. 3 the same
thresholds and transformations are applied to one of the
images in our series. In Column 3 the largest object (tadpole) is
detected (top) and then eroded back to its normal shape
(middle). This is the image from which the analogies are
measured for detecting the general morphology and blistering/
edema phenotypes. Regions of interest are then extracted such
as the ‘eye region’ shown in Column 3 (bottom) of Fig. 3. Finally,
Column 4 shows the regions on the tadpole detected as pig-
mented (top) and rounded pigmented cells (last screenshot).
Overall, and given by the results shown below, we believe that
this algorithm is suﬃciently robust for the classication of the
phenotypes described here. (In case phenotype denitions need
to be changed it should be noted that those are entirely exible,
so the user can adjust any of the parameters employed, if so
desired.)bottom of the ﬁgure appear to be a case where manual annotation
appeared to have missed the melanophore migration phenotype.Consistency of manually and automatically annotated
phenotypes and impact on subsequent mode-of-action
analysis
When comparing both annotations – the details of which are
given in Table 2 (full table of annotations and smiles are
provided in ESI Table 1†) – it was found that for ve out of the
six annotation comparisons the agreement achieved was
higher than 50%. Manual and automated annotations were in
better agreement for the phenotypes which are more
straightforward to dene such as general morphology (73.9%),
where only the analogies (the length and height of the tadpole
2D projection) of the tadpole are assessed. For melanophore
migration, however, the categorisation was in agreement for
only 37.6% of the cases, which was the lowest of all values
observed. We next investigated the reason underlying this low
agreement between both annotations, and a typical example is
displayed in Fig. 4, where the pictures on the le refer toTable 2 Diﬀerence and agreement in phenotype annotations betweenm
many cases agrees with the manual classiﬁcation, particularly in phenoty
for melanophore migration (highlighted in bold) it can be seen that there
purpose of investigating the reason behind diﬀerent annotations furthe
bioactivity spectra analysis. It was found that consistent annotations give
this particular dataset automated annotations seem to be advantageous
Phenotypic annotation and agreement
between manual and automated annotations
Absolute nu
Identical
Pigmentation 41
General morphology 51
Eye development 36
Melanophore migration 26
Melanophore morphology 40
Blistering/oedema 46
This journal is © The Royal Society of Chemistry 2014images annotated automatically (but not manually) to belong
to the melanophore migration phenotype, while those on the
right have a manual (but not automatic) class annotation. The
two images at the top are an indicator of more subtle diﬀer-
ences which may lead to classication diﬀerences (and where
it is not clearly apparent whether automatic or manual anno-
tation would be more appropriate to be used), while those on
the bottom of the gure appear to be a case where manual
annotation appeared to have missed the melanophore migra-
tion phenotype.
Given the low agreement between phenotype annotations we
hence in the next step subjected this phenotype subset to a
comparative bioactivity prole analysis, in order to evaluate how
inconsistent phenotype denitions change subsequent mode-
of-action analyses.anual and automatic phenotype detection. Automated classiﬁcation in
pes which are easier to deﬁne (such as general morphology). However,
is signiﬁcant disagreement between the two annotations. This was the
r, and evaluating the impact of diﬀerent annotations on subsequent
statistically superior results which are also easier to interpret, hence on
mbers Percentage
Diﬀerent Identical Diﬀerent
28 59.42 40.58
18 73.91 26.09
33 52.17 47.83
43 37.68 62.32
29 57.97 42.03
23 66.67 33.33
Med. Chem. Commun., 2014, 5, 386–396 | 391
Fig. 6 Mode-of-action decision tree based on automated annota-
tions. It can be observed that compared to the tree based on manual
annotations (Fig. 5) a smaller tree is required to explain a large part of
the phenotype, while giving at the same time better statistical results.
Combined with the fact that the targets identiﬁed in this tree have
more support in the scientiﬁc literature of being associated with the
phenotype, we conclude that automated phenotype annotation leads
to more consistent results, which are important for the annotations
themselves, but also for subsequent mode-of-action analysis.
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View Article OnlineMode-of-action analysis for the melanophore migration
phenotype
Thus far we have demonstrated the importance of consistent
denitions for phenotype classication. In this section, we will
show the impact diﬀerent annotations have on generating
subsequent models for in silico mode of action analysis (while
the conclusions drawn can likely be transferred also to other,
experimental mode of action analyses). In particular, we
generated decision trees (see Data analysis section of Materials
and methods) for both manually and automatically annotated
melanophore migration phenotypes to explore the impact of
this disagreement in annotation. For this analysis, the pre-
dicted bioactivity spectra were used as attributes for the class-
ier, from which the derived bioactivity proles were used to
analyse the diﬀerence in mode-of-action analysis for the active
compounds.
The resulting C4.5 (ref. 57) classication trees are shown in
Fig. 5 (manual annotation) and 6 (automated annotation).
Starting at the top (root) of each tree, each node comprises a
protein target being assessed for whether a query compound is
predicted to bind (“yes”) to the said target or not (“no”).
Depending on the prediction, arrows then lead to the assess-
ment of another target (node) or an outcome (leaf). At each leaf,
the rst number signies how many compounds follow this
predicted bioactivity prole while the second number high-
lights how many compounds are misclassied.Fig. 5 Mode-of-action decision tree resulting from manual pheno-
type annotation for all active compounds (originally annotated with a
phenotype). At each node (protein target) chosen by the algorithm, a
compound predicted to be active (‘yes’) or not (‘no’) is either classiﬁed
(showing the melanophore migration phenotype or not) or forwarded
to the next node (protein target) on the next level of the tree. The ﬁrst
number on each leaf signiﬁes how many compounds follow a
particular bioactivity proﬁle, whereas the second the number of these
compounds which are misclassiﬁed. We have found that the tree
shown here, derived from manual annotations, performs statistically
worse in phenotype classiﬁcation than the one based on automated
annotations (shown in Fig. 6), as well as being less supported by the
literature. Hence, we conclude that on the dataset evaluated here
automated phenotype classiﬁcation seems to be more appropriate
than manual annotation.
392 | Med. Chem. Commun., 2014, 5, 386–396Overall, the nal decision trees generated using manual and
automated annotation shown do not seem to diﬀer signicantly
in performance regarding correctly annotated instances (83%
and 79% for manual and automated annotation respectively).
However, the classication accuracy using 10-fold cross-valida-
tion improved from 47.1% (this is due to the small number of
molecules in the active set, the imbalance in instances anno-
tated as eliciting the phenotype and possibly inconsistent
phenotype classication) in the case of manual annotations to
56.5% in the case of automated and consistent phenotype
annotations. For the classication tree derived from automated
annotation, we can see that at every node, activity on a partic-
ular target leads to the compound being classied as eliciting
the migration phenotype, whereas inactivity leads to a further
node. This signies that the algorithm has located several
individual modes-of-action from the bioactivity proles which
can cause the melanophore migration phenotype. It can also be
observed that the number of leaves decreased from 9 to 6, the
tree size from 17 to 11 and the tree depth from 8 to 5,
comprising a tree that is simpler and hence easier to interpret.
Hence overall we conclude that the mode-of-action analysis
following automated phenotype classication gives a more
consistent picture than the identical analysis following
manual annotations. In the following we will now investigate
how meaningful the analyses are in both cases from the bio-
logical side.
In the decision tree in Fig. 5 (derived from manually anno-
tated phenotypes), predicted activity (indicated by the ‘Yes’
labels in the gure) on dual specicity protein kinase
CLK4, inosine-5-monophosphate dehydrogenase 2, carbonicThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineanhydrase 6 as well as cytochrome P450 1A2 has been detected
by our algorithm for compounds causing the melanophore
migration phenotype. (For the following discussion it should be
noted that the decision tree does not take into account agonism
or antagonism on the protein targets, hence we cannot predict
the sign of the eﬀect observed.) No literature support could be
found for connections of dual specicity protein kinase CLK4
and inosine-5-monophosphate dehydrogenase (IMPDH) 2 with
this phenotype. Mutations in the IMPDH1 gene, however, have
been shown to induce the RP10 form of autosomal dominant
retinitis pigmentosa.58 Regarding the remaining two targets for
which predicted activity has been classied as causing the
melanophore migration phenotype, carbonic anhydrase (CA)
6 and cytochrome P450 1A2, both may have indirect involve-
ment in the phenotype. In particular, CA activity has been
shown to be increased in the retinal pigmented epithelium in
rat,59 whereas another CA member, CA9, has been associated
with cell migration.60 Finally, for cytochrome P450 1A2, we
cannot infer a direct relationship in the mechanism of action of
these compounds but there may be involvement in metabolism.
An example of such an indirect link is the potential inhibition of
melatonin elimination or metabolism (which contracts
pigment-containing melanophores in frogs) by uvoxamine via
cytochrome P450 1A2 or 2C19.61
In the second tree (automatically annotated phenotypes), the
predicted targets used to separate between compounds causing
the melanophore migration phenotype are the dopamine D1a
receptor, cyclin-dependent kinase 2, the cytochrome P450 2C19,
prostaglandin G/H synthase 2 and sphingosine 1-phosphate
receptor 2. In particular, activation of the dopamine D1a
receptor may be responsible for the aggregation of melano-
phores shown to be mediated by dopamine in Pseudopleur-
onectes americanus,62 as well as blocking the release of
melanophore-stimulating hormone from neuroendocrine mel-
anotrope cells in Xenopus laevis.63 Dispersal of pigment was also
caused by dopamine in retinal pigment epithelium (RPE) cells
in Lepomis cyanellus.64 The next protein target used in the tree is
cyclin-dependent kinase 2, which is known to be involved in
melanocyte survival.65 Melanosome transport and synthesis are
thought to be regulated by the microphthalmia-associated
transcription factor (MITF), whose role inuences the expres-
sion of cyclin-dependent kinase inhibitors.66 As for the pre-
dicted enzyme cytochrome P450 2C19, similar to cytochrome
P450 1A2 (see above) we can only infer an indirect relationship
via melatonin elimination or metabolism inhibition.61 At the
next level of the decision tree, the algorithm has selected
prostaglandin G/H synthase 2 (cyclooxygenase-2) to separate the
compounds causing melanophore migration from the inactive
compounds in the set. Prostaglandin G/H synthase 2 is
expressed in RPE cells in both humans67 and rat.68 While this
target is hence linked to pigmentation itself, to our knowledge
no literature has reported its involvement in migration. On the
other hand, the nal target selected in this analysis, sphingo-
sine 1-phosphate (S1P) receptor 2 has a well-documented
involvement in cell migration and more specically in smooth
muscle cells.69–71 Amphibian melanophores have been shown to
be functionally modied smooth muscle cells, thereby lendingThis journal is © The Royal Society of Chemistry 2014support to this prediction.72 Finally, it is suggested that SP1 may
activate the extracellular signal-regulated protein kinase, which
in turn inhibits melanin synthesis through MITF degradation.73
Hence, overall a majority of targets from this decision tree can
be linked to the phenotype observed.
Following the evaluation of the predicted bioactivity proles
between both decision trees, we can conclude that there is more
literature support for the classication based on automated
phenotype annotation. In addition to the improved phenotype
classication results this leads us to the conclusion that the
denition of consistent phenotypes is crucial, both for the
quality of annotations themselves, as well as for the quality of
the subsequent mode-of-action analysis.
Conclusions
In this work, we investigated the interplay between the consis-
tence of phenotype denitions in phenotypic readouts and their
impact on subsequent in silico mode-of-action analysis. To this
end, we used both manual and automatic phenotype annota-
tions on a chemical genetic screen of Xenopus laevis tadpoles
treated with compounds from NCI diversity set II,45 and
compared predicted mode-of-action analyses of poly-
pharmacological nature between both approaches.
It was found that there was a wide variety in agreement and
disagreement between automated and manual classication
approaches, between 73.9% in the case of the general
morphology phenotype and 37.6% in the case of the melano-
phore migration phenotype. The automated categorisation
improved the decision tree classication accuracy of the mela-
nophore migration phenotype by 9.4% while at the same time
reducing its size by eight nodes and the number of leaves and
depth by three, rendering the model both more accurate and
easier to interpret. For many targets predicted to be involved in
this phenotype literature support could be found (such as the
dopamine D1a receptor, cyclin-dependent kinase 2, the cyto-
chrome P450 2C19, prostaglandin G/H synthase 2 and the
sphingosine 1-phosphate receptor 2), while the remainder
would be testable novel mode-of-action hypotheses.
Overall we conclude that a consistent phenotype denition is
important for subsequent mode-of-action studies, both when
considering the follow-up analysis of individual compounds, as
well as when analyzing the mode-of-action of groups of
compounds which are associated with the same phenotype.
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